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RÉSUMÉ 
L'objectif principal de ce travail est de démontrer qu'une approche de modélisation  
dynamique peut être utile pour comprendre le comportement du métabolisme central du 
carbone des cellules CHO. La première partie de ce travail se concentre sur le 
développement d'un modèle dynamique de cellules CHO du métabolisme primaire. Ce 
travail a été inspiré par un modèle cinétique métabolique auparavant développé dans 
notre groupe pour décrire le métabolisme cellulaire primaire decellules de plante. Le 
modèle métabolique a été développé et calibré à l'aide de données obtenues au préalable 
par notre groupe dans des cultures de cellules CHO produisant un activateur du tissu 
plasminogène recombinant en bioréacteur. En plus des données de base, telles les 
concentrations en biomasse, en glucose, en lactate, en glutamine et en ammoniac, les 
concentrations intracellulaires de plusieurs nucléotides et la consommation d'oxygène par 
cellule étaient également disponibles. 
Le principal résultat de cette partie consiste en un modèle métabolique cinétique qui 
permet de décrire le comportement des voies métaboliques majeures dans les cellules 
CHO, c'est-à-dire la glycolyse, la voie des pentoses phosphate, le cycle des acides 
tricarboxyliques, la glutaminolyse ainsi que la respiration cellulaire. Le modèle possède 
30 réactions et plus de 72 paramètres. Les simulations obtenues à l'aide du modèle 
permettent de décrire les données expérimentales, ce qui suggère que la structure 
proposée du modèle est en accord avec le fonctionnement biologique des cellules CHO. 
Le modèle a également été utilisé pour étudier l'effet qu'a l'induction par le  butyrate de 
sodium sur une culture de cellules CHO, celui-ci étant un produit chimique couramment 
utilisé pour augmenter la production spécifique de protéines recombinantes. En 
considérant le nombre élevé de paramètres, l'adaptation du modèle a été minime, 
nécessitant le changement de seulement quelques paramètres, en accord avec les 
modifications de l'expression des gènes rapportées pour décrire l'effet du butyrate de 
sodium sur des cellules CHO. 
Bien que principalement spéculatifs tout en reposant sur des simulations du modèle, les 
résultats concordent avec les données ainsi qu'avec les hypothèses issues de la littérature 
concernant l'effet du butyrate de sodium sur le métabolisme des cellules CHO. 
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Dans une seconde partie, la capacité descriptive du modèle a également été évaluée à 
l'aide de données provenant d'une autre lignée cellulaire CHO recombinante cultivée à 
des conditions de culture différentes. Le modèle a été testé pour simuler des cultures 
discontinues de différents clones d'une lignée de cellules CHO  ayant été génétiquement 
modifiée pour posséder un système d'expression inductible utilisant le cumate comme 
agent inducteur et permettant la production d'anticorps monoclonaux anti-CD 20. Une 
lignée présentant unefaible production spécifique et une lignée possédant une plus haute 
production ont été comparées à la lignée parentale. De plus, il a été possible d'augmenter 
le nombre de métabolites extracellulaires et intracellulaires à l'étude. Il a été démontré 
que la structure du modèle permet à celui-ci de facilement s'adapter à une autre lignée 
cellulaire CHO et ses clones, en ne nécessitant encore une fois qu'un nombre limité de 
modifications au modèle, qui ont été interprétés et analysés comme caractéristiques de 
lignées cellulaires spécifiques. La portée du modèle a été étendue ici de manière à décrire 
aussi le métabolisme des acides aminés et de la production d’anticorps. Il comprend donc 
maintenant 35 réactions et 92 paramètres. Toutefois, une modification limitée, c'est-à-dire 
trois et cinq paramètres pour la lignée à faible production et celle à production élevée 
respectivement, a permis des simulations qui décrivent avec précision les différences sur 
le plan métaboliques liées à la variation clonale. En se fiant à nos résultats, il est clair que 
ce modèle dynamique peut être facilement adapté à l'ensemble des cultures existantes. 
Enfin, dans la troisième partie de la thèse, le comportement du modèle a été étudié tout en 
intégrant la régulation métabolique de la glycolyse. Le but de cette étude était d'évaluer 
dans quelle mesure notre modèle cinétique peut décrire l'effet d'une perturbation soudaine 
sur le comportement du métabolisme cellulaire, tout en ayant été calibré à l'aide des 
données de culture montrant une dynamique lente. Les mécanismes de régulation connus 
de la glycolyse des cellules de mammifères, tels que les mécanismes d'inhibition par 
rétroaction, par anticipation et les mécanismes d'activation par des métabolites 
glycolytiques et les variables énergétiques ont été intégrés dans le modèle. Une 
expérience in silico a été réalisée en ajoutant un stress hypoxique soudain, diminuant à 
10% de saturation de l'air. Le modèle a ensuite été modifié pour inclure l'effet de sept 
fonctions de régulation, à savoir l'inhibition par anticipation ou par rétroaction et 
l'activation de métabolites de la glycolyse et l'activation par rétroaction de l'état 
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énergétique de la cellule, dans la voie de la glycolyse avec un paramètre pour chaque cas. 
Fait intéressant, la structure du modèle avec la glycolyse régulée résulte à la simulation 
du passage d'un métabolisme de phosphorylation oxydative à un métabolisme de la 
glycolyse anaérobique, un résultat qui est en accord avec la littérature. Le modèle 
développé a ainsi montré une capacité prédictive. En conclusion, ce travail a abouti à un 
modèle dynamique décrivant le comportement du métabolisme des cellules CHO, et qui 
pourrait être utile comme outil in silico pour l'optimisation des bioprocédés.  
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ABSTRACT 
The main objective of the work was to demonstrate that a dynamic modelling approach 
can be useful to elucidate the behaviour of CHO cells’ central carbon metabolism. The 
first part of this work focuses on the development of a dynamic model of CHO cells 
primary metabolism.This work was inspired by a previously developed kinetic metabolic 
model in our group to describe plant cell primary metabolism. The metabolic model was 
developed and calibrated using data previously obtained in our group from bioreactor 
cultures of CHO cells expressing recombinant t-PA. In addition to routine datasets, 
including the concentration of cells, glucose, lactate, glutamine and ammonia with time, 
intracellular concentrations of energetic nucleotides and cell specific oxygen 
consumption were also available. The main outcome of this part consists in a kinetic 
metabolic model that allows describing the behaviour of the major metabolic pathways, 
i.e. glycolysis, pentose phosphate pathway, TCA cycle, glutaminolysis as well as cell 
respiration,in CHO cells. The model has 30 metabolic reactions and 72 parameters. 
Model simulations were shown to agree with experimental data, which is suggesting that 
the proposed model structure copes with CHO cells’ biology. The model was also used 
for studying the effect of inducing CHO cell culture by adding sodium butyrate, a widely 
used chemical to enhance recombinant protein production. Albeit the high number of 
parameters, limited model adaptation was required (i.e. the changing of only few 
parameters values), in agreement with gene expression modifications reported in 
literature, to describe the effect of sodium butyrate on CHO cells. Results from model 
simulations further supports our previous findings that butyrate treatment at mid 
exponential phase may induce a shift in cellular metabolism by increasing the efficiency 
of glucose utilization, with a greater fraction of this nutrient channeled through TCA 
cycle. Although mostly speculative while based on model simulations, the results agreed 
with data as well as common hypothesis found in literature of the effect of sodium 
butyrate on CHO cell metabolism.  
In a second part, the descriptive capacity of the model was further assessed using data 
from another recombinant CHO cell line under different culture conditions. The model 
was then challenged to simulate batch cultures for different clones of a CHO cell line 
genetically modified with an inducible expression system, called the cumate gene-switch, 
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for the production of anti CD-20 monoclonal antibody. Low- and high-producer cell lines 
were compared to parental. The extra- and intra-cellular metabolites quantification was 
also included in the study. The model structure showed to be easily adaptableto another 
CHO cell line and its clones, by only requiring limited model modifications, which were 
interpreted and analysed as specific cell line characteristics. The model was extended 
hereto also describe amino acids metabolism and recombinant monoclonal antibody 
production kinetics. It thus now includes 35 reactions and 92 parameters. However, 
limited modification, i.e. changing few parameters in both low-and high-producing 
clones, allowed simulations that accurately described metabolic variations related to 
clonal variation. Different patterns of metabolic flux distribution specially in high-
producer clone was simulated by the model and the increased efficiency of cell 
metabolism,  i.e. greater portion of glucose incorporated into the TCA as opposed to 
being converted to lactate, and up regulation of TCA cycle,  has shown to be more 
induced by clonal variation than by recombinant protein induction. From our results, it is 
clear that such dynamic model can be readily adapted to existing culture datasets. Finally, 
in a third part of the thesis, model behaviour was studied while integrating metabolic 
regulation of glycolysis. The aim of that study was to evaluate to what extent our kinetic 
model can describe the effect of a sudden perturbation on cell metabolic behaviour, while 
having been calibrated using culture data showing slow dynamics. Regulatory 
mechanisms known to apply along the glycolysis pathway in mammalian cells, i.e. 
feedback and feedforward inhibition and activation regulatory mechanisms from 
glycolytic metabolites and energetic variables, were integrated in the model. An in silico 
experiment was performed adding a sudden hypoxic stress, decreasing oxygen level at 
10% of air saturation. The model was then modified to include the effect of seven 
regulatory functions in glycolysis pathway with one parameter for each case. 
Interestingly, the model structure with a fully regulated glycolysis results in the 
simulation of a shift from an oxidative phosphorylation metabolism to an anaerobic 
glycolysis metabolism, a result that is in agreement with literature. The implemented 
model thus showed a predictive capacity. In conclusion, this work has led to a dynamic 
model describing CHO cell metabolic behaviour that could be useful as an in silico tool 
for bioprocess optimization. 
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CHAPTER 1 INTRODUCTION 
 
1.1 The mammalian cell industrial production platform 
Mammalian cells have attracted industrial attention over the last decades because of their 
unique ability to synthesize human-like high value products that can hardly be made by 
microorganisms (Aggarwal et al., 2011). These products, often highly glycosylated 
proteins such as antibodies, are now widely used for diagnostic and therapeutic 
applications (Leader, Baca, & Golan, 2008). Since the first approval of a therapeutic 
protein by the USA Food and Drug Administration (FDA) with recombinant insulin in 
1982 (Leader et al., 2008) and up to 2011, a total of 96 recombinant protein therapeutics 
produced from mammalian cells have been approved. The annual revenue for the USA 
only is now reaching $112.93 billion dollars (www.pipelinereview.com). These numbers 
continue to increase following biopharmaceutical industry improvements with an average 
of 15 new drug approvalsper year by the FDA from 2006 to 2011 (Lai, Yang, & Ng, 
2013). Nowadays, the majority of biopharmaceutical products are produced at industrial 
scale in multi-m3 bioreactors using mammalian cell lines such as Chinese Hamster Ovary 
(CHO) cells. The CHO platform is used to produce over 40% of monoclonal antibody 
products currently approved by the FDA (Grillari et al., 2001) while murine myeloma 
(NS0) account for 25% of monoclonal antibody products (Barnes, Bentley, & Dickson, 
2000) and hybridoma cell lines for the production of murine monoclonal antibodies 
mostly for research and analysis purposes (Davies, Gallo, & Corvalan, 1999). However, 
there are few other cell lines that are assessed for the production of human-like 
monoclonal antibody products and human cells are seen as potential alternatives to CHO 
cells (Jones et al., 2003). Moreover, some other cell lines have a specific niche such as 
the baby hamster kidney (BHK) cells that are mainly used for virus and vaccine 
production (Pitti et al., 1994).  However, although the industry has now reached high 
expression titers using mammalian-cell platforms (mg to g L-1), the limited level of 
understanding on the links between cell behaviour and the physico-chemical environment 
still affects production reproducibility in quantity and quality (e.g. glycosylation profile), 
as well as reducing time to market (i.e. cell line and media selection and cell culture 
management). This thesis thus aims at developing an in silico tool that could contribute to 
minimize the impacts of such limitations.
 
 2 
1.1.1 Mammalian cells versus other cell culture platforms 
Glycosylation, which consists in the attachment of a sugar molecule to an amino acid 
residue of a protein, is a crucial process known to confer multiple specific functional 
properties to proteins, and thus of protein-based therapeutics (Beck et al., 2008). As a 
biotherapeutic, a protein glycolytic profile qualifies its in vivo efficacy (Durocher & 
Butler, 2009; Higgins, 2009), and it is highly dependent on the expression cell platform 
as well as on culture conditions (Ghaderi et al., 2012). It has been shown possible to 
specifically engineer a biotherapeutic protein glycosylation, in various cell production 
platforms, to impose human-like characteristics (Higgins, 2009). Fundamentally, 
bacterial expression systems are not genetically equipped to glycosylate proteins; these   
prokaryotic cells are lacking the enzymatic machinery required for mammalian-type 
glycosylation such as N- and O-glycosylations, which are affecting the 3D 
conformational structure of proteins. Recently, some promising strain/genetic engineering 
approaches were applied to bacterial platforms with the transfer of mammalian 
glycosylation machinery (Nothaft & Szymanski, 2011; Schwarz et al., 2010). Although 
these modifications allowed synthesis of mammalian-like N-glycans and thus markedly 
enhanced bacterial capacities for recombinant protein production, some issues still need 
to be addressed. First, strong transcriptional promoters are required to enable high-level 
gene expression. Promoters thus have to be induced while most inducers can be toxic and 
are expensive (Samuelson, 2011). Second, recombinant proteins should be released into 
the medium to ease their harvesting.In bacterial expression systems, however, they are 
directed to three different locations i.e. the cytoplasm, the periplasm, and to a lesser 
extent the growth medium (Jana & Deb, 2005). It is generally more preferable that 
expression of recombinant proteins occurs in cytoplasm since it leads to higher 
production yields. Low temperature, i.e. the use of cold inducible promoters, has proven 
to enhance protein folding in cytoplasm. However, that often leads to wrong interactions 
of amino acids and and not a well-defined three-dimensional structure known as protein 
misfolding (Khow & Suntrarachun, 2012). 
As such, additional improvements are needed in establishing cost-efficient, reliable 
bacteria-based expression systems. Protein glycosylation can also be performed a 
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posteriori, chemically, on purified proteins, but the costs can be prohibitive and the yields 
in adequate glycolytic profile are still low (Macmillan et al., 2001). 
Yeast, an eukaryotic cell, also provides an attractive expression platform offering 
considerable advantages,  such as ease of culture, ability to maintain high growth rate and 
to reach high densities using chemically defined media, and finally sharing the same N-
glycan core structure with humans (Böer et al., 2007). However, the yeast expression 
system is also subject to certain drawbacks such as hyper-glycosylation, in which case 
additional mannose residues are bond to the N-linked carbohydrate chain of the proteins, 
which is of allergenic potential (Gellissen et al., 2005). Although this issue has been 
addressed over the past decade with various genetic modifications strategies, any 
commercialized human-like recombinant N-linked glycoprotein expressed in yeasts has 
not yet been reported, to the best of our knowledge. Plant-based expression systems also 
offer some advantages over other recombinant protein production platforms such as 
lower production costs and ease of scaling up to commercial production (Gomord et al., 
2010). Probably the best advantage of plants resides in an unbeatable time-to-market of 
only few weeks, from product identification to mass production, using the recent agro-
infiltration technique based on transient transfection approach (Golemboski, 
Lomonossoff, & Zaitlin, 1990; Vezina et al., 2013). This transient approach looks 
promising and many efforts are now placed into the niche of the rapid production of 
vaccines or virus like particles to face pandemia (Paul & Ma, 2010). However, the first 
recombinant protein obtained from plant biotech was from transgenic carrot cells cultured 
in suspension, and homologated by the FDA for the treatment of Gaucher’s disease in 
2012 (www.protalix.com). Therefore, it has been shown possible to produce proteins in 
plants that are biosimilar to those in human. Although plant cells can synthesize 
mammalian type complex N-glycans, glycoproteins expressed in plants have a different 
glycan structure caused by differences in the plant and human N-glycan processing 
machinery (Gomord et al., 2010). Therefore, intensive research is directed towards the 
modification of plant glycosylation pathways for the production of completely humanized 
proteins (Cox et al., 2006). 
Similarly to the plant-based platform, the glycans produced by insect cells also differ 
significantly from those present in human. Recombinant proteins expressed in insect cells 
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completely lack some essential parts, such as galactose and sialic acids, both present in 
human proteins (Ailor et al., 2000). Consequently, more research has to be done on this 
platform to compete with mammalian cells. 
Taking all of the above into consideration, one can understand that the mammalian cell 
expression platform is still predominant in industry to produce recombinant proteins. 
However, other platforms may benefit, in a near future, from the coming developments in 
glycosylation engineering, as well as from the identification of more simple ways to 
produce drugs’ active sub-parts. 
1.2 Challenges in the optimization of therapeutic proteins production 
The mammalian cell platform is attracting most of the research investments worldwide in 
order to be continuously improved for recombinant protein production, as well as cell line 
selection and culture protocols to reduce time-to-market (Ailor et al., 2000). Bioproducts 
obtained from mammalian cells are highly complex, and because these therapeutics can 
induce strong and undesired side effects, their production is highly constrained by the 
regulatory agencies worldwide. The global development process of a new therapeutic 
product, and its acceptance and homologation by regulation agencies, can require up to 
10 years of efforts and significant financial investments; this includes cell line 
development and the production process, as well as conducting extensive testing of the 
end-product therapeutic to demonstrate both its medical efficiency and innocuity 
(DiMasi, Hansen, & Grabowski, 2003). In cases of diseases that are affecting only a 
small population, in which case the will of pharmaceutical companies could be low to 
inexistent because of the little size of the market, regulatory agencies allow accelerating 
the homologation process for these so-called “orphan” drugs. This can thus favor these 
drugs development whatever their financial context. Although the maximum recombinant 
protein concentration that is now reported has increased by 1000-fold (mg/L to g/L) in 
the past decades, there are still important drawbacks limiting product quality and process 
productivity reproducibility at the industrial scale(Wurm, 2004).Basically, reproducibility 
of the results is among the most fundamental requirements of mammalian cell culture 
processes to be acceptable industrially. The clones that are selected should generate 
cultures reproducing the characteristics of the very first culture, up to the large scale 
production (Jayapal et al., 2007). Mammalian cells, however, can exhibit a considerable 
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degree of variability and the sourcesof this variability remain often obscure. This 
variability in the performance of cell culture processes is mainly related to  lot-to-lot 
inconsistency of production in terms of both quantity and quality. First, one major 
challenge facing therapeutic protein production in mammalian cells is that the 
expressionof proteins declinesover time (with cell generation) and is often unstable 
during the time of development (Anderson & Krummen, 2002a). Since cells are 
genetically modified (at least for producing a recombinant product), they are even more 
sensitive to genetic drift and loss of high-producer capacity due to intrinsic genetic repair 
mechanisms (Palomares, Estrada-Mondaca, & Ramírez, 2013). This implies that the long 
time required from cell line construction and selection to clinical trials mayface genomic 
instability of a selected mammalian cell line, and see a high-producer clone becoming a 
low-producer one.Second, therapeutic product glycosylation profile variations, besides 
variations in production level, can dramatically lower or even remove any commercial 
value. Glycosylation pattern has been reported to be extensively affected bycell type, 
culture process and culture media conditions(Hossler, Khattak, & Li, 2009). Therefore, 
any mistake in culture protocols or misunderstanding of culture behavior leading to non-
reproducible product quality level may dramatically impact the therapeutic safety 
evaluation by regulatory agencies, thus resulting in the reject of product homologation. 
So, there is still a need to engineer a well-characterized cell line to expand its capacity so 
that it can control the glycosylation profile towards optimal pattern in differentculture 
conditions(Hossler et al., 2009). Third, there are still reports of potential product 
heterogeneities where a single optimal glycan profile cannot be achieved in mammalian 
cell culture processes. Glycoform heterogeneity, that highly depends on the 
manufacturing process, can even occur throughout a batch culture and may decrease the 
desired therapeutic efficiency. (Abu-Absi et al., 2010). The depletion of nutrients 
throughout batch cultures has been reported to cause such product heterogeneity (Castro 
et al., 1995) .So, the status of homogeneous glycoform profiles that can be systematically 
screened for in mammalian cell culture processes is still too low. Forth, to achievehigh 
titres of the product, both high cell specificproductivity and cell density should be 
achieved. Apoptosis, or programmed death, is known to be the major cause of cell death 
for mammalian cell lines used at industrial scale (Al-Rubeai, 1998; Laken & Leonard, 
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2001). Engineering of cell lines with anti-apoptotic factors, to be overexpressed during 
the culture, has been reported to delay the onset of apoptosis (Andersen & Krummen, 
2002; Birch, Mainwaring, & Racher, 2005). However, the overexpression of these factors 
can cause stresses during cell culture that can compromise the productivity (figueroa et 
al., 2007; Ishaque & Al-Rubeai, 2002). Therefore, enhancement of cellular viability will 
not necessarily improve the overall productivity.Taken all of the above into account, it is 
clear that the mammalian cell platform is complex, and the keys allowing reaching an 
adequate mastering of its output, i.e. a therapeutic product having a high commercial 
value, require additional fundamental studies linking process conditions and cell 
physiology. Consequently, the industry has developed impressive high-throughput 
approaches enabling massive assays for the identification of optimized culture media and 
cell lines. However, the use of mathematical tools simulating cell and bioprocess 
behavior may help at defining favorable conditions at a lower cost and more rapidly, thus 
accelerating high-throughput studies. 
1.3 Mathematical modeling of biochemical networks: rationale and 
objectives 
1.3.1 Modeling as a tool for the control of a bioprocess 
It is now clear that the development of a bioprocess involving the mammalian cell 
platform is, indeed, a multi-factorial task implying various disciplines from molecular 
biology to biochemical engineering (Koutinas, Kiparissides et al., 2011). Molecular 
biology works are required to generate stable cell lines producing a recombinant product 
of interest. Although significant breakthrough have been reached enabling the insertion of 
a new gene expression capacity in cells (Kayser et al., 2006), the challenge is to obtain 
high titers. As previously explain, cell behavior can be highly affected by its environment 
(Clark et al., 1990) and the result from an intuitive genetic modifications can be opposite 
to expectations (Andersen & Krummen, 2002). So, reaching high titers may rely on the 
combination of various factors such as 1) defining optimal culture media, 2) selecting a 
parental cell line, 3) identifying the genetic modification protocol, and 4) selecting high-
producer stable cell lines (Fox, 2004). Moreover, the final production bioreactor unit may 
also require a subtle medium management strategy, such as fed-batch or perfusion culture 
protocols, in order to maximize cell productivity (Chu & Robinson, 2001).  Indeed, a 
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valuable protocol should specifically define optimal feeding time profile, optimizing 
medium composition at all time. In that context, mathematical models may be expected 
to play an important role in both bioprocess characterization and control.Classical 
modelling approaches normally limit bioprocess characterization to mass balances around 
the bioreactor to determine the concentration time course of nutrients, products and 
byproducts (Bastin & Dochaln, 1990). These approaches were shown to allow for the 
control of bioreactor production with the mammalian cell platform (Dhir et al., 2000; 
Tremblay et al., 1992; Zhou et al., 2006). However, although such modelling approach 
lead to valuable process information, it may be too partial for enabling a complex control 
level involving many nutrients that are not necessarily limiting but which respective 
effects on cell behaviour reside within intracellular flux dynamics. Different 
compositions of media have been proven to lead to distinct cellular behaviours with 
regard to metabolic efficiency and reduced formation of by-products (Bonarius et al., 
2001; Bonarius et al., 1998; Xie & Wang, 1996). Different medium protein and amino 
acid concentrations have also been shown to lead to different metabolic states (e.g. higher 
TCA activity), although the main nutrients, glucose and glutamine, were present in 
sufficient amounts (Nadeau et al., 2000; Xie & Wang, 1996).Replacement or 
supplementation of the nutrients with other available sources, e.g. galactose, also showed 
to modulate cell metabolism with regard to metabolic branch points, e.g. glycolysis and 
TCA (Altamirano et al., 2006; Altamirano et al., 2000; Wilkens, Altamirano, & Gerdtzen, 
2011). An adequate information level ethat permits defining an effective control strategy 
may thus require a more descriptive model of cell behaviour. Such model could even 
have predictive properties of cell behaviour. This approach is directly in line with the 
"Process Analytical Technology" (PAT), an essential quality element of the 
“Pharmaceutical Current Good Manufacturing Practices (CGMPs)” for the 21st Century 
(Rathore, Bhambure, & Ghare, 2010), promoted by Food and Drug Administration 
(FDA) in 2004 (Gnoth et al., 2007).   
Moreover, production bioprocesses using a mammalian cell platform normally include 
defined perturbations from the use of chemical additives (Kumar, Gammell, & Clynes, 
2007), inducible promoters (Mullick et al., 2006) or a transient transfection strategy 
(Durocher, Perret, & Kamen, 2002; Pham, Kamen, & Durocher, 2006). Therefore, the 
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problem of defining an optimal culture management strategy becomes even more 
complex when sudden stresses affecting cell metabolism are imposed. Taken all of the 
above together, it seems obvious that mathematical models able to characterize and 
describe cell behaviour from various perturbations along bioprocesses are mostly 
required. 
1.3.2 Models to better characterize a living cell 
A cell can be considered as an open system which exchange energy and matter with the 
environment. This, in turn, enables the cell to maintain internal order and to synthesize 
building blocks for its functions, growth and survival. The material taken up by a cell 
follows a series of transformations usually referred as cellular metabolism (Alberts et al., 
2002a). Cell metabolism is thus a dynamic coordinated ensemble of processes involving 
biochemical reactions all interrelated within a metabolic network. Metabolites are 
generally synthesized along metabolic pathways, i.e. the units of a metabolic network (De 
la Fuente et al., 2013). A living cell has its metabolic activities regulated and controlled 
by intricateregulatory mechanisms. To efficiently characterize cell physiology, a detailed 
mathematical representation of the metabolism is required. Depending on the level of 
detailed information available, different mathematical representations of cell metabolism 
may be developed. A lumped model, which considered only substrate, product and 
growth using Monod kinetics, for instance, represents the early attempts at developing 
metabolic models with a low level of details. A mathematical approach named as 
metabolic flux analysis (MFA), has then been developed for describing metabolic fluxes 
rates under steady state condition. In MFA, intracellular fluxes are calculated based on 
measured exchange rates (Price, Reed, & Palsson, 2004). Metabolic flux balance analysis 
(MFBA) is a special case of MFA in which a solution for the reaction rates of a network 
is obtained through the optimization of a particular network function (Edwards et al., 
1999). The MFBA approach is not confined to measured reaction rates but it is limited to 
the assumption of an optimal behaviour of cells. Therefore, living cells are now studied 
more as a metabolic network with components, i.e. metabolites and biochemical reactions 
that are highly interconnected. In this regard, mathematical models have proven to 
provide a framework in which data obtained from high throughput experiments can be 
analyzed to reveal new insights into the functioning of cellular metabolism. Based on the 
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concept that cells in culture generally exhibit completely different behaviors depending 
on the environmental fluctuations, this mathematical framework should get its best use to 
predict how metabolic network responds dynamically to a changing environmental 
condition (Chin et al., 2008). 
Different concentrations of glucose, glutamine, and  amino acids can induce many 
cultures to shift to different metabolic states, i.e. oxidative metabolism or anaerobic 
glycolysis, different levels of inhibitory metabolites (Altamirano et al., 2004; chen & 
Harcum, 2007; Xie & Wang, 2006; Zhang, Shen, & Zhang, 2004). In addition to nutrient 
concentrations, growth factors, and lipids in culture medium have also shown to effect 
cellular behaviour, i.e. cell growth. Addition of product enhancers such as sodium 
butyrate to cell cultures has also proven to effect metabolic efficiency and promote 
special pathways (De Leon et al., 2007; McMurray-Beaulieu et al., 2009; Yee et al., 
2008). More specific conditions include supplementing culture media with intracellular 
metabolites, i.e. pyruvate, also influencing particular cellular metabolic pathways (Genzel 
et al., 2005). Therefore, the role of a cell regulatory machinery is crucial to ensure 
metabolic homeostasis; i.e. maintaining intracellular conditions at defined setpoints (De 
la Fuente et al., 2013). 
Moreover, the mathematical framework should also be able to predict how the 
introduction of perturbations to a cell, e.g. environmental or genetic, can effect cell 
metabolism (Cloutier & Wang, 2011). This is encouraged by the fact that cellular 
pathways are complex and highly interconnected while modulation of metabolic fluxes 
due to local genetic perturbation should not be studied separately, i.e. increased flux 
through the overexpression of the corresponding enzyme, but as a network (Morandini, 
2009). This lack of systematic analysis is mostly well-known in the field of metabolic 
engineering. In many studies the overexpression of an enzyme, i.g.  phosphofructokinase 
in glycolysis failed to increase flux rates in glycolysis pathway (Thomas et al., 1997). 
Therefore, there is a need for a dynamic mathematical framework that can reproduce 
some of these important observations. Such dynamic model should grasp cellular 
dynamics and the regulatory mechanisms involved in different conditions and operational 
systems (Bonarius, Schmid, & Tramper, 1997). MBA and MFBA methods bring valuable 
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insights into metabolic flux distribution at steady state, however, they lack information on 
the dynamics of the process.  
1.3.1 Modeling cell behaviour: a long term objective of the research group 
In 2007, Professor Mario Jolicoeur’s research group, at the Ecole Polytechnique de 
Montréal, developed a kinetic-metabolic model framework adapted to plant cells 
(Cloutier, Perrier, & Jolicoeur, 2007). It was demonstrated that the model can 
successfully describe the dynamics of plant cells metabolism. It was also applied to the 
control of intracellular concentration such as of the cytoplasmic inorganic phosphate at a 
defined set-point (Cloutier et al., 2009). It was even used as an in silico tool to design a 
culture management strategy to maximize secondary metabolites production in a 
bioreactor culture (Cloutier et al., 2009).  Therefore, we have explored this kinetic-
modelling approach for its use on mammalian cells. 
1.4 Project objectives and methodology 
This work aims to develop a mathematical model capable to describe CHO cell transient 
behavior in culture. Paying a particular attention to keeping a biologically relevant 
description of the CHO cell central metabolism, including cell growth and production in a 
recombinant product such as a protein and a monoclonal antibody (mAb), we have 
challenged our modelling approach with different CHO cell lines. A first series of data 
was limited to basic culture datasets (including cell growth, production, respiration, 
glucose, glutamine, lactate, and ammonia and intracellular concentrations of energetic 
nucleotides and cell energetics with time) for a cell line producing a recombinant t-PA 
(transplaminogen activator). This was used to develop the model structure and for the 
calibration of its parameters. Although mainly extracellular data were used (except for 
cell energetic), the model was assessed for its capacity to simulate intracellular events 
such as metabolic fluxes and metabolites concentrations. Then, we tested the adaptability 
of the model structure by challenging it with another cell line containing an inducible 
cumate gene switch enabling the production of a monoclonal antibody. We had access to 
the parental cell line as well as low- and high-producer cell lines. Finally, we assessed for 
the model predictive capacity while it was challenged to describe an in silico perturbation 
experiment, using a hypoxic stress as a case study. 
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1.5 Organization of the thesis 
The thesis contains nine chapters. Chapter one presents a brief introduction describing the 
thesis context and objectives. The current status of knowledge on the mammalian cell 
platform and the challenges at improving bioprocess reproducibility and productivity are 
discussed. Mathematical modelling of cell behaviour, as a method to study mammalian 
cell metabolism, is finally introduced. In chapter two we elaborate on the most important 
characteristics of CHO cells while developing a kinetic metabolic model, putting a 
particular attention at cell metabolismand regulatory interactions involved in metabolic 
hemostasis. In the third chapter, the general methodology used in this work is presented, 
and the general algorithm followed to develop the kinetic metabolic model is shown. In 
chapter four, a metabolic model is developed on the basis of biochemical information 
available for CHO cells metabolic network, and assumptions on unknown information are 
discussed. The model is first calibrated on previously published experimental data 
obtained in our research group (McMurray-Beaulieu et al., 2009).In chapter five, the 
capacity of the model to be adapted to another recombinant CHO cell line is presented. 
Extensive measurements of extra- and intra-cellular metabolites concentrations were 
obtained for another CHO cell line; a parental and its high- and low-producer derived 
clones producing a recombinant monoclonal antibody under the induction of a cumate 
gene switch. 
In chapter six, the model is implemented with regulation mechanisms of glycolysis 
pathway and assessed to study the dynamics of metabolic network in response to a 
hypoxic stress.  
In chapter seven, we present the general discussion, in chapter eight, the main 
conclusions and in chapter nine proposed future works are summarized. 
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CHAPTER 2 LITERATURE REVIEW 
 
2.1 CHO cells for the production of mAbs 
The domestic Chinese hamster originates from Beijing (Peking), and the first report on 
the use of this animal for the treatment of Pneumococcal infection goes back to 1919 by 
Hsiehin China (Hsieh, 1919). Much later, subsequent research on Chinese hamster ovary 
in the mid-20th century suggested that the low chromosome number of this animal made 
it a good candidate for research. It was at that time that Dr. Theodore T. Puck, a pioneer 
in mammalian cell culture, established the first Chinese hamster ovary cells (CHO) in 
plate (Tjio & Puck, 1958).It soon became clear that these cells were readily good 
candidate in in vitro culture. Up to now, CHO cells showed a high adaptive ability and 
ease of maintenance which make them good candidates for fundamental research in 
biomedical, pharmacology and cell signaling (Figler et al., 2003; Schulte & Fredholm, 
2003). This cell, which naturally grows as adherent cells, can also be adapted to 
suspension culture showing adequate resistance to shear stress when cultured in 
bioreactors (Jayapal et al., 2007). Nowadays, over 70% of all recombinant proteins are 
produced by CHO cell derived platforms (Jayapal et al., 2007). In addition of being 
predisposed to genetic modification and in vitro culture, CHO cells are also being used 
from the mass effect created after the homologation of various recombinant therapeutics 
using these cells; i.e. it facilitates homologation of a new product since the cell platform 
is now well known by the regulatory agencies (Meyer et al., 2008). Among all 
recombinant proteins, monoclonal antibodies have received special attention during the 
past decades. Antibodies are large proteins with a Y-shape which are produced by B-cells 
in response to foreign object and used by the immune system to identify and neutralize it 
(Riechmann et al., 1988). When antibodies are produced from a population of B cells 
which is derived from a single parental cell they are homogeneous and named 
monoclonal antibodies.Monoclonal antibodies have received most of the industrial 
attention because of the important market share with almost 376 preclinical to market 
products (Pavlou & Belsey, 2005). For example Vectibix (Anti-EGFR mAb), Avastin 
(Anti-VEGF mAb), and Herceptin (Anti-HER2 mAb) have been commercialized as 
therapeutic agents regarding colorectal, lung, and breast cancer respectively. Xolair 
(Anti-IgE mAb), Raptiva (Anti-CD11a mAb), Campath (Anti-CD52 mAb), and Rituxan 
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(Anti-CD20 mAb) are also some examples of mAbs commercialized to treat asthma, 
psoriasis, and lymphoma respectively (Jayapal et al., 2007). From an industrial point of 
view, CHO cells are highly efficient for the production of antibodies for a couple of 
reasons. First, they exhibit a stable growth, in terms of cell counts and prolonged cell 
viability, due to their robust nature (Chu & Robinson, 2001). Second, they can be easily 
adopted to grow in suspension culture which is favorable for large scale industrial 
production (Boeger et al., 2005). Third, glycoproteins that are expressed in CHO cells 
have a glycosylation profile that is more human-like comparing to other cell 
lines(Ghaderi et al., 2012). Fourth, there is a good record of several genetic amplification 
systems (e.g. chaperones such as Hsp70 and Hsp27) in CHO cells (Lee et al., 2009). 
Fifth, host-cell related contaminating impurities are well understood in CHO cells 
resulting in more efficient downstream processes comparing to other mammalian cell 
lines (Wurm, 2005). All these factors ultimately results in higher titers of recombinant 
proteinreaching  up to 5 g/L (Kim, Kim, & Lee, 2012) in fedbatch cultures. CHO cells 
viability has been improved through genetic modifications such as, complementing the 
cell machinery with growth factor endogenous proteins (e.g. insulin like growth factors) 
(Galbraith et al., 2006; Sunstrom et al., 2000; Zanghi et al., 2000) or optimizing cell-
cycle control genes (e.g. cyclin-dependent kinases) (Fussenegger et al., 1998), or through 
the enhancement of cellular metabolism (Irani et al., 1996; Wlaschin & Hu, 2006). 
Various strategies also showed to be successful in enhancing CHO cells productivity at 
the genomic level, i.g. the use of cytomegalovirus (CMV) and  beta-actin and EF-1α as 
strong promoters, and the insertion of dihydrofolate reductase (DHFR) as an 
amplification marker (Cacciatore, Chasin, & Leonard, 2010), just to name a few. Above 
all these, the complete sequencing of CHO Genome has recently been accomplished and 
can support future breakthroughs in CHO-cell production platform (Xun et al., 2011). 
However, there is still a risk in terms of performance variability during scaling-up and 
manufacturing (Li et al., 2010).  
2.2 Physiology andmetabolism ofmammalian cells 
Thissection presents themain metabolic pathwayspresentin CHO cells, as well as their 
common behaviour. Mammalian cellsare eukaryoticcells that have a phospholipid 
membrane composed of proteins and lipids that surround the cytoplasm of the cell 
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(Figure 2.1). The cytoplasm is filled with dispersed particles and compartments such 
asnucleus,ribosome, Golgi apparatus, and mitochondria. Thesecompartmentshaveunique 
properties. The nucleus containsmostof the genetic material. Ribosome is involved in 
protein synthesis. Golgi apparatus modifies the proteins, specially those for excretion. In 
mammaliancells, thepower generation mostly takes place inthe mitochondria. 
Mitochondria, which is the location where theKrebs cycleandoxidative 
phosphorylationprovidesmost ofthe energy of acellunder aerobic conditions.  
 
 
 
Figure  2.1Schematic diagram ofmammalian cells 
(Boumphrey, 2009) 
 
 
 
2.2.1 Nutrition management 
Mammalian cellsneed various classes ofnutrients: the macronutrients, presents in mM in 
the culture medium, carbohydrates, amino acids, vitamins, and micronutriments, present 
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in M, inorganic ions, each bringingthe cell elementary content in atomssuch ascarbon 
(C), oxygen (O), hydrogen(H), phosphorus (Pi), sodium, potassium, calcium, magnesium, 
and nitrogen (N). There are other trace elements (<M) such as zinc, selenium, copper, 
manganese oriron (Fe) (to name a few)alsorequired by thecellsbut inmuch smaller 
amounts plus defined growth factors. Ithas been demonstrated that the nutritional statusof 
mammalian cellsstronglyinfluencetheir ability for growth and production.In other words, 
medium composition is known to affect the productivity ofmammalian cells in vitro 
(Grosvenor, 2008). Furthermore, fed-batch culture protocols are now widely used since 
these allow for maintaining and controlgrowth condition and is now seen essentialto 
extend culture durationfor improving final product titers (up to 5 g/L) (Yang & Xiong, 
2012). Fed-batch processes are currently highly favorable for industrial scale production 
because they are reproducible, easy to operate and scale up to as high as 20,000-liter 
volumes (Whitford, 2006). In order to develop a fed-batch protocol, parameters as 
optimal feed profile and time should be identified which requires an efficient process 
monitoring system. Although on-line measurements techniques have been developed 
during past years, an available tool allowing prediction of cell behaviour in response to 
culture conditions is still desirable. In that context, kinetic models can be useful as a tool 
for a priori determination of cells requirements for further implementation of control 
(Pörtner, Schwabe, & Frahm, 2004). Nutrients are then feeding the entry points of the cell 
metabolism. 
2.2.2 Cellular metabolism - The way from genotype to phenotype 
Cell functions and operations are accomplished through a series of biochemical reactions 
usually occurring inside a cell. biochemical reactions involve in the processes of taking 
up complex molecules (sources of carbon, nitrogen), and further breaking down to 
produce energy and other intermediate molecules (Alberts et al., 2002). Intermediate 
molecules finally build up new macromolecules and cellular components (Barnes et al., 
2000). Enzymes are protein catalysts that control biochemical reactions and a protein 
itself consists of a string of amino acids, each one of which is coded by the string of DNA 
constituting a gene. Recalling that biochemical reactions involve in the conversion of 
substrates into products, often by transporting chemical groups, giving the function to the 
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compound, to or from the substrates.Thereare sixmajor classes ofbiochemical reactions 
involved in cellular metabolism (Berg, Tymoczko, & Stryer, 2002)(Table 2.1). 
 
Table  2.1    Types of reactions involved in metabolism 
 
Classes of reaction Mechanism  Nomenclature 
Enzyme Commission 
Oxidation - Reduction Electron Transfer EC 1 : Oxydoreductases 
Transfer of a group Transfer of a functional group from one to another 
EC 2 : Transferases 
 
Hydrolysis Hydrolysis of a biochemical bond EC 3 : Hydrolases  
Addition / Subtractionof 
functional groups 
Additionof a functional groupsto 
a double bondorsubtractionforma 
double bond 
EC 4 : Lyases 
 
Isomeration Rearrangementof atoms EC 5 : Isomerases  
“ Ligation “ involving ATP 
lysis Formation of covalent bonds 
EC 6 : Ligases 
 
  
 
Biochemical reactions are thus managed through enzyme-powered pathways in cells. 
These series of biochemical reactions are collectively known as cellular metabolism. Cell 
metabolism thus leads to the passage of information between genotype (information held 
in genome) and phenotype (growth and cell metabolism) (Lewontin, 2011). 
2.2.2.1  Catabolism and anabolism – Inputs and outputs of cellular primary metabolism 
The cell metabolism consists of two major interdependent parts, with the catabolism and 
the anabolism (Figure 2.2). Catabolism is responsible for the breakdown of complex 
organic compounds, nutrients, and macromolecules, while providing positive energy 
(ATP) and redox potential (NADH, and NADPH) and feeding the rest of the metabolism 
in precursor molecules. The other part, the anabolism, is responsible for the synthesis of 
metabolites and macromolecules, from precursors, which are required for cell functions, 
growth and viability. Anabolism is known to be highly demanding in energy and redox 
potential (Steuer et al., 2006). Under aerobic condition, oxidative phosphorylation is 
responsible for massive energy production in support of anabolism (Lunt & Vander 
Heiden, 2011).  
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The main metabolic pathwayspresent inCHO cells and integrated in this work, i.e. 
glycolysis,pentosephosphatepathway, the Krebs cycle, oxidation phosphorylationas well 
as aminoacids catabolism are described in the following. 
 
 
Figure  2.2    The overview of cellular metabolism 
 
Glycolysis 
The glycolysis is a fundamental catabolic pathway that is present in almost all living 
cells, and which role is to provide an entry point for organic carbon source such as 
glucose and fructose. It also provides metabolic intermediates feeding interrelated 
pathways such as pentose phosphate pathway and tricarboxylic acid (Kreb's) Cycle 
(TCA). It is the pathway through which glucose (C6H12O6) as a carbon source, is first 
phosphorylated (feeding PPP and other anabolic pathways), then split (or lysed) into two 
3 carbon molecules, glyceraldehyde-3-phosphate, which are then partially oxidized to 
form two molecules of pyruvate (CH3COCO2-) (Figure 2.3). The whole pathway has two 
main functions: it allows the oxidation of glucose with the release of energy in the form 
of two ATP and two NADH, and the synthesis of pyruvate, which feeds the Krebs cycle 
(Figure 2.4). 
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The overall balanceof glycolysisis: 
Glucose + 2 NAD+ + 2 Pi + 2 ADP → 2 pyruvate + 2 NADH + 2 ATP + 2 H+ + 2 H2O 
 
 
 
 
Figure  2.3    An overview of glycolysis 
(Solomon, Berg, & Martin, 2005) 
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Figure  2.4Summary of glucose utilization through glycolysis 
(Solomon et al., 2005) 
 
Tricarboxylic Acid (Kreb's) Cycle (TCA) 
The Krebs cycle or tricarboxilic acid cycle (TCA), which occurs in the mitochondria, is 
another essential pillar of the global cell metabolism. It has a dual role: on the one hand, 
it is associated with the oxidation of carbon molecules providing reducing power for the 
oxidative phosphorylation pathway (see next section), and it is also involved in the 
anabolism providing many precursors of amino acids synthesis, including glutamate 
(Mackenzie & McIntosh, 1991). There are multiple entry points from glycolysis. 
Pyruvate (PYR), a 3-carbon molecule, wills subsequently to be decarboxylated (passage 
2 carbons) to react with coenzyme A and gives acetyl-coenzyme A, which feeds the 
Krebs cycle (Figure 2.5).  
 
Reaction summary: 
2 pyruvate + 2 NAD + 2 CoA → 2 Acetyl CoA + 2 NADH + 2 CO2 
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Figure  2.5The formation of acetyl CoA from pyruvate 
(Solomon et al., 2005) 
 
 
As in glycolysis, C-C bonds are cleaved and carbon is oxidized in TCA cycle (Figure 
2.6).  
 
Reaction summary: 
 2 Acetyl CoA + 6 NAD+ + 2 FAD + 2 ADP + 2 Pi + 2 H2O → 4 CO2 + 6 NADH + 2 
FADH2 + 2 ATP + 2 CoA 
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Figure  2.6Overview of the citric acid cycle 
(Solomon et al., 2005) 
 
Pentose phosphate pathway  
The pentose phosphate pathway (Figure 2.7) can be either feed from Glucose-6-
phosphate (G6P) and from Fructose-6-phosphate, all branch points of glycolysis. It aims 
principally to form a main precursor, ribose-5-phosphate (R5P), used for the biosynthesis 
of ribose, precursor of cell building blocks. It also allows the production of reducing 
power in the form of NADPH, which is needed for the synthesis of fatty acids and for the 
assimilation of inorganic nitrogen (Kruger & von Schaewen, 2003). Pentose phosphate 
pathway is partly controlled by the concentrations of NADP+-to-NADPH ratio, both 
redox shuttles assisting various intracellular reactions (Kather, Rivera, & Brand, 1972). 
In particular, the first reaction catalyzed by glucose-6-phosphate dehydrogenase 
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(G6PDH) is known as the limiting step of the pentose phosphate pathway, where it 
controls the flow (Hames & Hooper, 2005; Kruger & von Schaewen, 2003). 
 
G6P + 2NADP+ + H2O → R5P + 2NADPH + 2H+ + CO2 
 
 
 
Figure  2.7An overview of pentose phosphate pathway and the formation of five-carbon 
sugars (Boeger et al., 2005) 
 
Amino acid metabolism 
Amino acids contain both an amino (-NH2) and carboxylic acid (-COOH) functional 
groups, along with a side-chain specific to each amino acid. They are considered as the 
building blocks for the cell to synthesize proteins. Among eighteen amino acids, some are 
known as essentials, the ones which cannot be synthesized by the cell, and must be 
therefore provided in cell culture medium.Another group of amino acids refers to 
nonessentials that are synthesized by a cell metabolism from metabolic intermediates 
(Table 2.2). In addition of being used to build proteins, amino acids are involved in the 
synthesis of other kinds of small molecules with important biological roles such as 
purines and pyrimidines, which are precursors of DNA and RNA synthesis (Berg et al., 
2002). 
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Table  2.2    Essential and nonessential amino acids for mammalian cells 
 
Essential aminoacids Nonessential aminoacids 
arginine alanine 
isoleucine aspartate 
leucine cysteine 
lysine glutamate 
methionine glutamine 
phenylalanine glycine 
threonine proline 
tryphtophan serine 
valine tyrosin 
 
 
Besides their biosynthetic role, individual amino acids can also be catabolized, in a 
recycling manner, to bring back with nitrogen sources such as NH4+, a precursor to amino 
acid synthesis. In the general overview, the α-amino group is removed and mostly 
transferred to α-ketoglutarate to form glutamate, and the remaining carbon skeletons are 
transformed to acetyl CoA, and pyruvate or oxidized by the citric acid cycle and 
transferred into one of the intermediates of the citric acid cycle such as oxaloacetate, 
fumarate and succinate.  Some amino acids like alanine and aspartate are processed in the 
citric acid cycle through a transamination reaction, catalyzed by transaminases, with the 
transfer of an α-amino group from an amino acid to α-ketoglutarate. The amination of α-
Ketoglutarate then produces glutamate and other TCA cycle intermediates, i.e. 
oxaloacetate and pyruvate (Figures 2.8, 2.9).  
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Figure  2.8Aspartate transaminase reaction 
 
 
 
 
 
Figure  2.9Alanine transaminase reaction 
 
 
Produced glutamate can further be de-aminated mostly through the glutamate 
dehydrogenase reaction (Figure 2.10). 
 
 
 
Figure  2.10  Glutamate dehydrogenase reaction 
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Glutamine metabolism as part of amino acid metabolism 
Glutamine, C5H10N2O3, is classified as the most important non-essential amino acids. It 
contains one atom of nitrogen as an amide, which is used in the synthesis of precursor 
molecules of nucleotides. Glutamine is taken up by cells feeding the glutaminolysis 
pathway, resulting in glutamate and ammonia. Glutamate is then catabolyzed in the TCA 
cycle through the processes of transamination or oxidative deamination, as explained in 
the previous section. These catabolic pathways are reversible and thus contribute, in part, 
to homeostasis of nitrogenous substrates (Meng et al., 2010).The key steps of glutamine 
and glutamate metabolism are: (1) Glutamine synthetase (GS), (2) Phosphate-activated 
glutaminase (PAG), (3) Glutamate dehydrogenase (GDH), (4) Aspartate transaminase, 
and (5) Alanine transaminase (Figure 2.11). 
 
 
 
Figure  2.11The key steps of glutamine and glutamate metabolism. 
(1) Glutamine synthetase (GS), (2) Phosphate-activated glutaminase (PAG), (3) 
Glutamate dehydrogenase (GDH), (4) Aspartate transaminase, and (5) Alanine 
transaminase. 
Adopted from McDermott & Butler (1993) (McDermott & Butler, 1993) 
 
Cellular bioenergetics system 
The cell bioenergetic system is based on molecular shuttles that are continuously 
recycled, being coupled to energy demanding and producing biochemical reactions, as 
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previously discussed. These shuttles are mostly made of nucleotides. Nucleotides, 
composed of a nucleo-base (nitrogenous base), a five-carbon sugar (either ribose or 2-
deoxyribose), coupled to one or more phosphate groups, and di-nucleotides, composed 
from the assemblage of two nucleotidesjoined through their phosphate groups, are 
involved in many cellular reactions (Coghill, 2006) (Table 2.3). 
 
Table  2.3Functional and regulatory roles of nucleotides 
 
Nucleotides (ratio) Function 
ATP, ADP, and AMP ATP as an energy source for metabolic processes 
convertible to AD(M)P (Knowles, 1980) , ATP and 
ADP are involved in the kinetic regulation of 
enzymatic reactions catalysed by either ATP or 
ADP. AMP is also involved in regulation of 
glycolytic reaction. 
GTP Essential for many metabolic reactions specially 
protein synthesis and some polysaccharides of 
cellular membrane (Berg et al., 2002). 
UTP,UDP and UDP Involved in different anabolic reactions that are 
mostly growth-related (membrane lipids synthesis, 
strand break repair and protein glycosylation 
processes) (Berg et al., 2002). 
CTP Involved in phospholipid synthesis (Berg et al., 
2002). 
NAD(P) NAD: the oxidized NAD participates in redox 
reactions,ߚ-oxidation andkinetic regulation of TCA 
cycle reactions (Reich & Sel'Kov, 1981).  
NADP: participates in biosynthetic reactions as 
reduced form (NADPH). 
NADP(H): is involved in the regulation of the 
penthose phosphate pathway  (Atkinson, 1977) 
 
Adenylate nucleotides (ATP, ADP, and AMP) act as energy carriers. A healthy cell 
usually maintains ATP-to-ADP high in the order of 1:10 while keeping the ratio of AMP-
to-ATP very low in the order of 1:100 (Hardie & Hawley, 2001). So the ratios of 
adenylate nucleotides even play more important role in the regulation of cellular 
processes and pathways (Atkinson, 1968).Given the importance for the cell to maintain 
appropriate values of ATP-to-ADP and ATP-to-AMP ratios, different stages of cellular 
bioenergetics system are involved to keep these ratios close to their optimal values 
(Hardie & Hawley, 2001).  
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Oxidative phosphorylation 
The main site of the bioenergetics system for the cell capacity to generate energy in an 
aerobic mode is in the oxidative phosphorylation pathway, also called the respiratory 
chain or cell respiration. Thanks to oxygen, which acts as an electron acceptor, this is 
where most of cell energy is continuouslyrecycledin cellATPfromADP.Itis therefore 
necessary togeneratethe energy neededforthe oppositereaction.Reducingintermediaries 
(electron donor) inthe form ofNADH orFADH2formed viaglycolysis, and the Krebs 
cyclewill enter the mitochondria and then be used (Figure 2.12). These electronsare 
transferredthroughseveral stageson aconveyor line(calledrespiratory chain) to finally 
reachoxygen, the final electron acceptor. Thesereactionsleadtoa strongoxido-
reductionelectrochemicalgradientΔΨon eitherside of themitochondrialmembrane.It isthis 
gradientwhich providesenergy forthe enzymeATPsynthaseto reformATPfromADPandPi, 
reaction calledoxidative phosphorylation(Siedow & Umbach, 1995). 
 
Figure  2.12  Schematic view of the mechanism of oxidative phosphorylation 
(Solomon et al., 2005) 
Reactions summary in the electron transport chain: 
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NADH+3ADP+3Pi+1/2O2→NAD++3ATP+H2O 
FADH2+2ADP+2Pi+1/2O2→FAD++2ATP+H2O 
So, ATP can be directly produced from substrate level phosphorylation or indirectly in 
the oxidative phosphorylation process. In substrate level production a phosphate group is 
transferred from a molecule to ATP in an enzymatic reaction.The net ATP production 
from glycolysis is two ATP's and the total number of ATP molecules generated from the 
oxidation of pyruvate and the Krebs cycle accounts for two other ATP molecules (Figure 
2.13). Glycolysis and TCA cycle produce other shuttles compounds besides ATP and 
GTP (which potentially can be considered as ATP), namely NADH and FADH2. These 
redox shuttles are molecules that are oxidized (i.e., give up electrons) spontaneously in 
the oxidative phosphorylation reaction. Although there is a theoretical yield of 36-38 
ATP molecules per glucose, such conditions are not generally achieved in cells and the 
efficiency is lower because pyruvate is not fully metabolized to TCA cycle but is reduced 
to lactate. In case of oxygen limitation down to levels as low as ~ 20 µM (~10 % air 
saturation) as reported for CHO cells, (Froncisz, Lai, & Hyde, 1985; Lai et al., 1982) 
more glucose is consumed by cells an even more pyruvate is converted to lactate. By 
increasing glycolytic rate, with only 2 ATP molecule produced per molecule of glucose 
catabolized, compared to 38 ATP produced (maximum) when including the oxidative 
phosphorylation, a cell tends to maximize the energy production per each molecule of 
glucose consumed via anaerobic glycolysis (Harper et al., 2002). 
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Figure  2.13Summary of ATP generation from one glucose molecule in glycolysis and 
oxidative phosphorylation 
(Solomon et al., 2005) 
Energy buffer reactions 
Energy buffer reactions are present in mammalian cells mostly for the homeostasis of the 
ATP-to-ADP ratio. The role of these reactions is thus to adapt the cell energetic state 
under changing external conditions (Harper et al., 2002). There are many systems and we 
will cover the most important ones here. Creatine kinase is involved in one of the 
buffering reactions, as it favors the breakdown of one molecule of PCr (phosphocreatine) 
to Cr (creatine) coupled to the generation of one molecule of ATP from ADP, without 
any contribution from other cellular subsystems (see Figure 2.14). Adenylate kinase, a 
second buffer system, interconverts ATP, ADP and AMP, tending to act in a reciprocal 
direction. Under ideal conditions, when the rate of ATP consumption matches its 
generation, adenylate kinase operate from left to right (see Figure 2.15), keeping AMP 
concentration very low (AMP-to-ATP 1:100). 
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Figure  2.14  Creatine kinase reaction as an energy buffering reaction 
 
 
Figure  2.15  Adenylate kinase reaction as an energy buffering reaction 
 
 
The mass balance on ATP thus includes its production from glycolysis and oxidative 
phosphorylation, buffering reactions as well as its consumption for biomass synthesis, 
antibody production, maintenance-related processes, transmembrane transport, and other 
ATPases-related reactions. There are also reactions that produce intermediate metabolites 
for pathways, pyruvate to oxaloacetate, known as anaplerotic reactions consuming ATP 
as well which should be included in its balance.  
2.2.3 Mechanisms of metabolic regulation 
Homeostasis, originated from two greek words homo (same, like) and stasis (to stand, 
posture) which means to remain the same, is the property of cells to regulate its internal 
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environment to keep that in a stable condition. As such, the phenotypic characteristics of 
mammalian cells are an output of regulatory processes at different functional layers 
including cellular metabolic system (Cascante et al., 2002). As previously mentioned, a 
high level of interconnected regulation mechanisms enable cells to grow and stay viable 
while facing a dynamic environment (Riehl & Segrè, 2008). We thus cover in the 
following the multiple layers involved in the regulation of a cell metabolism. 
2.2.3.1 Enzymatic regulation: The basis of metabolic hemostasis  
Enzymes have an intrinsic role on the metabolic homeostasis phenomenon (Koshland, 
1968) originating at the genomic level, changes in the induction of a specific gene 
enables the control of quantitative signals (mRNA) managing a protein expression level 
(i.e. protein concentration), for finally, but rapidly, modifying the rate of a reaction flux. 
Then,concentrations in substrate(s), product(s), and enzyme’s effector(s) (either activator 
or inhibitor), in addition to environmental factors such as temperature, also affect an 
enzyme’s activity level. This has been widely studied since early works of Michaelis and 
Menten in 1913 (Michaelis et al., 2011). Therefore, at any given time (i.e. culture 
conditions), the flux rate of each enzymatic reaction is controlled by an ensemble of 
parameters, and as being highly interconnected, the network of biochemical reactions will 
exhibit a high regulation state at metabolic level.  
 
Regulation of enzymes’ activity 
 
Substrate availability  
The rate of an enzymatic reaction is primarily affected by its substrate concentration. 
Mostly, the rate of an enzymatic reaction increases as substrate concentration increases 
and finally reaches a plateau and does not increase any further at high substrate 
concentration 
 (Figure 2.16). 
Product inhibition 
The rate of an enzymatic reaction can also be responsive to its product concentration. 
Accumulation of the product can inhibit the activity of some enzymatic reactions. This 
form of regulation can limit the formation of product when it is produced beyond the use 
of cells (Figure 2.16). 
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Allosteric regulation 
Allosteric enzymes have a major role in the regulation of cell metabolism. These 
enzymes have basically two or more binding sites. One active site that recognizes the 
substrate for processing the biochemical reaction, and a regulatory site that recognizes a 
regulatory molecule (inhibitor or activator), which can also be the substrate. The activity 
of the enzyme can be modulated by the binding of the regulatory molecule, causing 
specific conformational changes that either activate or inhibit enzyme's activity (Figure 
2.16). 
Covalent modification 
Enzyme 3-D conformation, and thus its binding site receptivity, can be modified after 
covalent type reactions such as phosphorylation, acetylation, methylation, sulfation, 
glycosylation, amidation and hydroxylation. Among all these, regulation by 
phosphorylation is the most common. This type of regulation is taking place at the 
genomic, proteomic and at the enzyme level and kinases and phosphatases are involved 
in the process (Figure 2.16).  
 
Figure  2.16Regulation of the activity of existing Enzymes 
(Jakubowski, 2008) 
 
Types of enzymatic inhibition  
Competitive Inhibition 
In this case, there is one active site on the enzyme and the inhibitor binds to that and 
prevents binding of the substrate.  In case of competitive inhibition as the concentration 
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of the inhibitor increases, similar changes in substrate concentration can compensate or 
even predominate the inhibitory effect. Competitive inhibitors may thus be effective on 
isolated enzymes but much less effective within a pathway (Sauro, 2011). 
Uncompetitive inhibition 
In this case, the inhibitor binds to both the enzyme and substrate together so that the 
product cannot be formed, thus, inhibiting the formation of product. 
Noncompetitive Inhibition  
In this case the non-competitive inhibitor binds to the enzyme, however, does not 
compete with the substrate to reach the active site. Therefore, the substrate can also bind 
to free enzyme or even the enzyme and inhibitor together. However, the enzyme-
substrate inhibitor complex cannot form the product. 
 
Types of enzymatic activation  
 
Essential activation 
In this case, the reaction does not take place when there is no activator bound to that. 
Therefore, the enzyme should be activated to be able to bind to substrate to form the 
product. 
Non-essential activation 
It this case the activator is not essential: reaction occurs even in absence of the activator, 
but at a lower speed.  
2.2.3.2 Kinetic description of enzyme-catalyzed biochemical reactions 
Although biochemical reactions are mostly described in literature with the reaction 
mechanism, the affinity (Km) and maximum rate (Vmax) constants (Sauro, 2011), little to 
no a priori knowledge is available on the kinetics of the reactions as well as regulation 
interactions. One is often content to write the kinetic expression as the product of 
individual phenomena such as limitation, activation and inhibition: 
 
ݍ(ݏ) = ݍ௠௔௫∏ࢻ࢏(ࢉ࢏)(1) 
 
Where ݍ(ݏ) is the actual reaction rate and ݍ௠௔௫is the maximum reaction rate with  0	 ≤ ߙ௜ ≤ 1	,∀	݅. The simplest way to describe an enzyme-catalyzed reaction and also its 
regulation is referred to Michaelis-Menten kinetics or saturation kinetics. Monod’s model 
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is the most widely used kinetic expression for population behaviour due to its simplicity 
and its physical and phenomenological reliability (Table 2.4). Other kinetic models have 
also been developed within specific experimental range or specific description (Heinrich 
& Papoport, 1977). 
 
Table  2.4General expressions for kinetic description of enzymatic reactions 
Rate function Name of equation 
࢜ = ࢜࢓ࢇ࢞∗	 ࡿࡷ࢓
૚+ ࡿ
ࡷ࢓
 Michaelis-Menten equation 
࢜ = ࢜࢓ࢇ࢞ ∗ (૚ − ࢋషࡿࡷ࢓) Tessier equation 
࢜ = ࢜࢓ࢇ࢞ ∗ (૚ + ࡷ࢓ ∗ ࡿିࢽ)ି૚ Moser equation 
 
Due to the popularity of the Michaelis-Menten equation, various types of regulation, i.e. 
inhibition and activation, kinetics have also been reported based to which this equation is 
modified to also include the effect of an inhibitor/activator (Table 2.5). 
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Table  2.5Kinetic expressions for most common types of enzymatic regulations 
 
Type of action 
Modified  Michaelis-Menten rate 
law for the regulatory enzyme 
Inhibition 
Competitive 
ݒ = ݒ௠௔௫ ∗ ௌ௄೘1 + ௌ
௄೘
+ ூ
௄೔
 
Inhibition- 
Un-competitive ݒ = ݒ௠௔௫ ∗
ೄ
಼೘(ଵା ಺
಼೔
)
ଵ(ଵା ಺
಼೔
) + ௌ௄೘  
Inhibition- 
Non-competitive 
ݒ = ݒ௠௔௫ ∗ ௌ௄೘(1 + ௌ
௄೘
)(1 + ூ
௄೔
)  
Inhibition- 
Allosteric 
ݒ = ݒ௠௔௫ ∗ ௌ௄೘(1 + ௌ
௄೘
)(1 + ௅(ଵା ಺಼೔)೙(ଵା ೄ
಼೘
)೙) 
Activation 
Non-essential 
ݒ = ݒ௠௔௫ ∗ ௌ௄೘1 + ௄ೌ
஺
+ ௌ
௄೘
 
2.2.3.3 Mechanisms of metabolic flux regulation 
In addition to regulation within intrinsic enzyme properties, there are regulation mechanisms 
of enzyme activity that are driven directly from metabolites and other compounds (nutrients, 
signalling molecules, hormones, peptides, proteins, etc.) concentrations. Mathematical 
representations of the regulatory mechanisms on the regulated enzymes  have been explained 
in the previous section. 
Feedback regulation 
There is feedback regulation of a biochemical reaction when its enzyme activity is 
affected from the concentration of a metabolite (the effector) that is synthetized 
chronologically after the reaction (Figure 2.17). In that case, the accumulation state of an 
end product controls the reaction rate of a reaction leading to its production. Feedback 
regulation is the major regulatory mechanism when rate-controlling enzymes are within 
the early steps in a pathway. Regulation can either be negative, causing inhibition of a 
reaction, or positive, with the activation of a reaction. These inhibitory and activation 
effects obey specific interaction laws that are rarely alike on/off switches, but rather 
modulated from the effector concentration (Table 2.5).  
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Feedforward regulation 
In feedforward regulation of a biochemical reaction, its enzyme activity is affected from 
the concentration of a metabolite (the effector) that is synthesized before the reaction. 
Like the feedback mechanism, feedforword can either positively or negatively regulate 
the related enzyme from the effector concentration (Figure 2.17). 
 
 
 
 
Figure  2.17Feed-forward and feedback configurations.Adopted from Johnson el al. 
(1998) (Johnson & Prentice-Hall, 1998) 
 
2.2.3.4 Central carbon metabolism: regulation nodes  
As previously shown, regulation of enzymes in a cell central metabolism (i.e. glycolysis, 
TCA, etc.) occurs through both feedback and feedforward mechanisms, although their 
distribution can differ between cell types. Moreover, a metabolic network circuitry 
reveals another layer of regulation that is driven by reaction competition for metabolic 
intermediates at each branch point interconnecting the different pathways. As an 
example, the major enzymes involved in the regulation of glycolysis as well as the branch 
points connecting glycolysis to the citric acid cycle, together with their mechanism of 
action, are listed in Table 2.6. From all these additive non-linear regulation mechanisms, 
it becomes tedious to study cell behaviour without accounting for their quantitative 
analysis. 
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Table  2.6    List of major enzymes involved in the regulation of metabolic reactions 
 
 Effector of a regulation mechanism  
Enzyme activator inhibitor Reference 
Hexokinase AMP/ATP glucose-6 phosphate 
(Berg et al., 
2002) 
Phosphoglucose isomerase - phosphoenolpyruvate 
(Berg et al., 
2002) 
Phosphofructokinase AMP/ATP                 - 
(Berg et al., 
2002) 
Pyruvte kinase fructose-1,6-bisphosphate                 - 
(Berg et al., 
2002) 
Lactate dehydrogenase AMP/ATP pyruvate 
(Živadinovic & 
Nikcevic, 2010) 
Pyruvate Dehydrogenase AMP/ATP                - 
(Voet & Voet, 
2011) 
Isocitrate dehydrogenase AMP/ATP                - 
(Berg et al., 
2002) 
 
2.3 Characterization of mammalian cells metabolism 
2.3.1 Rationale behind the modelling of a cell metabolic network 
Acquisition of knowledge on cell platform behaviour is crucial for being able to optimize 
its culture and productivity for a product of interest at industrial scale. As previously 
mentioned, our level of knowledge on a biosystem will determine the level of control one 
can develop on this biosystem, and because of the complexity of its highly regulated 
metabolic network, the mammalian cell platform has to be characterized at the metabolic 
level, otherwise one can miss the role of the environment on cell behaviour. Most of the 
improvements on cell productivity have been accomplished from genetic engineering 
works, then enhancing cell metabolic capacity towards the product of interest. This field 
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of research has been called “Metabolic Engineering”. Metabolicengineering, as defined 
by Stephanopoulos et al. (1998)(Stephanopoulos, Aristodou, & Nielsen, 1998), is "the 
direct improvement ofproduction levelsof a molecule ofinterest orcellular 
propertiesthroughthe modification ofspecificbiochemical reactionsor the introduction of 
newreaction(s),usingtherecombinantDNA technology”. Nowadays, it has become 
obvious that genetic engineering strategy can accelerate the development of high-
producer cell lines but once this is done, one’s capacity to adequately manage culture 
composition with culture time may be crucial for reaching the expected productivity level 
of the re-engineered cell line. Therefore, in combination to enhancing cell metabolic 
capacity playing on internal (genes) factors, there is a need of mastering external (culture 
management) factors to reach expected enhanced cell catalytic capacity. 
There are different modeling approaches that have all proposed: models allowing 
metabolic flux analysis (MFA) and requiring a quasi steady-state hypothesis specially for 
CHO cells (Altamirano et al., 2006; Feist & Rosenbloom, 2011; Wilkens et al., 2011; 
Zamorano, Wouwer, & Bastin, 2010), metabolic flux balance analysis (MFBA) (Martínez 
et al., 2013; Savinell & Palsson, 1992), and kinetic models capable to describe transient 
behaviours (i.e. concentrations and metabolic fluxes) based on limiting nutrients of 
medium (Batt & Kompala, 1989; Bree et al., 1988; Cazzador & Mariani, 1993; Dalili & 
Ollis, 1989; Dalili, Sayles, & Ollis, 1990; Frame & Hu, 1991; Portner & Schafer, 1996; 
Provost & Bastin, 2004)and intracellular metabolites (Ghorbaniaghdam, Henry, & 
Jolicoeur, 2012; Nolan & Lee, 2010).  
2.3.1.1 Model structure and segregation 
There are several levels of complexity while describing mathematically cell behaviour 
(Tyson, Chen, & Novak, 2003). One perspective of this categorization is based on how 
the cell population is represented. Non-segregated models consider a homogeneous cell 
population while differences between cells within the population are not considered. In a 
segregated model, however, the cell culture is considered as a heterogeneous population 
where cells are distinguished from each other according to age, mass, or size. Another 
perspective is based on the intracellular structure. In structured models, the intracellular 
state is viewed as a multi-component environment. In unstructured models, however, 
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cells are viewed as black boxes in which substrates are converted to products (Castilho et 
al., 2008)(Figure 2.18). 
 
 
 
 
Figure  2.18Different approaches to the modeling of cell metabolism 
Based on Tsuchiya et al. (1966) (Tsuchiya, Fredrickson, & Aris, 1966); and Bailey and 
Ollis (1986) (Bailey & Ollis, 1986) 
 
2.3.2 Current approaches for structured non-segregated mathematical 
representations of metabolic network 
2.3.2.1 Metabolic control analysis  
Metabolic control analysis (MCA) is an approach at steady-state used to analyze the 
effect of a change in the activity level of an enzyme (i.e. change in flux rate) on the other 
fluxes and intermediate concentrations of a metabolic pathway, after compared to before 
applying a genetic modification. The two main control coefficients (ܥ௩௃,௉)are the flux and 
concentration control coefficients (Fell, 1997). 
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Flux control coefficient is defined by: 
ܥ௩
௃ = (ௗ௃ௗ௣ ೛಻)(ௗ௩
ௗ௣
೛
ೡ
) = ݈݀݊ܬ݈݀݊ݒ																																																																																																							(2) 
And concentration control coefficient is defined by: 
ܥ௩ௌ = (ௗௌௗ௣ ೛ೄ)(ௗ௩
ௗ௣
೛
ೡ
) = ݈݈݀݊ܵ݀݊ݒ																																																																																																							(3) 
Where ܥ௩
௃ and ܥ௩ௌ are flux and substrate control coefficients, respectively. ܬ is pathway 
flux and ܵ is the metabolite concentration in response to a relative change in the activity 
of an enzyme from its initial value at state v. In addition, another property which is 
characterized by MCA is sensitivity coefﬁcient. Sensitivity coefficient ൫ܥ௜
௃൯is used to 
study the effect of a change in substrate concentration or kinetic parameters of a reaction 
on the reaction rate. Sensitivity coefﬁcient can then be determined as: 
ܥ௜
௃ = ݀ܬ
݀݅
																																																																																																																													(4) 
Where ܬ is the pathway flux and ݅ is either the metabolite concentration or kinetic 
parameter. This approach, based on experimental results from genetically engineered 
cells is thus used to characterize the control level of a metabolic network in regards to an 
enzyme (Almaas et al., 2004; Alves & Savageau, 2000; Wang, Birol, & Hatzimanikatis, 
2004). Moreover, this method offers quantitative estimations of the responses of reaction 
rates and metabolite concentrations to the onset of change in the system such as 
enzymatic activities. Although this method attracts lots of attention specially in basic 
biology (Berthiaume et al., 2003; Hatzimanikatis & Bailey, 1997)it has no capacity for 
evaluating flux regulation nor it can predict the adaptive behaviour of cells in response to 
the engineering modifications.  
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2.3.2.2 Metabolic flux analysis  
The metabolic flux analysis (MFA) approach allows to determine flux rate distribution at 
steady-state, using extracellular data set (Henry, Perrier, & Kamen, 2005; Klamt & 
Schuster, 2002; Libourel & Shachar-Hill, 2008; Nadeau et al., 2000; Quek et al., 2010; 
van der Heijden et al., 1994; Xie & Wang, 1996; Xie & Wang, 1996). From known 
metabolic network stoichiometry, linearalgebra manipulation enables to transform 
information of extracellular data set into intracellular flux rate distribution (Steuer & 
Jenker, 2008).  
The first step in MFA is to define metabolic reactions and then mathematically represent 
them. Metabolic reactions are mathematically represented through a stoichiometric 
matrix (S) with m rows and n columns. Each row of the stoichiometric matrix belongs to 
one compound where each column represents a reaction.  The values of each column are 
the stoichiometric coefficients of the corresponding metabolites in a reaction. Negative 
values represent consumption, positive values represent production, and values equal to 
zero demonstrate that the metabolite does not participate in the reaction. There are other 
vectors, v, which represents reaction fluxes and X for metabolites (Figure 2.19 a-c). The 
general equation for mass balances on metabolites can be written as follow: 
 
݀ܺ
݀ݐ
= ܵ. ݒ − ߤ.ܺ																																																																																																																						(5) 
Whereߤis the cell specific growth rate, accounting for intracellular metabolites dilution 
from cell division. The equation that represents steady state is thus given as: 
ܵ.ݒ = 0																																																																																																																																							(6) 
In large-scale metabolic networks, however, there is more than a unique solution to this 
equation. Introduction of theoretical constrains (Bonarius et al., 1996; Bonarius et al., 
2000; Sidorenko et al., 2008; Wahl et al., 2008) or the use of labeling experiments to 
identify some intracellular fluxes (Antoniewicz, 2006; Bonarius et al., 1998; Goudar et 
al., 2010; Metallo, Walther, & Stephanopoulos, 2009; Savinell & Palsson, 1992; 
Sheikholeslami, Jolicoeur, & Henry, 2013; Zupke & Stephanopoulos, 1995) have been 
suggested and successfully used to overcome this problem. Although MFA is still widely 
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used for accurately analyzing metabolic pathways by comparing metabolic fluxes 
intensities, the steady-state hypothesis on metabolite concentrations requires 
experimental conditions that are rarely encountered in industrial processes. Moreover, 
because of the steady-state constraint, there are important limitations of this approach; it 
is highly tedious to study the dynamics ofmetabolism (Rios-Estepa & Lange, 2007). In 
many cases, a steady state observed in terms of the cell specific growth rate does not 
necessarily mean a metabolic or nutritional steady state (Cloutier et al., 2007). To study 
the dynamics of a biosystem metabolism, its regulation and control, transient approaches 
are required. Therefore, metabolic models that include fluxes kinetics and metabolic 
regulation functions may enable to describe transient metabolic behaviours.  
2.3.2.3 Metabolic flux balance analysis 
Similarly to metabolic flux analysis, flux balance analysis (MBFA) is an approach 
leading to the identification of metabolic fluxes in an assumed metabolic network 
bordered with finite constrained space of solutions. In MBFA approach, a metabolic 
network should be developed to identify the stoichiometry coefficient of each metabolite 
in biochemical reactions. This knowledge is then represented mathematically by 
constructing a stoichiometric matrix in which every row belongs to one compound and 
every column represents a reaction. An objective function is then defined to decrease the 
number of unknowns (Figure 2.19 a-d).   
ܼ = ்ܿ ∗ ݒ																																																																																																																																				(7) 
 The vector c is called the weight vector which demonstrates the contribution of each 
reaction to the objective. Normally, there is only one reaction desired to be either 
maximized or minimized. Therefore, the rows of this vector are all zero except for the 
one at the position representing the reaction of interest. Finally, metabolic flux 
distribution is defined using linear programming while the constraints regarded to mass 
balance equations are also taken into account. This method is mostly used to identify the 
maximum and minimum possible fluxes for a particular reaction in order for an objective 
function to be close to or equal to its optimal value (Mahadevan & Schilling, 2003). 
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Figure  2.19Different stages for the formulation of MFA and MFBA problems. 
Adopted fromOrth, Thiele, & Palsson (2010) (Orth, Thiele, & Palsson, 2010)(a) 
construction of a metabolic network (b) formation of a stoichiometric matrix (labeled S) 
(c) identification ofmass balance equations at steady state (S*v = 0) (d) maximization of 
an objective function (Z = cTv). 
 
2.3.2.4 Kinetic modeling of metabolic fluxes 
As explained in MFA method, mass balances on metabolites can be written as follow:  
 
ࢊࢄ
ࢊ࢚
= ࡿ.࢜ − ࣆ.ࢄ																																																																																																																												(ૡ) 
 
While some works have been proposed using MFA analyses by deviding the problem 
into exponential and non-exponential phases to detect important metabolites (Gao et al., 
2007), the use of kinetic models including the description of flux kinetics is gaining in 
interest. Kinetic models cover the dynamic behavior whereas stoichiometric approaches, 
MFA and MFBA, can only capture a static view of metabolic activity but not time course 
evolution of the system. Kinetic models allow simulation of the dynamics of the 
metabolic processes and in case that they also consider regulatory effects, they may have 
the ability to predict cellular response under different conditions. Therefore, kinetic 
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mathematical descriptions of the metabolism seem to have a large advantage compared to 
constraint-based stoichiometric models.Many kinetic formulations have been proposed in 
literature for simple systems, specially single-substrate, single-biomass, and single-
product systems, most of them found heuristically in order to describe a specific 
phenomenon (Haag et al., 2005). However, there has been growing interest for the 
development of mathematical descriptions of cellular system, thus including the 
description of flux kinetics.There are also kinetic models that describe fluxes kinetics of 
some pathways of cell metabolism. These kinetic models mostly describe glycolysis 
(Gagneur, Jackson, & Casari, 2003; Hynne, Danø, & Sørensen, 2001; Wolf et al., 2000), 
TCA cycle (El-Mansi, Dawson, & Bryce, 1994; Wright, Butler, & Albe., 1992; Wu et al., 
2007), and to a lesser extent glutamine metabolism (Van den Berg & Garﬁnkel, 1971) 
and pentose phosphate pathway (Vaseghi et al., 1990). In that context, a fully dynamic 
metabolic model describing metabolite mass balances, enzyme kinetics and pathway 
regulation, can be a useful tool improving our capacity to analyze hypotheses and 
experimental data on metabolic network behavior. 
2.3.3 Current metabolic models for the mammalian cell platform 
Over the last decades, our approach towards the understanding of cellular processes has 
been changed due to increased availabilityof information about cellular processes. 
Because the biotherapeutics that we are producing are getting more complex, and that we 
look to lower their side effects by, for instance, a better control of the glycosylation 
process, we need to develop new tools enabling mastering cell culture processes. 
Therefore, it becomes clear that our intuitive capacity is no more enough to analyse the 
massive experimental datasets that are now available (“omics”) and required for 
adequately characterizing cell behaviour in its complexity(Gerdtzen, 2012). The strategy 
for building up a model mainly depends on the final objective of the analysis and the type 
and amount of data which is available. There are different approaches aiming at 
understanding cellular systems ranging from completely qualitative such as graph theory 
and topology analysis, which is beyond the scope of this work and a complete review on 
them can be found in (Ma’ayan, Blitzer, & Iyengar, 2005), to quantitative such as a 
comprehensive mathematical description of cells including genomic, proteomic and 
metabolic networks as well as their interactions. These approaches, however, are either 
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too complex, require too much datasets, or are not enough mature to deliver valuable 
information. Models aim basically at better understanding of how complex functions and 
behaviors emerged from the intracellular interactions lead to a specific cells behavior 
observed during the time course of a culture. This then helps to predict the effects of 
different conditions on cell behavoiur and to rationally design control strategies to keep 
cells in desired state. To do this, kinetic models that have predictive power are needed 
and these models should capture important biochemical and mechanistic details to 
systematicallydescribe the use ofnutrients, synthesis of primary and 
secondarymetabolites, the stoichiometry of themetabolic network, and kinetics of 
metabolic reaction. Such Models, however, require a critical level of knowledge (e.g. 
about pathway description and regulation), and reliability (e.g. about kinetic 
representations of reactions, the components and reactions to include, and kineic 
parameter values). In conclusion,this more elaborate way of representing cells comes 
with the cost of more complex computations and requires more amounts of experimental 
data but with the gain of obtaining more complete insight to a bioprocess.  
2.3.4 Analytical methods for metabolomic analysis 
Chemical analysistechniqueshave improved dramaticallyin recent yearsspeciallyin 
theirversatility.Indeed,long-termexpertisewith analytical 
chemistryallowedthemeasurementofspecific familiesof moleculessuch asorganic 
compounds,lipids, ions, orsugars.The sensitivity (or detection limit), however, nowadays 
becomes increasinglyimportant. While manytechniques exist, some are particularly 
prevalent such asnuclear magneticresonance (NMR), liquid/gas chromatography (LC or 
GC),andmass spectrometry(MS). The choice ofone technique overanotherofteninvolvesa 
compromise betweenspeed of analysis, selectivity andsensitivity (Table 2.7).For example, 
NMR is fast andselectivebutisinsensitivewhile theGC/MSorLC/MShavegood sensitivity 
andselectivity, but arelativelylonganalysis time (Sumner, Mendes, & Dixon, 2003).  
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Table  2.7Different orders of detection forchemical analysis techniques 
 
Method of analysis NMR LC/UV GC/MS LC/MS 
The order of analyte 10-6 mole 10-9 mole 10-12 mole 10-15 mole 
 
2.3.4.1  NMR spectroscopy 
NMRspectroscopy is atechnique based onphysicalproperties ofsomenuclei 
atoms(such as 1H, 13C, and 31P). The basic principle of NMR spectroscopy is that certain 
nuclei possess intrinsic magnetic moments which are sensitive to magnetic fields. When 
these nuclei are submitted to strong magnetic fields a net magnetization signal is 
produced proportional to the number of nuclei present. Therefore, NMR can be used as a 
quantitative tool (Fernande, 1987). This non-invasive technique has applicationsin 
chemistry andbiologyallowingdynamic studiesfollowingthe effect of astimulus such aspH 
change,or dissolved oxygen. However,thedetection threshold isrelativelylow in the order 
ofmM (orµM), which requiresthequantification ofmolecules with relativelyhigh 
concentrations,oraccumulation of the spectra for severalminutes orhours toachievea good 
signal-to-noise ratio. However, few critical metabolites are found in low concentrations 
(less than 0.1 mM). The most common way to circumvent this problem is by increasing 
cell density until high quality spectra are achieved. Typically, NMR studies of suspended 
cells call for high cell densities depending on cell type and size (Fernande, 1987). 
Therefore, certain process or operating requirements must be met allowing for a viable 
high cell density which are sometimes not easy to be met (Morris, 1988). 
2.3.4.2 Liquid and gas chromatography 
Theprincipleis to separatethesample mixture wherethe sampleflowsto the mobile 
(liquid/gas)  phase, due tosequential injections, in order to be separated one by one 
through specific physical interactions with a detectorcalled stationary phase. 
A stationaryphase (solid) conventionallymade of a resinwith specific properties, e.g.  
size, polarity, and branching, which can retainroughly different analytes. Mobile phase 
(liquid or gas) known as eluentcan transportthemolecules along 
ofthe separation columnto be analyzed.This phase canbe a mixtureof particular 
properties, e.g. flow, pH, and Vander Waalsforces, which may be adjustedduring ascan, 
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andare determinedby the user toimprove the resolution ofpeaks.Thedetection can be 
donethenbyopticalmeasurement(absorbanceorfluorescence)orby electrical 
measurementforredox reactionsand even on amass spectrometer oraNMR. This 
techniqueis widely usedformetabolic measurements, but one or theotheris 
favoreddepending on the nature of themolecules to be detected(more or less polar) 
(Figure 2.20). (Theodoridis, Gika, & Wilson, 2008).  
 
Figure  2.20UsingGCorLCfor metabolicmeasurements 
 
2.3.4.3 Mass spectroscopy  
Mass spectrometry(MS) is a technique for the identification of moleculeswith regard to 
their atomic mass.The device (mass spectrometer) ionizesmoleculeswhich 
aredetectedbytheir identical mass-to-charge ratio(m/z).The informationis thus 
primarilyqualitativerather than quantitativebecause itidentifies the molecules present 
inthe sample. Although the sensitivity of themass spectrometry is high up topicomole, 
their criterion of "molecular weight" is sometimes not enoughto discernmolecules. This is 
the caseof proteins thatcome outat the sameratiom/z(Wysocki et al., 2005). To address 
this usually multiple steps of mass spectrometry is applied to the sample, with some form 
of fragmentations occurring in between calledMS-MS (Bedair & Sumner, 2008). 
Traditionally,LCorGCchromatography is coupled to mass spectrometry which enablethe 
quantification andidentification of awidenumber of metabolitessuch as proteins, 
lipids,sugars, nucleic acids, amino acids (Kanani, Chrysanthopoulos, & Klapa, 2008). 
With the emergence of high through-put analytical methods, it seems that steps are being 
taken towards a more fundamental approach in a bioprocess 
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CHAPTER 3 METHODOLOGY 
CHO clones that stably produce a recombinant monoclonal human anti-CD20 at different 
specific productivities (high- and low-producer) were provided by Viropro International 
Inc. (Montreal, Canada). These cells were derived from CHO-Cum2 cells and stably 
express the reverse cumate transactivator, as described in details by Mullick et al. (2006) 
(Mullick et al., 2006). Cells were seeded at 2×105 cells/mL in 300 mL of a protein-free 
medium in 1-L shake flasks, and cultured on a shaker (150 rpm) in a humidified 
incubator at 37°C and 5% CO2. The medium used was a customized chemically-defined 
SFM4CHO medium supplemented with 30 mM glucose, 4 mM glutamine and 0.05 
mg/mL dextran sulphate. For the comparative study, the parental clone, together with 
high- and low-producer clones, were cultured in duplicate. High- and low-producer 
clones were cultured both in the presence and in absence of cumate, the latter serving as 
non-induced control. In case of induction, 1 µg/mL of cumate was added after 48 hours 
of incubation, to trigger the recombinant protein expression. It should be mentioned that 
no visible effectsonmorphologyorgrowthrates were reported for mammalian cells 
cultured at a cumate concentration below 200 µg/mL (Mullick et al., 2006). More details 
of complete cell culture protocols and culture condition are described in Chapter 5 within 
the Material and Methods section (5.5.1) and in appendices 1-2. 
3.1 Metabolomic analysis 
Quantification of cell metabolites, i.e. metabolic intermediates and energetic and redox 
nucleotides,are particularlycritical because of their high instability and their low 
concentrations. The main steps consist in the sampling of the cell suspension, cell 
separation from the medium, extraction of metabolites and then the 
chemicalidentification andquantification of metabolites of interest.The liquid medium 
composition in nutrients and metabolites also needed to be characterized, and it was 
obtained after cell separation from the suspension. For more details, the complete method 
is described in Chapter 5 within the Material and Methods section (5.5.2) and in appendix 
3. 
3.1.1 Extraction of metabolites 
During ametabolicmeasurement, numerous handling stepsof the biological sampleshould 
beas neutral as possiblewith regards to the analyte moleculesand thusskewthe results the 
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least possible.In other words,at this stagewe try tostop the metabolism as 
quickly as possible so that the biochemical process does not change themolecular 
concentrationsand thus givesan unrepresentativeresult of thecellular stateat the time 
ofsampling.This stepisparticularly criticalsince itoccurs firstinthe stepsrelatedto a 
measurement ofmetabolites.The methodsof interruption ofmetabolism (quenching) 
typically consistin exposingthe sample toconditions of extremepHor 
temperatureallowingthe rapiddenaturation ofenzymes,without alteringthemetabolites of 
interest(Álvarez-Sánchez, Priego-Capote, & Castro, 2010). The first methodis byadding 
sodium hydroxideora strong acidsuch astrichloroaceticacidorperchloric(Mashego et al., 
2007). The second is tobring the sample below -20оC throughthe addition of 
acoldaqueoussolution (lower than -40оC) ofmethanolor withliquid nitrogen at -
196оC(Dettmer, Aronov, & Hammock, 2007; Hiller et al., 2007).Methanol hasthe 
advantage of beingmiscible with waterand has alower freezing temperature thanethanolor 
glycerol. Moreover, itpreventsthe increase in temperatureas that may leadto the 
degradation ofthermally labilemolecules. The addition of cold methanol causes 
cellpermeabilization and a separation step (e.g. by centrifugation) of the biomass from the 
culture medium at the end is performed torecover endo-metabolome from cell debris. 
This step is the most difficultstep even forbiotechnological processeswhichseek to 
followthe metabolic stateof thecellline. An automated way("on-line" measuresor"at-line") 
thus is supported byindustriallyProcess AnalyticalTechnology. Severalsystems have been 
developedbased ona samplerconnected to thebioreactorwhich opens upto -50oC and200 
mbar which is combined with an aqueous solution of60%methanolusedin bacteria 
andyeasts cultures (Hiller et al., 2007).For more details of the extraction procedure, the 
complete method is described in Chapter 5 within the Material and Methods section 
(5.5.2) and in appendix 4. 
3.1.2 Quantification of metabolic concentration 
Table3.1 summarizesthe intra- and extracellular moleculesanalyzed in thiswork including 
the methods of analysis. 
 
 
 
 
 50 
 
 
Table  3.1    Summary of analytical methods applied to this work 
 
Metabolite Analytical method Analytical tool 
(instrument/assay) 
Extracellular glucose, lactate, 
glutamine and glutamate 
Enzyme-based via oxidization 
of the analyte by the enzyme 
immobilized on a membrane 
Dual-channel immobilized oxidase 
enzyme biochemistry analyzer 
(2700 SELECT, YSI Inc. Life 
Sciences, USA) 
Extracellular ammonia Enzyme-basedvia glutamate 
dehydrogenaseand 
absorbanceofNADPHat 
340nm 
Ammonia Assay Kit (Sigma, 
Oakville, Canada) 
 
Extracellular amino acids Chemical-based via separation 
on a solid phase due to 
different physiochemical 
properties 
1290 UPLC system coupled to a 
6460 triple quadruple mass 
spectrometer (Agilent Technologies, 
Canada). 
 
Extracellular monoclonal 
antibody 
Enzyme-based via enzyme-
conjugated antibody and the 
absorbanceof  color substrate 
at 340nm 
enzyme-linked immunosorbent 
assay (ELISA) 
protocol in appendix 3 
NAD(P) and NAD(P)H Enzyme-based via an enzyme 
cycling reaction and the 
absorbance of NAD(P)H at 
450 nm 
NAD(P)/NAD(P)HQuantificationKit 
(BioVision, USA) 
-Extraction by NADP/NADPH 
extraction Buffer through  
freeze/thaw two cycles 
 
Adenylate nucleotides (ATP,  
ADP, and AMP) 
Chemical-based via separation 
on a solid phase due to 
different physiochemical 
properties 
1290 UPLC system coupled to a 
6460 triple quadruple mass 
spectrometer (Agilent Technologies, 
Canada). 
-Extraction by 80%  cold methanol 
Organic acids and 
sugar phosphates 
Chemical-based via separation 
on a solid phase due to 
different physiochemical 
properties 
1290 UPLC system coupled to a 
6460 triple quadruple mass 
spectrometer (Agilent Technologies, 
Canada). 
-Extraction by 80%  cold methanol 
protocol in appendix 4 
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3.2 A general algorithm as a guide in the development of a metabolic 
kinetic model 
The model developed in this work is presented in details in Chapter 4, with the initial 
structure and in Chapters 5 and 6, with a fully developed regulated flux kinetics. We also 
detailed the model structure development as well as parameters calibration procedure in 
those following chapters. However, in order to expose in a unique section the steps we 
followed for developing our model, an algorithm is presented in Figures 3.1 and 3.2. As a 
first step metabolic reactions and metabolites should be defined following by the step of 
their mathematical representation by stoichiometric matrix. At the next step, a rate 
equation should be assigned to each reaction. Information on the initial values for kinetic 
parameters is usually obtained from databases listed in table 3.4.Kinetic parameters 
determined in vitro may be far from biological ones, giving some latitude on parameter 
values. Afterwards, the global simulation error should be minimized. Minimization of 
simulation is then accomplished by non-linear optimization technique, i.e. least-squares 
fit. Finally, model properties such as adaptability to other conditions, applicability and 
the reliability of its structure and parameters should be studied (Figure 3.2). 
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Figure  3.1    A general algorithm for the development of a kinetic metabolic model 
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Figure  3.2An algorithm for the estimation of model parameter values 
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Table  3.2    Web resources and databases for components and pathways for various 
organisms 
 
 
Name 
 
Web address and description 
 
Reference 
KEGG PATHWAY 
http://www.genome.jp/kegg/pathway.html  
Encyclopedia of pathway maps for various organisms 
(Kanehisa et al., 2008) 
BRENDA http://www.brenda-enzymes.org 
The comprehensive enzyme information system 
including  biochemical, and metabolic knowledge for 
various organisms 
(Chang et al., 2009) 
METACYC  
http://MetaCyc metacyc.org 
Database for  metabolic pathways and enzymes  
 
(Caspi et al., 2010) 
SABIO RK  
http://sabio.villabosch.de/SABIORK 
Database for Biochemical Reactions and their Reaction 
Kinetics 
 
(Rojas et al., 2007) 
BioCyc http://biocyc.org 
pathway and genome database for a large number of 
organisms including mammalian cells 
(Karp et al., 2005) 
Sigmoid  
http://www.sigmoid.org 
Collection of the models for  cellular signaling and 
metabolic pathways 
 
(Saunders et al., 2008) 
Reactome  
http://www.reactome.org 
Curated knowledgebase of biological pathways in 
humans 
 
(Vastrik et al., 2007) 
BioModels  
http://www.ebi.ac.uk/biomodels 
A data resource of Annotated Published Models 
 
(Le NovŁre et al., 2006) 
ResNet Mammalian 
Database 
http://www.ariadnegenomics.com/products/databases 
Commercial database for  cellular process and metabolic 
pathways in  human, rat, and mouse 
(Szklarczyk et al., 2011) 
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4.1 Presentation of the article 
In this article, the kinetic modelling framework is developed describing CHO cell 
primary metabolism. This framework is adapted from a previous work on the modelling 
of plant cells metabolism and derived from the metabolic network of CHO cells. The 
model considers the catabolism of the main nutrients (glucose and glutamine), including 
glycolysis, pentose phosphate pathway, TCA cycle and respiratory chain. Therefore, 
more details of model development are presented in this chapter and the ability of the 
model in describing anabolic pathways, nutrients uptakes and cell growth in different 
culture conditions is discussed. 
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4.2 Abstract 
A kinetic-metabolic model approach describing and simulating Chinese hamster ovary 
(CHO) cells behaviour is presented. The model includes glycolysis, pentose phosphate 
pathway, TCA cycle, respiratory chain, redox state and energetic metabolism. Growth 
kinetic is defined as a function of the major precursors for the synthesis of cell building 
blocks. Michaelis-Menten type kinetic is used for metabolic intermediates as well as for 
regulatory functions from energy shuttles (ATP/ADP) and cofactors (NAD/H and 
NADP/H). Model structure and parameters were first calibrated using results from 
bioreactor cultures of CHO cells expressing recombinant t-PA. It is shown that the model 
can simulate experimental data for all available experimental data, such as extracellular 
glucose, glutamine, lactate and ammonium concentration time profiles, as well as cell 
energetic state. A sensitivity analysis allowed identifying the most sensitive parameters. 
The model was then shown to be readily adaptable for studying the effect of sodium 
butyrate on CHO cells metabolism, where it was applied to the cases with sodium 
butyrate addition either at mid-exponential growth phase (48 h) or at the early plateau 
phase (74 h). In both cases, a global optimisation routine was used for the simultaneous 
estimation of the most sensitive parameters, while the insensitive parameters were 
considered as constants. Finally, conﬁdence intervals for the estimated parameters were 
calculated. Results presented here further substantiate our previous findings that butyrate 
treatment at mid exponential phase may cause a shift in cellular metabolism toward a 
sustained and increased efficiency of glucose utilization channeled through TCA cycle. 
 
4.3 Keywords 
Metabolic modeling, CHO cells, kinetic model, metabolic regulation, energy 
regulation, sodium butyrate  
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4.4 Introduction 
In the past decades, high-producer cell lines for recombinant proteins have been 
developed concomitantly to optimal culture media and bioprocess management strategies. 
On the cell engineering side, emphasis has been placed at prolonging culture longevity. 
Genetic modifications were directed mostly toward the increase of Chinese Hamster 
Ovary (CHO) cells viability such as complementing the cell machinery with growth 
factor endogenous production (e.g. insulin like growth factors) (Galbraith et al., 2006; 
Sunstrom et al., 2000) or optimizing cell-cycle control genes (e.g. cyclin-dependent 
kinases) (Fussenegger et al., 1998). Cell specific productivity has also been increased 
using various strategies: with the use of strong promoters, such as cytomegalovirus 
(CMV), beta-actin and EF-1α, through the identification of favorable location of 
integration on the genome, or by the insertion of amplifiable markers, such 
asdihydrofolate reductase (DHFR) (Cacciatore et al., 2010). Some studies have also 
focused on protein synthesis steps and modulation of the glycosylation process, mostly 
by the incorporation of specific de novo glycosylation sites (Elliott, Chang, et al., 2004; 
Elliott, Egrie, et al., 2004; Elliott et al., 2003). In parallel, bioprocess engineering 
approaches, such as imposing temperature and pH shifts to prolong productive stationary 
phase (Quek et al., 2010) , and the addition of chemicals (e.g. sodium butyrate, pentanoic 
acid, quinidine and thymidine) (Kumar et al., 2007), or development of efficient fed-
batch protocols (Birch & Racher, 2006), have allowed to achieve high viable cell 
densities (10*106 cells/mL) and cell specific productivities for up to 3 weeks (Wurm, 
2004). Interestingly, most optimal culture management protocols have resulted in more 
efficient nutrient utilization and reduced waste formation. 
Today's primary challenge, however, is to increase product quality, i.e. drugs specificity, 
while maintaining high productivity and reproducibility levels, from lot to lot. This 
objective refers, among others, to minimizing glycoform diversity of a protein-based 
therapeutic; variants that are contaminating the final product and are mostly responsible 
for undesired secondary effects. Various efforts are being explored to this end (Jenkins, 
2007), but at the industrial level, such multi-objectives control of a bioprocess (i.e. 
protein quality and quantity, cell viability, culture longevity and reproducibility) can only 
be achieved through the fine management of bioreactor culture conditions under fed-
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batch or perfusion operation modes. Therefore, the problem of defining an optimal 
culture management strategy becomes even more complex when sudden stresses 
affecting cell metabolism are imposed from the use of chemical additives, inducible 
promoters or a transient transfection strategy. In that context, there is a strong interest at 
characterizing and describing cell behaviour from the dynamic changes occurring along 
with bioprocesses. However, classical approaches can hardly bring an adequate 
information level and a descriptive and predictive metabolic model of cell behaviour is 
needed. Dynamic models have been developed to describe microbial (Chassagnole et al., 
2002), CHO (Nolan & Lee, 2010) as well as plant cells (Cloutier et al., 2007). 
Particularly in the case of CHO cells, Nolan et al. (2010) (Nolan & Lee, 2010) have 
describe the transient behaviour of extracellular metabolite concentrations and used 
metabolic flux analysis (MFA) to calculate intracellular fluxes, assuming that all 
intermediate metabolites are at pseudo-steady-states. That model also includes parameters 
related to temperature shift and redox state. To be of general applicability, however, a 
model must be able to capture the dynamics of the cell metabolic network in a wide range 
of relevant conditions. In a recent work, we have developed a kinetic-metabolic model 
framework based on cell energetic and redox states and adapted to plant cells (Cloutier et 
al., 2007). We have shown that the model can successfully be applied either to control 
cytoplasmic inorganic phosphate to a defined set-point, or to maximize secondary 
metabolites productionthrough the in-silico design and real implementation of a 
bioreactor culture management strategy (Cloutier et al., 2007). We thus propose here to 
transpose our plant cell model framework, which describes flux kinetics and pathway 
regulation from cell energetic and redox states, to CHO cells. In order to challenge the 
model, we have studied its capacity to describe cell behaviour either under standard batch 
culture conditions or following sodium butyrate addition, a widely used chemical to 
enhance recombinant protein production (Hendrick et al., 2001; Kim & Lee, 2001; Lee & 
Lee, 2003; Palermo et al., 1992). The model was first successfully calibrated on 
previously published experimental data (McMurray-Beaulieu et al., 2009) for a bioreactor 
culture without the addition of sodium butyrate, where a combination of literature and 
parameter sensitivity analysis assisted us to manually and mathematically tune the 
parameters. An a posteriori sensitivity analysis was then performed on parameter 
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estimates to identify which kinetic parameters were to be included or excluded from 
further estimation processes for bioreactor cultures with sodium butyrate.Confidence 
intervals for kinetic parameters with relatively high sensitivity were also calculated in 
order to verify how well the parameters were determined with the available experimental 
data sets. Finally, model simulations were used to study the effects of sodium butyrate 
addition on cell metabolism where simulated fluxes and ratios with their confidence 
intervals were interpreted in relation to statistical signiﬁcance.  
4.5 Material and Methods 
4.5.1  Biological material and bioreactor cultures 
A detailed description of the cell line, culture conditions and analytical methods can be 
found in previous work (McMurray-Beaulieu et al., 2009). Briefly, a recombinant t-PA 
producing CHO cell line (ATCC, CRL9606) was cultured in a 3.5-L stirred tank 
bioreactor (ChemapAG, Switzerland) equipped with a helical-ribbon impeller (Jolicoeur, 
Chavarie, Carreau, & Archambault, 1992). One culture was performed as control and two 
were treated with 1 mM Na-butyrate (Cat. No.B5887, Sigma-Aldrich Canada Ltd., 
Ontario, Canada); one at mid-exponential phase 48 h post-inoculation (NaBu-48h), and 
one at the end of exponential phase 74 h post inoculation (NaBu-74h). Dissolved oxygen 
concentration was measured by a polarographic probe (Cat. No. InPro 6800, Mettler 
Toledo, Mississauga, Ontario, Canada) connected to a data acquisition and control system 
(Virgo, Longueuil, Quebec, Canada). Glucose, glutamine, ammonia and lactate 
concentrations as well as t-PA concentration in the medium were evaluated using 
enzymatic assays. Intracellular nucleotides were extractedusingperchloric acidas 
described by Ryll and Wagner (Ryll & Wagner, 1991) and quantified by HPLC-MS 
(Micromass ZQ, Waters, Milford, MA, USA). Column specification, mobile phase 
composition and detection method are detailed in McMurray-Beaulieu et al. (2009) 
(McMurray-Beaulieu et al., 2009). 
4.5.2 Model description 
4.5.2.1 The model structure 
A predictive kinetic-metabolic model previously developed and validated for plant cell 
culture (Cloutier et al., 2007; Leduc et al., 2006) has been transposed to CHO cells. The 
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model metabolic network is presented in Figure 4.1.A series of biologically relevant 
mathematical representations of metabolic flux kinetics are presented in Table 4.1, and 
the stoichiometry of the reactions is listed in Table 4.2 and the final (calibrated; see 
below for detailed explanations) model is described in Table 4.3. The major metabolic 
pathways are considered: glycolysis, pentose phosphate pathway, TCA cycle, 
glutaminolysis as well as cell respiration. The latter includes phosphorylative oxidation 
with ATP and H2O synthesis, and mitochondrial proton leakleading to H2O synthesis 
where the P/O ratio is estimated to have a value of 2, which is in agreement with the 
typical values reported for CHO cells (Nolan & Lee, 2010). In addition, we also 
considered the reversible reactions involving creatine and adenylate kinases. AMP 
synthesis from R5P (Table 4.2, reaction 28) is also considered (Zamorano et al., 2010). 
The cell specific growth rate (µ) is described (Table 4.2) by considering the precursors of 
major cell building blocks: G6P (leading to phospholipids and organic phosphate 
compounds), citrate (to lipids), R5P (to DNA, RNA and nucleotides), glutamate (GLU) 
and glutamine (GLN) (to proteins); a strategy we previously successfully applied to plant 
cells (Leduc et al., 2006). t-PA synthesis has not been described in the model 
because of a flux rate range of ~10-7 mmol (106 cells)-1 h-1 (at a specific productivity 
of 0.05 g (106 cells)-1 h-1) (Figure 4.9E), which was over 2-3order of magnitude lower 
than all intracellular fluxes rates and was thus unfortunately mathematically non-
significant. The consumption of each precursor metabolite is calculated as proposed by 
Martens (Martens, 2007) and considered in mass balances. The stoichiometric 
coefficients for biomass synthesis, reaction 30 in Table 4.2, were taken from literature 
(Ahn & Antoniewicz, 2011), including that 3.78 moles of ATP required to form one mole 
of biomass (Nolan & Lee, 2010)(Table 4.2, reaction 30). The mass balance onATP 
thus includes its production from glycolysis and oxidative phosphorylation, as well as its 
consumption for biomass synthesis, maintenance-related processes, transmembrane 
transport, and other ATPases-related reactions; the sum of consuming processes being 
integrated within a unique reaction (Table 4.2, reaction 25).At this stage of model 
development, and similarly to our previous model for plant cells (Cloutier et al., 2007), 
CHO cells were taken as a unique compartment with no intracellular sub-compartments 
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(e.g. mitochondria, nucleus, etc.), and Michaelis-Menten kinetics was used to describe 
each metabolic reaction flux rate. 
 
Figure  4.1    The metabolic network described by the model 
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Table  4.1    Mathematical formulations of metabolic fluxes kinetic 
 
  
 
 
Regulation 
 
Kinetic Expression 
 
࢜ቌ෍ࡿ࢏
ࡺࡿ
࢏ୀ૚
ࡼ૚ ⤻ ࡼ૛
→
ࡾ૚ ⤻ ࡾ૛
෍ࡼ࢏
ࡺࡼ
࢏ୀ૚
ቍ 
 
Objective 
Function 
Value 
 
 
1 
 
The flux rate is only a function of 
its substrates concentration with a 
Michaelis-Menten type kinetic, 
even when it is coupled to energy 
and/or electron transfer. 
 
 
ݒ௠௔௫ ቎ෑ
ܥௌ೔
ܭ௠ௌ೔ + ܥௌ೔ேೞ௜ୀଵ ቏ 
 
181.64 
 
 
2 
 
The flux rate is a function of its 
substrates concentration as well as 
energy (ATP/ADP) and/or electron 
(NADH/NAD+, NADPH/ 
NADP+) transfer nucleotides. 
 
 
 
ݒ௠௔௫ ቎ෑ
ܥௌ೔
ܭ௠ೄ೔ + ܥௌ೔ேೞ௜ୀଵ ቏ ቈ ܥ௉భܭ௠௣భ + ܥ௉భ቉ 
ቈ
ܥோభ
ܭ௠ೃభ + ܥோభ቉ 
 
 
170.1 
 
 
3 
 
Similar to mathematical formulation 
#2 but with a Michaelis-Menten 
type kinetic using substrates and 
nucleotides ratio. 
 
 
 
ݒ௠௔௫ ቎ෑ
ܥௌ೔
ܭ௠ೄ೔ + ܥௌ೔ேೞ௜ୀଵ ቏
⎣
⎢
⎢
⎢
⎡ ஼ುభ
஼ುమ
ܭ௠಴ುభ
಴ುమ
+ ஼ುభ
஼ುమ ⎦
⎥
⎥
⎥
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ܭ௠ ಴ೃభ
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+ ஼ೃభ
஼ೃమ ⎦
⎥
⎥
⎥
⎤
 
 
138.2 
 
4 
 
Combination of mathematical 
formulations #2 and #3. 
 
ݒ௠௔௫ ቎ෑ
ܥௌ೔
ܭ௠ೄ೔ + ܥௌ೔ேೞ௜ୀଵ ቏
⎣
⎢
⎢
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⎡ ஼ುభ
஼ುమ
ܭ௠಴ುభ
಴ುమ
+ ஼ುభ
஼ುమ ⎦
⎥
⎥
⎥
⎤
 
⎣
⎢
⎢
⎢
⎡ ஼ೃభ
஼ೃమ
ܭ௠ ಴ೃభ
಴ೃುమ
+ ஼ೃభ
஼ೃమ ⎦
⎥
⎥
⎥
⎤
 
 
ቈ
ܥ௉భ
ܭ௠௣భ + ܥ௉భ቉ ቈ ܥோభܭ௠ೃభ + ܥோభ቉ 
166.7 
    
*p1, p2 are ATP or ADP and R1, R2 are either NAD[P]H or NAD[P]+. 
 
Understanding that a model is a simplified representation of a phenomenon, or of a 
network of biochemical reactions in this case, the kinetic parameters determined in this 
work have to be seen as global; they also include what is not described, such as metabolic 
regulation as well as other biochemical reactions that are taking place. The parameters 
values determined in this work may thus differ from the strict real value for a 
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biochemical reaction but these are bringing a global view on a group of regulated 
biochemical reactions occurring around each metabolite described in the model. In that 
context, a statistical analysis (see below) was performed on model parameters values as 
well as on the model structure in order to ensure that a unique model structure is able to 
describe either a control culture than stressed cultures with Na-butyrate. All the reactions 
related to primary metabolism are considered unidirectional at this stage of model 
development, except for the pyruvate-lactate and intracellular-extracellular glutamine 
exchangesas also reported by Nolan et al. (Nolan & Lee, 2010).Finally a sigmoidal 
function, based on a threshold concentration for extracellular glutamine, was used to 
manage the change between nitrogenous sources (i.e. glutamate and glutamine) at low 
extracellular glutamine level. 
4.5.2.2 Fluxes kinetic equation 
A series of biologically relevant mathematical representations of metabolic flux kinetics 
(Table 4.1) were evaluated based on the model capacity to fit experimental data. In a first 
kinetic expression formulation (#1), each metabolic flux rate is simply determined by the 
concentrations of the substrates (metabolites) using Michaelis-Menten type kinetics; and 
all of the followings are implementations of #1 formulation. Formulation #2 proposes a 
Michaelis-Mentenkinetic to account for energetic and redox nucleotides concentrations in 
the reactions they are involved, as described in other works on mitochondrial energetic 
metabolism (Bohnensack, 1981; Garfinkel, 1971a; Garfinkel, 1971b; Korzeniewski, 
1991; Wu et al., 2007) or on glycolysis (Kauffman et al., 2002). In formulation #3, 
nucleotide ratios are considered within a Michaelis-Menten kinetic, as proposed in the 
literature cited in Dash et al. (2007) (Dash, DiBella, & Cabrera, 2007). Finally,in 
formulation#4, multiplicative Michaelis-Menten kinetics for intracellular concentration of 
nucleotides and for nucleotide ratios are combined. It thus accounts for both the effect of 
nucleotide ratios and energetic/redox nucleotides concentrations. The model performance 
for each of these four kinetic expression formulations was then compared with regard to 
its ability to describe experimental data. 
 
 
Table  4.2Reactions of a metabolic network 
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No. Reaction 
1 EGLC+ATP→G6P+ADP 
2 G6P→F6P 
3 F6P+ATP→2GAP+ADP 
4 GAP+ADP+NAD++Pi→PEP+ATP+NADH 
5 PEP+ADP→PYR+ATP 
6 PYR+NADH↔ELAC+NAD+ 
7 G6P+2NADP+→R5P+2NADPH+CO2 
8 R5P→X5P 
9 R5P+2X5P→2F6P+GAP 
10 PYR+COA+NAD+→ACCOA+NADH+CO2 
11 ACCOA+OXA→CIT+CoA 
12 CIT+NAD+→AKG+NADH+CO2 
13 AKG+CoA+NAD+→SCOA+NADH+CO2 
14 SCOA+ADP+Pi→SUC+CoA+ATP 
15 SUC+2/3NAD+→MAL+2/3NADH+CO2 
16 MAL+NAD+→OAA+NADH 
17 MAL →PYR+CO2 
18 EGLN+ATP↔GLN+ADP 
19 GLN↔GLU+ENH4 
20 GLU+NAD+→AKG+NADH+ENH4 
21 GLU+PYR→AKG+ALA 
22 GLU+ADP+Pi→EGLU+ATP 
23 O2+(P/O ratio)*2ADP+2NADH+(P/O ratio)*2Pi→(P/O ratio)*2ATP+NAD++2H2O 
24 O2+2NADH→2NAD++2H2O 
25 ATP→ADP+Pi 
26 ATP+AMP↔2ADP 
27 Pcr+ADP↔Cr+ATP 
28 2GLN+0.6R5P+2ASP+GLY+2ATP→2GLU+2MAL+AMP+2ADP 
29 NADPH→NADP+ 
30 0.024R5P+0.029G6P+1.86CIT+0.033GLU+0.04GLN+3.78ATP→X 
Table  4.3Biokinetic equations of the metabolites fluxes (1-30) of the model 
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No. Biokinetic equations 
1 
 
ߥ(ܪܭ) = ߥ୫ୟ୶ு௄ ∗ ܧܩܮܥܭ௠ாீ௅஼ + ܧܩܮܥ ∗ ஺்௉஺஽௉ܭ
௠
ಲ೅ು
ಲವು
+ ஺்௉
஺஽௉
 
 
2 
 
ߥ(ܲܩܫ) = ߥ௠௔௫௙	௉ீூ ∗ ܩ6ܲܭ௠ீ଺௉ + ܩ6ܲ 
 
3 
 
ߥ(ܲܨܭ/ܣܮܦ) = ߥ୫ୟ୶௉ி௄/ா௅஽ ∗ ܨ6ܲܭ௠ி଺௉ + ܨ6ܲ ∗ ஺்௉஺஽௉ܭ
௠
ಲ೅ು
ಲವು
+ ஺்௉
஺஽௉
 
 
4 
 
 
ߥ(ܲܩܭ) = ߥ݉ܽݔܲܩܭ ∗ ܩܣܲܭ݉ܩܣܲ+ܩܣܲ ∗ ܣܦܲܣܶܲܭ
݉ܣܦܲܣܶܲ
+ܣܦܲܣܶܲ ∗ ܲ݅ܭ݉ܲ݅+ܲ݅* ܰܣܦܰܣܦܪܭ݉ ܰܣܦܰܣܦܪ+	 ܰܣܦܰܣܦܪ  
 
5 
 
ߥ(ܲܭ) = ߥ୫ୟ୶௉௄ ∗ ܲܧܲܭ௠௉ா௉ + ܲܧܲ ∗ ஺஽௉஺்௉ܭ
௠
ಲವು
ಲ೅ು
+ ஺஽௉
஺்௉
 
 
6 
 
ߥ(ܮܦܪ) = ߥ௠௔௫௙	௅஽ு ∗ ܻܴܲܭ௠௉௒ோ + ܻܴܲ ∗ ே஺஽ுே஺஽ܭ
௠
ಿಲವಹ
ಿಲವ
+ ே஺஽ு
ே஺஽
− ߥ௠௔௫௥	௅஽ு ∗
ܧܮܣܥ .
ܭ௠௅஺஼ + ܧܮܣܥ ∗ ே஺஽ே஺஽ுܭ
௠
ಿಲವ
ಿಲವಹ
+ ே஺஽
ே஺஽ு
 
7 
 
ߥ(ܩ6ܲܦܪ/ܲܩܮܿܦܪ) = ߥ୫ୟ୶ ீ଺௉஽ு/௉ீ௅௖஽ு ∗ ܩ6ܲܭ௠ீ଺௉ + ܩ6ܲ ∗ ே஺஽௉ே஺஽௉ுܭ
௠
ಿಲವು
ಿಲವುಹ
+ ே஺஽௉
ே஺஽௉ு
 
8 
 
 
ߥ(ܧܲ) = ߥ୫ୟ୶ா௉ ∗ ܴ5ܲܭ௠ோହ௉ + ܴ5ܲ 
 
9 
 
ߥ(ܶܭ/ܶܣ) = ߥ୫ୟ୶்௄/்஺ ∗ ܴ5ܲܭ௠ଶோହ௉ + ܴ5ܲ ∗ ܺ5ܲܭ௠௑ହ௉ + ܺ5ܲ 
 
 
10 
 
	ߥ(ܲܦܪ) = ߥ௠௔௫	௉஽ு ∗ ܻܴܲܭ௠௉௒ோ + ܻܴܲ ∗ ே஺஽ே஺஽ுܭ
௠
ಿಲವ
ಿಲವಹ
+ ே஺஽
ே஺஽ு
 
 
 
 
Table 4.3   Biokinetic equations of the metabolites fluxes (1-30) of the model (continued) 
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11 
 
 
ߥ(ܥܵ) = ߥ௠௔௫஼ௌ ∗ ܣܥܥܱܣܭ௠஺஼஼ை஺ + ܣܥܥܱܣ ∗ ܱܺܣܭ௠ை௑஺ + ܱܺܣ 
 
12 
 
ߥ(ܥܫܶܵ/ܫܱܵܦ) = ߥ୫ୟ୶஼ூ்ௌ/ூௌை஽ ∗ ܥܫܶܭ௠஼ூ் + ܥܫܶ ∗ ே஺஽ே஺஽ுܭ
௠
ಿಲವ
ಿಲವಹ
+ ே஺஽
ே஺஽ு
 
 
13 
 
ߥ(ܣܭܩܦܪ) = ߥ௠௔௫	஺௄ீ஽ு ∗ ܣܭܩܭ௠஺௄ீ + ܣܭܩ ∗ ே஺஽ே஺஽ுܭ
௠
ಿಲವ
ಿಲವಹ
+ ே஺஽
ே஺஽ு
 
 
14 
 
ߥ(ܵܥܱܣܵ) = ߥ௠௔௫	ௌ஼ை஺ ∗ ܵܥܱܣܭ௠ௌ஼ை஺ + ܩܣܲ ∗ ஺஽௉஺்௉ܭ
௠
ಲವು
ಲ೅ು
+ ஺஽௉
஺்௉
∗
ܲ݅
ܭ௠௉௜ + ܲ݅ 
 
 
 
15 
 
ߥ(ܵܦܪ/ܨܷܯ) = ߥ୫ୟ୶ௌ஽ு/ி௎ெ ∗ ܷܵܥܭ௠ௌ௎஼ + ܷܵܥ ∗ ே஺஽ே஺஽ுܭ
௠
ಿಲವ
ಿಲವಹ
+ ே஺஽
ே஺஽ு
 
 
16 
 
ߥ(ܯܦܪ) = ߥ௠௔௫	ெ஽ு ∗ ܯܣܮܭ௠ெ஺௅ +ܯܣܮ ∗ ே஺஽ே஺஽ுܭ
௠
ಿಲವ
ಿಲವಹ
+ ே஺஽
ே஺஽ு
 
 
17 
 
 
ߥ(ܯܧ) = ߥ௠௔௫	ொ ∗ ܯܣܮܭ௠ெ஺௅ + ܯܣܮ 
 
 
 
18 
 
ߥ(ܩ݈݊ܶ) = ߥ௠௔௫௙ீ௟௡் ∗ ܧܩܮܰܭ௠ாீ௅ே + ܧܩܮܰ ∗ ஺்௉஺஽௉ܭ
௠
ಲ೅ು
ಲವು
+ ஺்௉
஺஽௉
− ߥ௠௔௫௥	ீ௟௡் ∗
ܩܮܰ
ܭ௠ீ௅௎ + ܩܮܰ ∗ ஺஽௉஺்௉ܭ
௠
ಲವು
ಲ೅ು
+ ஺஽௉
஺்௉
 
 
 
19 
 
ߥ(ܩܮܰܵ) = ߥ௠௔௫௙ீ௅ேௌ ∗ ܩܮܰܭ௠ீ௅௎ + ܩܮܰ − ߥ௠௔௫௥	ீ௅ேௌ ∗ ܩܮܷܭ௠ீ௅௎ + ܩܮܷ ∗ ܰܪସܭ௠ேுర +ܰܪସ ∗ ൬ 11 + ݁(୉ୋ୐୒ିଶ)൰ 
 
 
20 ߥ(ܩܮܦܪ) = ߥ௠௔௫	ீ௅஽ு ∗ ܩܮܷܭ௠ீ௅௎ + ܩܮܷ ∗ ே஺஽ே஺஽ுܭ
௠
ಿಲವ
ಿಲವಹ
+ ே஺஽
ே஺஽ு
 
 
 
 
Table 4.3    Biokinetic equations of the metabolites fluxes (1-30) of the model (continued) 
 
 
21 ߥ(ܣ݈ܽܶܣ) = ߥ௠௔௫	஺௟௔்஺ ∗ ܩܮܷܭ௠ீ௅௎ + ܩܮܷ ∗ ܻܴܲܭ௠௉௒ோ + ܻܴܲ 
22  
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ߥ(ܩ݈ݑܶ) = ߥ௠௔௫ீ௟௨் ∗ ீ௅௎௄೘ಸಽೆାீ௅௎ ∗ ಲವುಲ೅ು௄
೘
ಲವು
ಲ೅ು
ା
ಲವು
ಲ೅ು
* ௉௜
௄೘ು೔ା௉௜
 
 
23 
 
ߥ(ݎ݁ݏ݌) = ߥ௠௔௫	௥௘௦௣ ∗ ܱଶܭ௠ைమ +ܱଶ ∗ ஺஽௉஺்௉ܭ௠ಲವು
ಲ೅ು
+ ஺஽௉
஺்௉
∗
ܰܣܦܪ
ܭ௠ே஺஽ு +ܰܣܦܪ ∗ ܲ݅ܭ௠௉௜ + ܲ݅ 
 
24 
 
ߥ(݈݁ܽ݇) = ߥ௠௔௫	௟௘௔௞ ܰܣܦܪܭ௠ே஺஽ு +ܰܣܦܪ 
 
25 
 
ߥ(ܣܶܲܽݏ݁) = ߥ௠௔௫	஺்௉௔௦௘ ∗ ܣܶܲܣܶܲ + ܣܶܲ 
 
26 
 
ߥ(ܣܭ) = ߥ௠௔௫௙	஺௄ ∗ ܣܶܲܭ௠஺்௉ + ܣܶܲ ∗ ܣܯܲܭ௠஺ெ௉ + ܣܯܲ − ߥ௠௔௫௥	஺௄ ∗ ܣܦܲܭ௠஺஽௉ + ܣܦܲ 
 
27 
 
 
ߥ(ܥܭ) = ߥ௠௔௫௙	஼௄ ∗ ܣܦܲܭ௠஺஽௉ + ܣܦܲ ∗ ܲܿݎܭ௠௉௖௥ + ܲܿݎ − ߥ௠௔௫௥	஼௄ ∗ ܣܶܲܭ௠஺்௉ + ܣܶܲ ∗ ܥݎܭ௠஼௥ + ܥݎ 
 
 
28 
 
ߥ(ܴܲܲ݅ܤܲ) = ߥ୫ୟ୶௉௉ோ௜௕௉ ∗ ܴ5ܲܭ௠ோହ௉ + ܴ5ܲ ∗ ܣܵܲܭ௠஺ௌ௉ + ܣܵܲ ∗ ܩܮܰܭ௠ீ௅ே + ܩܮܰ ∗ ܩܮܻܭ௠ீ௅௒ + ܩܮܻ 
 
29 
 
 
ߥ(ܰܣܦܲܪ݋ݔ) = ߥ୫ୟ୶ே஺஽௉ு௢௫ ∗ ܰܣܦܲܪܭ௠ே஺஽௉ு +ܰܣܦܲܪ 
 
 
30 
 
ߥ(݃ݎ݋ݓݐℎ) = ߥ୫ୟ୶ ௚௥௢௪௧௛ ∗ ܴ5ܲܭ௠ோହ௉ + ܴ5ܲ ∗ ܩ6ܲܭ௠ீ଺௉ + ܩ6ܲ ∗ ܥܫܶܭ௠஼ூ் + ܥܫܶ ∗ ܩܮܷܭ௠ீ௅௎ + ܩܮܷ 
∗
ܩܮܰ
ܭ௠ீ௅ே + ܩܮܰ ∗ ஺்௉஺஽௉ܭ
௠
ಲ೅ು
ಲವು
+ ஺்௉
஺஽௉
 
 
 
 
Table  4.4State variables description and initial conditions 
 
Component Description Value Units 
ACCoA Acetyl-CoezymeA 1.39E-7 mmol (106 cells)-1 
AKG α-Ketoglutarate 1.4E-7 ‘‘ 
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ADP Adenosine diphosphate 4.9e-7 ‘‘ 
AMP Adenosine monophosphate 1.4e-8 ‘‘ 
ATP Adenosine triphosphate 2.72E-6 ‘‘ 
CIT Citrate 2E-6 ‘‘ 
CoA CoenzymeA 2E-8 ‘‘ 
Cr Creatine 3E-6 ‘‘ 
F6P Fructose 6-Phosphate 3E-7 ‘‘ 
G6P Glucose 6-Phosphate 6E-7 ‘‘ 
GAP Glyceraldehyde 3-Phosphate 1.6E-7 ‘‘ 
GLN Glutamine 9e-6 ‘‘ 
GLU Glutamate 8E-6 ‘‘ 
GLY Glycine 8E-6 ‘‘ 
MAL Malate 1.5E-7 ‘‘ 
NAD Nicotinamide adenine 
dinucleotide 
9E-7 ‘‘ 
NADH Nicotinamide adenine 
dinucleotide (reduced) 
3E-8 ‘‘ 
NADP Nicotinamide adenine 
dinucleotide phosphate 
9E-13 ‘‘ 
NADPH Nicotinamide adenine 
dinucleotide phosphate 
(reduced) 
1.4E-11 ‘‘ 
OXA Oxaloacetate 1E-5 ‘‘ 
O2 Intracellular oxygen 8E-6 ‘‘ 
PEP phosphoenolpyruvate 3.5E-7 ‘‘ 
PCr PhosphoCreatine 1E-7 ‘‘ 
Pi Inorganic phosphate 2E-6 ‘‘ 
PYR Pyruvate 2E-7 ‘‘ 
R5P Ribose 5-phosphate 1.5E-7 ‘‘ 
SCoA Succinyl-CoA 4E-7 ‘‘ 
SUC Succinate 4E-7 ‘‘ 
X5P Xylose-5-phosphate 1E-7 ‘‘ 
EALA Extracellular alanine 0.5 mM 
EASP Extracellular aspartate 0.5 ‘‘ 
EGLC Extracellular glucose 24 ‘‘ 
EGLN Extracellular glutamine 3.5 ‘‘ 
EGLU Extracellular glutamate 0 ‘‘ 
ELAC Extracellular lactate 1.5 ‘‘ 
ENH4 Extracellular ammonia 1.1 ‘‘ 
 
4.5.2.3 Model calibration and sensitivity analysis 
The model has 36 differential equations, i.e. mass balances on state variables listed in 
Table 4.4, which were solved using the Matlab software (The MathWorks Inc., Natick, 
MA, USA).The model has a high number of parameters with 35 affinity constants (listed 
in Table 4.5), 35 maximum reaction rates (Table 4.6), and two parameters for each 
sigmoidal switch functions (Table 4.3). Initial conditions (Table 4.4), at inoculation, and 
parameters values have been taken from literature, when available, or estimated as 
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previously described in Leduc et al. (Leduc et al., 2006) and as briefly summarized 
below. The objective function is formulated as the weighted sum of squared residuals 
(WSSRES) between available experimental data (Xmea) and simulated values (Xsim) for 
each state variable mat time k, where the weight is the inverse of the variance of the 
experimental data for each state variable, varm-1 
min WSSRES =ቂ∑ ∑ ൫ܺ௧,௠௦௜௠ − ܺ௧,௠௠௘௔൯ଶݒܽݎ௠ିଵ௡௠ୀଵ௞௧ୀଵ ቃ                                                     (9) 
The objective function was minimized in an iterative process using the Matlab 
Optimization Toolbox, Least-squares fit, and manual tuning of the parameters and initial 
conditionsto help the convergence. To avoid over parameterization, a parameter 
sensitivity analysis was first performed using experimental data from CHO cell control 
batch culture previously described (McMurray-Beaulieu et al., 2009). This step has 
facilitated the detection of the significant parameters from their initial values, and thus 
guided us in the following iterative cycle of optimization.In a second step, a sensitivity 
analysis was performed consisting in changing a parameter value over a range of -85% to 
+300% around its value, while holding all other parameters constant. The sensitivity of 
the model on each parameter was then quantified from the objective function. Once no 
further minimization of the objective function could be obtained, the values of parameters 
were considered determined. Thereafter, model parameters conferring a high sensitivity 
to the model were calibrated on the datasets of the two cultures with sodium butyrate, 
using whole culture data before and after sodium butyrate addition, and changing kinetic 
parameters at the time of sodium butyrate addition using a sigmoidal switch function to 
avoid any mathematical discontinuity. In one culture, sodium butyrate has been added at 
48 h during mid-exponential growth phase (NaBu-48h) and in the other at 74 h, which 
corresponded to the early plate growth phase (NaBu-74h) (McMurray-Beaulieu et al., 
2009). The process of parameter revision was continued until the simulated proﬁles 
closely followed experimental data, and that experimental data -orphans simulation 
profiles were within ranges found in literature. The parameter values for the final 
calibrated model are shown in Tables 4.5 and 4.6, those associated to 
glutamine/glutamate management are shown in Table 4.3. Confidence intervals for highly 
sensitive parameter estimates (Table 4.6) and simulated fluxes and ratios were then 
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evaluated using "nlparci.m" and"nlpredci.m", both Matlab built-in functions, 
respectively. Moreover, unpaired two-tailed Student’s t-test was used and related p-
values were calculated to statistically compare parameter values (Table 4.6) and 
simulated fluxes and ratios for the cultures with and without sodium butyrate (Table 4.7). 
4.6 Results 
4.6.1  Calibration of model structure and parameters on CHO cells control  
culture 
Model calibration was first performed, as described in the Material and Methods section, 
on control bioreactor culture data without sodium butyrate (McMurray-Beaulieu et al., 
2009). Four kinetic expression formulations (described in Table 4.1) were evaluated in 
parallel. The use of a Michaelis-Menten type kinetic for the only reaction substrates 
(formulation #1) led to the highest simulation error compared to experimental data 
(Table 4.1). Considering the cell energetic (ATP, ADP) and/or redox (NADH, NAD+, 
NADPH, NADP+) shuttles concentrations as well (#2) enabled to decrease the simulation 
error. However, the use of ratios (ATP/ADP, NADH/NAD+, NADPH/NADP+) in 
formulations #3 allowed to lower simulation error. Combining formulations #2 and #3 
(formulation #4) led to a high and similar error than for formulation #2. Therefore, 
because of a higher performance level (i.e. lower simulation error) as well as a lower 
formulation complexity kinetic expression, formulation #3 was used in the remaining of 
this study. A sensitivity analysis performed on the final calibrated model structure (i.e. 
kinetic formulation #3), shows that the model is sensitive to 25 of its 72 parameters, 
where these affected more than 5% the objective function, and thus model 
appropriateness, when changed from -85 to +300% from their calibrated values. 
However, based on comparative studies found in literature (Cloutier et al., 2008), we 
arbitrarily set the criterion to qualify a parameter as a sensitive one when a small 
variation of its value (±15%) causes an increase on the objective function of more that 
10%. The model showed to be more sensitive to rate constants than to affinity constants 
(Figure 4.2). A series of more precise sensitivity analyses were then performed without 
enabling to improve (lower) the objective function. As showed in Figure 4.2, the most 
influential parameters are mostly related to the maximum specific growth rate, 
(νmax,growth), and glycolysis (νmaxHK,νmaxPGI, νmaxPFK/ALD, νmaxPK, νmaxfLDH and νmaxrLDH), and 
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partially to TCA cycle (νmaxCIT/ISOD, νmaxSCOAS, andνmaxMLD), and glutaminolysis (νmaxfGlnT, 
νmaxfGLNS, andνmaxGLDH). To a lesser extent, parameters of the pentose phosphate pathway 
(νmaxEP) and of the reaction connecting glycolysis to TCA cycle (νmaxPDH) also showed to 
influence model simulations. Considering the energetic fuelling reactions, the model was 
highly sensitive to the parameter related to unaccounted ATP consuming reactions, 
(νmaxATPase), and NADH consuming reaction, (νmaxleak).  Therefore, a subset of 17 
parameters were first challenged to minimize the value of the objective function adapting 
the model to the cultures with sodium butyrate. All calibrated model parameters values 
for maximum reaction rates are within the ranges proposed in literature (Tables 4.5 and 
4.6). Kmvalues for intracellular metabolites were also withinranges reported in other 
studies (10-7-10-6 (mmol 106)-1 cells) (skeletal muscle cells: (Dash et al., 2007; Lambeth 
& Kushmerick, 2002).Finally, Km values for extracellular nutrients are within the ranges 
reported for CHO cells, except for extracellular lactate, which is higher than that found in 
literature (15 vs 6 mmol L-1) (Nolan & Lee, 2010). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table  4.5   Affinity (Km) constants 
 
Parameter Value Units 
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 Control NaBu-74h NaBu-48h  
ࡷ࢓ࡱࡳࡸ࡯ 4.29 4.29 4.29 mM 
ࡷ࢓ࡱࡳࡸࡺ 1.27 1.27 1.27 ‘‘ 
ࡷ࢓ࡱࡸ࡭࡯  15 15 15 ‘‘ 
ࡷ࢓ࡱࡺࡴ૝  2 2 2 ‘‘ 
ࡷ࢓ࡳ૟ࡼ  2E-7 2E-7 2E-7 mmol (10
6 cells)-1 
ࡷ࢓ࡲ૟ࡼ 9E-6 9E-6 9E-6 ‘‘ 
ࡷ࢓ࡳ࡭ࡼ  8E-7 8E-7 8E-7 ‘‘ 
ࡷ࢓ࡼࡱࡼ 9.6E-7 9.6E-7 9.6E-7 ‘‘ 
ࡷ࢓ࡾ૞ࡼ  1E-7 1E-7 1E-7 ‘‘ 
ࡷ࢓ࢄ૞ࡼ 3.4E-8 3.4E-8 3.4E-8 ‘‘ 
ࡷ࢓ࡼࢅࡾ  9E-7 9E-7 9E-7 ‘‘ 
ࡷ࢓࡭࡯࡯ࡻ࡭ 9.6E-7 9.6E-7 9.6E-7 ‘‘ 
ࡷ࢓ࡻࢄ࡭  2.4E-7 2.4E-7 2.4E-7 ‘‘ 
ࡷ࢓࡯ࡵࢀ 1E-7 1E-7 1E-7 ‘‘ 
ࡷ࢓࡭ࡷࡳ 3E-8 3E-8 3E-8 ‘‘ 
ࡷ࢓ࡿ࡯ࡻ࡭ 1.5E-7 1.5E-7 1.5E-7 ‘‘ 
ࡷ࢓ࡿࢁ࡯ 1.6E-7 1.6E-7 1.6E-7 ‘‘ 
ࡷ࢓ࡹ࡭ࡸ 2E-7 2E-7 2E-7 ‘‘ 
ࡷ࢓ࡳࡸࡺ  8.2E-6 8.2E-6 8.2E-6 ‘‘ 
ࡷ࢓ࡳࡸࢁ 1.25E-5 1.25E-5 1.25E-5 ‘‘ 
ࡷ࢓ࡳࡸࢅ 3E-8 3E-8 3E-8 ‘‘ 
ࡷ࢓࡭ࢀࡼ 7.6E-6 7.6E-6 7.6E-6 ‘‘ 
ࡷ࢓࡭ࡰࡼ 6.25E-7 6.25E-7 6.25E-7 ‘‘ 
ࡷ࢓࡭ࡹࡼ  2E-8 2E-8 2E-8 ‘‘ 
ࡷ࢓ࡼࢉ࢘ 7.6E-6 7.6E-6 7.6E-6 ‘‘ 
ࡷ࢓࡯࢘ 5E-6 5E-6 5E-6 ‘‘ 
ࡷ࢓ࡻ૛  4E-6 4E-6 4E-6 ‘‘ 
ࡷ࢓ࡼ࢏ 1E-6 1E-6 1E-6 ‘‘ 
ࡷ࢓ࡺ࡭ࡰࡴ 1E-7 1E-7 1E-7 ‘‘ 
ࡷ
࢓
࡭ࢀࡼ
࡭ࡰࡼ
            1            1            1 unitless 
ࡷ
࢓
࡭ࡰࡼ
࡭ࢀࡼ
 9.5E-6 9.5E-6 9.5E-6 ‘‘ 
ࡷ
࢓
ࡺ࡭ࡰࡴ
ࡺ࡭ࡰ
 0.0035 0.0035 0.0035 ‘‘ 
ࡷ
࢓
ࡺ࡭ࡰ
ࡺ࡭ࡰࡴ
 0.061 0.061 0.061 ‘‘ 
ࡷ࢓ࡺ࡭ࡰࡼࡴ 1E-9 1E-9 1E-9 ‘‘ 
ࡷ
࢓
ࡺ࡭ࡰࡼ
ࡺ࡭ࡰࡼࡴ
 1E-3 1E-3 1E-3 ‘‘ 
 
 
 
 
 
 
 
Table  4.6    Maximum reaction rates and comparison of highly sensitive parameters with 
their intervals in control, NaBu-48h and NaBu-74h cultures 
 
Parameter Value t-test 
Results 
Literature 
 Control                    NaBu-74h                  NaBu-48h 
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ࣇ࢓ࢇ࢞ࡴࡷ  2.25E-4 
(2.15E-4,2.35E-4) 
2.89E-4 
(2.59E-4,3.19E-4) 
2.25E-4 
 (1.94E-4,2.56E-4) 
p<0.1 + 10-4–10-3 
(Dash et al., 2007; 
Goudar et al., 
2010; Lambeth & 
Kushmerick, 
2002; Nolan & 
Lee, 2010; 
Zamorano et al., 
2010) 
ࣇ࢓ࢇ࢞ࢌࡼࡳࡵ 2E-4 
(5E-5,3.5E-4) 
1.8E-4 
(2.8E-5,3.32E-4) 
2E-4 
 (3.8E-5,3.62E-4) 
 
 
‘‘ 
ࣇ࢓ࢇ࢞ࡼࡲࡷ/࡭ࡸࡰ 2.5E-3 
(5E-5,3.5E-4) 
2.64E-3 
(1.91E-3,3.32E-3) 
2.5E-3 
 (1.93E-3,3.35E-3) 
 ‘‘ 
ࣇ࢓ࢇ࢞ࡼࡳࡷ 9E-4 9E-4 9E-4  ‘‘ 
ࣇ࢓ࢇ࢞ࡼࡷ 1.95E-3           
(1.6E-3,2.3E-3) 
1.95E-3           
(1.25E-4,2.65E-4) 
2.19E-3 
(1.58E-3,2.8E-3) 
 ‘‘ 
ࣇ࢓ࢇ࢞ࢌࡸࡰࡴ 1.5E-3            
(1.03E-3,1.97E-3) 
8.5E-4                 
(5.05E-4,1.2E-3) 
6.04E-4        (2.73E-
4,7.29E-3) 
p<0.1 * ‘‘ 
ࣇ࢓ࢇ࢞࢘ࡸࡰࡴ 7.25E-4          
(1.86E-3,1.26E-3) 
8.9E-4            
(4.25E-4,1.53E-3) 
6.04E-4          
(1.03E-4,1.1E-3) 
 ‘‘ 
ࣇܕ܉ܠ ࡳ૟ࡼࡰࡴ/ࡼࡳࡸࢉࡰࡴ 9E-4 9E-4 9E-4  10-5-10-4(Holzhutter, 
2004; Lambeth & 
Kushmerick, 
2002; Zamorano 
et al., 2010) 
ࣇ࢓ࢇ࢞ࡱࡼ 5E-4                
(4.3E-4,5.6E-4) 
5E-4                
(4.4E-4,5.55E-4) 
5E-4                
(4.5E-4,5.4E-4) 
 ‘‘ 
ࣇܕ܉ܠࢀࡷ/ࢀ࡭ 3E-5 3E-5 3E-5  ‘‘ 
ࣇ࢓ࢇ࢞ࡼࡰࡴ 1.6E-4           
(3.42E-5,2.85E-4) 
2E-4 
(8.75E-5,3.1E-4) 
1.12E-4 
(3.04E-5,1.94E-4) 
 10-5-10-4 
(Dash et al., 2007; 
Nolan & Lee, 
2010; Wu et al., 
2007) 
ࣇ࢓ࢇ࢞࡯ࡿ 2.65E-4 2.65E-4 2.65E-4  ‘‘ 
ࣇܕ܉ܠ࡯ࡵࢀࡿ/ࡵࡿࡻࡰ  1.16E-4         
(1.34E-5,2.18E-4) 
2.5E-4 
(1.1E-4,3.9E-4) 
2.5E-4 
(7E-5,4.3E-4) 
 ‘‘ 
ࣇ࢓ࢇ࢞࡭ࡷࡳࡰࡴ 9.5E-5 9.5E-5 9.5E-5  ‘‘ 
ࣇ࢓ࢇ࢞ࡿ࡯ࡻ࡭ࡿ 1.4E-4           
(4.02E-5,2.4E-4) 
2.75E-4 
(1.3E-4,4.1E-4) 
3E-4 
(1E-5,5E-4) 
 ‘‘ 
ࣇܕ܉ܠ ࡿࡰࡴ/ࡲࢁࡹ 2.5E-4 2.5E-4 2.5E-4  ‘‘ 
ࣇ࢓ࢇ࢞ࡹࡰࡴ 1.5E-4           
(3.97E-5,2.58E-4) 
2.5E-4 
(6E-5,4E-4) 
2.5E-4 
(4.9E-4,4.5-4) 
 ‘‘ 
ࣇܕ܉ܠ ࡿࡰࡴ/ࡲࢁࡹ 2.5E-4 2.5E-4 2.5E-4  ‘‘ 
ࣇ࢓ࢇ࢞ࡹࡰࡴ 1.5E-4 2.5E-4 2.5E-4  ‘‘ 
 
 
 
 
 Table 4.6     Maximum  reaction rates and comparison of highly sensitive parameters with their 
intervals in control, NaBu-48h and NaBu-74h cultures (Continued) 
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ࣇ࢓ࢇ࢞ࡹࡱ 2.5E-6 2.5E-6 2.5E-6  N/A 
ࣇ࢓ࢇ࢞ࢌࡳ࢒࢔ࢀ 8.7E-5           
(7.65E-5,9.75E-5) 
6E-5 
(4.4E-5,7.53E-5) 
4E-5 
(1.1E-5,6.9E-5) 
p<0.1 * + 10-6-10-4 
 (Nolan & Lee, 
2010) 
ࣇ࢓ࢇ࢞࢘ࡳ࢒࢔ࢀ 2.5E-5 2.5E-5 2.5E-5  ‘‘ 
ࣇ࢓ࢇ࢞ࢌࡳࡸࡺࡿ  9.5E-5           
(4.51E-5,1.36E-4) 
9.5E-5             
(6.01E-5,1.3E-4) 
9.5E-5             
(7.2E-5,1.18E-4) 
 ‘‘ 
ࣇ࢓ࢇ࢞࢘ࡳࡸࡺࡿ 1E-4 1E-4 1E-4  ‘‘ 
ࣇ࢓ࢇ࢞ࡳ࢒࢛ࢀ 5E-5 5E-5 5E-5  ‘‘ 
ࣇ࢓ࢇ࢞ࡳࡸࡰࡴ 1.8E-5    
(0,2.34E-5) 
1.8E-5          
(0,3.36E-5) 
1.8E-5        
(0,4.14E-5) 
 ‘‘ 
ࣇ࢓ࢇ࢞࢘ࢋ࢙࢖ 8E-4 8E-4 8E-4  10
-3-10-5 
 (Dash et al., 
2007) 
ࣇ࢓ࢇ࢞࡭ࢀࡼࢇ࢙ࢋ 4E-3            
(3.7E-3,4.3E-3) 
6E-3                  
(5.3E-3,6.7E-3) 
6E-3                
(5.4E-3,6.6E-3) 
p<0.1 * + ‘‘ 
ࣇ࢓ࢇ࢞࢒ࢋࢇ࢑ 4.7E-5            
(5E-6,8.9E-5) 
4.7E-5           
(5E-6,8.9E-5) 
4.7E-5           
[3E-6,9.1E-5) 
 ‘‘ 
ࣇ࢓ࢇ࢞ࢌ࡯ࡷ 2.3E-4 2.3E-4 2.3E-4  ‘‘ 
ࣇ࢓ࢇ࢞࢘࡯ࡷ 9E-5 9E-5 9E-5  ‘‘ 
ࣇ࢓ࢇ࢞ࢌ࡭ࡷ 2E-5 2E-5 2E-5  ‘‘ 
ࣇ࢓ࢇ࢞࢘࡭ࡷ 3E-5 3E-5 3E-5  ‘‘ 
ࣇ࢓ࢇ࢞ࡼࡼࡾ࢏࢈ࡼ 2E-8 2E-8 2E-8  N/A 
ࣇ࢓ࢇ࢞ࡺ࡭ࡰࡼࡴ࢕࢞ 4E-5 4E-5 4E-5  N/A 
ࣇ࢓ࢇ࢞ࢍ࢘࢕࢚࢝ࢎ 0.215    
(0.21,0.22) 
0.043                                            
(0.35,0.56) 
0.04     
(0.03,0.05) 
p<0.1 * + N/A 
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Figure  4.2Sensitivity analysis on model parameters for sodium butyrate control culture. 
Each column represents percentage change in the objective function (solid bars) for 
parameter adjustment of -85% to +300%. Parameters not shown have percentage changes 
that are below 5%. 
4.6.2 The model simulates CHO cells behaviour in sodium butyrate stimulated 
cultures 
Interestingly, the model simulates experimental data for CHO cells bioreactor control 
culture as well as for both NaBu-48h and NaBu-74h cultures (Figure 4.5). Cell growth is 
well simulated in all cultures. More importantly, the cell energetic state represented by 
intracellular ATP, ADP, and AMP levels, and the cell specific oxygen consumption rate 
(qO2) were also all well simulated, except for the data point of qO2 at 48h, for which we 
have no explanation. Model simulations for intracellular metabolites, for which no 
experimental data were available, are shown in supplementary material (Figure 4.11) for 
clarity purposes. However, we paid a rigorous attention at simulations of these non-
measured intracellular metabolites, defining constraints ensuring they all agree with the 
very few available data in literature. Using an average cell volume of 1000 µm3, as 
proposed by Li et al. (2006) (Li, Sun, & Zhang, 2006a) for CHO cells, simulated 
concentrations of intracellular intermediates were compared to literature (Figure 4.11). 
These results confirm that the model can provide a satisfactory description of cell 
behavior over the course of a culture, including at the metabolic level.Parameter 
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estimates together with their intervals (for highly sensitive ones), priorand posterior to 
sodium butyrate addition, are presented in Table 4.6. Weighted residuals were also 
verified to be both independent and normally distributed since all the points fell along a 
straight line as shown in the normal probability plot of the weighted residuals for the 
three cultures (Figure 4.4). 
4.6.3  Statistical analysis on estimated parameters 
In Figure 4.3, we show 95% confidence intervals for the highly sensitive parameter 
estimates for the three cultures, i.e. with and without sodium butyrate. In all cases, 
parameter estimates and model calculated 95-percent linear confidence intervals are 
within the reported ranges for these parameters. As clearly showed in Figure 4.3 and 
considering the p-values reported in Table 4.6, the effect of sodium butyrate can be 
described through 4 distinct parameters only, on a total of 72 considering 95% confidence 
interval, with some differences for a sodium butyrate addition at mid-exponential or the 
early plateau phases. More specifically, in the case of the NaBu-48h culture the 
νmaxfLDHneeded to be reduced by 66% from that determined for the control culture.In the 
case of the NaBu-74h culture, however, νmaxHKrequired a 28% increase of the maximal 
rate.Butyratehas been reported to affect Lactate dehydrogenaseactivity level (De Leon et 
al., 2007; Yee et al., 2008). Moreover, νmaxfGlnTneeded to decrease by 54 % in the NaBu-
48h culture and by 31% in the NaBu-74h culture. The inhibitory effect of butyrate on 
glutamine transport has been previously reported (Bode & Souba, 1994). In addition, our 
model parameters calibration strategy resulted in a 81 % reduction of the cell 
νmaxgrowthfrom sodium butyrate addition. However, only the parameter related to ATP 
consumption, (νmaxATPase), lumped as ATPase pumps requirements, needed to be increased 
by 48 % for both NaBu-48h and the NaBu-74h cultures. Interestingly, sodium butyrate, a 
four-carbon short chain fatty acid, has been reported of being transported across CHO 
cells membrane due to the presence of monocarboxylate transporters family (Rizhaupt et 
al., 1998). The transport process itself may then signal transcriptional and translational 
events, which are accompanied by higher energy requirements which is in agreement 
with an increase of νmaxATPase in this work. A similar result has been previously reported 
by Beauvieux et al. (1986) (Beauvieux et al., 1986) for CHO cells.  
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Figure  4.3Parameter estimates with their error bars for highly sensitive parameters of 
glycolysis (A), TCA cycle and redox state (B), glutaminolysis and pentose phosphate 
pathway (C), and energetic and growth (D). 
Horizontal lines are 1.96 standard error bars and represent parameter estimate 1.96  
standard error. Sodium butyrate was added at 48 h (NaBu-48h : open triangles for 
parameter estimates and dashed line for error bars) or 74 h (NaBu-74h : open circles and 
dotted line for error bars). Control culture (open squares and solid line for error bars) 
without sodium butyrate.A parameter is considered highly sensitive if a small variation in 
its value ( 15%) causes more than a 10 % increase of in the objective function. 
 
 
 
 
Figure  4.4Normal probability plot of the weighted residuals for Control (A), (NaBu-48h) 
(B) and (NaBu-74h) (C) cultures. 
 
 78 
 
 
 
 
Figure  4.5Simulated and experimental data for Control and cultures with sodium butyrate 
addition. 
Control: experimental data: open squares, simulated data: solid line. Cultures with 
sodium butyrate addition at 48 h (NaBu-48h): experimental data: open triangles, 
simulated data: dashed line) and at 74 h (NaBu-74h): experimental data: open circles, 
simulated data: dotted line. Experimental data are taken from a previous 
work(McMurray-Beaulieu et al., 2009) 
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4.7 Discussion 
Taking all of the above, it is clear that the model structure, which is based on the cell 
energetic state, allows simulating CHO cells culture behaviour. Therefore, in the 
following, the calibrated model is used as an in silico platform to analyse the effect of 
butyrate on CHO cells metabolic network behaviour. It is important to note that all results 
shown in Figures 4.6 to 4.10, and discussed in this section, were obtained from model 
simulations. In order to statistically interpret model simulations, confidence intervals are 
shown together with simulations at each 24 hours and a t-statistic associated significance 
value was calculated in case of statistical comparison (Table 4.7). 
4.7.1 Effect of sodium butyrate on CHO cells nutritional behaviour 
To further study the dynamic effects of sodium butyrate on CHO cell metabolism, 
simulated fluxes for CHO cells nutritional state were first analysed (Figure 4.6). The 
culture with butyrate addition at mid-exponential growth phase (NaBu-48h) exhibits a 
high and stable specific glucose uptake rate, with a slight decrease from 72 h. This 
decrease was more pronounced in the control culture where specific glucose uptake rate 
was 73% less at 144 h (Figure 4.6A). Interestingly, however, the cells seem to become 
more efficient when butyrate is added at mid-exponential phase since the ratio of lactate 
production rate-to-glucose consumption rate decreases by 18% after 72 h (Figure 4.6C). 
The values for the ratio of lactate production rate-to-glucose consumption rate showed to 
be in the range previously reported in the literature (1.4 – 2.2 to 0.05 – 0.5) (Wlaschin & 
Hu, 2006). In contrast, butyrate addition at the early plateau phase (NaBu-74h) causes an 
increase of the specific glucose uptake rate from 96 h; the NaBu-74h culture shows a 
22% increase of the specific glucose uptake rate at 120 h compared to control culture, 
which then decreases 44% below the value for 120 h. In parallel, the ratio of lactate 
production rate-to-glucose consumption rate stays initially constant and increases by 20% 
at 120 h when compared to the value for control culture. In cases of the specific 
glutamine uptake rate (Figure 4.6B) and the ratio of ammonia production rate-to-
glutamine consumption rate (Figure 4.6D), no statistical difference can be determined 
among the three cultures. The ratios of ammonia production rate-to-glutamine 
consumption rate were also within ranges reported in literature (0.5 – 1.3 to 0.1 – 0.3) 
(Wlaschin & Hu, 2006). The culture with butyrate addition at mid-exponential phase thus 
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shows a sustained and higher metabolic activity. 
 
 
 
Figure  4.6Simulated time profiles of specific glucose uptake rate (A), specific glutamine 
uptake rate (B), lactate production-to-glucose consumption ratio (C), and ammonia 
production-to-glutamine consumption  ratio  (D), over time. 
specific glucose uptake rate: ν(HK), specific glutamine uptake rate: νf(GlnT)-νr(GlnT)), 
lactate production-to-glucose consumption ratio: (νf(LDH)-νr(LDH))/ν(HK),  ammonia 
production-to-glutamine consumption ratio:  (νf(GLNS)-νr(GLNS)+ν(GLDH))/(νf(GlnT)-
νr(GlnT)). Vertical lines indicate the time of sodium butyrate addition. 95% confidence 
intervals for model simulations are shown. Same conditions as Figure 4.5 applied. 
 
4.7.2  Effect of sodium butyrate on CHO cells metabolism and energetic 
behaviour 
 
4.7.2.1 G6P branch point 
The glycolytic flux (Figure 4.7A) follows closely the evolution of the specific glucose 
uptake rate for all three cultures, where in the case of an addition at mid-exponential 
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phase, the model simulates a final value that is 22 % higher at 120 h compared to that for 
the control culture. We then looked at the major branch points within glycolysis. First, we 
evaluated the portion of glucose that goes to cell mass. The glucose used for the synthesis 
of DNA/RNA (via R5P pool) and carbohydrates (via G6P pool), and taken as going to 
biomass synthesis, rapidly decreases by 69 % and 64% for the NaBu-48h and the NaBu-
74h at 120 h, respectively (Figure 4.7B) . The value identified for the percentage of 
glucose derived to biomass is consistent with the reported value in literature (hybridoma 
cells: 3.9 %) (Follstand et al., 2000). The percentage of glucose flowing through the 
pentose phosphate pathway, defined as the ratio of pentose phosphate oxidative flux to 
glucose uptake rate, does not show an increase when butyrate was added at mid 
exponential phase with a 34.5% lower value at 144 h (Figure 4.7C). Around 23.14 % of 
the glucose uptake flux enters the pentose phosphate pathway at mid-exponential phase 
for all cultures while a value of 41% has been reported for CHO cells (Goudar et al., 
2010). The ratio of pentose phosphate reflux to glycolysis (non-oxidative) (ν(TK/TA)) to 
the pentose phosphate oxidative flux (ν(G6PDH/PGLcDH)) shows stable values in all 
cultures (Figure 4.7D).A simulated average ratio of 0.320.2 is in agreement with 
literature for CHO cells (0.33±0.056) (Goudar et al., 2010), hybridoma cells (0.37) 
(Bonarius et al., 1996) and hepatic cells (~0.3) (Maier et al., 2008) where the first and last 
results are based on independent measurement of intracellular fluxed using tracers. 
Consequently, the addition of butyrate has not modified the pentose phosphate pathway 
fluxes distribution, except for the NaBu-48h culture at the end of exponential phase. 
Therefore, since less glucose is used for biomass synthesis (Figure 4.7B), and that less 
lactate is produced per glucose consumed (Figure 4.6C), one can expect the glycolytic 
flux to pyruvate to be increased. 
4.7.2.2 Pyruvate branchpoint ratio 
The pyruvate branch point ratio shows a 44 % increase in the NaBu-48h culture at 120 h 
compared to the control culture. (Figure 4.8A) and, however, a decreasing trend when 
butyrate was only added at the early plateau phase. Simulation results are thus in 
agreement with that for the lactate-to-glucose ratio (Figure 4.6C). Although butyrate 
addition leads to lower values of pyruvate branch point ratio in the NaBu-74h culture, the 
increased glucose consumption rate simulated by the model can compensate as seen by 
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elevated values for the TCA flux (Figure 4.8B). Moreover, Altamirano et al. (2001) 
(Altamirano et al., 2001) have also reported, in CHO cell cultures, a higher metabolic 
efficiency in terms of higher pyruvate branch point ratios. Albeit experimental data for 
NADH/NAD were not available, simulated values are in agreement with a reported value 
of 0.05 for CHO cells in a recent study (Zhang et al., 2006). Therefore, taken together, 
model simulations coupled to experimental data clearly suggest that adding butyrate at 
mid-exponential growth phase sustains a high cell metabolic activity level favouring 
energy production.  
 
Figure  4.7Simulated time profiles of glycolytic flux (A), the percentage of glucose 
derived to biomass (B), pentose phosphate activity (C), and pentose phosphate non-
oxidative branch activity (D). 
The percentage of glucose derived to biomass is determined as the glucose contribution 
to biomass synthesis and calculated as the percentage of glycolytic flux toward the 
synthesis of biomass precursors. The pentose phosphate activity is defined as the 
percentage of the glycolytic flux channeled through pentose phosphate pathway, i.e. the 
ratio of pentose cycle oxidative flux to the glucose uptake (ν(G6PDH/PGLcDH)/ν(HK)). 
Pentose phosphate non-oxidative branch activity is identified as the ratio of the pentose 
phosphate reflux to glycolysis to the pentose phosphate oxidative flux 
(ν(TK/TA)/(ν(G6PDH/PGLcDH)). Same conditions as Figure 4.6 applied. 
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Figure  4.8Simulated values of metabolic flux distribution around pyruvate branch point, 
defined as the ratio of the pyruvate influx through TCA cycle to the glycolytic flux (A), 
TCA cycle flux (B), and cellular redox state (NADH/NAD) (C). 
The ratio of the pyruvate influx through TCA cycle to the glycolytic flux:  v(PDH/ν(PK), 
TCA cycle flux: ν(SCOAS). Same conditions as Figure 4.6 applied. 
 
4.7.2.3  ATP production 
The addition of sodium butyrate caused an increase of the specific ATP production rate, 
with more stable high values for the NaBu-48h culture, compared to the control and the 
NaBu-74h cultures (Figure 4.9A). However, the contribution of the oxidative 
phosphorylative respiration to ATP production is estimated to be similar for all cultures 
and of 597%, at mid exponential phase (Figure 4.9B), which is in agreement with 
reported values for CHO cells (Van der Valk et al., 1998). Model simulations also show a 
similar tendency for the ATP generation yield from glucose to increase, with time, among 
all cultures, with, however, higher average values (but not statistically different) in the 
NaBu-48h culture between 96 h and 120 h (Figure 4.9D). This may suggest a more 
efficient utilization of glucose (i.e. for ATP and biosynthesis reactions) induced by the 
addition of sodium butyrate at mid-exponential phase. As summarized in Figure 4.10, our 
results, both from model simulations and experimental data (McMurray-Beaulieu et al., 
2009), suggest that the addition of butyrate at mid-exponential phase enhances the 
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stability of specific glucose (higher) (Figures 4.6A and 4.10A) and glutamine (lower) 
(Figures 4.6B and 4.10A) uptake rates. It also shows a lower lactate production-to-
glucose consumption rate, with both forward and backward fluxes of lactate 
dehydrogenase decreased (Figures 4.6C and 4.10A). Higher fluxes for protonleak and 
oxidative phosphorylation are also simulated (Figure 4.10A),suggesting an increased 
specific O2 consumption rate compared to the control culture (Figures 4.5). The increased 
oxidative phosphorylative respiration (i.e. qO2) is supported by the increased pyruvate 
branch point ratio (Figure 4.8A), TCA cycle activity (Figures 4.8B and 4.10A) and 
NADH-to-NAD ratio (Figure 4.8C). In the case of pyruvate branch point ratio, the 
glycolytic flux to pyruvate, as well as the pyruvate influx to TCA cycle, were also 
increased (Figure 4.10A). This was not the case for Na-Bu 74h asboth forward and 
backward fluxes of lactate dehydrogenase increased simultaneously (Figure 4.10B).The 
model simulated higher pentose phosphate pathway fluxes (Figure 4.10A) although 
related ratios remained the same (Figure 4.7C and 4.7D). The cells that are stimulated by 
sodium butyrate at mid-exponential phase may thus stabilize their glucose uptake per cell 
per unit of time. ATP is then being produced at a higher rate per cell as supported by qO2 
experimental data (Figure 4.5). Finally, although a high energetic state is thought to 
coincide to a higher global metabolic activity, it was not possible, in this work, to 
establish a statistically significant correlation between the cell energetic state and its 
productivity level in recombinant t-PA, probably due to the low productivity level of the 
cell line under study. 
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Figure  4.9Simulation of CHO cell energetic state. ATP turnover rate (A), contribution of 
oxidative metabolism to overall ATP production (B), contribution of aerobic glycolysis to 
overall ATP production (C), contribution of glucose to total ATP production (D), and the 
net specific productivity in recombinant t-PA observed experimentally (E), over time. 
ATP turnover rate is defined as ν(PGK)+ν(PK)+v(SCOAS)+νr(GlnT)+ 
νf(CK)+vr(AK)+2P/O ratio*ν(resp). The contribution of oxidative metabolism to overall 
ATP production is defined as the portion of ATP generated from oxidative metabolism 
divided by the total ATP production rate (2P/O ratio *ν(resp)/ 
(ν(PGK)+ν(PK)+v(SCOAS)+ νr(GlnT)+ νf(CK)+vr(AK)+2P/O ratio*ν(resp)). The 
contribution of glucose to ATP production is defined as the molar ratio of ATP 
production rate (ν(HK)/(ν(PGK)+ν(PK)+v(SCOAS)+νr(GlnT)+νf(CK)+vr(AK)+2P/O 
ratio*ν(resp)) over glucose uptake rate. The contribution of glycolysis was determined as 
the sum of glycolytic fluxes producing ATP over the total ATP production rate 
((ν(PGK)+ν(PK))/( ν(PGK)+ν(PK)+v(SCOAS)+ νr(GlnT)+ νf(CK)+vr(AK)+2P/O 
ratio*ν(resp)).Values for net specific t-PA productivity were obtained from experimental 
data published in a previous work (McMurray-Beaulieu et al., 2009). Control 
(opensquares), NaBu-48h (open triangles), and NaBu-74h (open circles). Same 
conditions as Figure 4.6 applied for (A-D). 
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Figure  4.10Comparison of metabolic flux maps for CHO cells NaBu-48h culture (A) and 
NaBu-74h culture (B) from model simulations at 120 h. 
α is defined as the ratio of specific flux (mmol  (106cells)-1 h-1) in either NaBu-48h or 
NaBu-74h cultures to that in the control culture.  α is considered statistically different 
when p<0.05. 
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4.8 Conclusion 
A model simulating CHO cells metabolic behaviour and describing metabolic network 
fluxes kinetics, as well as the cell redox and energetic states, has been proposed and 
calibrated. Simulation results were shown to satisfactorily describe experimental data and 
to agree with literature data.Moreover, the proposed model proved to be useful to 
describe the effect of sodium butyrate on CHO cells, with limited model adaptation 
requirements (i.e. the changing of only few parameters values) that are in agreement with 
gene expression modifications reported in literature. The model was also used to analyse 
the effect of butyrate at the metabolic network level, and the previous observations by 
McMurray et al. (2009) of a sustained high metabolic activity following butyrate addition 
was further confirmed from model simulations with higher glucose flux and TCA 
activity, and high cell redox (NADH-to-NAD+ ratio), while energetic states (specific 
ATP turnover rate) did not significantly change. Finally, albeit the model structure 
includes a high number of parameters, it showed to describe not only all in-line and off-
line experimental data, but most of the metabolic changes simulated following sodium 
butyrate addition showed statistical significance. Finally, most of the sensitive parameters 
were also estimated with relatively narrow confidence intervals. However, in a future 
work, it would be of interest to have access to extended experimental datasets of 
intracellular metabolites for a high producer cell line, conditions enhancing model 
parameters identification. From our results, it thus seems conceivable that our model can 
be readily calibrated on different industrial CHO cell lines. It can then be used as an in 
silico platform for characterizing the cell lines as well as to search for "optimal" culture 
management by rational adjustment of the main nutrient concentrations playing on 
glucose and/or glutamine concentration with time. However, much work remains to be 
done, anchoring the model onto larger datasets including both extra- and intracellular 
experimental data in order to test and validate the platform as a predictive tool. 
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Table  4.7(Supplementary) Metabolic fluxes and ratios with their intervals in Control, 
NaBu-48h and NaBu-74h cultures at 120 h. Same conditions as Table 4.6 applied. 
 
 
 
Metabolic Flux/Ratio 
 
Control 
 
NaBu-48h 
 
 
NaBu-74h 
 
t- test  
Result 
 
 Value 
Interval 
      Value 
       Interval 
  
Value 
Interval 
   
Glucose uptake rate 
mmol (106 cells)-1h-1 
 1.4E-4  
(1.26E-4,1.57E-4) 
1.66E-4  
(1.59E-4,1.72E-4) 
2.07E-4 
(1.87E-4,2.27E-4) 
p<0.1 * + 
Lactate production - to -glucose 
Consumption 
1.44    
(1.3,1.54) 
1.18 
(1.06,1.31) 
1.72 
(1.58,1.86) 
p<0.1 * + 
Glutamine uptake rate 
mmol (106 cells)-1h-1 
           6.6E-6 
(1.76E-6,1.05E-5) 
         1.48E-5 
(8.7E-6,2.09E-5) 
9.03E-6 
(4.33E-6,1.75E-5) 
 
 
Ammonia production - to -
glutamine consumption  
 
             0.94 
(0.84,1.04) 
0.81 
(0.72,0.91) 
1.07 
(0.96,1.19) 
 
Glycolytic flux                         
mmol (106 cells)-1h-1 
        2.6E-4 
(2.4E-4,2.95E-4) 
 
3.18E-4 
(2.97E-4,3.41E-4) 
3.94E-4 
(3.65E-4,4.24E-4) 
p<0.1 * + 
Percentage of glucose derived to 
biomass 
               1.93  
    (1.55,2.31) 
 
0.59 
(0.19,1) 
0.68 
(0.3,1.08) 
p<0.1 * + 
Pentose phosphate activity 
(% of glycolysis) 
           23.14  
(19.2,27.1) 
 
21.2 
(17.4,25) 
25.39 
(21.1,29.7) 
 
Pentose phosphate  
non oxidatie - to - oxidative ratio 
             0.31 
(0.24,0.38) 
0.31 
(0.26,0.39)] 
0.32 
(0.27,0.37) 
 
Pyruvate branch point ratio                0.25   
     (0.19,0.3) 
0.36 
(0.31,0.42) 
0.2 
(0.14,0.27) 
p<0.1 * 
TCA flux 
mmol (106 cells)-1h-1 
           7.1E-5 
(4.9E-5,9.3E-5) 
 
         1.12E-4 
(8.9E-5,1.3E-4) 
1.25E-4 
(0.943E-5,1.5E-4) 
p<0.1 + 
NADH/NAD            0.031  
(0.014,0.049) 
 
0.068 
     (0.052,0.084) 
0.069 
(0.048,0.089) 
p<0.1 * + 
Specific ATP production rate 
mmol (106 cells)-1h-1 
 
             1.1E-3 
(6.6E-4,1.7E-3) 
 
1.8E-3 
(1.2E-3,2.4E-3) 
1.9E-3 
(1.3E-3,2.5E-3) 
 
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Table 4.7    (Supplementary) Metabolic fluxes and ratios in Control, NaBu-48h and 
NaBu-74h cultures at 144 h (Continued). 
 
 
 
Metabolic Flux/Ratio 
 
Control 
 
NaBu-48h 
 
 
NaBu-74h 
 
t- test 
Result 
 
  
          Value 
Interval 
 
    Value 
       Interval 
  
Value 
Interval 
   
            Glucose uptake rate 
mmol (106 cells)-1h-1 
          3.97E-5 
(2E-5,5.94E-5) 
 
          1.48E-4 
(1.28E-4,1.67E-4) 
9.51E-5 
(7.46E-5,1.16E-4) 
p<0.1 * + 
Lactate production - to -glucose 
consumption 
            1.19  
(0.95,1.44) 
 
            1.09 
(0.89,1.29) 
              1.2 
(0.99,1.42) 
p<0.1 * + 
Glutamine uptake rate 
mmol (106 cells)-1h-1 
2.8E-7 
(0,1.62E-6) 
1.03E-5 
(4.67E-6,1.59E-5) 
3.64E-6 
(0,7.92E-6) 
 
 
Ammonia production - to -
glutamine consumption 
 
0.853 
(0.73,0.96) 
0.785 
(0.68,0.88) 
0.98 
(0.84,1.12) 
 
Glycolytic flux                          
mmol (106 cells)-1h-1 
         1.09E-4 
(5.78E-5,1.6E-4) 
 
2.83E-4 
(2.5E-4,3.15E-4) 
2.4E-4 
(2.09E-4,2.71E-4) 
p<0.1 * + 
Percentage of glucose derived to 
biomass 
           0.47 
(0.16,0.78) 
 
            0.54 
(0.23,0.85) 
0.2 
(0.07,0.61) 
p<0.1 * + 
Pentose phosphate activity 
(% of glycolysis) 
           34.74 
(30.7,38.8) 
 
22.76 
(18.4,27.2) 
37.38 
(32.7,42) 
 
Pentose phosphate  
non oxidatie - to - oxidative ratio 
0.33 
(0.26,0.4) 
0.33 
(0.26,0.4) 
0.33 
(0.27,0.39) 
 
Pyruvate branch point ratio            0.39 
(0.33,0.45) 
 
0.42 
(0.37,0.48) 
0.42 
(0.24,0.4) 
p<0.1 * 
TCA flux 
mmol (106 cells)-1h-1 
         6.16E-5 
(3.7E-5,8.5E-5) 
 
1.14E-4 
(9.3E-5,1.3E-4) 
1.2E-4 
(9.6E-5,1.4E-4) 
p<0.1 + 
NADH/NAD 0.026 
(0.06,0.046) 
0.067 
 (0.047,0.088) 
0.075 
(0.052,0.098) 
p<0.1 * + 
Specific ATP production rate 
mmol (106 cells)-1h-1 
8.8E-4         
(2.4E-4,1.3E-4) 
1.78E-3 
(1E-3,2.5E-3) 
 1.36E-3 
(7.8E-4,1.9E-3) 
 
 
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Figure  4.11   (Supplementary)Simulated data of intracellular metabolites for Control, and 
cultures with sodium butyrate addition at 48 h (NaBu-48h) and at 74 h (NaBu-74h). 
Control: solid line, NaBu-48 h: dashed line, NaBu-74h: dotted line. 
Axis units are mmol (106 cells)-1. Simulated values of intracellular concentrations showed 
to be within the range found in literature for TCA cycle intermediates (10-7-10-6 mmol 
(106 cells)-1) (Lu et al., 2003; F. Zhang et al., 2006), intracellular sugar phosphates (10-7-
10-6 mmol (106cells)-1) (CHO cells: (Sellick et al., 2009); Hepatic cells: (Maier et al., 
2007); MDCK cells: (Ritter, Wahl, S., Genzel, & Reichl, 2010), intracellular glutamine 
(10-7-10-6 mmol (106 cells)-1) and glutamate (10-6-10-5 mmol (106 cells)-1) (CHO cells: 
(Kontoravdi et al., 2007; Lu, Sun, & Zhang, 2005); HEK-293 cells: (Kontoravdi et al., 
2007).  
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5.1 Presentation of the article 
The kinetic modelling approach for cell metabolism has proven efficient to study CHO 
cell cultures.Due to the rather high number of parameters it was of great interest to 
challenge model adaptability to other CHO cell lines and its engineered clones. Towards 
this end, the model was further developed to describe another CHO cell line. Previous 
estimates for most of the parameter values were remained unchanged using results 
from our previous work. Model simulations were then used to quantify the main 
intracellular fluxes and ratios in clonal derivatives. Comparison of experimental data 
completed by model simulations then shed light to metabolic changes associated with 
clonal variations and onset of protein expression. 
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5.2 Abstract 
Monoclonal antibodyproducingChinese hamster ovarycells have been shown to undergo 
metabolic changes whenengineered to produce high titers of recombinant proteins. Inthis 
work, we have studied the distinct metabolism of Chinese hamster ovary cell clones 
harboring an efficient inducible expression system, based on the cumate gene switch, and 
displaying different expression levels, high and low productivities,  compared to that of 
the parental cells from which they were derived. A kinetic model for Chinese hamster 
ovary cell metabolismwas further developedto includemetabolic regulation. Model 
calibration was performed using intracellular and extracellular metabolite profiles 
obtained from shake flask batch cultures. Model simulations of intracellular fluxes and 
ratios known as biomarkers revealed significant changes correlated with clonal variation 
but not to the recombinant protein expression level. Metabolic flux distribution mostly 
differs in the reactions involving pyruvate metabolism, with an increased net flux of 
pyruvate into the tricarboxylic acid cycle in the high-producer clone, either being induced 
or non-induced with cumate. More specifically, Chinese hamster ovary cell metabolism 
in this clone was characterized by an efficient utilization of glucose and a high pyruvate 
dehydrogenase ﬂux. Moreover, the high-producer clone shows a high rate of anaplerosis 
from pyruvate to oxaloacetate, through pyruvate carboxylase and from glutamate to -
ketoglutarate, through glutamate dehydrogenase, and a reduced rate of cataplerosis from 
malate to pyruvate, through malic enzyme. Indeed, the increase of flux through pyruvate 
carboxylase was not driven by an increased anabolic demand. It is in fact linked to an 
increase of the TCA cycle global flux, which allows better regulation of higher redox and 
more efficient metabolic states. 
5.3 Author Summary 
Therapeutics of the future are now mostly produced by animal cells, such as from the 
Chinese Hamster Ovary cell (CHO) platform, cultured in bioreactors. Although this 
mammalian cell platform can produce recombinant proteins at the gram-per-liter level, 
there are still significant pitfalls in the generation and selection processes of stable high-
producing cell lines. In this work, we specifically address these problems by the 
development of an in-silico simulation plarform enabling to deeply characterize the effect 
of recombinant protein productionon a cell line metabolic behaviour. Thus, in order to 
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establish the in-silico platform reliability, we first performed cultures for two different 
clones of a parental CHO cell line and the experimental data accounting for a wide 
diversity of metaboliteswere used to further develop and challenge a metabolic model 
that is mathematically describing cell metabolism with time. Using our model, we were 
then able to identify changes in the metabolic fingerprint associated with clonal variation 
and the onset of recombinant protein production. In particular, we were able to predict the 
up-regulation in the tricarboxylic acid cycle. Importantly, changes observed were not 
directly linked to recombinant protein production. This kind of in-silico platform thus 
tends to show being useful to the cell line selection process as well as ultimately as to 
identify target for cell engineering works.  
5.4 Introduction 
Monoclonal antibodies (mAbs) are among the largest segment of 
today's therapeuticproteinsmarket, with a 21% annual increase rate in launching into 
clinical trial (Pavlou & Belsey, 2005). However, a low FDA approval success rate has 
been reported for mAbs.Indeed, although CHO cells is now the major cell line used 
industrially with culture and production protocols that have been largely optimized 
(Durocher & Butler, 2009), mAbs production at high quantities and of high quality, e.g. 
with defined glycosylation profile, still has to be achieved. Among many factors affecting 
mAbs quality, the stability with time of high producing level CHO cell clones with 
enhanced endogenous pathways (e.gendogenous CHO GS gene) (Bebbington et al., 
1992), and presenting a prolonged cell viability level due to the over-expression of 
some cytoplasmic proteins(e.g. chaperones such as Hsp70 and Hsp27)is highly 
critical(Lee et al., 2009). Moreover, media composition and culture conditions, as well as 
their management along with culture duration, have to be optimized to achieve not only 
the objective of desired cell productivity and viability but also mAbs quality 
specifications (Bi, Shuttleworth, & Al-Rubeai, 2004). Ultimately and within this context, 
efficient process control strategies, fed through on-line and off-line analyses, may allow 
seeking and maintaining desired optimal conditions with time. However, due to the large 
number of variables and decision steps associated with the development and the 
identification of a stable high-producer cell line, it is a highly challengingand time 
consuming process (Eppink et al., 2009; Shukla et al., 2007). Indeed, high-throughput 
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screening approaches are normally used for clone selection, but there is a risk of 
performance discrepancy during scaled-up and manufacturing (Li et al., 2010). Therefore, 
only a knowledge-based strategy capable to detect at each step desired and undesired cell 
traits, as well as to extrapolate its behavior at the process scale, can efficiently guide and 
accelerate cell line screening works. Indeed, such level of knowledge has thus to be based 
on an adequate description of cell behaviour in a managed environment.In that context, 
various “omic” approaches have been applied to cell linecharacterization. Clonal 
variations in rat fibroblasts (Clarke, 1965) and hepatoma cells (Peterson, 1976) were first 
reported and revealed differences in growth characteristics under both oxygen deficient 
and aerobic culture conditions.  Proteomic and genomic studies on various NS0 (Alete et 
al., 2005; Seth et al., 2007; Smales et al., 2004) and murine cell lines (Oh et al., 2003), 
and of their recombinant derivative clones, allowed to clearly demonstrate that clones 
differing in their mAb productivities also differ in the abundance of proteins involved in 
cellular functions such as energetic metabolism, mAb folding/assembly, and cytoskeletal 
organization. The issue of clonal variation in recombinant CHO cell cloneshas also been 
largely addressed. Early works compared clones for their growth and morphological 
aspects, and showed altered cell morphology and different sub-population spatial 
organization types between clones when grown on agar (Konrad et al., 1977; Zdzienicka, 
Cupido, & Simons, 1985). Clone-specific variations at the functional genetic level were 
also extensively described. It has been reported that high- and low-producer CHO-mAb 
subclones differ mainly in their DNA fragment sizes where high numbers of differentially 
expressed genes were identified (Kim, Byun, & Lee, 2001). Analyses at the proteomic 
level also revealed that different clones show different behaviours at different culture 
phases, mid-exponential and stationary phases (Chusainow et al., 2009; Davies et al., 
2012; Hayduk, Choe, & Lee, 2004; Hayduk & Lee, 2005; Nissom et al., 2006). The effect 
of culture conditions on different CHO cell clones, with respect to cell growth and 
productivity, was also investigated at reduced temperature (Yoon, Hwang, & Lee, 2004). 
Regarding specific productivity, different enhancing effects of low culture temperature 
were observed in different clones. Recently, a metabolomic study focusing on clonal 
variations in response to culture condition variation has been conducted (Dahodwala et 
al., 2012). Comparing clone-to-clone changes, beside specific productivity, strong 
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variations in cell density, nutrient uptake and metabolic generation patterns were also 
detected. Indeed, various fluxomic approaches (Mo, Palsson, & Herrgård, 2009)have 
been developed to estimate metabolic fluxes rates, such as using labeling techniques 
(Ahn & Antoniewicz, 2011; Dean & Reddy, 2013; Metallo et al., 2009; Sheikholeslami, 
Jolicoeur, & Henry, 2013; Templeton et al., 2013) and metabolic mathematical models 
(Dorka et al., 2009; Ghorbaniaghdam, Henry, & Jolicoeur, 2012; Naderi et al., 2011; 
Nolan & Lee, 2010; Zamorano et al., 2012; Zomorrodi et al., 2012).Using isotope 
labeling experiments,  MFA techniques, and mathematical models different metabolic 
patterns in CHO cells were  demonstrated, mostly  higher metabolic efficiency as a result 
of lower production of by-products,  to be  highly associated  with different states of 
growth and productivity either over the course of one culture or in different clones.Taken 
together, these works have significantly improved our knowledge on CHO cell 
behaviour, as well as our conviction on the need for developing tools allowing a more in-
depth capacity to describe cell metabolic behaviour. In that context, kinetic models, when 
they describe transient behaviours, can serve as in silico platform enabling either intuitive 
or counter-intuitive metabolic flux exploration.In this work, we have further developed a 
kinetic-metabolic model for CHO cells. The model, which is based on cell energetic and 
redox states (Ghorbaniaghdam, Henry, & Jolicoeur, 2012), was implemented with 
metabolic regulation aspects and then applied as an in silico platform to the 
characterization of clonal variation comparing a parental CHO cell line to its high- and 
low-producer derived clones. High- and low-producer clones, engineered with the 
inducible cumate gene-switch expression system (Gaillet et al., 2010; Mullick et al., 
2006) were cultured in shake flask cultures, under both induced and non-induced 
conditions. The model was calibrated on experimental data of extra- and intracellular 
metabolites. In the present work, the descriptive precision as well as the predictive 
capacity of the model were thus improved. 
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5.5 Materials and methods 
 
Ethics statement 
All cell culture experiments were approved by the ethics committee of the Ecole 
Polytechnique.  
5.5.1 CHO clones and culture 
CHO clones that stably produce a recombinant monoclonal human anti-CD20 at different 
specific productivities (high- and low-producer) were provided by Viropro International 
Inc. (Montreal, Canada). These cells were derived from CHO-Cum2 cells and stably 
express the reverse cumate transactivator, as described in details by Mullick et al. (2006) 
(Mullick et al., 2006). Cells were seeded at 2×105 cells/mL in 300 mL of a protein-free 
medium in 1-L shake flasks, and cultured on a shaker (150 rpm) in a humidified 
incubator at 37°C and 5% CO2. The medium used was a customized chemically-defined 
SFM4CHO medium (Hyclone, Utah, USA) supplemented with 4 mM glutamine 
(Hyclone, Utah, USA, cat. # SH30034), 30 mM glucose (Sigma, Oakville, Canada, cat. # 
G8270), and 0.05 mg/mL dextran sulphate (MW: 500000, Sigma, Oakville, Canada, cat. 
# D7037). For the comparative study, the parental clone, together with high- and low-
producer clones, were cultured in duplicate. High- and low-producer clones were cultured 
both in the presence and in absence of cumate, the latter serving as non-induced control. 
In case of induction, 1 µg/mL of cumate was added after 48 hours of incubation, to 
trigger the recombinant protein expression. It should be mentioned that no visible 
effectsonmorphologyorgrowthrates were reported for mammalian cells cultured at a 
cumate concentration below 200 µg/mL(Mullick et al., 2006). Cell culture samples were 
taken every 24 h for cell counts, biochemical assays, and quantification of amino acids 
and human IgG, the recombinant mAb. Samples were centrifuged at 300 g for 5 min to 
remove cells, and supernatant samples were stored at -20C for further analysis. Cultures 
were monitored for a total of 6 days. 
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5.5.2 Analytical methods 
Cell density was determined by cell counting using a hemocytometer,and cell viability 
was estimated using the trypan blue (sigma, Oakville, Canada cat. # T8154) exclusion 
method. The concentration of glucose, lactate, glutamine and glutamate in the culture 
supernatant were determined using a dual-channel immobilized oxidase enzyme 
biochemistry analyzer (2700 SELECT, YSI Inc. Life Sciences, Yellow Springs, OH, 
USA), using calibration buffers provided by the manufacturer. Ammonia concentration in 
supernatants was assayed by an enzymatic kit with respect to manufacturer technical 
instructions: Ammonia Assay Kit (Sigma, Oakville, Canada cat. # AA0100). NAD(P) 
and NAD(P)H were also extracted and assayed by an enzymatic kit with respect to 
manufacturer technical instructions: NAD(P)/NAD(P)H QuantitationKit 
(BioVision,CA,USA, cat. # K337-100).Monoclonal antibody concentration was 
quantified using an enzyme-linked immunosorbent assay (ELISA).  First, 96-well plates 
(Costar) (Fisher Scientific,Burlington, Canada, cat. # 3795)were coated with a goat anti-
human IgG1 (H+L) solution (Jackson ImmunoResearch, PA, USA, cat. # 109-165-003) 
diluted to 2.5 µg/mL in 50 mM sodium carbonate (Fischer Scientific, Burlington, 
Canada, cat. # S263-1), and incubated at 4C overnight. Then, the blocking of non-
specific sites was carried out by adding PBS solution containing 1% casein. After 
incubation for 1 h at 37C, either samples or standards diluted in PBS-casein were added 
in triplicate to each well and incubated for 1 h at 37C. After the plates were incubated 1 
h at 37C, peroxidise-conjugated affinipure fragment Goat anti-human IgG (Jackson 
Immuno Research, PA, USA, cat. # 109-035-003) (1:10,000 dilution) was added to each 
well, and the plates were incubated for 1 h at 37C. After each of the previous steps, the 
wells were washed three times (PBS with 1% w/v Tween 20). Finally, the reaction was 
revealed by 3,3,5,5′-Tetramethylbenzidine (TMB) (Sigma, Oakville, Canada, cat. # 
T0440) and stopped after 15-20 min by adding1 N hydrochloric acid and the plates were 
read by an automatic plate reader at 450 nm usinga Victor3V microplate reader (Perkin-
Elmer, Vaudreuil-Dorion, Canada). The analysis of amino acid concentrations was 
performed on an Agilent 1290 UPLC system (Agilent technologies, Montreal, Canada) 
coupled to an Agilent 6460 triple quadruple mass spectrometer (Agilent technologies, 
Montreal, Canada). The underivatized amino acids were separated by a 2.1×150 mm 
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ZICTM-Hilic column (3.5 µm, 200 A, PEEK) (Merck SeQuant,Peterborough, Canada) 
and 2.1×20 mm ZICTM-Hilic guard column (5 µm, 200 A, PEEK) (Merck SeQuant, 
Peterborough, Canada) at a column temperature of 35oC and injection volume of 5 µL. 
The mobile phase buffer contained 20 mM HCOONH4 (Sigma, Oakville, Canada, cat. # 
74314) at pH 4. The mobile phase A was 10% of the mobile phase buffer in water, and 
the mobile phase B was 10% of the mobile phase buffer in acetonitrile (ACN) (Sigma, 
Oakville, Canada, cat. # A3396). The mobile phase B was linearly decreased from 90% 
to 35% in 19 min, then was increased to 90% in one minute and hold at 90% for 15 min 
at a flow rate of 0.1 mL/min. 
5.5.2.1 Respirometry test 
Respirometry assays were performed as described by Lamboursain et al. (2002) 
(Lamboursain, St-Onge, & Jolicoeur, 2002). Briefly, 3 mL of cell suspension containing 
at least 5×106 cells were inoculated in a 10-mL borosilicate glass syringe (Sigma, 
Oakville, Canada), in which the plunger was substituted by an In-gold pO2 probe (Mettler 
Toledo, Canada). At low cell densities, a volume of cell suspension containing5×106 cells 
was collected and centrifuged, and the pellet was re-suspended in a total of 3 mL of spent 
media.  The respirometer was kept at 37°C and magnetically agitated (60 RPM) to ensure 
the homogeneity of cell suspension. Dissolved oxygen was recorded by an acquisition 
system (Virgo, Longueuil, Canada). 
5.5.2.2 Extraction of intracellular metabolites 
For intracellular metabolomic analysis, 5×106 cells were obtained daily, washed twice 
with cold PBS and extracted with 400 μL of 80% cold methanol in the presence of 0.2 g 
of Sand (Sigma, Oakville, Canada, cat. # 274739). After 10 min on dry ice, the mixture 
was vortexed and then sonicated in ice and water for 5 min. Suspensions were then 
centrifuged at 4°C for 7 min at 21,000 g. The supernatants were then transferred to a 
clean tube as extracts. Pellets were re-extracted as mentioned above with 200 μL of 50% 
cold methanol and 200 μL of cold water. At each extraction, supernatants were combined 
with the first extract and stored in −80 °C prior to analysis. 
5.5.2.3 Energetic nucleotide concentrations 
Extracts were filtered through 0.2 μm filters (Millipore, Etobicoke, Canada) before 
analysis. Nucleotides in CHO cells extracts were analyzed using a 1290 UPLC system 
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coupled to a 6460 triple quadruple mass spectrometer (both from Agilent Technologies, 
Montreal, Canada). Nucleotides were separated by a Symmetry C18 column 
(150×2.1mm, 3.5μm) (Waters, Milford, USA) equipped with a Security C18 guard-
column (Waters, Milford, USA 10×2.1mm, 3.5μm) by the ion-pair method. DMHA 
(N,N-dimethylhexylanine, Sigma, Oakville, Canada, cat. # 308102) was used as an ion-
pair reagent to improve the signal-to-noise ratio with positive ionization mode. The 
mobile phase consisted of Buffer A: 10mM ammonium acetate, 15mM DMHA at pH 7.0, 
and Buffer B: 50/50% (v/v) acetonitrile, 20mM NH4OAc at pH 7.0. Mobile phase flow 
rate was set at 0.3mL/min with the following gradient: 0–10min at 10% B, 10–20min at 
linear gradient from 10 to 30% B, 20–21min at linear gradient from 30 to 60% B, 21–
26min at 60% B, 26–27min at linear gradient from 60 to 10% B and 27–35min at 10% B.  
5.5.2.4 Organic acid and sugar phosphate concentrations 
Extracts were filtered through 0.2 μm filters (Millipore, Etobicoke, Canada) before 
UPLC–MS/MS (Agilent, Montreal, Canada) analysis equipped with a Hypercarb column 
(100×2.1 mm, 5 μm) and a Hypercarb pre-column (2.1×10, 5 μm) (Thermo Fisher, 
Burlington, Canada). Mobile phase consisted in Buffer A: 20 mM ammonium acetate at 
pH 7.5, and Buffer B: 10% (v/v) methanol in water. Flow rate was set at 0.3 mL/min 
using the following gradient: 0–5 min at 10% A, 5–10 min at linear gradient from 10% to 
20% A, 10–20 min at linear gradient from 20% to 100% A, 20–30 min at 100% A, 30–
32 min at linear gradient from 100% to 10% A and 32–40 min at 10% A.  
5.5.3 Model development 
The mathematical model developed and presented here is based on a previous model 
describing CHO cells central metabolism (Ghorbaniaghdam, Henry, & Jolicoeur, 2012). 
In the present work, the descriptive precision as well as the predictive capacity of the 
model were improved, by including catabolic pathways of amino acids metabolism along 
with other biochemical pathways (glycolysis, pentose phosphate pathway, TCA cycle, 
glutaminolysis as well as cell respiration) providing carbon skeletons to the central 
metabolism. Amino acids are pooled into 3 groups channeled through TCA intermediates 
such as succinate, oxaloacetate and α-ketoglutarate (Figure 5.1). The other entry points 
for amino acid carbon skeletons are lumped to pyruvate. A special care was taken to 
preserve all stoichiometric relationships while lumping and/or combining reactions. We 
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also further described the cell specific growth rate from its precursor’s building blocks by 
considering G6P (leading to phospholipids and organic phosphate compounds), R5P (to 
DNA, RNA and nucleotides), and extracellular glutamine together with other amino acids 
(to proteins) (reaction 34, Table 5.2). Cell growth is described from the main cell 
building blocks for which experimental data were available; thus excluding precursors of 
lipids. This approach, although simplistic, allowed describing cell growth, as well as 
identifying the major anabolic pathways that are logically expected to affect growth 
behavior. Furthermore, a description of the cell-specific recombinant protein production 
rate is incorporated into the model. Extracellular amino acid concentrations are included 
individually in the kinetic expression for both the cell specific growth rate and mAb 
productivity. For simplification purposes and because of a lack of available data in 
literature, a single affinity constant value is used for each amino acid, either as a substrate 
for biomass formation or antibody production, except for glutamine. Indeed, 
experimental data show that cell growth stopped specifically upon depletion of 
glutamine, while it has not limited antibody production.Consumption rate of each 
precursor for the synthesis of biomass or recombinantprotein is calculated as proposed by 
Martens (2007) (Martens, 2007), considering the stoichiometry of precursor metabolites 
(Table 5.1, reactions 34-35). The stoichiometric coefficients of the respective 
biosynthetic equations were taken from literature (Ahn & Antoniewicz, 2011).The global 
metabolic network is presented in Figure 5.1, and a detailed summary of each flux 
reactions is given in Table 5.1.  
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Figure  5.1    The metabolic network considered in the model 
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Table  5.1    Reactions of a metabolic network 
 
No. Reaction 
1 GLC+ATP→G6P+ADP 
2 G6P→F6P 
3 F6P+ATP→2GAP+ADP 
4 GAP+ADP+NAD++Pi→PEP+ATP+NADH 
5 PEP+ADP→PYR+ATP 
6 PYR+NADH↔LAC+NAD+ 
7 G6P+2NADP+→R5P+2NADPH+CO2 
8 R5P→X5P 
9 R5P+2X5P→2F6P+GAP 
10 PYR+COA+NAD+→ACCOA+NADH+CO2 
11 ACCOA+OXA→CIT+CoA 
12 CIT+NAD+→AKG+NADH+CO2 
13 AKG+CoA+NAD++ADP+Pi →SUC+NADH+CO2+CoA+ATP 
14 SUC+2/3NAD+→MAL+2/3NADH+CO2 
15 MAL+NAD+→OAA+NADH 
16 MAL+NADP →PYR+NADPH+CO2 
17 PYR →OAA+CO2 
18 GLN+ATP↔GLU+ADP+NH4 
19 GLU+NAD+↔AKG+NADH+NH4 
20 GLU+PYR↔AKG+ALA 
21 GLU+ADP+Pi→EGLU+ATP 
22 O2+(P/O ratio)*2ADP+2NADH+(P/O ratio)*2Pi→(P/O ratio)*2ATP+NAD++2H2O 
23 O2+2NADH→2NAD++2H2O 
24 ATP→ADP+Pi 
25 ATP+AMP↔2ADP 
26 Pcr+ADP↔Cr+ATP 
27 2GLN+0.6R5P+2ASP+GLY+2ATP→2GLU+2MAL+AMP+2ADP 
28 NADPH→NADP+ 
29 SER→PYR+ NH4 
30 ASX→ASP+ NH4 
31 ASP+AKG↔GLU+OAA+NH4 
32 HIS+ARG+AKG→GLU+NH4+CO2 
33 LYS+ILE+LEU+HIS+VAL+TYR+7AKG+ATP+9NAD+2NADP→4GLU+3SUC+MAL+8ACCOA+ADP+
9NADH+2NADPH+4CO2 
34 0.024R5P+0.029G6P+0.04GLN+0.013ALA+0.007ARG+0.0261ASP+0.003HIS+0.0084ILE+0.013LEU+0.0
1LYS+0.099SER+0.004TYR+0.0096VAL+0.016GLY+3.78ATP→X 
35 0.01GLU+0.01GLN+0.01ALA+0.005ARG+0.007ASN+0.008ASP+0.003HIS+0.005ILE+0.014LEU+0.014L
YS+0.026SER+0.008TYR+0.018VAL+0.0145GLY+4ATP→mAb 
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Only amino acids measured in this work are considered in the model. For amino acids, 
only extracellular pools were considered except for glutamate; extracellular glutamine is 
directly converted to intracellular glutamate, and intracellular glutamate exchangefor 
extracellular glutamine is also considered to account for the management of nitrogenous 
sources as the culture enters the plateau phase. Intracellular glutamate is channeled 
through TCA cycle via a bidirectional exchange for α-ketoglutarate, as reported by Nolan 
et al. (2010) (Nolan & Lee, 2010).From experimental data obtained in this work, 
extracellular aspartate concentration showed low constant values as the culture reaches 
the plateau phase, which suggests a possible exchangeof intracellular oxaloacetatefor 
extracellular aspartate, a phenomenon that has thus been described in the model. Finally, 
it is assumed that at low extracellular glutamine level, the cells take up extracellular 
alanine; an activation term based on a threshold concentration for extracellular glutamine 
was thus included in the model. 
5.5.3.1 Description of flux kinetic regulation 
Mathematical formulations of metabolic flux kinetics have been determined in a previous 
work (Ghorbaniaghdam, Henry, & Jolicoeur, 2012),based on the model capacity to 
simulate experimental data for another CHO cell line in bioreactor cultures. In this work, 
additional regulatory functions, mainly in glycolysis (Figure 5.2), were introduced and 
evaluated, one by one, to either describe activation or inhibition of enzyme kinetics, as 
documented in literature (Chang et al., 2009). Indeed, hexokinase feedback-inhibition by 
its product (term I), G6P, phosphoglucose isomerase (term II) and phosphofructokinase 
inhibition (term III) by PEP and G6P, thefeed-forward activation of pyruvate kinaseby 
F6P (term IV), as well as the substrate inhibition of lactate dehydrogenase forward 
reaction (term V) were integrated in the model and simulations compared were to 
experimental data, as described in the next section. 
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Table  5.2    Biokinetic equations of the metabolites fluxes (1-35) of the model 
 
No. Biokinetic equations 
1 ߥ(ܪܭ) = ߥ୫ୟ୶ு௄ ∗ ܩܮܥܭ௠ீ௅஼ + ܩܮܥ ∗ ஺்௉஺஽௉ܭ
௠
ಲ೅ು
ಲವು
+ ஺்௉
஺஽௉
∗
ܭௗீ଺௉
ܭௗீ଺௉ + ܩ6ܲ 
2 
 
ߥ(ܲܩܫ) = ߥ௠௔௫௙	௉ீூ ∗ ܩ6ܲܭ௠ீ଺௉ + ܩ6ܲ ∗ ܭௗ௉ா௉ܭௗ௉ா௉ + ܲܧܲ 
3 
 
ߥ(ܲܨܭ/ܣܮܦ) = ߥ୫ୟ୶௉ி௄/ா௅஽ ∗ ܨ6ܲܭ௠ி଺௉ + ܨ6ܲ ∗ ஺்௉஺஽௉ܭ
௠
ಲ೅ು
ಲವು
+ ஺்௉
஺஽௉
 
4 
 
ߥ(ܲܩܭ) = ߥ௠௔௫௉ீ௄ ∗ ீ஺௉௄೘ಸಲುାீ஺௉ ∗ ಲವುಲ೅ು௄
೘
ಲವು
ಲ೅ು
ା
ಲವು
ಲ೅ು
∗
௉௜
௄೘ು೔ା௉௜
*
ಿಲವ
ಿಲವಹ
௄
೘
ಿಲವ
ಿಲವಹ
ା	
ಿಲವ
ಿಲವಹ
 
5 
 
ߥ(ܲܭ) = ߥ୫ୟ୶௉௄ ∗ ܲܧܲܭ௠௉ா௉ + ܲܧܲ ∗ ஺஽௉஺்௉ܭ
௠
ಲವು
ಲ೅ು
+ ஺஽௉
஺்௉
 
6 
 
ߥ(ܮܦܪ) = ߥ௠௔௫௙	௅஽ு ∗ ܻܴܲܭ௠௉௒ோ + ܻܴܲ ∗ ே஺஽ுே஺஽ܭ
௠
ಿಲವಹ
ಿಲವ
+ ே஺஽ு
ே஺஽
− ߥ௠௔௫௥	௅஽ு ∗
ܮܣܥ .
ܭ௠௅஺஼ + ܮܣܥ ∗ ே஺஽ே஺஽ுܭ
௠
ಿಲವ
ಿಲವಹ
+ ே஺஽
ே஺஽ு
 
7 
 
ߥ(ܩ6ܲܦܪ/ܲܩܮܿܦܪ) = ߥ୫ୟ୶ ீ଺௉஽ு/௉ீ௅௖஽ு ∗ ܩ6ܲܭ௠ீ଺௉ + ܩ6ܲ ∗ ே஺஽௉ே஺஽௉ுܭ
௠
ಿಲವು
ಿಲವುಹ
+ ே஺஽௉
ே஺஽௉ு
 
8 
 
ߥ(ܧܲ) = ߥ୫ୟ୶ா௉ ∗ ܴ5ܲܭ௠ோହ௉ + ܴ5ܲ 
9 
 
ߥ(ܶܭ/ܶܣ) = ߥ୫ୟ୶்௄/்஺ ∗ ܴ5ܲܭ௠ଶோହ௉ + ܴ5ܲ ∗ ܺ5ܲܭ௠௑ହ௉ + ܺ5ܲ 
10 
 
ߥ(ܲܦܪ) = ߥ௠௔௫	௉஽ு ∗ ܻܴܲܭ௠௉௒ோ + ܻܴܲ ∗ ே஺஽ே஺஽ுܭ
௠
ಿಲವ
ಿಲವಹ
+ ே஺஽
ே஺஽ு
 
11 
 
ߥ(ܥܵ) = ߥ௠௔௫	஼ௌ ∗ ܣܥܥܱܣܭ௠஺஼஼ை஺ + ܣܥܥܱܣ ∗ ܱܣܣܭ௠ை௑஺ +ܱܣܣ 
 
12 ߥ(ܥܫܶܵ/ܫܱܵܦ) = ߥ୫ୟ୶஼ூ்ௌ/ூௌை஽ ∗ ܥܫܶܭ௠஼ூ் + ܥܫܶ ∗ ே஺஽ே஺஽ுܭ
௠
ಿಲವ
ಿಲವಹ
+ ே஺஽
ே஺஽ு
 
 
 
Table 5.2    Biokinetic equations of the metabolites fluxes (1-35) of the model 
(Continued) 
13 
 
ࣇ(࡭ࡷࡳࡰࡴ) = ࣇ࢓ࢇ࢞	࡭ࡷࡳࡰࡴ ∗ ࡭ࡷࡳࡷ࢓࡭ࡷࡳ + ࡭ࡷࡳ ∗ ࡺ࡭ࡰࡺ࡭ࡰࡴࡷ
࢓
ࡺ࡭ࡰ
ࡺ࡭ࡰࡴ
+ ࡺ࡭ࡰ
ࡺ࡭ࡰࡴ
∗
࡭ࡰࡼ
࡭ࢀࡼ
ࡷ
࢓
࡭ࡰࡼ
࡭ࢀࡼ
+ ࡭ࡰࡼ
࡭ࢀࡼ
∗
ࡼ࢏
ࡷ࢓ࡼ࢏ + ࡼ࢏ 
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14 
 
ߥ(ܵܦܪ/ܨܷܯ) = ߥ୫ୟ୶ௌ஽ு/ி௎ெ ∗ ܷܵܥܭ௠ௌ௎஼ + ܷܵܥ ∗ ே஺஽ே஺஽ுܭ
௠
ಿಲವ
ಿಲವಹ
+ ே஺஽
ே஺஽ு
 
15 
 
ߥ(ܯܦܪ) = ߥ௠௔௫	ெ஽ு ∗ ܯܣܮܭ௠ெ஺௅ +ܯܣܮ ∗ ே஺஽ே஺஽ுܭ
௠
ಿಲವ
ಿಲವಹ
+ ே஺஽
ே஺஽ு
 
16 
 
ߥ(ܯܧ) = ߥ௠௔௫	ொ ∗ ܯܣܮܭ௠ெ஺௅ + ܯܣܮ ∗ ே஺௉஽ே஺஽௉ுܭ
௠
ಿಲವು
ಿಲವುಹ
+ ே஺஽௉
ே஺஽௉ு
 
17 
 
ߥ(ܲܥ) = ߥ௠௔௫	ொ ∗ ܻܴܲܭ௠௉௒ோ + ܻܴܲ 
18 
 
ߥ(ܩܮܰܵ) = ߥ௠௔௫௙ீ௅ேௌ ∗ ܩܮܰܭ௠ீ௅ே + ܩܮܰ ∗ ஺்௉஺஽௉ܭ
௠
ಲ೅ು
ಲವು
+ ஺்௉
஺஽௉
− ߥ௠௔௫௥	ீ௅ேௌ ∗
ܩܮܷ
ܭ௠ீ௅௎ + ܩܮܷ ∗ ஺஽௉஺்௉ܭ
௠
ಲವು
ಲ೅ು
+ ஺஽௉
஺்௉
∗
ܰܪସ
ܭ௠ேுర + ܰܪସ 
19 
 
ߥ(ܩܮܦܪ) = ߥ௠௔௫௙	ீ௅஽ு ∗ ܩܮܷܭ௠ீ௅௎ + ܩܮܷ ∗ ே஺஽ே஺஽ுܭ
௠
ಿಲವ
ಿಲವಹ
+ ே஺஽
ே஺஽ு
− ߥ௠௔௫௥	ீ௅஽ு ∗
ܣܭܩ
ܭ௠஺௄ீ + ܣܭܩ
∗
ே஺஽ு
ே஺஽
ܭ
௠
ಿಲವಹ
ಿಲವ
+ ே஺஽ு
ே஺஽
∗
ܰܪସ
ܭ௠ேுర + ܰܪସ 
20 
 
ߥ(ܣ݈ܽܶܣ) = ߥ௠௔௫௙	஺௟௔்஺ ∗ ܩܮܷܭ௠ீ௅௎ + ܩܮܷ ∗ ܻܴܲܭ௠௉௒ோ + ܻܴܲ − ߥ௠௔௫௥	஺௟௔்஺ ∗ ܣܮܣܭ௠஺௅஺ + ܣܮܣ ∗ ܣܭܩܭ௠௉௒ோ + ܣܭܩ
∗ (1 +ܭ௔ீ௅ே
ܩܮܰ
) 
21 
 
ߥ(ܩ݈ݑܶ) = ߥ௠௔௫	ீ௟௨் ∗ ீ௅௎௄೘ಸಽೆାீ௅௎ ∗ ಲವುಲ೅ು௄
೘
ಲವು
ಲ೅ು
ା
ಲವು
ಲ೅ು
* ௉௜
௄೘ು೔ା௉௜
 
22 
 
ߥ(ݎ݁ݏ݌) = ߥ௠௔௫	௥௘௦௣ ∗ ܱଶܭ௠ைమ +ܱଶ ∗ ஺஽௉஺்௉ܭ௠ಲವು
ಲ೅ು
+ ஺஽௉
஺்௉
∗
ܰܣܦܪ
ܭ௠ே஺஽ு +ܰܣܦܪ ∗ ܲ݅ܭ௠௉௜ + ܲ݅ 
23 
 
ߥ(݈݁ܽ݇) = ߥ௠௔௫	௟௘௔௞ ܰܣܦܪܭ௠ே஺஽ு +ܰܣܦܪ 
24 
 
ߥ(ܣܶܲܽݏ݁) = ߥ௠௔௫	஺்௉௔௦௘ ∗ ܣܶܲܣܶܲ + ܣܶܲ 
 
Table 5.2    Biokinetic equations of the metabolites fluxes (1-35) of the model 
(Continued) 
25 
 
ࣇ(࡭ࡷ) = ࣇ࢓ࢇ࢞ࢌ	࡭ࡷ ∗ ࡭ࢀࡼࡷ࢓࡭ࢀࡼ + ࡭ࢀࡼ ∗ ࡭ࡹࡼࡷ࢓࡭ࡹࡼ + ࡭ࡹࡼ− ࣇ࢓ࢇ࢞࢘	࡭ࡷ ∗ ࡭ࡰࡼࡷ࢓࡭ࡰࡼ + ࡭ࡰࡼ 
26 
 
 
ߥ(ܥܭ) = ߥ௠௔௫௙	஼௄ ∗ ܣܦܲܭ௠஺஽௉ + ܣܦܲ ∗ ܲܿݎܭ௠௉௖௥ + ܲܿݎ − ߥ௠௔௫௥	஼௄ ∗ ܣܶܲܭ௠஺்௉ + ܣܶܲ ∗ ܥݎܭ௠஼௥ + ܥݎ 
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27 
 
ߥ(ܴܲܲ݅ܤܲ) = ߥ୫ୟ୶௉௉ோ௜௕௉ ∗ ܴ5ܲܭ௠ோହ௉ + ܴ5ܲ ∗ ܣܵܲܭ௠஺ௌ௉ + ܣܵܲ ∗ ܩܮܰܭ௠ீ௅ே + ܩܮܰ ∗ ܩܮܻܭ௠ீ௅௒ + ܩܮܻ 
 
28 
 
ߥ(ܰܣܦܲܪ݋ݔ) = ߥ୫ୟ୶ே஺஽௉ு௢௫ ∗ ܰܣܦܲܪܭ௠ே஺஽௉ு +ܰܣܦܲܪ 
29 
 
ߥ(ܵܣܮ) = ߥ௠௔௫	ௌ஺௅ ∗ ܵܧܴܭ௠ௌாோ + ܵܧܴ 
30 
 
ߥ(ܣܵܺ) = ߥ௠௔௫	஺ௌ௑ ∗ ܣܵܺܭ௠஺ௌ௑ + ܣܵܺ 
31 
 
ߥ(ܣܵܶܣ) = ߥ௠௔௫௙	஺ௌ்஺ ∗ ܣܵܲܭ௠஺ௌ௉ + ܣܵܲ ∗ ܣܭܩܭ௠஺௄ீ + ܣܭܩ − ߥ௠௔௫௥	஺ௌ்஺ ∗ ܩܮܷܭ௠ீ௅௎ + ܩܮܷ ∗ ܱܣܣܭ௠ை௑஺ + ܱܣܣ
∗
ܰܪସ
ܭ௠ேுర + ܰܪସ 
32 
 
ߥ(ܪܫܵܣܴܩܶܣ) = ߥ୫ୟ୶ுூௌ஺ோீ்஺ ∗ ܪܫܵܭ௠ுூௌ + ܪܫܵ ∗ ܣܴܩܭ௠஺ோீ + ܣܴܩ ∗ ܣܭܩܭ௠஺௄ீ + ܣܭܩ 
33 
 
ߥ(ܮܻܵܫܮܧܮܧܷܪܫܸܵܣܮܻܴܶܶܣ) = ߥ୫ୟ୶ ௅௒ௌூ௅ா௅ா௎௏஺௅்௒ோ்஺௪௧௛ ∗ ܮܻܵܭ௠௅௒ௌ + ܮܻܵ ∗ ܫܮܧܭ௠ூ௅ா + ܫܮܧ ∗ ܮܧܷܭ௠௅ா௎ + ܮܧܷ 
∗
ܸܣܮ
ܭ௠௏஺௅ + ܸܣܮ ∗ ܪܫܵܭ௠ுூௌ +ܪܫܵ ∗ ܻܴܶܭ௠்௒ோ + ܻܴܶ ∗∗ ܣܭܩܭ௠஺௄ீ + ܣܭܩ ∗ ஺்௉஺஽௉ܭ
௠
ಲ೅ು
ಲವು
+ ஺்௉
஺஽௉
∗
ே஺஽
ே஺஽ு
ܭ
௠
ಿಲವ
ಿಲವಹ
+ ே஺஽
ே஺஽ு
∗
ே஺஽௉
ே஺஽௉ு
ܭ
௠
ಿಲವು
ಿಲವುಹ
+ ே஺஽௉
ே஺஽௉ு
 
34 
 
ߥ(݃ݎ݋ݓݐℎ) = ߥ୫ୟ୶ ௚௥௢௪௧௛ ∗ ܴ5ܲܭ௠ோହ௉ + ܴ5ܲ ∗ ܩ6ܲܭ௠ீ଺௉ + ܩ6ܲ ∗ ܩܮܰܭ௠ீ௅ே + ܩܮܰ ∗ ܣܮܣܭ௠஺௅஺ + ܣܮܣ ∗ ܣܴܩܭ௠஺ோீ + ܣܴܩ
∗∗
ܣܵܲ
ܭ௠஺ௌ௉ + ܣܵܲ ∗ ܪܫܵܭ௠ுூௌ +ܪܫܵ ∗ ܫܮܧܭ௠ூ௅ா + ܫܮܧ ∗ ܮܧܷܭ௠௅ா௎ + ܮܧܷ ∗ ܮܻܵܭ௠௅௒ௌ + ܮܻܵ
∗
ܵܧܴ
ܭ௠ௌாோ + ܵܧܴ ∗ ܻܴܶܭ௠்௒ோ + ܻܴܶ ∗ ܸܣܮܭ௠௏஺௅ + ܸܣܮ ∗ ܩܮܻܭ௠ீ௅௒ + ܩܮܻ ஺்௉஺஽௉ܭ
௠
ಲ೅ು
ಲವು
+ ஺்௉
஺஽௉
 
 
 
 
 
 
Table  5.3State variables description and initial conditions 
 
Component Description Value Units 
ACCoA Acetyl-CoezymeA 1.4E-7 mmol.(106 cells)-1 
AKG α-Ketoglutarate 4E-7 ‘‘ 
ADP Adenosine Diphosphate 1.4E-7 ‘‘ 
AMP Adenosine Monophosphate 2E-8 ‘‘ 
ATP Adenosine Triphosphate 1.5E-6 ‘‘ 
CIT Citrate 2E-7 ‘‘ 
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CoA CoenzymeA 2E-8 ‘‘ 
Cr Creatine 4E-6 ‘‘ 
F6P Fructose 6-Phosphate 3E-7 ‘‘ 
G6P Glucose 6-Phosphate 5E-8 ‘‘ 
GAP Glyceraldehyde 3-Phosphate 4E-7 ‘‘ 
GLU Glutamate 7E-4 ‘‘ 
GLY Glycine 8E-6 ‘‘ 
MAL Malate 1 E-6 ‘‘ 
NAD Nicotinamide Adenine 
Dinucleotide 
9E-7 ‘‘ 
NADH Nicotinamide adenine 
dinucleotide(reduced) 
2E-8 ‘‘ 
NADP Nicotinamide Adenine 
Dinucleotide Phosphate 
9E-13 ‘‘ 
NADPH Nicotinamide Adenine 
Dinucleotide 
Phosphate(reduced) 
5.3E-12 ‘‘ 
OXA Oxaloacetate 5E-5 ‘‘ 
O2 Intracellular Oxygen 8E-6 ‘‘ 
PEP Phosphoenolpyruvate 4E-8 ‘‘ 
PCr PhosphoCreatine 2E-6 ‘‘ 
Pi Phosphate 2E-6 ‘‘ 
PYR Pyruvate 5E-7 ‘‘ 
R5P Ribose 5-Phosphate 1.5E-7 ‘‘ 
SUC Succinate 5.3E-7 ‘‘ 
X5P Xylose-5-Phosphate 9.2E-8 ‘‘ 
ALA Extracellular Alanine 0.75 mM 
ARG Extracellular Arginine 2.8 ‘‘ 
ASP Extracellular Aspartate 1 ‘‘ 
ASX Extracellular Aspartate and 
Asparagine 
2.8 ‘‘ 
GLY Extracellular Glycine 1 ‘‘ 
HIS Extracellular Histidine 0.95 ‘‘ 
ILE Extracellular IsoLeucine 1 ‘‘ 
LUE Extracellular Leucine 0.8 ‘‘ 
LYS Extracellular Lysine 1.2 ‘‘ 
SER Extracellular Serine 2.1 ‘‘ 
TYR Extracellular Tyrosine 0.55 ‘‘ 
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Figure  5.2Regulation scheme of the model through the activation or inhibition of the 
enzymes. 
Symbol “↓” indicates activation and “” inhibition. Glycolytic enzymes are either 
inhibited ( ࡷ࢏ࢻ
ࡷ࢏ࢻାࢻ
) or activated(૚ + ࡷࢇࢻ
ࢻ
)by an effecter “α“ where “α” is mainly one of the 
glycolytic metabolites. The corresponding activation/inhibition terms labeled as I, II, III, 
IV, and V. The bottom diagram represents model simulations for parental, induced low- 
and induced high-producer cell lines with no regulation (solid black line), with the 
addition of term I (solid red line), with the addition of terms I and II (solid blue line), and 
the addition of all terms (solid green line).  Experimental data are represented by triangles 
(parental culture), squares (induced low-producing culture), and circles (induced high-
producing culture) for cell density (A), glucose (B), ATP-to-ADP ratio (C), and NADH-
to-NAD ratio (D). Error bars are standard deviations from duplicate flasks. Error bars are 
standard deviations for duplicate cultures. 
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5.5.3.2 Model calibration 
The final fully dynamic model includes 35 reactions and 46 variables. The kinetic 
equations for the flux regulation are presented in Table 5.2. The model has 95 kinetic 
parameters, 48 affinity constants (listed in Table 5.4), 42 maximum reaction rates (Table 
5.5) and one parameter for each regulatory function (Table 5.4). Initial conditions for 
most of the variables were available from culture data (Table 5.3), while those remaining 
were taken from literature for similar conditions. The set of kinetic parameters previously 
determined for another CHO cell line in bioreactor cultures (Ghorbaniaghdam, Henry, & 
Jolicoeur, 2012) was used as initial estimates, and the new parameters were taken from 
literature for similar biological systems. The parameter estimation approach used 
isextensively discussed in a previous study (Ghorbaniaghdam, Henry, & Jolicoeur, 2012). 
Briefly, foreach of the five cultures under investigation, a sensitivity analysis was 
performed for evaluating the influence of each parameter on the model output. In order to 
define their influence, parameters were systematically varied from their initial value 
comparing respective model output, defined as the weighted sum of squared residuals 
(WSSRES) between available experimental data (Xmea) and simulated values (Xsim) for 
each state variable mat time k, where the weight is the inverse of the variance of the 
experimental data for each state variable, varm-1. 
 min WSSRES =ቂ∑ ∑ ൫ܺ௧,௠௦௜௠ − ܺ௧,௠௠௘௔൯ଶݒܽݎ௠ିଵ௡௠ୀଵ௞௧ୀଵ ቃ                                                (10) 
The sensitivity analysis procedure allowed to rank the parameters by their decreasing 
influence, and to remove parameters that were not contributing to model sensitivity from 
further optimization cycle, keeping them at their initial value. Optimal parameter values 
(for the sensitive ones) were then obtained by minimizing the normalized sum-squared 
errors using a Least-squares minimization function in MATLAB's Optimization Toolbox 
for non-linear regression. Finally, 95% confidence intervals for both model sensitive 
parameters and model predictions were calculated using built-in MATLAB functions  
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5.6 Results 
5.6.1 Model structure fine-tuning and characterization 
The model was first applied to parental cell line culture data obtained in shake flasks. 
Model performance assessment with cumate-induced and non-induced cultures of low-
producer and high-producer clones is presented thereafter. 
5.6.1.1 Describing the regulation of glycolysis ameliorates model simulations of 
experimental data 
Biologically relevant scenarios (Figure 5.2) of enzyme regulation mechanisms, known to 
play a role in glycolysis robustness, were successively evaluated from model 
performance to simulate experimental data. For clarity reasons, only simulations for four 
significant model variables, such as cell density, glucose, ATP-to-ADP and NADH-to-
NAD ratios, are shown here (Figure 5.2) for parental, induced low- and high-producer 
cultures and the remaining results can be found as supplementary materials (Figures 5.10-
5.15). The last two model variables are markers of cell energetic and redox states, 
respectively (Reich & Sel'Kov, 1981). Interestingly, one can observe that model 
simulations of cell growth agreed with experimental data in all regulation scenarios. 
However, the errorbetween model simulation and experimental datafor extracellular 
glucose and energetic nucleotides ratio shows to be high, when no regulation term are 
included in kinetic flux expressions. Hexokinase inhibition by G6P (term I) decreases the 
simulation error for extracellular glucose and redox nucleotides ratio, and to a lesser 
extent for energetic nucleotides ratio. Adding a term (II) to account for PGI inhibition by 
PEP further reduces the error between model simulations and experimental data, and this 
is particularly obvious for energetic nucleotide ratios. This suggests that variations in 
sugar phosphate cell concentrations, although of low magnitudes, may trigger the first 
two regulatory mechanisms to control glycolytic fluxes.To verify whether incorporating 
other regulatory terms into rate expressions significantly influences simulation results, a 
formulation with all main regulatory steps was also tested. The last formulation also 
shows to allow simulating experimental data almost similarly to the case when the first 
two terms are considered. This may suggest that not all the regulatory terms are solicited 
within experimental conditions in this study. Therefore, because of a higher performance 
level as well as a lower formulation complexity, a kinetic formulation including the first 
and the second regulatory terms was used in the remaining of this study. Considering 
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extracellular metabolites, presented in supplementary material, (Figures 5.10, 5.12, 5.14) 
the model is far from predicting experimental data when no regulatory terms are 
considered. However, model simulations are closer to experimental data when only 
adding the first (I) and the second (II) regulatory terms, respectively hexokinase 
feedback-inhibition by its product, G6P, and phosphoglucose isomerase inhibition by 
PEP.  Interestingly, our experimental data set accounts for a wide diversity of metabolites 
such as by-products (lactate, NH4+, glutamate), amino acids (alanine, glutamine, serine, 
aspartate, and  amino acid pools to TCA cycle), sugar phosphates of glycolysis (G6P and 
PEP) as well as glucose, cell density and energetic nucleotides, which are all well 
simulated  by the model implemented with I and II regulation terms. Similar observations 
can be drawn for scenarios of intracellular organic acids such as PYR and SUC. In 
addition, model simulations corresponded more closely to experimental data for organic 
acids such as AKG and MAL in induced low- and high-producer cultures, but to a lesser 
extent to no clear effect for other amino acids and AMP, presented in supplementary 
material, (Figures 5.11, 5.13, 5.15). Finally,the same behaviour can be observed for the 
cell specific oxygen consumption rate (qO2), for which simulations were closer to 
experimental data comparing to the case with no regulation (Figures 5.10, 5.12, 5.14). 
5.6.1.2 A limited subset of model parameters drives the in silico cell behaviour 
A sensitivity analysis was performed on the resulting model, aiming to identify the most 
critical parameters. Values of model parameters were changed from -85 to +300%, one at 
a time, from their optimal value, and the normalized sum-squared differences 
(WSSRES)were calculated as previously described. Resulting WSSRESvalues were then 
further normalized to that obtained for original optimal parameter values (i.e. 0% 
change). Parameters showing a deviation of ±15% and higher were considered sensitive; 
a colormap (Figure 5.3) was drawn to illustrate the extent to which normalized 
WSSRESvalues vary from that of the optimal value (i.e. minimal simulation error). The 
model reveals to be primarily sensitive to parameters of glycolysis, TCA cycle and 
energetic reactions, amino acid catabolism pathways, partially to glutaminolysis, and to a 
lesser extent to the pentose phosphate pathway. The specific glucose uptake rate (νmaxHK) 
and other parameters of glycolysis (νmaxPGI, νmaxPK, νmaxf LDH and νmaxr LDH) show to strongly 
affect simulation error. Moreover, maximum reaction rates for three enzymes in TCA 
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cycle (νmaxAKGDH, νmaxCS, andνmaxMLD), and for the reaction connecting glycolysis to TCA 
cycle (νmaxPDH,νmaxME, andνmaxPC),also reveal to be significant. The model is also highly 
sensitive to three reactions related to glutaminolysis (νmaxfGLNS, νmaxrGLNS, νmaxfGLDH, 
νmaxrGLDH, νmaxfAlaTA, andνmaxASX), and to a lesse extent to two parameters related to the 
pentose phosphate pathway oxidative branch (νmaxG6PDH, and νmaxEP). The model shows a 
high sensitivity to energetic reactions, represented here by parameters related to non-
specifically described ATP (νmaxATPase) and NADH consuming reaction (νmaxresp). 
Furthermore, the maximum specific growth rate (νmaxgrowth) also strongly influences the 
simulation error. Finally, parameters related to amino acid catabolism (νmaxrAlaTA, νmaxSAL, 
νmaxfASTA,νmaxHISARGTA, andνmaxLYSILELEUHISVALTYRTA) also demonstrate to be influential. There 
are therefore a high number of non-influential parameters with 65 out of 95. This lack of 
sensitivity may partially come from the experimental space in hand that was used to 
calibrate and to challenge the model. Although these non-sensitive parameters are 
biologically relevant describing existing active pathways and enzymatic reactions, they 
may require more varying experimental culture conditions to be solicited (Mailier et al., 
2011). For space limitation only sensitivity results for parental culture are shown while 
the other cultures exhibited almost the same results. Therefore, the model was kept as is 
at this point because actual non-sensitive parameters may become sensitive and thus be 
useful in a future study exploring outside the actual experimental space. 
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Figure  5.3Sensitivity analysis on model parameters for parental cell line culture. 
The colormap represents the normalized sum of squared difference between model 
simulations and experimental data, when the parameter (row) is changed from -85% to 
+300% (column) of the optimal value. The values for sum of squared difference are 
normalized by the value corresponding to optimal values for parameters. 
 
5.6.1.3 A limited subset of measured variables contribute to the overall model sensitivity 
The specific contribution of each measured variable to the overall model sensitivity was 
also investigated. Among measured variables, cell density, extracellular glucose, 
glutamine, lactate, ammonia, ASX (ASN+ASP), amino acids pool to glutamate and 
nucleotide ratios showed a high sensitivity level compared to pyruvate and succinate 
(Figure 5.4). Not surprisingly, energetic nucleotide ratios exhibited the highest sensitivity 
as it is affected by multiple reactions in various parts of the metabolic network, through 
their regulatory role. Interestingly, parameters with a relatively high global sensitivity on 
model overall output may not systematically impact on all variables simulated. Here 
again, results are conditioned by the experimental space studied. It may thus suggest that 
experimental intracellular concentrations have never reached threshold levels, above or 
below which a higher impact could have been observed. The whole procedure of model 
parameters calibration has then been performed on the cumate-inducible cell lines, 
induced and non-induced. For space limitation and clarity reasons, only final calibrated 
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results are shown and discussed in the following sections (see Tables 5.4 and 5.5 for 
parameters values) 
 
 
Figure  5.4    Partial Sensitivity analysis on model parameters for parental cell line culture. 
Each colormap represents the normalized sum of squared difference between the 
simulated and measured extracellular metabolite concentration over time, when the 
parameter (row) is changed from -85% to +300% (column) of the optimal value. The 
values for sum of squared difference are normalized by the value corresponding to 
optimal values for parameters. The number for each row corresponds to the parameter 
presented next to the same row in figure 5.3. 
 
5.6.2 Assessment of the in silico platform performance 
5.6.2.1 The model describes intra- and extracellular metabolites concentration 
profiles and growth kinetics 
The model assumed for cell specific growth rate, as multiplicative Michaelis-Menten 
kinetics for precursors of cell building blocks, was able to simulate the viable cell 
concentration profile in all CHO cells cultures under study (Figure 5.6). High- and low-
producing clones exhibit almost similar growth profiles, reaching maximum viable cell 
densities of ~3.5×106cells mL-1, while parental cell line reached slightly higher maximum 
viable cell density (~4.5×106 cells mL-1). The model also simulates extracellular 
metabolites profile with time althoughsignificant differences in behaviour are observed 
between the parental, low- and especially high- producer clones(Figure 5.6). 
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Interestingly,differences between induced and non-induced cultures of the same cloneare 
non-significant. Irrespective of the clone or induction state, all cultures were not glucose-
limited (> 5-15 mM at culture harvest), with the higher consumption in high-producer 
clone cultures. Parental and low-producer cultures exhibit similar glutamine profiles, and 
a faster depletion is again observed for the high-producer clone. Growth cessation 
coincided with the depletion of glutamine.  Interestingly, unlike glucose, lactate 
concentration profile differs among clones but the modelstructure is able to simulate each 
case. Lactate is produced all along cultures but, however, the high-producer clone seems 
to start consuming lactate at glutamine depletion, suggesting the coupling of these 
phenomena as suggested by Zagari et al. (2013) (Zagari et al., 2013). Ammonia 
production was almost similar in parental and low-producer cultures reaching a final 
concentration of approximately ~4 mM, whereas it was ~5 mM in the case of the high-
producer clone. Similarly to lactate, the high-producer clone seems to start consuming 
ammonia following glutamine depletion. Differences in extracellular metabolites profiles 
are significantly related to amino acids metabolism (see table 5.6 for statistical 
analysis).Globally,all amino acids exceptalanine andglutamate were consumed and the 
consumption/production rates were greater in the case of high-producer clone (Figure 
5.6). Glutamate concentration constantly increases in all culture media, and alanine is 
also constantly produced during exponential phase but consumed thereafter (from ~96 h), 
with a more pronounced decrease inthe high-producer clone. In that culture, alanine may 
have compensated for the lack of glutamine, once the later was depleted. Beside alanine, 
extracellular concentrations in (ASN+ASP) and SER in the high-producer reached 
depletion. These amino acids are expected to contribute to pyruvate synthesis. Although a 
higher consumption of grouped amino acids channeled through succinate and glutamate 
can be identified in the high-producer culture, there is no depletion observed. 
Interestingly, most intracellular metabolites show constant and similar levels between 
cultures except for G6P and PEP with an increasing trend after exponential phase (Figure 
5.16). 
 
 
 
 
 120 
 
Table  5.4    Affinity (Km), activation (Ka), and inhibition (Kd) constants 
 
Parameter Value units 
Parental Low-
producing  
High-
producing 
ࡷ࢓ࡳࡸ࡯ 4.19 4.19 4.199  mM 
ࡷ࢓ࡳࡸࡺ 1.58 1.5893 1.5893 ‘‘ 
ࡷ࢓ࡸ࡭࡯ 5 5 3.5 ‘‘ 
ࡷ࢓ࡺࡴ૝ 0.5 0.5 0.5 ‘‘ 
ࡷ࢓࡭ࡸ࡭ 1 1 1 ‘‘ 
ࡷ࢓࡭ࡾࡳ 0.05 0.05 0.05 ‘‘ 
ࡷ࢓࡭ࡿࡼ 0.015 0.015 0.015 ‘‘ 
ࡷ࢓࡭ࡿࢄ 0.15 0.15 0.15 ‘‘ 
ࡷ࢓ࡳࡸࢅ 0.05 0.05 0.05 ‘‘ 
ࡷ࢓ࡴࡵࡿ 0.5 0.5 0.5 ‘‘ 
ࡷ࢓ࡵࡸࡱ 0.025 0.025 0.025 ‘‘ 
ࡷ࢓ࡸࢁࡱ 0.025 0.025 0.025 ‘‘ 
ࡷ࢓ࡸࢅࡿ 0.05 0.05 0.05 ‘‘ 
ࡷ࢓ࡿࡱࡾ 0.015 0.015 0.015 ‘‘ 
ࡷ࢓ࢀࢅࡾ 0.05 0.05 0.05 ‘‘ 
ࡷ࢓ࢂ࡭ࡸ 0.05 0.05 0.05 ‘‘ 
ࡷࢇࡳࡸࡺ 10 10 10 ‘‘ 
ࡷ࢓ࡳࡸࡺ࢓࡭࢈  0.01 0.01 0.01 
 
ࡷ࢓ࡳ૟ࡼ 8.20E-08 8.20E-08 8.20E-08 mmol.(10
6 cells)-1 
ࡷ࢓ࡲ૟ࡼ 4.00E-07 4.00E-07 3.22E-07 ‘‘ 
ࡷ࢓ࡳ࡭ࡼ 8.00E-07 8.00E-07 8.00E-07 ‘‘ 
ࡷ࢓ࡼࡱࡼ 1.70E-07 1.73E-07 1.70E-07 ‘‘ 
ࡷ࢓ࡾ૞ࡼ 1.30E-08 1.35E-08 1.35E-08 ‘‘ 
ࡷ࢓ࢄ૞ࡼ 3.40E-08 3.40E-08 3.40E-08 ‘‘ 
ࡷ࢓ࡼࢅࡾ 9.80E-07 7.98E-07 9.80E-08 ‘‘ 
ࡷ࢓࡭࡯࡯ࡻ࡭ 9.60E-07 9.60E-07 9.80E-07 ‘‘ 
ࡷ࢓ࡻࢄ࡭ 2.40E-07 2.40E-07 2.46E-07 ‘‘ 
ࡷ࢓࡯ࡵࢀ 1.00E-07 8.51E-08 9.00E-08 ‘‘ 
ࡷ࢓࡭ࡷࡳ 8.60E-07 9.40E-07 7.11E-07 ‘‘ 
ࡷ࢓ࡿࢁ࡯ 2.80E-08 2.03E-07 1.62E-07 ‘‘ 
ࡷ࢓ࡹ࡭ࡸ 8.50E-07 8.54E-07 6.21E-07 ‘‘ 
ࡷ࢓ࡳࡸࢁ 1.28E-04 1.28E-04 1.28E-04 ‘‘ 
ࡷ࢓࡭ࢀࡼ 4.20E-06 5.00E-06 4.61E-06 ‘‘ 
ࡷ࢓࡭ࡰࡼ 3.65E-07 3.65E-07 3.65E-07 ‘‘ 
ࡷ࢓࡭ࡹࡼ 2.52E-08 2.52E-08 2.52E-08 ‘‘ 
ࡷ࢓ࡼࢉ࢘ 7.70E-6 7.70E-06 7.70E-06 ‘‘ 
ࡷ࢓࡯࢘ 6.00E-7 6.00E-07 6.00E-07 ‘‘ 
ࡷ࢓ࡻ૛ 4.00E-6 4.00E-6 4.00E-6 ‘‘ 
ࡷ࢓ࡼ࢏ 1.00E-6 1.00E-6 1.00E-6 ‘‘ 
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Table  5.5    Maximum reaction rates (νmax) and Comparison of highly sensitive 
parameters in parental, low-producing and high-producing clones. 
Asterisks (*) and (+) denote statistically significant difference between parental and 
either induced low-producing or induced high-producing cell lines considering shown 
confidence intervals. All units are in mmol. (106cells)-1.h-1except for νmax growth  which is in 
h-1. 
 
Parameter Value t-test 
Results 
    Parental                             Low-producing           High-producing  
ࣇ࢓ࢇ࢞ࡴࡷ  2.65E-4 
[2.35E-4,2.98E-4] 
2.73E-4 
[2.54E-4,2.93E-4] 
2.98E-4 
[2.76E-4,3.21E-4] 
 
ࣇ࢓ࢇ࢞ࢌࡼࡳࡵ 2E-4 
[3.75E-5,3.05E-4] 
1.76E-4 
[3.42E-5,3.14E-4] 
1.47E-4 
[1.08E-5,2.62E-4] 
 
 
ࣇ࢓ࢇ࢞ࡼࡲࡷ/࡭ࡸࡰ 2.40E-3 
 
2.40E-3 
 
2.40E-3 
 
 
ࣇ࢓ࢇ࢞ࡼࡳࡷ 9.00E-4 9.00E-4 9.00E-4  
ࣇ࢓ࢇ࢞ࡼࡷ 5.78E-4           
[2.21E-4,9.32E-4] 
6.00E-4                      
[3.48E-4,8.75E-4] 
6.00E-4              
[3.44E-4,8.67E-4] 
 
ࣇ࢓ࢇ࢞ࢌࡸࡰࡴ 3.62E-4            
[1.65E-4,5.65E-4] 
3.50E-4                 
[8.15E-5,6.2E-4] 
5E-4                   
[2.13E-4,7.87E-4] 
 
ࣇ࢓ࢇ࢞࢘ࡸࡰࡴ 2.75E-5           
[1.95E-5,3.51E-5] 
1.20E-4              
[6.78E-5,1.73E-4] 
2.10E-4              
[1.23E-4,3.01E-4] 
p<0.1 * + 
ࣇܕ܉ܠࡳ૟ࡼࡰࡴ/ࡼࡳࡸࢉࡰࡴ 1.00E-4                
[7.85E-5,1.25E-4] 
9.93E-5                                        
[5.46E-5,1.46E-4] 
6.80E-5                                                            
[5.48E-5,8.29E-5] 
 
ࣇ࢓ࢇ࢞ࡱࡼ 9.50E-6                
[1.53E-6,1.75E-5] 
 9.91E-6                
[1.63E-6,1.82E-5] 
9.61E-6                
[3.9E-6,1.54E-5] 
 
ࣇܕ܉ܠࢀࡷ/ࢀ࡭ 2.00E-5 2.00E-5 2.00E-5  
ࣇ࢓ࢇ࢞ࡼࡰࡴ 1.40E-4           
[1.01E-4,1.79E-4] 
1.47E-4 
[1.25E-4,1.61E-4] 
2.60E-4 
[2.1E-4,3.04E-4] 
p<0.1 + 
ࣇ࢓ࢇ࢞࡯ࡿ        6.30E-5    
[4.34E-5,8.23E-5] 
9.67E-5              
[2.19E-5,1.7E-4] 
1.52E-4              
[6.57E-5,2.39E-4] 
 
ࣇܕ܉ܠ࡯ࡵࢀࡿ/ࡵࡿࡻࡰ  8.20E-5         8.20E-5 
 
8.20E-4 
 
 
ࣇ࢓ࢇ࢞࡭ࡷࡳࡰࡴ 1.50E-4            
[4.57E-5,2.51E-4] 
1.44E-4                      
[4.34E-5,2.4E-4] 
1.95E-4                 
[1.11E-4,2.8E-4] 
 
ࣇܕ܉ܠࡿࡰࡴ/ࡲࢁࡹ 8.51E-5 8.51E-5 8.51E-5  
ࣇ࢓ࢇ࢞ࡹࡸࡰ 6.40E-5           
[8.76E-6,1.21E-4] 
6.61E-5 
[8.45E-6,1.31E-4] 
1.85E-4 
[1.2E-4,2.35-4] 
 
ࣇ࢓ࢇ࢞ࡹࡱ 7.14E-5                
[3E-5,2.58E-4] 
4.56E-5              
[1.55E-5,7.58E-4] 
1.05E-4                                
[6.07E-5,1.58E-4] 
 
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Table 5.5    Maximum reaction rates (νmax) and Comparison of highly sensitive 
parameters in parental, low-producing and high-producing clones (Continued). 
 
ࣇ࢓ࢇ࢞ࢌࡼ࡯ 8.00E-5             
[4.44E-6,1.58E-4] 
8.11E-5             
[3.51E-5,1.28E-4] 
9.95E-5            [4.39E-
5,1.58E-4] 
 
 
ࣇ࢓ࢇ࢞ࢌࡳࡸࡺࡿ  6.40E-5          
[3.86E-5,9.11E-5] 
7.65E-5             
[5.91E-5,9.36E-5] 
9.00E-5 
[7.57E-5,1.18E-4] 
ࣇ࢓ࢇ࢞࢘ࡳࡸࡺࡿ 3.25E-6           
[2.49E-6,3.95E-6] 
3.25E-6            
[2.71E-6,3.82E-6] 
3.65E-5               
[2.42E-5,4.88E-4] 
 
ࣇ࢓ࢇ࢞ࢌࡳࡸࡰࡴ  1.06E-5         
[2.97E-7, 2.15E-5] 
1.31E-5         
[6.33E-7,2.56E-5] 
2.05E-5              
[7.00E-7,3.14E-5] 
 
ࣇ࢓ࢇ࢞࢘ࡳࡸࡰࡴ 5.35E-5             
[2.00E-6, 4.50E-5] 
3.61E-5         
[2.42E-5,4.80E-5] 
3.10E-6             
[2.33E-5,4.00E-5] 
 
ࣇ࢓ࢇ࢞ࢌ࡭࢒ࢇࢀ࡭ 6.00E-5            
[3.55E-5,8.50E-5] 
6.00E-5            
[3.71E-5,8.36E-5] 
1.15E-4           [6.29E-
5,1.66E-4] 
 
ࣇ࢓ࢇ࢞࢘࡭࢒ࢇࢀ࡭ 1.07E-6    
[0,12.53E-6] 
1.22E-6       
[0,2.56E-6] 
5.50E-6            [3.81E-
6,7.16E-6] 
 
ࣇ࢓ࢇ࢞ࡳ࢒࢛ࢀ 1.28E-6 1.65E-6 2.5E-6  
ࣇ࢓ࢇ࢞࢘ࢋ࢙࢖ 7.00E-4              
[5.61E-4,8.70E-4] 
8.13E-4            
[5.53E-4,1.00E-3] 
8.70E-4            [7.67E-
4,9.98E-4] 
 
ࣇ࢓ࢇ࢞࡭ࢀࡼࢇ࢙ࢋ 5.451E-3           
[4.12E-3,6.84E-3] 
9.16E-3 
[8.13E-3,1.02E-2] 
9.30E-3 
[8.04E-3,1.06E-2] 
p<0.1 * + 
ࣇ࢓ࢇ࢞࢒ࢋࢇ࢑ 9.70E-5          9.70E-5           9.70E-5             
 2.30E-4 2.30E-4 2.30E-4  
ࣇ࢓ࢇ࢞ࢌ࡯ࡷࣇ࢓ࢇ࢞࢘࡯ࡷ 9.00E-5 9.00E-5 9.00E-5  
ࣇ࢓ࢇ࢞ࢌ࡭ࡷ 2.00E-5 2.00E-5 2.00E-5  
ࣇ࢓ࢇ࢞࢘࡭ࡷ 3.00E-5 3.00E-5 3.00E-5  
ࣇ࢓ࢇ࢞ࡼࡼࡾ࢏࢈ࡼ 2.00E-8 1.00E-8 1.00E-8  
ࣇ࢓ࢇ࢞ࡺ࡭ࡰࡼࡴ࢕࢞ 4.00E-3             4.00E-3             4.00E-3              
ࣇ࢓ࢇ࢞ࡿ࡭ࡸ 6.65E-6            
[5.18E-6,8.13E-6] 
8.54E-6             
[4.70E-6,1.23E-5] 
1.00E-5                     
[4.22E-6,1.58E-5] 
 
ࣇ࢓ࢇ࢞࡭ࡿࢄ 8.05E-6           
[4.19E-6,1.20E-5] 
9.91E-6                       
[3.7E-6,1.63E-5] 
1.29E-5                       
[5.07E-6,2.08E-5] 
 
ࣇ࢓ࢇ࢞ࢌ࡭ࡿࢀ࡭ 5.41E-6           
[4.32E-6,6.55E-6] 
5.65E-6                        
[5.00E-6,6.3E-6] 
3.50E-5                        
[2.97E-6,4.03E-5] 
p<0.1  + 
ࣇ࢓ࢇ࢞࢘࡭ࡿࢀ࡭ 3.25E-6            2.16E-6                        3.2E-6                       
ࣇ࢓ࢇ࢞ࡴࡵࡿ࡭ࡾࡳࢀ࡭ 1.50E-5           
[5.4E-6,2.46E-5] 
1.85E-5                                
[8.10E-6,2.89E-5] 
2.05E-5                        
[1.07E-5,3.3E-5] 
 
ࣇ࢓ࢇ࢞ࡸࢅࡿࡵࡸࡱࡸࡱࢁࡴࡵࡿࢂ࡭ࡸࢀࢅࡾࢀ࡭ 2.61E-5           
[1.81E-5,3.43E-5] 
2.80E-5                                                       
[1.85E-5,3.75E-5] 
3.45E-5                                                       
[2.27E-5,4.65E-5] 
 
ࣇ࢓ࢇ࢞ࢍ࢘࢕࢚࢝ࢎ 0.34             
[0.25,0.43] 
0.42 
[0.38,0.54] 
0.49 
[0.45,0.54] 
 
ࣇ࢓ࢇ࢞࢓࡭࢈  0           1.60E-6         
[1.05E-6,2.15E-6]   
 
1.00E-5             
[5.55E-6,1.5E-5]         
p<0.1 * + 
 
5.6.2.2 Model simulates CHO cells clonal variations in energetic state 
As previously mentioned for the parental cell line, the cell energetic state represented by 
ATP-to-ADP, NADH-to-NAD ratios, and the cell specific oxygen consumption rate 
 
 123 
(qO2) are well simulated for all cultures (Figure 5.6). Although the cell specific oxygen 
consumption rate is generally greater for the high-producer clone, the ATP-to-ADP ratio, 
a marker of respiration and energy consumption, showed relatively stable and similar 
values in all cultures. NADPH-to-NAPD was also substantially similar and stable in 
exponential phase in all cell lines, with a slight decrease after exponential phase 
suggesting the down-regulation of NADPH production.Finally, the NADH-to-NAD ratio, 
which is a marker of TCA cycle activity, was considerably higher in high-producer clone 
than in parental and low-producer cell lines, indicating a sustained up-regulated TCA 
activity, as discussed in the next sections. 
 
Clonal variation in physiology can be inferred from a limited set of model kinetic 
parameters 
In order to further evaluate parameters adjustment attributed to clonal variation, the 
associated p-values for each pair of estimates (control vs. either induced low-producer or 
high- producer cultures) were calculated (Table  5.5). In low- and high- producer clones, 
only two and four parameters, respectively, were statistically different from those for 
parental to allow the model to simulate the effect of cumate induction. Briefly, in the case 
of the induced low-producer clone, main differences can be observed for parameters 
related to glycolysis (νmaxrLDH), and ATP consumption reactions, which are lumped as 
ATPase pumps requirements (νmaxATPase). However, in the case of the induced high-
producer clone, νmaxr LDH and νmaxATPase are both significantly changed in addition to one 
parameter related to glutaminolysis (νmaxfASTA) and one related to the reactions connecting 
glycolysis to TCA cycle (νmaxPDH). The high-producer clone thus resulted in a 
significantly different in silico behaviour compared to the parental cell line and, to a 
lesser extent, to the low-producer clone (Figure 5.5 and Table 5.5) regarding the 
simulations that are however in agreement with experimental data. Interestingly, the 
high-producer clone only requires the adjustment of four parameters values from those of 
the parental for the simulations to cope with experimental data.  
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Figure  5.5    Parameter estimates with their error bars for sensitive parameters. 
Glycolysis (A), TCA cycle and Redox state (B), glutaminolysis and pentose phosphate 
pathway (C), amino acid metabolism (D) and energetic and growth (E). Horizontal solid 
lines are 1.96 standard error bars and represent parameter estimate 1.96 standard error. 
Parental cell line: open triangles for parameter estimates, induced low-producer cell line: 
open squares for parameter estimates, andinduced high-producer cell line: open circles 
for parameter estimates. A parameter is considered highly sensitive if a small variation in 
its value ( 25%) causes more than a 15 % increase of in the objective function.  
 
5.6.2.3 The model simulates mAb production 
The dynamics of mAb production, modeled as multiplicative Michaelis-Menten kinetics 
of amino acids, resulted in the simulation of mAb titers (Figure 5.6) in low- and high-
producer clones. The model fits to experimental data in induced cultures while it 
simulates the production resulting from the leaky expression of the inducible system.  
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Figure  5.6Simulated and experimental data for parental and induced/non-induced cell 
lines. 
Parental (experimental data: black triangles, simulated data: solid black line), induced 
low-producer (experimental data: black squares, simulated data: dashed black line), non-
induced low producer (experimental data: blue squares, simulated data: dashed blue line), 
induced high-producer (experimental data: black circles, simulated data: dotted black 
line), and non-induced high-producer (experimental data: red circles, simulated data: 
dotted  red line). 
5.7 Discussion 
5.7.1 The kinetic-metabolic model is a reliable in silico tool to assess CHO 
cells clonal variations 
Induction of recombinant proteins in microbial cell platforms has been shown to cause an 
increased energy demand in support to a metabolic burden (Heyland, Blank, & Schmid, 
2011a; Heyland et al., 2011b). Unlike microbial cells, the links between cell metabolic 
load and protein productivity in engineered mammalian cells has yet to be tackled, 
although some progress has been accomplished with the help of 13C-labeling 
(Sheikholeslami, Jolicoeur, & Henry, 2013). In this work, an inducible system with a 
high-producer clone has been selected in order to study an induction effect on CHO cell 
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metabolic behaviour and load. Towards this goal, the use of an in silico platform, made of 
a kinetic-metabolic model, confers a unique capacity to explore mAbCHO producing 
cells beyond experimental observations onto which the model has been anchored a priori. 
Therefore, the remaining discussion will be based on the results derived from the 
developed in silico platform.  
5.7.2 Clone to clone variations yield more significant metabolic changes than 
recombinant protein expression 
In the previous sections, we reported large differences in behaviour between the low- and 
the high- producer clones, comparing non-induced and induced cells (Figure 5.6). 
However, it is of interest to evaluate the source of these differences. The contribution of 
mAb production is estimated to account for atmost 5% of total carbon uptake by the cells, 
even for the high-producer clone, and one can expect the de novo metabolic load 
associated to the recombinant proteins to be low compared to the intrinsic one related to 
endogeneous protein synthesis. This estimate is calculated taking the carbon mass in 1 
mol of mAb to the augmentation of the total mass of carbon from cellular growth, 
considering a specific productivity of ~ 1×10-6 mmol 10-6 cells h-1  and growth rate of  ~ 
0.04 h-1,and assuming a dry cell weight of 350 pg cell-1, a cellular molecular weight of 
150 g mol-1 and the reported elemental formulas for both biomass and mAb (Nolan & 
Lee, 2010).Therefore, the production capacity is thought not to be limited at the anabolic 
level, but rather at the protein processing stage (assembly and the folding) (Dinnis et al., 
2006). We then used the model to evaluate the effect of cumate induction on the 
metabolic load, and similar intracellular flux distribution, metabolic fluxes and ratios 
were found when normalized to their time-corresponding values in non-induced controls 
(Figure 5.7). Only metabolic fluxes and ratios of major metabolic networks such as 
glycolysis and TCAare shown.Interestingly, most normalized values of metabolic fluxes 
and ratios are close to 1 for the high-producer clone, while the low-producer clone 
exhibits deviations from 0 to 10% for a series of fluxes with +10% for VHK, VPGK, VGLNS, 
TCA flux and ATP turnover rate. In the case of the high-producer clone, the contribution 
of glutamine to TCA cycle is lower in the induced culture. Indeed, the higher deviation 
between the induced and non-induced cells is observed comparing the mAb specific 
production rates with time, with production rates that are 13 to 8 times higher in the low-
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producer clone and 5 to 1 times higher in the high-producer clone. This higher deviation 
level in the low-producer clone looks surprising but it can be attributed to a higher 
leakage level of the cumate gene switch in the high-producer clone in the absence of 
cumate induction (Figure 5.6). Our results, both experimental and from simulations, thus 
suggest that within our experimental conditions, differences in metabolic pattern caused 
by clonal variation (Dahodwala et al., 2012) exceeded that induced by recombinant 
protein expression (Heyland et al., 2011a; Heyland et al., 2011b). 
5.7.3 High producer clone selection favors metabolically efficient cell 
population subsets 
5.7.3.1 The high-producer clone shows a more efficient lactate metabolism 
Model simulations (Figure 5.7) suggest that distinct metabolism of the high-producer 
clone is simply somehow more favorable for production irrespective of cumate induction. 
Induced and non-induced high-producer show similar glycolytic rates (VHK, VPGK), 
glutamine metabolism (VGLNS) and ATP turnover rate for the whole culture duration. 
However, interestingly, although hexokinase and phosphoglucose isomerase activities are 
both not affected by cumate induction, lactate dehydrogenase activity shows the lowest 
values for the high-producer clone, and to a lesser extent for the low-producer clone 
(Figure 5.8). Lactate production rate for the high-producer clone is lower (-46% at mid 
exponential phase and -56% at the end of exponential phase)than that for parental 
(Figure 5.8, Table 5.6). Therefore, although an overflow of glycolytic flux to lactate has 
been extensively reported under non-limiting glucose conditions (Europa et al., 2006), 
irrespective to recombinant protein expression, the high-producer CHO cell clone seems 
to maintain a more efficient metabolic state; a result that is also supported form simulated 
lower values of lactate production rate-to-glucose consumption rate ratio (Figure 5.9). 
While a quasi-constant ratio value is maintained for the parental clone, the low-producer 
also exhibits a decreasing trend, but to a lower extent than for the high-producer. With 
ratios lower than 1, while literature usually reports a 1-2 range, one can clearly conclude 
of a respiratory metabolism, coupled to a high feeding rate of intermediates to anabolic 
reactions. 
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Figure  5.7    Comparison of metabolic fluxes and ratios. 
Specific glucose uptake rate (ν(HK)), glycolytic flux(ν(PK)), lactate production-to-
glucose consumption ratio ((νf(LDH)-νr(LDH))/ν(HK)), pyruvate branch point as the 
ratio of the pyruvate influx through TCA cycle divided by the total flux into pyruvate 
pool ((v(PDH)+ ν(PC)/(ν(PK)+ν(SDH)+ν(ME)+ν(AlaTA)), when the last two fluxes 
positively fed pyruvare, percentage of pyruvate derived from glucose 
(v(PK/(ν(PK)+ν(SAL)+ν(ML-PC)+ν(AlaTA)), Contribution of glucose to TCA cycle as 
the ratio of pyruvate influx to TCA cycle via ν(PDH)  , considering most of the ν(PDH) 
has beenoriginated fromν(PK), to the total flux channeled through TCA cycle via its 
intermediates (v(PDH)/(ν(PDH)+ ν(ASTA)+ ν(GLDH)+ 
ν(LYSILELEUVALTYRTA)+ν(PC)), Contribution of glutamine to TCA cycle as the ratio 
of glutamate  influx to TCA cycle  via ν(GLDH) to the total flux channeled through TCA 
cycle via its intermediates 
(v(GLDH)/(ν(PDH)+ν(ASTA)+ν(GLDH)+ν(LYSILELEUVALTYRTA)+ν(PC))), 
Contribution of other amino acids to TCA 
cycle((v(LYSILELEUVALTYRTA)+ν(ASTA))/(ν(PDH)+ν(ASTA)+ν(GLDH)+ν(LYSILEL
EUVALTYRTA)+ν(PC))), TCA cycle flux (ν(SDH/FUM)), specific glutamine uptake rate 
(νf(GLNS)-νr(GLNS)), ATP turnover rate (ν(PGK)+ν(PK)+v(SCOAS)+νr(GlnT)+ 
νf(CK)+vr(AK)+2P/O ratio*ν(resp)), Specific growth rate ν(growth), and specific 
production rate ν(mAb),between induced and non-induced low-producer (dashed line) and 
high-producer (dotted line) cell lines. The values are defined as the ratio of specific 
metabolic fluxes (mmol  (10 6cells)-1 h- 1) or ratio in induced cultures to that in the non-
induced control cultures at each time point. 
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Table  5.6Comparison of metabolic fluxes and ratios in parental, induced low-producing 
and induced high-producing cell lines at 48 h. Same conditions as table 5.5 applied. 
 
 
 
Metabolic 
Flux/Ratio 
 
 
Parental 
 
 
        Low-producing 
 
 
 
High-producing 
 
Significan
ce Level 
(t- test 
Result) 
 
  
Value                  Interval 
 
Value 
 
Interval 
 
 Value 
 
Interval 
ࣇࡴࡷ 7.67E-5 
 
[6.33E-5,9.03E-5] 7.32E-5 
 
[6.11E-5,8.52E-5] 7.66E-5 [6.14E-5,9.18E-5]  
ࣇࡼࡳࡷ 1.35E-4 [8.19E-5,1.88E-4] 1.31E-4 [8.78E-5,1.74E-4] 1.38E-4 [1.08E-4,3E-4]  
ࣇࡸࡰࡴ 8.74E-5 [7.13E-5,1.04E-4] 7.36E-5 [5.68E-5,9.09E-5] 4.49E-5 [2.68E-5,6.30E-5] p<0.1
+ 
ࣇࡼࡰࡴ 4.04E-5 [2.64E-5,5.45E-5] 4.86E-5 [3.65E-5,6.08E-5] 7.06E-5 [5.60E-5,8.52E-5] p<0.1
+ 
ࣇࡿࡰࡴ/ࡲࢁࡹ 4.90E-5 [3.23E-5,6.57E-5] 6.16E-5 [4.68E-5,7.63E-5] 9.35E-5 [7.65E-5,1.11E-4] p<0.1+ 
ࣇࡹࡱ − ࣇࡼ࡯ 3.70E-6 [1.73E-6,5.67E-6] 4.72E-6 [2.75E-6,6.69E-6] -3.57E-6 [-1.86E-6,-5.27E-6] p<0.1
+ 
ࣇࡳࡸࡺࡿ 2.91E-5 [2.05E-5,3.80E-5] 3.89E-5 [2.69E-5,3.89E-5] 3.81E-5 [2.74E-5,4.87E-5]  
ࣇࡳࡸࡰࡴ 5.27E-7 [2.43E-7,8.11E-7] 3.23E-7   [1.19E-7,5.27E-7] 6.73E-6 [3.29E-6,1.02E-5] p<0.1
+ 
ࣇ࡭࢒ࢇࢀ࡭ 1.36E-5 [9.46E-6,1.77E-5] 1.61E-5 [1.20E-5,2.02E-5] 2.02E-5 [1.52E-5,2.53E-5]  
ࣇࡴࡵࡿ࡭ࡾࡳࢀ࡭ 3.16E-6 [2.14E-6,4.25E-6] 4.38E-6 [3.14E-6,5.62E-6] 4.99E-6 [3.45E-6,6.53E-6]  
ࣇࡿ࡭ࡸ 5.95E-6 [5.67E-6,6.23E-6] 7.95E-6 [4.37E-6,1.15E-5] 9.71E-6 [6.12E-6,1.33E-5]  
ࣇ࡭ࢀࡼࢇ࢙ࢋ 4.78E-4 [2.13E-4,7.43E-4] 5.51E-4 [2.86E-4,8.16E-4] 9.93E-4 [4.27E-4,1.56E-3]  
ࣇ࢘ࢋ࢙࢖ 9.32E-5 [4.99E-5,1.36E-4] 1,44E-4 [1.09E-4,1.79E-4] 2.10E-4 [1.68E-4,2.53E-4]  
ࣇ࢒ࢋࢇ࢑ 1.52E-5 [9.06E-6,2.13E-5] 1.75E-5 [8.16E-6,2.68E-5] 2.47E-5 [1.16E-5,3.77E-5]  
ࣇࢍ࢘࢕࢚࢝ࢎ 0.035 [0.031,0.038] 0.028 [0.025,0.031] 0.031 [0.026,0.035]  
ࣇ࢓࡭࢈ - - 6.43E-7 [5.43E-7,7.43E-7] 3.11E-6 [2.21E-6,9.00E-7]  
Lactate 
Production - to -
Glucose 
Consumption 
1.07 [0.75,1.39] 0.97 [0.69,1.25] 0.58 [0.43,0.73] p<0.1+ 
Pyruvate 
Branch point 
Ratio 
0.26 [0.15,0.36] 0.33 [0.14,0.51] 0.54 [0.37,0.70] p<0.1+ 
Percentage of 
Pyruvate 
Derived from 
Glucose 
84.9 [71,98] 85.42 [68,101] 76.75 [62,91]  
Contribution of 
Glucose to TCA 
Cycle 
65.03 [50,79] 61.95 [47,76] 57.05 [41,72]  
 
 
 
 
Table 5.6Comparison of metabolic fluxes and ratios in parental, induced low-producing 
and induced high-producing cell lines at 48 h (Continued) 
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Metabolic 
Flux/Ratio 
 
 
Parental 
 
 
Low-producing 
 
 
 
High-producing 
 
Significance   
Level 
(t- test 
Result) 
 
  
 Value 
 
Interval 
 
Value 
 
Interval 
 
Value 
 
Interval 
Contribution of 
Glutamine to TCA 
Cycle 
1.21 [0.83,1.58]       - - 7 [5.23,8.76] p<0.1+ 
Contribution of 
Aminoacids  to 
TCA Cycle 
4.89 [2.80,6.97] 14.35 [10.52,18.17] 12.54 [9.45,15.62]  
Specific ATP 
Production Rate 
mmol (106 cells)-1h-1 
7.20E-4 [3.69E-4,1.07E-3] 9.36E-4 [4.85E-4,1.38E-3] 1.24E-3 [7.28E-4,1.75E-3]  
Percentage of ATP 
Consumption for 
Biomass Synthesis 
7.95 [5.57,10.33] 4.91 [3.03,6.79] 3.91 [2.53,13.81]  
Percentage of ATP 
Consumption for 
mAb Synthesis 
- - 0.28 [0.26,0.31] 1.02 [0.82,1.22] p<0.1* + 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 5.6B     Comparison of metabolic fluxes and ratios in parental, induced low-
producing and induced high-producing cell lines at 74 h. Same conditions as table 5.5 
applied. 
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Metabolic 
Flux/Ratio Parental 
 
Low-producing 
 
High-producing 
 
Significan
ce Level 
(t- test 
Result) 
 
 
Value Interval Value Interval Value Interval 
       
ࣇࡴࡷ  
7.61E-5 
 
[6.51E-5,8.71E-5] 
 
7.33E-5 
 
[6.42E-5,8.25E-5] 7.73E-5 [6.70E-5,8.75E-5]  
ࣇࡼࡳࡷ 1.35E-4 [9.03E-5,1.80E-4] 1.33E-4 [7.81E-5,1.88E-4] 1.41E-4 [9.16E-5,1.91E-4]  
ࣇࡸࡰࡴ 8.53E-5 [7.20E-5,9.86E-5] 6.85E-5 [5.22E-5,8.48E-5] 3.64E-5 [2.12E-5,5.18E-5] p<0.1
+ 
ࣇࡼࡰࡴ 4.15E-5 [2.63E-5,5.67E-5] 5.29E-5 [3.26E-5,7.31E-5] 7.84E-5 [6.62E-5,9.06E-5] p<0.1
+ 
ࣇࡿࡰࡴ/ࡲࢁࡹ 5.06E-5 [2.63E-5,5.67E-5] 6.51E-5 [4.79E-5,8.21E-5] 1.01E-4 [8.54E-5,1.17E-4] p<0.1+ 
ࣇࡹࡱ − ࣇࡼ࡯ 2.51E-6 [1.03E-6,3.99E-6] 3.37E-6 [1.9E-6,4.85E-6] -4.53E-6 [-2.48E-6,-6.58E-6] p<0.1
+ 
ࣇࡳࡸࡺࡿ 2.48E-5 [1.87E-5,3.09E-5] 3.21E-5 [2.43E-5,3.20E-5] 3.01E-5 [2.33E-5,3.68E-5]  
ࣇࡳࡸࡰࡴ -1.41E-6 [-3.4E-7,-2.45E-6] -1.44E-6 [-1.18E-6,-2.9E-6] 4.75E-6 [3.29E-6,6.20E-6] p<0.1+ 
ࣇ࡭࢒ࢇࢀ࡭ 1.38E-5 [1.07E-5,1.68E-5] 1.69E-5 [1.29E-5,2.09E-5] 1.80E-5 [1.50E-5,2.11E-5]  
ࣇࡴࡵࡿ࡭ࡾࡳࢀ࡭ 3.01E-6 [1.53E-6,4.49E-6] 4.25E-6 [2.23E-6,6.26E-6] 4.76E-6 [2.61E-6,6.91E-6]  
ࣇࡿ࡭ࡸ 5.94E-6 [3.38E-6,8.50E-6] 7.92E-6 [5.36E-6,1.05E-5] 9.56E-6 [6.69E-6,1.26E-5]  
ࣇ࡭ࢀࡼࢇ࢙ࢋ 4.89E-4 [2.12E-4,7.64E-4] 5.91E-4 [3.13E-4,8.68E-4] 1.06E-3 [4.62E-4,1.68E-3]  
ࣇ࢘ࢋ࢙࢖ 9.53E-5 [5.35E-5,1.37E-4] 1.54E-5 [1.30E-4,1.78E-4] 2.94E-4 [2.15E-4,2.43E-4]  
ࣇ࢒ࢋࢇ࢑ 1.52E-5 [1.01E-5,2.04E-5] 1.86E-5 [7.92E-6,2.92E-5] 2.66E-5 [1.03E-5,4.30E-5]  
ૅࢍ࢘࢕࢚࢝ࢎ 0.03 [0.027,0.032] 0.025 [0.022,0.027] 0.023 [0.021,0.025]  
ࣇ࢓࡭࢈ - - 5.71E-7 [4.51E-7,6.91E-7] 2.59E-6 [1.79E-6,3.39E-6]  
Lactate 
Production - to 
-Glucose 
Consumption 
1.06 [0.65,1.46] 0.88 [0.56,1.20] 0.47 [0.29,0.65] p<0.1+ 
Pyruvate 
Branch 
pointRatio 
0.29 [0.16,0.41] 0.35 [0.14,0.55] 0.55 [0.33,0.76] p<0.1+ 
Percentage of 
Pyruvate 
Derived from 
Glucose 
84.55 [70,98] 84.68 [71,98] 75.44 [62,88]  
Contribution of 
Glucose to TCA 
Cycle 
66.02 [50,81] 63.02 [47,78] 59.36 [41,76]  
 
 
 
Table 5.6B    Comparison of metabolic fluxes and ratios in parental, induced low-
producing and induced high-producing cell lines at 48 h (Continued) 
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Metabolic 
Flux/Ratio Parental 
 
Low-producing 
 
High-producing 
 
Significance 
Level 
(t- test 
Result) 
 
 
Value Interval Value Interval Value Interval 
       
Contribution of 
Glutamine to TCA 
Cycle 
- 
 
               - 
 
- 
 
- 4.47 [2.97,5.96] p<0.1+ 
Contribution of 
Aminoacids  to 
TCA Cycle 
4.15 [1.92,6.37] 13.44 [10.82,16.05] 11.47 [9.40,13.53]  
Specific ATP 
Production Rate 
mmol (106 cells)-
1h-1 
7.19E-4 [4.00E-4,1.00E-3] 9.72E-4 [5.21E-4,1.41E-3] 1.32E-3 [7.43E-4,1.89E-3]  
Percentage of ATP 
Consumption for 
Biomass Synthesis 
6.86 [3.95,9.77] 4.19 [2.28,6.11] 2.72 [1.81,3.63]  
Percentage of ATP 
Consumption for 
mAb Synthesis 
- - 0.24 [0.14,0.33] 0.81 [0.69,0.91] p<0.1* + 
 
 
5.7.3.2 Anaplerosis/cataplerosis requirements allows for different flux distribution around 
pyruvate node in the high-producer clone 
Lower values for the lactate production rate-to-glucose consumption rate ratio were 
concomitant to higher fluxes through pyruvate dehydrogenase in high-producer clone. 
Pyruvate dehydrogenase activity remains almost constant in parental, while it increases of 
75% in high-producer and of 45% in low-producer at mid exponential phase (Figure 5.8, 
Table 5.6). In addition, both pyruvate carboxylase and malic enzyme show non-zero 
fluxes in all clones (Figure 5.8). Our values agree in the order of magnitude with non-
zero values that has been recently obtained for CHO cells using tracer technique (Ahn & 
Antoniewicz, 2011). These anaplerotic/cataplerotic reactions are known to be important 
for the replenishment of TCA-cycle intermediates (Lehninger, 1977). Unlike parental and 
low-producer, the balance between these two fluxes favors the formation of oxaloacetate 
from the beginning of the culture, which implies a higher activity of pyruvate carboxylase 
and a lower activity of malic enzymes in high-producer clone. Higher efflux of malate 
out of TCA cycle implies a higher rate for its conversion to pyruvate, and finally to 
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lactate in parental clone. The latter agrees with higher values of lactate production rate, 
both observed experimentally and from simulations (Figure 5.8, Table 5.6).  In addition, 
slightly higher values of the NADPH-to-NADP ratio suggest a greater contribution of 
malic enzyme in both lactate and NADPH production in parental cell line.Moreover,a 
higher pyruvate carboxylase activity in the high-producer may decrease the available 
pyruvate pool, which could in fine reduce lactate formation rate. The anaplerotic flux 
through glutamate dehydrogenase stay moderate in all three cultures, suggesting that 
acetyl coenzyme A derived from pyruvate is by far the most important intermediate 
fuelling the TCA cycle. This result is supported by a high glucose contribution to TCA 
cycle (50-60%)  (Figure 5.9, Table 5.6). A higher portion of pyruvate directed to TCA 
leads to  higher values of the pyruvate branch point ratio (+75%) estimated in high-
producer, and in low-producer to a lesser extent (Figure 5.9, Table 5.6). While a large 
fraction of pyruvate enters the TCA cycle (55 to 75%), only 15-35% is converted into 
lactate in the high-producer clone. A lower value of lactate production-to-glucose 
consumption rate has been associated to the over-expression of pyruvate dehydrogenase 
in other animal cells (Fogolín et al., 2004; Irani, Beccaria, & Wagner, 2002). The fraction 
of pyruvate entering the TCA is noticeably higher compared to values previously 
reported for other CHO cell lines (Altamirano et al., 2001; Goudar et al., 2010), but they 
are in agreement with recent reports on low values of lactate production (Sengupta, Rose, 
& Morgan, 2011) or even showing a net lactate consumption (Ahn & Antoniewicz, 
2011). The pyruvate branch point ratio shows an increasing trend in the high-producer 
clone, with a more active TCA cycle along culture time. Independently of the clone, the 
flux distribution around the pyruvate branch point suggests that a high proportion of 
pyruvate is derived directly from glycolysis (~80%) (Figure 5.9, Table 5.6), while the 
remaining 20% may mainly originate from malic enzyme activity, through the efflux of 
malate from TCA cycle, and amino acids catabolism. The estimated flux from malate to 
pyruvate is high at the beginning but this flux drops and stays at a low value as culture 
progressed (Figure 5.8); a behavior that has also reported recently (Niklas et al., 2011).   
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Figure  5.8Selected metabolic fluxes of parental (solid line), induced low-producer 
(dashed line), and induced high-producer cell lines. 
The fluxes (y-axis) are given in mmol  (106 cells)-1 h- 1 and the time (x-axis) in days. 
Negative values indicate fluxes in the opposite direction of the arrow.       
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Figure  5.9Comparison of metabolic ratios. 
Lactate production-to-glucose consumption ratio ((νf(LDH)-νr(LDH))/ν(HK)), pyruvate 
branch point as the ratio of the pyruvate influx through TCA cycle divided by the total 
flux into pyruvate pool (v(PDH/(ν(PK)+ν(SAL)+ν(ML-PC)+ν(AlaTA)), when the last 
two fluxes positively fed pyruvare, percentage of pyruvate derived from glucose 
((v(PK)+ ν(PC))/(ν(PK)+ν(SAL)+ν(ML)+ν(AlaTA)), Contribution of glucose to TCA 
cycle as the ratio of pyruvate influx to TCA cycle via ν(PDH)  , considering most of the 
ν(PDH) has beenoriginated fromν(PK), to the total flux channeled through TCA cycle via 
its intermediates (v(PDH)/(ν(PDH)+ ν(ASTA)+ ν(GLDH)+ 
ν(LYSILELEUVALTYRTA)+ν(PC)), Contribution of glutamine to TCA cycle as the ratio 
of glutamate  influx to TCA cycle either via ν(GLDH) to the total flux channeled through 
TCA cycle via its intermediates (v(GLDH) 
/(ν(PDH)+ν(ASTA)+ν(GLDH)+ν(LYSILELEUVALTYRTA)+ν(PC))), Contribution of 
other aminoacids  to TCA cycle 
((v(LYSILELEUVALTYRTA)+ν(ASTA))/(ν(PDH)+ν(ASTA)+ν(GLDH)+ 
ν(LYSILELEUVALTYRTA)+ν(PC))), ATP turnover rate 
(ν(PGK)+ν(PK)+v(SCOAS)+νr(GlnT)+ νf(CK)+vr(AK)+2P/O ratio*ν(resp)), 
percentage of ATP consumption for 
biomasssynethesis(0.00043*3.78*ν(growth)/(v(LYSILELEUVALTYRTA)+ν(ASTA))/(ν(P
DH)+ν(ASTA)+ν(GLDH)+ν(LYSILELEUVALTYRTA)+ν(PC)),and percentage of ATP 
consumption for antibody synthesis 
(4*ν(mAb)/(v(LYSILELEUVALTYRTA)+ν(ASTA))/(ν(PDH)+ν(ASTA)+ν(GLDH)+ν(LYSI
LELEUVALTYRTA)+ν(PC)),between parental (solid line), induced low-producer (dashed 
line) and induced high-producer (dotted line) clones. 
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5.7.3.3 Ammonia accumulation impaires the contribution of glutamine-metabolism to TCA 
cycle activity in all clones except in high-producer 
Although glutamine has been shown to be the major amino acid catabolized in the TCA 
cycle (Martens, 2007; Sheikholeslami, Jolicoeur, & Henry, 2013), its contribution to 
TCA decreases with respect to time to values close to zero at ~48 h for the parental and 
the low-producer clones only, while it reduces to ~4.5% for the high-producer clone at 72 
h for then remaining quasi-constant until the end of the culture (Figures 5.8, 5.9). It even 
appears that the direction of the glutamate dehydrogenase flux is reversing from an α-
ketoglutarate-producing (positive flux) to a glutamate-producing (negative flux) reaction 
in parental and low-producing cultures. This result suggests that the CHO cell lines under 
study may redirect the flux through glutamate dehydrogenase when the ammonia 
concentration increases, since glutamate dehydrogenase provides an alternative for the 
uptake (i.e. detoxification) of NH4+. It was reported in the literature that at 10 Mm NH4+ 
in the medium, the flux was reversed (Bonarius et al., 1998). However, it seems from our 
experimental data for extracellular ammonia even below that value that the reverse 
direction of the glutamate dehydrogenase flux is favored. NH4+ concentrations staying in 
the order of magnitude of the Michaelis affinity constant of glutamate dehydrogenase for 
NH4+ (KmNH4) (0.5 to 3.2 mM) may partially explain the low level for the direct 
contribution of glutamine to TCA cycle, via glutamate dehydrogenase. Interestingly, 
alanine, which is constantly produced during cell growth, is then consumed after 
glutamine depletion, and at higher rates for the high-producer, and to a lower extent for 
the low-producer. The alanine aminotransferase flux even shows to turn negative (Figure 
5.8). This also suggests that under low glutamine concentration, a-ketoglutarate is re-
channeled to the TCA cycle through aminotransferase, thus maintaining TCA cycle 
activity. The combined catabolism of all other amino acids represents ~7% (parental) to 
~15% (low- and high-producers) of the total carbon metabolized through the TCA cycle 
(Figure 5.9), entering as either succinate or oxaloacetate. However, this contribution 
decreases of ~5%  with time in the three cultures. The slow increasing contribution of 
glycolysis (expressed as glucose contribution) to TCA cycle suggests that extracellular 
glutamine and other amino acids may contribute less with time as they are getting 
depleted from the culture medium. Further analyzing of both lactate and glutamine 
profiles reveals that the high-producer clone switches to lactate consumption toward the 
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end of the culture from glutamine depletion (Figure 5.8). Once glutamine was depleted, 
lactate was readily consumed presumably to compensate for the reduced glutamine entry 
to TCA cycle. This also shows that generally, a low contribution of glutamine to TCA 
cycle may result in a lower net lactate production rate, resulting from a metabolic switch 
while glucose is still non-limiting, as observed in the high-producer clone and to a lesser 
extent in the low-producer clone. 
5.7.3.4 The high-producer clone showed enhanced TCA cycle activity and ATP turnover rate 
Greater pyruvate dehydrogenase and pyruvate carboxylase fluxes provide higher TCA 
cycle activity in the high-producer compared to the low-producer clone, and to the 
parental. Concurrently, the high-producer clone exhibits high values of NADH-to-NAD 
(Figure 5.6). In agreement with this result, high-producer CHO cells were reported to 
have higher levels of intracellular NADH when compared to low-level producers (Mo et 
al., 2009). Hence, a higher NADH-to-NAD combined to higher TCA cycle fluxes in the 
high-producer suggests both active glycolysis and oxidative phosphorylation, meaning an 
intense production of intermediates as well as of energy. This result is in agreement with 
a higher ATP turnover rate and as reported in literature that experimental values for that 
energetic phosphate concentrations remain constant over a range of ATP turnover rates 
(Beard, 2006). Indeed, cell respiration determined experimentally is well simulated by the 
model. Interestingly, the analysis of cell respiration rate and oxidative phosphorylation 
activity (Figure 5.6) reveals that ~15 % of the total oxygen uptake rate is not devoted to 
ATP-producing purposesbut may be consumed through theproton leak phenomenon in 
the mitochondria. However, this is still speculative given the large confidence intervals 
associated with the flux representing ATP production, but it is in agreement with values 
found in literature (10%-13%) (Harper et al., 2002). Although high-producer cultures 
undergo metabolism with a high energy yield, the specific cell concentration in ATP 
stays constant (data not shown) whereas the ATP-to-ADP is similar to that observed in 
the parental and low-producer cultures (Figure 5.6). This may be due to a higher 
mitochondrial proton leak in addition to a higher ATP consumption rate by the 
maintenance processes, which are lumped as ATPas flux in the model. Overall, 
simulations suggest that biomass synthesis only requires a minor part of ATP production 
with ~15% (parental), ~10% (low-producer) and ~7% (high-producer) (Figure 5.9, Table 
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5.6). Recombinant protein synthesis is simulated to consume below 2% of the ATP 
production rate, respectively for the high- and the low-producer, regularly decreasing 
until the end of the culture(Figure 5.9, Table 5.6). The major portion of ATP production 
goes into maintaining catabolic and anabolic reactions, such as endogenous protein 
synthesis (80%-90%). Thus, as also suggested by Link et al.(2004) (Link et al., 2004) the 
rate of oxidative phosphorylation, and consequently ATP production rate, may positively 
affect cell specific productivity but unlike bacterial cells (Heyland et al., 2011b), no 
direct correlation has been established yet linking the ATP turnover rate and the 
recombinant protein productivity in CHO cells. A higher ATP production rate may thus 
favor a better coordination of cellular functions, including enabling a better processing of 
endogenous proteins as well as of a recombinant protein, in extensio. This result 
correlates with our observation that ATP production rate is similarly elevated in both 
induced and non-induced high-producer cultures, i.e. independently of the recombinant 
mAb production rate. Taken together, it is clear both from our experimental data and 
model simulations, that the higher productivity level of the high-producer clone in 
recombinant mAb may be a consequence of its higher global metabolic activity. This up-
regulation of central carbon metabolism was not a cause or a consequence of protein 
production but clonal variation since the same result was observed in non-induced 
cultures. Therefore, one may think the major criterion for a successful clonal selection 
relies on the identification of clones showing a high metabolic efficiency and activity. In 
conclusion, this work on the characterization of different CHO mAb cell clones and their 
parental cell line, brings a wide set of experimental data for extra- and intracellular 
metabolites concentrations that were used to develop a descriptive and predictive kinetic-
metabolic model. An in silico platform then enabled to better describe and quantify the 
metabolic differences resulting from CHO cells clonal variability. Such platform 
represents a valuable tool for cell line selection, as well as bioprocess development, but it 
may have also interesting applications in biomedical and medical applications. 
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Figure  5.10(Supplementary) Comparison of model simulations with regard to enzymatic 
regulation for parental culture for extracellular and energetic metabolites. 
Same conditions as in figure 5.2  applied. 
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Figure  5.11(Supplementary)  Comparison of model simulations with regard to enzymatic 
regulation for parental culture for intracellular metabolites. 
Same conditions as in figure 5.2  applied. 
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Figure  5.12(Supplementary) Comparison of model simulations with regard to enzymatic 
regulation for induced low-producing culture for extracellular and energetic metabolites. 
Same conditions as in figure 5.2  applied.  
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Figure  5.13   (Supplementary) Comparison of model simulations with regard to enzymatic 
regulation for induced low-producing culture for intracellular variables. 
Same conditions as figure 5.2  applied.  
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Figure  5.14(Supplementary) Comparison of model simulations with regard to enzymatic 
regulation for induced high-producing culture for extracellular and energetic metabolites. 
Same conditions as in figure 5.2 applied.  
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Figure  5.15   (Supplementary) Comparison of model simulations with regard to enzymatic 
regulation for induced high-producing culture for intracellular metabolites. 
Same conditions as in figure 5.2  applied. 
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Figure  5.16   (Supplementary) Simulated and experimental data for parental, induced 
low-producer, non-induced low producer, induced high-producer, and non-induced high-
producer. 
Parental: experimental data: black triangles, simulated data: solid black line, induced 
low-producer: experimental data: black squares, simulated data: dashed black line, non-
induced low producer: experimental data: blue squares, simulated data: dashed blue line, 
induced high-producer: experimental data: black circles, simulated data: dotted black 
line, and non-induced high-producer: experimental data: red circles, simulated data: 
dotted  red line  cell lines. 
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6.1 Presentation of the article 
In line with the general purpose of this work to describe CHO cells culture, we here 
attempted to elucidate the regulatory background of metabolism. This was translated to 
the question that to what extent our modeling approach can be used to dynamically 
describe the contribution of regulatory mechanisms involved in the glycolysis pathway. 
The model is used to design an in silico experiment to impose a sudden change in CHO 
cell culture with a hypoxic shock. Combining model simulations with available biological 
knowledge, we were able to comment on the capacity of this modeling framework to 
describe the regulation of cell metabolism. 
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6.2 Abstract 
In this work, a kinetic metabolic model previously developed for CHO cells is used to 
study glycolysis regulation. The model is assessed for its biological relevance by 
analyzing its ability to simulate metabolic events induced following a hypoxic 
perturbation. Feedback and feedforward regulatory mechanisms known to occur to either 
inhibit or activate fluxes of glycolysis, are implemented in various combined scenarios 
and their effects on the metabolic response were analyzed. This study aims at 
characterizing the role of intermediates of glycolysis and of the cell energetic state, 
described as the AMP-to-ATP ratio, as inhibitors and activators of glycolysis pathway. In 
addition to the glycolysis pathway, we here describe the transient metabolic response of 
pathways that are connected to glycolysis, such as the pentose phosphate pathway, TCA 
cycle, cell energetic state, glutamine and amino acids metabolisms. Taken individually, 
each regulatory mechanism leads to an oscillatory behaviour in response to a hypoxic 
perturbation, while their combination clearly damps oscillations. However, only the 
addition of the cell energetic state to the regulatory mechanisms results in a non-
oscillating response leading to metabolic flux rate rearrangement corresponding to the 
anaerobic metabolism expected to prevail under hypoxic conditions. We thus 
demonstrate in this work, from model simulations, that the robustness of a cell energetic 
metabolism can be described from a combination of feedback and feedforward inhibition 
and activation regulatory mechanisms of glycolysis fluxes, involving intermediates of 
glycolysis and the cell energetic state itself. 
Keywords:metabolic regulation, hypoxic stress, kinetic metabolic model, glycolysis, 
CHO cells 
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6.3 Introduction 
Phenotypic characteristics of mammalian cells, such as Chinese hamster ovary cells 
(CHO), consist of an integrated output of regulatory processes occurring at various 
interconnected functional levels, including the genome, the transcriptome, the proteome 
and the metabolome (Cascante et al., 2002). This complex system can now be tractable 
thanks to the use of multi “omics” technologies, which, however, generate an impressive 
amount of data that are still difficult to be comprehensively understood. Although 
restricted to the effective expression of the cell system, metabolomic studies have 
allowed characterizing highly interconnected and regulated cellular metabolic networks 
(Grimbs , Selbig , Bulik, Holzhutter, & Steuer, 2007), under various culture conditions 
(Riehl & Segrè, 2008). In this context, metabolic flux analysis (MFA) and metabolic flux 
balance analysis (MFBA) approaches have been widely used to allow the estimation of 
metabolic flux distribution. Moreover, metabolic control analysis (MCA) approach 
allows identifying control points in a metabolic network, based on experimental data 
obtained after genetically re-engineering a cell metabolic capacity. Significant 
improvements in the performance of various biosystems have then been realized by 
applying MFA (Altamirano et al., 2006; Feist & Rosenbloom, 2011; Wilkens, 
Altamirano, & Gerdtzen, 2011; Zamorano, Wouwer, & Bastin, 2010) , MFBA  (Martínez 
et al., 2013; Savinell & Palsson, 1992)  and MCA (Almaas et al., 2004; Wang, Birol, & 
Hatzimanikatis, 2004) approaches. However, although highly useful to identify flux 
redistribution (MFA), optimal solution for flux rates (MFBA) and metabolic network 
control (MCA), these approaches were developed to draw a precise picture of a cell 
metabolic steady-state at a given time. Indeed, production bioprocesses using a 
mammalian cell platform normally include defined perturbations from the use of 
chemical additives (Kumar, Gammell, & Clynes, 2007), inducible promoters (Mullick et 
al., 2006) or a transient transfection strategy (Durocher, Perret, & Kamen, 2002; Pham, 
Kamen, & Durocher, 2006). Therefore, since steady-state conditions rarely prevail in 
biological processes, some modelling approaches now include the description of flux 
kinetics (Gallazo & Bailey, 1990; Hatzimanikatis, Floudas, & Bailey, 1996; Starbuck & 
Lauffenburger, 1992). Mathematical modelling approaches are drawing increasing 
interest, as they offer a complementary tool for characterizing the dynamic properties of  
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biosystems (D’Alexandri, Scolari, & Ferreira, 2010). Models can also allow to 
investigate outside the experimental space (Steuer et al., 2006). Indeed, we have 
developed in previous works a kinetic metabolic model framework that was shown to be 
adaptable to plant (Cloutier, Perrier, & Jolicoeur, 2007; Valancin et al., 2013) and CHO 
cells (Ghorbaniaghdam, Henry, & Jolicoeur, 2012), simulating experimental data of 
transient cell cultures. This model describes central carbon metabolism without 
accounting, however, for metabolic regulation. In a perspective of enabling a model to 
predict dynamic behaviours in constantly changing environments, it is thus crucial that it 
includes regulatory mechanisms governing metabolic homeostasis (Kitano, 2002). 
Indeed, cells have developed various regulation mechanisms for adapting to sudden 
changes in their environment, with the major aim of maintaining a capacity to 
continuously extract energy from available resources. In that context, oxygen has a 
specific role because it acts, in many cell types, as the final electron acceptor driving 
ATP turnover along the respiratory chain (Solomon, Berg, & Martin, 2005). Glycolysis is 
thus a key pathway while being the entry point of the major carbon sources, such as 
glucose, as well as generating intermediates that are feeding most of the anabolic 
pathways including TCA, which directly supports respiration. The mechanisms allowing 
the regulation of a cell energetic metabolism with regard to the availability of oxygen are 
well described in literature, including the establishment of anaerobic glycolysis following 
hypoxic conditions (Frezza et al., 2011). Therefore, in this work, we have challenged our 
model with a hypoxic perturbation and assessed its ability to describe this well 
documented phenomenon by accounting for most probable feedback and feedforward 
regulatory mechanisms of glycolysis described in literature (Bali & Thomas, 2001; 
Chandra, Buzi, & Doyle, 2009; Cloutier & Wellstead, 2010; Connett & Sahlin, 1996; 
Frezza et al., 2011; Korzeniewski & Liguzinski, 2004). 
6.4 Methods 
6.4.1 The kinetic metabolic model 
As mentioned previously, a kinetic metabolic model describing the primary metabolism 
of CHO cells recently developed was used as a framework for the analysis presented in 
(Ghorbaniaghdam, Henry, & Jolicoeur, et al., 2012) and Ghorbaniaghdam et al. (2013) 
(Chapter 5). The complete description of the model, withmass balances, kinetic equations 
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and hypotheses is given in (Ghorbaniaghdam, Henry, & Jolicoeur, et al., 2012) and in 
chapter 5 and illustrated in Figure 6.1. Briefly, the model has 46 differential equations, 
i.e. mass balances on state variables, which are solved using the Matlab software (The 
MathWorks Inc., Natick, MA, USA). Each flux (reaction rate) is described by a 
Michaelis-Menten kinetic formulation. The model response was analyzed qualitatively 
and quantitatively after a step-wise change of the dissolved oxygen concentration. 
According to previous studies showing that CHO cells oxygen consumption rate is not 
affected at oxygen concentrations above ~ 20 µM (Froncisz, Lai, & Hyde, 1985; Lai, 
Hopwood, Hyde, & Lukiewicz, 1982), a step change from 100% to 10% air saturation 
resulting in a sudden decrease of the dissolved oxygen concentration to 22 µM, was 
induced at 48 h post inoculation corresponding to the middle of the exponential growth 
phase (see supplementary material for details) assuming that the cell growth rate will 
remain similar in normal and hypoxia conditions (Ghorbaniaghdam, Henry, & Jolicoeur, 
et al., 2012). Oxygen concentration is used in a monod-type relation to evaluate the 
oxygen consumption rate.  Initial parameter values for the inhibition and activation 
regulatory mechanisms were taken from literature, as indicated in the caption of Table 
6.2, and then optimized (see below) for each of the scenarios of regulatory mechanisms 
studied, keeping with all the other model parameters as identified in a recent work. 
6.4.2 Regulatory mechanisms of glycolysis 
The regulatory mechanisms involved in glycolysis are described as follows (Figures 6.1). 
Regulation of hexokinase, phosphoglucose isomerase, pyruvate kinase, and of backward 
lactatedehydrogenase were considered based on information derived from the literature as 
detailed in Figure 6.1. Given the importance for the cell to maintain its energetic status 
(Hardie & Hawley, 2001), regulatory mechanisms related to the AMP-to-ATP ratio were 
also studied. Activation and inhibition mechanisms of the enzymatic reactions are 
expressed through negative and positive feedback and feedforward loops, modifying the 
Michaelis-Menten rate laws as illustrated in Table 1 (Heinrich & Papoport, 1977). 
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Figure 6.1The metabolic network considered in the model. 
Glycolytic enzymes are either activated (↓) or inhibited () by an effector as 
indicated.Each regulationmechanism is taken from literature with mechanism (a) in 
(Berg, Tymoczko, & Stryer, 2002), (b) in (Berg, Tymoczko, & Stryer, 2002), (c) in 
(Garreau & Buc-Temkine, 1972), (d) in (Wang, 1977), and (e) in (Berg, Tymoczko, & 
Stryer, 2002; Jing & Ismail-Beigi, 2007). 
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Table 6.1Kinetic expression for each of the regulatory mechanisms. 
All regulatory scenarios, metabolites and fluxes are defined in Figure 6.1. 
 
 
Regulatory mechanism 
 
                                        Kinetic expression 
(a) 
࢜ࡴࡷ = ࢜࢓ࢇ࢞ࡴࡷ ∗ ࡳࡸ࡯ࡳࡸ࡯+ ࡷ࢓ࡳࡸ࡯ ∗ ࡭ࢀࡼ࡭ࡰࡼ࡭ࢀࡼ
࡭ࡰࡼ
+ࡷ࢓࡭ࢀࡼ
࡭ࡰࡼ
∗
ࡷ࢏ࡳ૟ࡼ
ࡳ૟ࡼ+ ࡷ࢏ࡳ૟ࡼ 
(b) ࢜ࡼࡳࡵ = ࢜࢓ࢇ࢞ࡼࡳࡵ ∗ ࡳ૟ࡼࡳ૟ࡼ+ ࡷ࢓ࡳ૟ࡼ ∗ ࡷ࢏ࡼࡱࡼࡼࡱࡼ +ࡷ࢏ࡼࡱࡼ 
 
(c) ࢜ࡼࡷ = ࢜࢓ࢇ࢞ࡼࡷ ∗ ࡼࡱࡼ
ࡼࡱࡼ+ ࡷ࢓ࡼࡱࡼ(૚+ ࢑ࢇࡲ૟ࡼࡲ૟ࡼ ) 
 
(d) ࢜࢘ࡸࡰࡴ = ࢜࢓ࢇ࢞࢘ࡸࡰࡴ ∗ ࡸ࡭࡯ࡸ࡭࡯+ࡷ࢓ࡸ࡭࡯ ∗ ࡷ࢏ࡼࢅࡾࡼࢅࡾ +ࡷ࢏ࡼࢅࡾ 
 
(e)  
(e1) 
࢜ࡴࡷ = ࢜࢓ࢇ࢞ࡴࡷ ∗ ࡳࡸ࡯
ࡳࡸ࡯+ࡷ࢓ࡳࡸ࡯ ቆ૚+ ࢑ࢇ࡭ࡹࡼ࡭ࢀࡼ࡭ࡹࡼ
࡭ࢀࡼ
ቇ
 
 
 
(e2) 
࢜ࡼࡲࡷ = ࢜࢓ࢇ࢞ࡼࡲࡷ ∗ ࡲ૟ࡼ
ࡲ૟ࡼ +ࡷ࢓ࡲ૟ࡼ ቆ૚ + ࢑ࢇ࡭ࡹࡼ࡭ࢀࡼ࡭ࡹࡼ
࡭ࢀࡼ
ቇ
 
 
 
(e3) 
࢜ࢌࡸࡰࡴ = ࢜࢓ࢇ࢞ࢌࡸࡰࡴ ∗ ࡼࢅࡾ
ࡳࡸ࡯+ࡷ࢓ࡼࢅࡾ ቆ૚ + ࢑ࢇ࡭ࡹࡼ࡭ࢀࡼ࡭ࡹࡼ
࡭ࢀࡼ
ቇ
 
 
 
6.4.3 Characterization of the oscillatory behaviour 
Damped oscillatory behaviour can be characterized from a parameter referred as the 
quality factor (qf). Generally, the quality factor represents the number of oscillations that 
are completed before attenuating to a negligible value (< 5 % of initial value). 
Considering an exponential decay of the signal amplitude with time, damped oscillations 
are mathematically described as follows: 
x(t)= a(t) cos (ωt - φ)                                                                                          (10)                                                                   
With a(t)  (amplitude of the oscillation, the unit depends on the nature of the signal), ν 
(damping constant, h-1), ω (fixed angular frequency, radians h-1), and φ (phase angle, 
radians). This equation is interpreted as a periodic oscillation whose amplitude decays 
exponentially in time (Fitzpatrick, 2013) as follows: 
a(t)=a0exp (-ν/2 t)                                                                                                       (11)       
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where a0 is the initial amplitude of the oscillation. The quality factor of an oscillatory 
system is then obtained as the ω-to-ν ratio. In this work, we have focused our analysis on 
the different regulatory mechanisms looking at qf, a0, ν, and ω values for the oscillatory 
behaviour of the ATP-to-ADP ratio. Lower values of qf, a0, and ω, and higher values of ν, 
indicate the damping of an oscillatory behaviour. 
6.4.4 Calibration of the activation or inhibition parameters 
In a first step and for each of the scenarios studied, initial values for the activation and 
inhibition parameters were found in literature (see references in caption of Table 6.2) and 
then optimized to maximize the damping of the ATP-to-ADP oscillatory behaviour, while 
minimizing the simulation error from the ideal smooth response behaviour (a(t) = a0 exp 
(-ν/2 t)) using the Matlab optimization toolbox (see caption of Supplementary Figure 
6.1). This approach was selected because of the lack of experimental data to compare 
with. Briefly, optimal parameter values were obtained by minimizing the normalized 
sum-squared errors using a Least-squares minimization function in MATLAB's 
Optimization Toolbox for non-linear regression. Finally, 95% confidence intervals for 
regulatory parameters and model simulation behaviour (qf, a0, and ω) were calculated 
using built-in MATLAB functions "nlparci.m" and "nlpredci.m", respectively.  
6.5 Results and discussion 
This study is limited to the early cell response (< 24 h) following the establishment of 
hypoxic conditions (10% air saturation), during which cell death by either necrosis or 
apoptosis is not expected to occur massively, as previously reported in CHO cells (Van 
der Valk et al., 1998) and in mouse embryonic stem cell cultures (M. H. Kim, Kim, Heo, 
Kim, & Han, 2008). 
6.5.1 Integration of the regulation mechanisms of glycolysis into the model 
The calibration step of regulatory parameters (Ki and Ka) showed that minimization of ݍ௙ 
did not result in unique solutions but in space of solutions within a 95% confidence 
interval, in all scenarios (Table 6.2), as confirmed by a sensitivity analysis on these 
model parameters (Supplemental Figure 6.1). Therefore, because of the latter observation 
as well as for their biological relevance, the optimal parameters values determined for 
each regulatory mechanism and within each scenario (Table 6.2) were used thereafter. 
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Table 6.2Characterize of ATP-to-ADP oscillatory behaviour and of regulatory parameters 
for various regulatory scenarios. 
Optimal parameters values are indicated and their 95% confidence interval in [brackets]. 
Initial values of parameters used for the optimization procedure were taken from 
literature; KiG6P= 8e-8 (Aragón et al., 1980), KiPEP= 2e-7(Aragón et al., 1980), KaF6P=2e-
7(Wang, 1977), KiPYR= 7e-9 (Aragón et al., 1980), KAamp/atp= 0.01 (Hardie & Hawley, 
2001). See the Methods section for the definition of qf, a, v and ω parameters as well as 
for the description of the parameter optimization procedure. All regulatory scenarios are 
defined in Figure 6.1.  
 
 
Regulatory 
scenario 
 
qf a ν ω Parameter value 
KiG6P 
 
KiPEP 
 
Kaf6p 
 
KiPYR 
 
KaAMP/ATP 
 Single mechanism 
- [16,17.5] [0.8,1.1] [0.7,1.4] [11.3,12.5] - - - - - 
a [8.8, 10] [0.7,0.9] [1.1,1.3] [11,11.5] 2e-8 
[8e-9,8e-7] 
- - - - 
b [9.5,10] [0.6,0.8] [1.2,1.4] [12.3,13.3] - 1e-7 
[¨2e-8,6e-7] 
- - - 
c [9.7,10.2] [0.7,0.9] [0.99,1.1] [11.7,12.6] - - 9e-8 
[2e-8,5e-7] 
- - 
d [8.3,9.5] [0.6,0.8] [1.2,1.3] [11.6,12] - - - 3e-8 
[7e-10,7e-8] 
- 
e1 
 
[8.1,13.5] [0.4,0.6] [1.1,1.4] [12.2,12.5] - - - - 0.01 
[0.001,0.1] 
e2 
 
[8.4,13.9] [0.4,0.6] [1.1,1.4] [12.2,12.5] - - - - 0.01 
[0.001,0.1] 
e3 
 
[7.9,13.3] [0.4,0.6] [1.1,1.4] [12.2,12.5] - - - - 0.01 
[0.001,0.1] 
 
Combined 
mechanisms 
         
a-b [3.3,4.0] [0.5,0.7] [2.5,2.6] [8.2,9.2] 1e-8 
[8e-9,4e-7] 
6e-7 
[2e-8,2e-6] 
- - - 
a-c [1.5,2.1] [0.4,0.6] [3.7,4.6] [7.1,8] 3e-8 
[8e-9,6e-7] 
1e-6 
[2e-8,2e-6] 
3e-7 
[2e-8,1e-6] 
- - 
a-d critical 
damping 
[0.7,1.2] [4.7,6.3] 0 5e-8 
[8e-9,7e-7] 
6e-7 
[2e-8,2e-6] 
1e-6 
[2e-8,2e-6] 
5e-9 
[7e-10,4e-8] 
- 
a-e1 - - - -       3e-8 
[8e-9,5e-7] 
       1e-6 
[2e-8,2e-6] 
      9e-7 
[2e-8,2e-6] 
       9e-9 
[7e-10,4e-8] 
0.02 
[0.001,0.1] 
a-e1,e2 - - - -      5e-8 
[8e-9,6e-7] 
     8e-7 
[2e-8,2e-6] 
      1e-6 
[2e-8,2e-6] 
      1e-8 
[7e-10,8e-8] 
      0.04 
[0.001,0.08] 
a-e - - -         - 1e-7 
[8e-9,8e-7] 
5e-7 
[2e-8,1e-6] 
5e-7 
[2e-8,1e-6] 
4e-8 
[7e-10,7e-8] 
0.01 
[0.001,0.1] 
e 
(e1, e2 and e3 
combined) 
- - - - - - - - 0.01 
[0.001,0.1] 
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Figure  0.2Model simulations of energetic ratios following a hypoxic perturbation. 
Adenylate energy charge (ATP+0.5ADP-to-ATP+ADP+AMP ratio)(A), ATP-to-ADP 
ratio (B), ATP-to-AMP ratio (C), and dissolved O2concentration (D). No regulation: solid 
black line, accounting for regulatory scenario a: solid red line, scenario a-b: solid blue 
line, scenario a-d: solid green line, and scenario a-e: solid gray line. All values are 
relative to control conditions, i.e. model simulations at air saturation oxygen 
concentration. All regulatory scenarios are defined in Figure 6.1. 
6.5.2 Cell energetic robustness relies on the regulation of glycolysis 
The calibrated model was first used, for every scenario, to assess the cells’ response to a 
hypoxic stress, focusing on the cell energetic state. Various energetic markers such as the 
adenylate energy charge, (ATP+0.5ADP)-to-(ATP+ADP+AMP), ATP-to-ADP and ATP-
to-AMP ratios were considered. As expected, the level of regulation of glycolysis 
strongly affects the cell energetic stability and the final quasi-steady-state level (Figure 
6.2). Without any regulation, a stepwise decrease of the dissolved oxygen concentration 
to a hypoxic level of 10 % of air saturation in the culture medium induces immediate but 
transient (i.e. damped) oscillations for all cell energetic markers. The responses indicate 
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that the stress occurrence was sufficient to take the system from initial steady state to a 
lower ATP-to-ADP ratio. The adenylate energy charge and the ATP-to-ADP ratio both 
oscillate rapidly at around 50% and 55% of their initial values, respectively, showing a 
similar quality factor of 16.75±0.75 (Table 6.2). Initial response shows ATP 
concentrations to reach almost a zero value, while the adenylate energy charge reaches 
27% of the initial level. Although the absence of any flux regulation (other than the 
various substrate concentrations) leads to an oscillatory behaviour of cell energetics, 
these oscillations were shown to attenuate with time, reaching ~ 5% of their initial 
amplitude after 18 complete oscillation cycles. Hexokinase feedback inhibition by G6P 
(Figure 6.1, mechanism a) increases the damping of the oscillatory behaviour, both in 
time and in amplitude with a qf of 9.4±0.6, while reaching similar final levels than the 
case without any regulation. It can be seen that the single regulatory mechanism slowly 
damp the oscillations by decreasing hexokinase inhibition (Figure 6.3A, red line). 
Accounting for both phosphoglucose isomerase (Figure 6.1, mechanism b) and 
hexokinase feedback inhibition mechanisms limits the oscillatory response to ~3 h and a 
qf of 3.64±0.35, while still reaching similar steady-state values as when there is no 
regulation. The respective regulatory mechanisms are shown to accelerate their 
contributions in damping the oscillations by decreasing both enzymes inhibition (Figure 
6.3 A-B, blue lines). The influence of negative feedback mechanisms rapidly increases 
glycolytic fluxes to compensate for the reduced energy production. However, the high 
gain in energy production by oxidative phosphorylation is still exacerbating the increase 
in glycolytic fluxes to remove the destabilizing effect. Then, incorporating pyruvate 
kinase feedforward activation by F6P (Figure 6.1, mechanism c) to that of hexokinase 
and phosphoglucose isomerase decreases qf to 1.8±0.35 and the oscillatory response to ~2 
h (data not shown). Furthermore, incorporating the feedforward inhibition regulation 
mechanism of the reverse lactate dehydrogenase reaction by pyruvate (Figure 6.1, 
mechanism d) to the latter combined scenario results in a single oscillatory cycle that 
stabilizes at a similar adenylate energy charge value, but at a ~ 10% lower ATP-to-ADP 
ratio. From that scenario, each regulatory mechanism shows no oscillation, while 
decreasing enzymes inhibition and decreasing enzyme activation (Figure 6.3 A-D, green 
lines). Addition of feedback activation regulatory mechanisms directly involving the 
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energetic output (Figure 6.1, mechanism e1) to that of a-d improves the robustness of the 
predicted cell metabolic response to the hypoxic perturbation (Figure 6.4). Finally, the 
addition of all feedback activation regulatory mechanisms directly involving the energetic 
output of the metabolic network system, i.e. the cell energetic level described as the 
AMP-to-ATP ratio (Figure 6.1, mechanisms e1,e2,e3), further improves the robustness of 
the predicted cell metabolic response to the hypoxic perturbation. As expected and in 
agreement with literature, the cell energetic state then shows no oscillation with, indeed, 
contributions of the regulatory mechanisms, i.e. increasing hexokinase and  
phosphoglucose isomerase inhibition, increasing pyruvate kinase activation and more 
pronounced increasing hexokinase, Phosphofructokinase and the forward reaction of 
lactate dehydrogenase activation (Figure 6.3 A-E, gray lines). Moreover, although the 
cells’ ATP-to-ADP ratio and the adenylate energy charge decrease respectively at ~ 75% 
and ~ 78% of their initial values, these levels were 25% to 50% higher than when not 
accounting for energetic regulatory mechanisms. Therefore, simulated CHO cells when 
accounting for scenario a-e reach new energetic quasi steady states that are closer to the 
initial ones (prior to the hypoxic perturbation) when the cell energetic state plays an 
active role in the regulation of enzymes of glycolysis, as clearly shown when comparing 
responses of the ATP-to-ADP ratio in all non-oscillatory scenarios (Figure 6.4). 
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Figure 6.3Specific contribution of the regulatory mechanisms. 
The inhibitory term proportional to G6P (mechanism a) (A); red line (scenario a), blue 
line (scenario a-b), green line (scenario a-d), gray line (scenario a-e) , the inhibitory term 
proportional to PEP (mechanism b)  (B); (blue line (scenario a-b), green line (scenario a-
d), gray line (scenario a-e), the activation term corresponding to F6P (mechanism c) (C); 
green line (scenario a-d), gray line (scenario a-e), the inhibitory term proportional to PYR 
(mechanism d) (D); green line (scenario a-d), gray line (scenario a-e), the activation term 
corresponding to AMP-to-ATP ratio (mechanism e) (E); gray line (scenario a-e). All 
regulatory scenarios are defined in Figure 6.1. 
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Figure 6.4Model simulations of ATP-to-ADP with 95% confidence intervals for 
regulatory scenarios avoiding oscillatory responses. 
Solid black line: scenario a-d, Solid red line: scenario a-e1, Solid blue line: scenario  a-
e1,e2, Solid  green  line: scenario  e (e1,e2,e3), Solid  gray  line: scenario a-e (e1,e2,e3). 
Dashed lines are 95% confidence intervals for each regulatory scenario with respective 
colors,  all regulatory scenarios are defined in Figure 6.1. 
 
6.5.3 The model simulates biomarkers of anaerobic glycolysis 
Simulated metabolic fluxes of glycolysis (V(HK), V(PK), V(LDH)) rapidly exhibit a 
transient oscillatory behaviour following a hypoxic perturbation. Interestingly, all these 
fluxes reach new steady states that are at ~50% of their respective control values. The 
complete regulation scenario, i.e. including mechanisms of feedback regulation by the 
AMP-to-ATP ratio (mechanisms a-e in Figure 6.1), however, results in a distinct 
behaviour with higher fluxes rates than control values for the hexokinase (~ +75%; 
including glucose transport as well), pyruvate kinase (~ +75%) and lactate dehydrogenase 
(~ +200%) enzymes (Figure 6.5 A, B, C). This behaviour agrees with an anaerobic 
glycolysis, a phenomenon that is observed under oxygen limitation (Frezza et al., 2011). 
 
 165 
Elevated level of glycolysis eventually leads to an increased ratio of lactate produced 
toglucose consumed, at a value ~ 50% higher than respective controls (Figure 6.6A). This 
suggests that lactate production accounts for the excess glucose consumption in anaerobic 
glycolysis. When direct activation of glycolysis is not considered, however, this value 
remains unchanged (Figure 6.6A). Hypoxic condition has been reported to result in the 
up-regulation of the key glycolytic enzymes studied here (as illustrated in Figure 6.1) (J. 
W. Kim, Tchernyshyov, Semenza, & Dang, 2006; Wheaton & Chandel, 2011). In all 
cases where glycolysis is regulated only from intermediates (i.e. mechanisms a-d in 
Figure 6.1), the main metabolites (i.e. G6P, GAP and PYR) (Figure 6.7 C, D, G) exhibit a 
decrease in concentration in accordance with glycolytic fluxes. But when feedback 
regulatory mechanisms involving the cell energetic state are also considered glycolytic 
intermediates concentrations are instead found to increase. (Figure 6.7 C, D). Indeed, the 
increase of G6P (~ 50%), GAP (~125% to 60%), and LAC (~ 300 %) (Figure 6.7 B) cope 
with the decrease of PYR (~ -30%) (Figure 6.7 G); the latter being consistent with the 
metabolic regulation of lactate dehydrogenase by ATP-to-AMP ratio and a lower value 
for the pyruvate branch point ratio (Figure 6.6B). These simulation results are in 
agreement with expected physiological ranges, including extreme intermediates 
metabolites accumulation, reported for hypoxia condition in human cells (Wheaton & 
Chandel, 2011). Model simulations show similar final values for the contribution of 
glycolysis to TCA cycle (Figure 6.6C), suggesting that less carbon skeleton is available 
to enter TCA cycle, which in turn explains a lower TCA cycle flux (Figure 6.5E). The 
values for the glucose level when feedback regulatory mechanisms involving the cell 
energetic state are also considered exhibit a ~ 90% decrease (Figure 6.7A) that can be 
attributed to the higher simulated glucose uptake rates (Figure 6.5A). 
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Figure 6.5Model simulations of metabolic fluxes following a hypoxic perturbation. 
ν(HK) (A), ν(LDH) (B), ν(PK) (C), v(PDH) (D), v(SDH/FUM) (E), v(G6DPH) (F), 
v(GLNT) (G), v(Amino acids Catabolism). v(Amino acids Catabolism) as 
(v(SAL)+v(ASX)+v(HISARGTA)+v(LYSILELEUVALTYRTA)+v(AlaTA)).All 
captions are the same as in Figure 2. All fluxes are defined in Figure 6.1. 
6.5.3.1 Amino acid metabolism 
glutamine is typically another important carbon and energy source for mammalian cells 
and its metabolism is often linked to that of glucose . Glutamine shows a decreased 
uptake rate (V(GLNT)) in all regulation scenarios (Figure 6.5G). This metabolic flux 
(V(GLNT)) thus followed the behaviour for TCA cycle (V(SDH/FUM)) (Figure 6.5E), 
with a final glutamine uptake rate at ~ 50% of its control value and remained at ~ 75% of 
its control value when applying all regulatory terms (Figure 6.5G). This simulated 
observation suggests a decreased demand in glutamine under hypoxic condition, a result 
that is expected because TCA cycle is also down-regulated. The contribution of 
glutamine to TCA cycle also decreases with theestablishment of an anaerobic glycolysis 
(Figure 6.6D). Finally, amino acids catabolic rate, which feeds TCA cycle (V(amino 
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acids catabolism)), reaches similar lower steady state levels (~70%) than for the control 
following the hypoxic perturbation, irrespectively of the regulation mechanism studied 
(Figure 6.5H). 
6.5.3.2 Pyruvate branch point 
 
The pyruvate branch point ratio shows a ~ 44 % decrease when the metabolism is 
switching to an anaerobic glycolysis (Figure 6B), which means a reduction (-45%) of the 
flux from pyruvate to TCA (V(PDH)) (Figure 6.5D). The TCA cycle flux  
(V(SDH/FUM)) also show to decrease at ~ 50% of its control value when considering 
only regulation involving intermediates of glycolysis, while it remained at 75% of its 
control value when applying all regulatory mechanisms (Figure 6.5E). The reduction of 
TCA activity has also been described as an adaptive response to hypoxia (Wheaton & 
Chandel, 2011). The reduction of metabolic intermediates and fluxes in the TCA cycle 
can also be expected from the decreased levels of pyruvate under anaerobic glycolysis 
(Figure 6.7G). Finally, the sudden increase of the cell redox state, which is expressed as 
the NADH-to-NAD ratio in our model, is also simulated by the model (Figure 6.7F); a 
result that is in agreement with lower values of the pyruvate branch point ratio as well as 
with literature (Frezza et al., 2011). This result may suggest NADH accumulation as a 
result of a decreased oxidative phosphorylation (i.e. cell respiration). Lactate 
dehydrogenase activation, by reducing NADH oxidation through TCA cycle, also 
contributes to the increase of the NADH-to NAD ratio. The case with feedback activation 
of glycolysis from cell energetic state shows a moderate increase of NADH-to-NAD level 
compared to the other cases (Figure 6.7F). Due to the activation of lactate dehydrogenase, 
pyruvate conversion to lactate (V(LDH) proceeds at a higher rate (Figure 6.7B), a 
reaction fuelled by NADH and thus contributing to the oxidation of NADH to NAD. 
6.5.3.3 G6P branch point 
Taking its source from G6P, the global flux through the pentose phosphate pathway (V(G6DPH)) 
follows the same trend as glycolysis (Figure 6.5F), although to a lesser extent. While reduced at 
~75% of that for the control for scenarios a-d, V(G6DPH) only increases by ~ 25% when adding 
feedback activation mechanisms from cell energetic state (Figure 6.5F). This phenomenon of an 
increased pentose phosphate pathway has been reported in human cells submitted to hypoxic 
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conditions (Frezza et al., 2011). A part of the glycolytic flux overflow is thus automatically re-
directed to feed pentose phosphate pathway intermediate metabolites such as R5P (Figure 6.7E) 
with a ~ 25% concentration increase for the scenario incorporating all regulatory mechanisms. 
Although higher levels of R5P were simulated by the model, induction of anaerobic glycolysis 
causes a ~ 25% decrease in the percentage of glucose flowing through the pentose phosphate 
pathway, defined as the ratio of pentose phosphate oxidative flux to glucose uptake rate (Figure 
6.6E). Lower values for the percentage of glucose flowing through the pentose phosphate 
pathway in the case of anaerobic glycolysis suggests, in counterpart, a higher glucose overflow to 
lactate production. The ratio of the pentose phosphate reflux to glycolysis (non-oxidative) to the 
pentose phosphate oxidative flux, however, shows stable values (Figure 6.6F). Therefore, since 
higher flux levels are channeled through pentose phosphate pathway (V(G6DPH)), and higher 
flux levels are chanelled back to glycolysis, one can expect that the establishment of anaerobic 
glycolysis does not reasonably modify the pentose phosphate pathway fluxes distribution (Figure 
6.6F). Moreover, similar dynamic behaviours, characterized by the strength of the oscillations, 
have been observed for both G6P and R5P. 
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Figure 6.6Model simulations of metabolic flux distribution and metabolic ratios 
following a hypoxic perturbation. 
Lactate production-to-glucose consumption (A), pyruvate branch point (B), contribution 
of glucose to TCA cycle (C), contribution of glutamine to TCA cycle (D), pentose 
phosphate activity (E), pentose phosphate non-oxidative branch activity (F).Lactate 
production-to-glucose consumption ratio as ((νf(LDH)-νr(LDH))/ν(HK)), pyruvate branch 
point as the ratio of the pyruvate influx through TCA cycle divided by the total flux into 
pyruvate pool (v(PDH/(ν(PK)+ν(SAL)+ν(ML-PC)+ν(AlaTA)), when the last two fluxes 
positively fed pyruvare, Contribution of glucose to TCA cycle as the ratio of pyruvate 
influx to TCA cycle via ν(PDH), considering most of the ν(PDH) has been originated 
from ν(PK), to the total flux channeled through TCA cycle via its intermediates 
(v(PDH)/(ν(PDH)+ ν(ASTA)+ ν(GLDH)+ ν(LYSILELEUVALTYRTA)+ν(PC)), 
Contribution of glutamine to TCA cycle as the ratio of glutamate  influx to TCA cycle 
either via ν(GLDH) to the total flux channeled through TCA cycle via its intermediates 
(v(GLDH) /(ν(PDH)+ν(ASTA)+ν(GLDH)+ν(LYSILELEUVALTYRTA)+ν(PC))),  The 
pentose phosphate activity is defined as the percentage of the glycolytic flux channeled 
through pentose phosphate pathway, i.e. the ratio of pentose cycle oxidative flux to the 
glucose uptake (ν(G6PDH/PGLcDH)/ν(HK)). Pentose phosphate non-oxidative branch 
activity as the ratio of the pentose phosphate reflux to glycolysis to the pentose phosphate 
oxidative flux (ν(TK/TA)/(ν(G6PDH/PGLcDH)) (see Figure 6.1). All captions are the 
same as in Figure 6.2. All fluxes are defined in Figure 6.1. 
 
 
 
 
 170 
 
 
Figure 6.7Model simulations of metabolic concentrations following a hypoxic 
perturbation. 
GLC (A), LAC (B), G6P (C), GAP (D), R5P (E), NADH-to-NAD (F), PYR (G), MAL 
(H),GLN(I),AA(J).AAas(SER+ASX+HIS+ARG+ALA+LYS+LUE+ILE+HIS+VAL+TY
R) (see Figure 6.1). All captions are the same as in Figure 6.2. All metabolites are defined 
in Figure 6.1. 
6.5.4 The model simulates cell alternatives to an efficient energy production 
From in silico model simulations, it was shown that applying to glycolysis pathway a 
limited  but crucial set of feedback and feedforward regulation mechanisms that are 
known to occur in mammalian cells, the model description of metabolism gains in 
robustness in its response to a strong O2 perturbation. We observed that not only each 
intracellular metabolic intermediate and metabolic flux gained in stability, but that the 
expected activation of an anaerobic glycolysis was simulated so as to maintain a high cell 
energetic state. Interestingly, immediately after the onset of the oxygen stress, the flux 
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through oxidative phosphorylation (respiration) decreases at 60% of the control (Figure 
6.8D), following a transient oscillatory pattern depending on the regulatory mechanisms 
involved. The total ATP turnover rate reduces to ~ 50% of the control when no feedback 
related to energy is involved (Figure 6.8E). Of the remaining energy production capacity, 
the contribution of glycolysis reduces to ~ 48% (Figure 6.8F), while that from oxidative 
phosphorylation only shows to slightly reduce (Figure 6.8G), both showing highly 
attenuated oscillatory patterns. The only increase is attributed to a ~ 125% higher 
contribution from the kinases associated to energetic shuttles such as 
creatin/phosphocreatin and adenylate kinases (Figure 6.8H), both showing slowly 
attenuated oscillations. However, the switch to anaerobic glycolysis predominantly favors 
ATP turnover from glycolysis, as expected. Indeed, although the total ATP turnover rate 
reduces at ~ 70% of the control (Figure 6.8E), the contribution of glycolysis increases of 
~ 100% while that from oxidative phosphorylation reduces  by ~ 40% (Figure 6.8 F, G). 
The contribution of kinases from the management of the energetic shuttles reduces by ~ 
50% (Figure 6.8H). Therefore, the complete regulatory scenario leads to simulations 
suggesting a total ATP turnover rate of only ~ 30% lower than the control, compared to a 
~ 50% lower level when cell energetic is not included in the regulation of glycolysis. 
Thus, under hypoxic condition, the cells compensate the reduced contribution of TCA by 
increasing the glycolytic activity, a less efficient  process but occuring at a higher rate 
comparing to TCA which is more efficient but the fluxes are much lower (Harper, 
Antoniou, Bevilacqua, Bezaire, & Monemdjou, 2002).  
Finally, given its importance, the cellular bioenergetics system must be properly 
controlled when facing environmental changes, and the role of energetic shuttles in the 
ATP homeostasis phenomenon has been widely described (Dzeja & Terzic, 2003). In our 
model, the respective reversible reactions catalyzed by creatine kinase and adenylate 
kinase are described (Figure 6.1) as an energy buffering system. Indeed, as shown here 
(Figure 6.8H), the combined contributions of both kinases in ATP generation rate 
increase of ~ 125% when considering regulation mechanisms involving intermediates 
metabolites of glycolysis only. However, and it may seem surprising, the combined 
kinases contribution decreases when the full regulatory scenario is considered, although 
 
 172 
creatine kinase reaction is only slightly being reduced, its relative contribution to the total 
is more reduced than in the other cases. 
 
 
Figure 6.8Model simulations of cell bioenergetics state following a hypoxic perturbation. 
Glycolytic fluxes producing ATP (A), v(AK) (B), v(CrK) (C), OP (D), total ATP 
turnover rate (E), ATP turnover from glycolysis-to-total ATP turnover rate (F), ATP 
turnover from OP-to-total ATP turnover rate (G), ATP turnover from Kinases-to-total 
ATP turnover rate (H). Glycolytic fluxes as (ν(PGK)+ν(PK)), OP as ν(resp), ATP 
turnover rate as (ν(PGK)+ν(PK)+v(SCOA)+ νr(GlnT)+ νf(CK)+vr(AK)+2P/O 
ratio*ν(resp)), ATP turnover from OP-to-total ATP turnover rate as the portion of ATP 
generated from oxidative metabolism divided by total ATP production rate (2P/O 
ratio*ν(resp)/ (ν(PGK)+ν(PK)+v(SCOA)+ νr(GlnT)+ νf(CK)+vr(AK)+2P/O 
ratio*ν(resp)), ATP turnover from glycolysis-to-total ATP turnover rate as the sum of 
glycolytic fluxes producing ATP over the total ATP production rate ((ν(PGK)+ν(PK))/( 
ν(PGK)+ν(PK)+v(SCOA)+ νr(GlnT)+ νf(CK)+vr(AK)+2P/O ratio*ν(resp)), ATP 
turnover from Kinases-to-total ATP turnover rate 
as(νf(CK)+vr(AK))/(ν(PGK)+ν(PK)+v(SCOA)+ νr(GlnT)+ νf(CK)+vr(AK)+2P/O 
ratio*ν(resp))(see Figure 6.1).All captions are the same as in Figure 6.2. All metabolites 
and fluxes are defined in Figure 6.1. 
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6.6 Conclusion 
In this work, we have demonstrated that a kinetic-metabolic model can be used to 
simulate the fast response of CHO cells to a hypoxic perturbation. By including a 
combination of regulatory mechanisms that are known to occur in the glycolysis pathway 
of mammalian cells, model simulations of the cell metabolic and energetic behaviours 
were in agreement with responses described in literature. The model was thus able to 
predict the shifting from an oxidative metabolism to an anaerobic glycolysis. We report 
here that this metabolic shift can only be properly described by the model when 
accounting for the cell energetic state as a regulatory mechanism of the glycolysis, in 
addition to mechanisms involving metabolic intermediates of this pathway. For all other 
regulatory scenarios, an oscillatory behaviour was simulated. Although glycolytic 
oscillations have been reported in literature under specifically designed experimental 
conditions and by using mathematical models, there are no obvious known physiological 
role that has been identified so far, to the best of our knowledge. Indeed, these simulation 
results clearly suggest the biologically relevance of the mathematical model structure. 
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Figure 6.9(Supplementary) Sensitivity analysis on the parameters of regulatory 
mechanisms for  individual mechanisms a, b, c, d, and e1. 
The colormap represents qf values corresponding to model simulations of ATP-to-ADP 
ratio when the parameter value of each mechanism is changed between 0.1x to 10x of its 
optimal value. Colors denote qf values for each sampling of the parameter space. All 
regulatory scenarios are defined in Figure 6.1. 
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Figure 6.10(Supplementary) Sensitivity analysis on the parameters of regulatory 
mechanisms for scenario a-b. 
The colormap represents qf values corresponding to model simulations of ATP-to-ADP 
ratio when the parameter value of mechanisms a and b changed between 0.1x to10x of 
their respective optimal values. Colors denote qf values for each sampling of the 
parameter space. All regulatory scenarios are defined in Figure 6.1. 
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Figure  0.11(Supplementary) Sensitivity analysis on the parameters of regulatory 
mechanisms for scenario a-c. 
The colormap represents qf values corresponding to model simulations of ATP-to-ADP 
ratio when the parameter value mechanisms a and b changed between 0.1x to10x of their 
respective optimal values at different parameter values for mechanism c. Colors denote qf 
values for each sampling of the parameter space. All regulatory scenarios are defined in 
Figure 6.1. 
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CHAPTER 7 GENERAL DISCUSSION 
The main objective of this work was to shed light on the transient metabolic behaviour of 
CHOcells grown under batch conditions. In particular, we aimed at characterizing CHO 
cells metabolism, and its regulation, in responseto various perturbations. We have also 
devoted a large part of the work developing a modelling tool able to capture cell 
dynamics, namely a fully kinetic-metabolic model. In this regard, a previously described 
kinetic-metabolic framework that was shown to be successful at describing (Cloutier et 
al., 2007) as well as for controlling bioreactor cultures of plant cells(Cloutier et al., 
2009)provided the initial motivation of the present work. The model was first developed 
and calibrated on previously published experimental data from our research group on a 
stable CHO cell line producing a recombinant t-PA, and stimulated by the addition of 
sodium butyrate, a chemical compound that is widely used to enhance recombinant 
protein production (McMurray-Beaulieu et al., 2009). In this work, we investigated to 
what extent our modelling approach could be adapted and calibrated having only a 
limited amount of experimental data (the concentration of cells, glucose, lactate, 
glutamine and ammonia, and intracellular concentrations of energetic nucleotides and cell 
specific oxygen consumption, with time). These data are generally the ones routinely 
measured in the biopharma industry. Moreover, the model has been challenged to 
describe the effect of sodium butyrate addition. Indeed, model simulation results clearly 
show that it can be applied to describe culture behaviour prior and after butyrate 
stimulation, with only limited model adaptation requirements. The effect of sodium 
butyrate was described through changing only 4 kinetic parameters (on a total of 72) at 
the time of sodium butyrate addition. These modifications were related to the fluxes 
corresponding to lactate production, glutamine uptake rate, energy consumption, and 
finally cell growth rate, all reported in literature to vary in response to sodium butyrate 
addition. These results have proven the biological relevance of such modeling 
framework. Our simulation results of difficult-to-measure metabolic fluxes and ratios 
agreed and even were complementary to the experimental results of our previous work 
(McMurray-Beaulieu et al., 2009). Determination of confidence intervals and sensitivity 
analysis were then performed on model parameters, and relatively narrow confidence 
intervals were obtained for the most sensitive parameters. Model simulations of 
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metabolic fluxes suggested a distinct cellular behaviour in response to sodium butyrate 
addition, i.e. enhanced stability of glucose and glutamine uptake, a lower lactate 
production-to-glucose consumption rate,as well as a higher oxidative phosphorylation 
rate, all corresponding to asustained high cell metabolic activity level favouring energy 
production. The model thus showed its ability to describe the switch to a more efficient 
metabolism in response to a production enhancer such as sodium butyrate, a phenomenon 
that is also reported in literature (De Leon et al., 2007; McMurray-Beaulieu et al., 2009; 
Yee et al., 2008). 
This first contribution led to some important clarifications on specific mathematical 
aspects of this kind of models, and at the same time suggested that one can use such 
model to explore the behaviour of key physiological markers while drawing biologically 
relevant conclusions. However, although model simulations tend to agree with literature 
and with the known biology of CHO cells, given the high number of model parameters, 
we have focused at minimizing the simulation global error without being able to identify 
adequately all the parameter values. We then decided to push further the validation of the 
modelling approach by increasing significantly the size of the experimental dataset in 
both extra- and intracellular metabolites concentrations.  In the second contribution, we 
studied another CHO cell system by considering two cell clones (a high-producer and a 
low-producer) and the parental cell line from which they were derived. The producing 
cell lines have been stably transformed to produce a monoclonal antibody (mAb) under 
the induction of a cumate gene switch. The model was then challenged in multiple ways, 
looking (a) to what extent two CHO cell lines metabolomically differ from each other, (b) 
two sub-clones differ from each other and (c) from their parental cell line, and (d) how 
far the induction of recombinant protein expression affects the cell metabolism. A major 
effort has then been accomplished to obtain a series of metabolomics measurements that 
are highly difficult to obtain, specially from cell extracts for intracellular metabolites 
concentrations. Then, keeping the same model structure determined in our first 
contribution (Ghorbaniaghdam, Henry, & Jolicoeur, 2012), the framework was extended 
to also describe recombinant monoclonal antibody production kinetics usinga larger set 
of experimental data. In this process, only a limited number of parameters had to be 
modified for adapting the model to the second CHO parental cell line.  
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From a total of 92 parameters, only 11 needed being modified from those of our first 
contribution, in addition to newly introduced parameters, i.e. the ones related to amino 
acids metabolism. These sensitive parameters were related to glucose uptake and lower 
part of glycolysis, i.e. pyruvate kinase and lactate dehydrogenase, pentose phosphate 
pathway, i.e. epimerase, TCA cycle, i.e. citrate synthase, reactions connecting glycolysis 
to TCA cycle, i.e. malic enzyme, amino acid and glutamine catabolism, i.e. alanine 
transaminase and glutamate transferase, NADH consuming reactions, i.e. proton leak, 
and fuelling reactions, i.e. oxidation of NADPH. All of these are known to be involved in 
the major metabolic pathways and thus, their value is thought to define specific traits of 
different cell lines grown under different experimental conditions.  
Moreover, the low- and high-producer clones only required the adjustment of few 
parameters, i.e. the ones related to lactate and ATP consumption, TCA cycle, connections 
of glycolysis and TCA cycle and mAb production, from those of the parental, for 
enabling the model simulations to cope with experimental data. So, a limited subset of 
model parameters are driving, in fact, the in silico clonal variation in cell behavior.While 
adapting the model structure, we have also inserted a more detailed description of fluxes 
regulation within the glycolysis pathway, which was shown to enable further 
improvements of the descriptive and the predictive capacities of the model. Another 
motivation selecting this second cell line set was to examine clone-to-clone variations 
using the model, analyzing growth characteristics, as well as mAb productivity and 
metabolic profiling.Significant metabolic changes between different clones were 
observed experimentally and also simulated by the model. The differences were more 
pronounced between the parental cells and the high-producer clone, and to a lesser extent 
between the low-producer clone and either the parental or the high-producer clone. A 
more efficient metabolic state was assessed in the high-producer clone, i.e. lower values 
of lactate production rate-to-glucose consumption at non-limiting glucose conditions, and 
higher glycolytic fluxes channeled into pyruvate and consequently causing the up 
regulation of TCA. In addition to more efficient glucose metabolism, model simulations 
of anaplerotic reactions also showed an higher replenishment of TCA cycle intermediates 
from these reactions, a result which is also supporting the up regulation of the TCA. 
However, the two low- and high- producer clones, both exhibited fairly similar behaviour 
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with or without the induction of recombinant protein (mAb) synthesis. Taken together the 
experimental results and model simulations showed a more efficient metabolic activity, 
an enhanced oxidative phosphorylation activity and a higher energy yield from glycolysis 
in the high-producer clone. We demonstrated the use of a kinetic metabolic model to 
investigate the key characteristics of recombinant Chinese hamster ovary (CHO) cell 
clones producing respectively high and low monoclonal antibody titers. In accordance 
with our first contribution, in silico analysis of the different cultures, involving the 
parental as well as the low- and the high-producer, provided reliable and valuableinsights 
for theunderstanding of these sub-clones different behaviours, all in agreement with 
literature or in line with biological relevant hypotheses.  
In the first two contributions, we applied the model to study slow dynamics of a 
metabolic network in the context of a batch culture, which does normally last one to two 
weeks. In a third and final contribution, however, we focused on challenging the model 
with a sudden external perturbation that can unfortunately easily occur in cell culture, i.e. 
a hypoxic stress. In this context, the concept of dynamic stability was introduced as the 
cellular ability to reach a new steady state after the introduction of a perturbation. The 
dynamic stability of the parental cell line metabolism (investigated in contribution 
number two) was thus characterized from its transient simulated response. An emphasis 
has been placed on evaluating different regulatory mechanisms, alone or in combination, 
while limiting our focus on the regulation of fluxes of the glycolysis pathway. The 
transient behaviour of the model was then analyzed looking at specific responses, i.e. 
fluxes and fluxes ratios, and metabolites concentrations, of central metabolic pathways. 
Without any regulation, the model simulated an immediate oscillatory response. 
However, different levels of regulation of glycolysis clearly showed to induce the 
damping of the oscillatory behaviour. 
Accounting for the complete regulation of glycolysis, the combination of regulatory 
mechanisms led to a smooth non-oscillatory transient response.The model structure was 
thus readily adaptable to include regulation mechanisms, since no obvious known 
physiologicalrole of glycolytic oscillations has been identified so far, to the best of our 
knowledge, for the experimental condition designed in silico by our model. In silico 
model simulations of metabolic flux distribution, metabolic ratios and metabolic 
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concentrations showed higher glycolytic fluxes and concentrations, lower TCA cycle 
activity and TCA intermediates concentrations, an overflow of glycolytic fluxes to lactate 
production, and higher contribution of glycolysis to ATP production corresponding 
clearly to anaerobic glycolysis. This anaerobic glycolysisphenomenon has been widely 
reported in mammalian cells under hypoxia conditions. The model has thus shown its 
capacity to predict a switch from respiration to an anaerobic glycolysis metabolism. 
Despite all the advantages revealed in this work about having a descriptive mathematical 
model that is biologically relevant, the approach has some important limitations that need 
to be discussed. On the one hand, and this is mostly what we were able to do here, we 
keep a high number of non-identifiable parameters because our focus is on the model 
biological relevancy level, although simplified. Mathematically speaking, one parameter 
is considered identifiable if changing its value influences the model output. In the first 
and second contributions, we followed a classical approach to quantify the influence of a 
parameter and scanned all model parameters to verify which ones can be identified within 
the related experimental space, i.e. sensitivity analysis. A high number of non-sensitive 
parameters were found due to the lack of experimental solicitation. However, parameters 
that we were able to identify with confidence intervals still in biological range were 
mostly related to the major reactions of CHO cells primary metabolism, i.e. glucose 
uptake and glycolytic fluxes, the reaction connecting glycolysis to TCA cycle, glutamine 
uptake and channeling into TCA cycle, catabolic reactions in amino acid metabolism, and 
specific growth rate. All other non-identifiable parameters were kept at this stage of 
model development since they are biologically relevant for describing existing metabolic 
pathways and kinetics of enzymatic reactions. This approach has also allowed us to 
interpret model simulations, i.e. metabolic fluxes and ratios, in relation to statistical 
significance within the experimental space. On the other hand, one can still work at 
simplifying this model with the aim of ending with a structure having only identifiable 
parameters. Although mathematically validated, the cost of proceeding this way is 
definitely a loss of biological relevancy.  
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CHAPTER 8 CONCLUSION 
This PhD thesis proposed a dynamic modeling approach for CHO cell metabolism to 
make a new step forward in the understanding of mammalian cells metabolism. One of 
the main contributions of this work lies in the richness and diversity of the metabolomic 
data collected. Few projects have reported this large number of measurements for the 
intermediate metabolites of CHO cells and for their monitoring over time. Another 
significant contribution is the development of a comprehensive dynamic model giving 
information about the transient behavior of CHO cells. Using the information available 
on metabolite levels and enzyme kinetics from literature, a kinetic model representing 
significant parts of central carbon metabolism was constructed. It was therefore built to 
provide some answers to the question on the effect of changing a cell environmental 
condition, through the introduction of a stimulus (e.g. the depletion of main nutrients) on 
the primary metabolism. In a first part, we have constructed a kinetic model describing 
CHO cell central carbon metabolism following sodium butyrate addition. The model 
presented in this part was the first complete metabolic model describing the kinetics of 
primary metabolism for CHO cells. In addition, although having been calibrated to a 
limited dataset normally see in industry, the model showed a real predictive capacity with 
simulations of intracellular flux distributions that were in agreement with literature. Then, 
the kinetic metabolic model was applied to another CHO cell line cultured under different 
conditions, which enabled further model improvements, including regulation mechanisms 
of glycolysis pathway. A large set of experimental data also allowed the extension of the 
model to describe recombinant monoclonal antibody production kinetics. Furthermore, 
fitting the model to the new cell line and culture conditions, only a limited number of 
parameters needed to be adjusted, which demonstrated that the model is readily adaptable 
to other CHO cell lines. The model also showed its ability to describe clonal variation 
with relatively slight adjustments. This second contribution did enhance our confidence 
level in the model structure and parameters estimates. Also, it is important to note that 
parameters values agree with ranges proposed in literature. The model was thus 
consistent with respect to cell biology. Finally, an in silico perturbation experiment, 
mimicking the sudden introduction of an oxygen limitation into the system, was 
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performed. Interestingly, the model produced some unexpected oscillatory behaviour, 
which was identified to originate from the lack of regulatory mechanisms. 
Implementation of a combination of known regulatory interactions into the model 
demonstrated that the regulation of central carbon metabolism is crucial in many 
scenarios including sudden perturbations in the oxygen level, and that a cell strongly 
looks at the homeostasis of its energetic level. Indeed, we observed through model 
simulations that the controlling regulatory metabolism may mainly relies on the cell 
energetic state itself. 
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CHAPTER 9 RECOMMENDATIONS 
We assume that the future of the modelling approach developed in this work should push 
further its description of regulatory mechanisms for enabling a better understanding of 
cellular behavior. The following are some suggestion following the current work: 
1. Although a large amount of experimental data were made available in this study, there 
are some important ones that were not measured, such as lipids and sugar nucleotides, 
and these are needed to increase the confidence on the model structure and parameter 
estimates.  
2. Although some statistical analysis has been performed to assess identifiable parameters 
a more elaborated and systematic approach in view of estimating the ‘‘quantitative 
identifiability’’, or estimability of model parameters should be applied. This approach is 
completely explained in Meshram et al. (2013) (Meshram et al., 2013). The method 
begins with the determination of the scaled sensitivity of the ݆௧௛  parameter on the 
݅௧௛model output for which experimental data is available at each sampling timeݐ from 
which a scaled sensitivity matrix can be calculated as follows:  
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 Parameters estimability can then be determined by the orthogonalization method as first 
proposed by Yao et al. (2003)  (Yao et al., 2003) . First the magnitude of each column of  
ܯ (the sum of squares of each column) should be calculated. The first estimable 
parameter is selected whose column has the largest magnitude. The corresponding 
column is marked as ଵܺ and the magnitude of largest sum of squares of the column 
elements is called estimable score. ܯ෡  as an estimate of the sensitivity matrix using this 
subset of column is the calculated as :  ܯ෡ = ݕଵ ∗ (ݕଵ்ݕଵ)ିଵݕଵ்ܯ. The residual matrix 
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ܴ = ܯ −ܯ෡ is then calculated to proceed the analysis with respect to the remaining 
parameters. The sum of squares of the residuals in each column this time for ܴ is 
calculated and the parameter whose column has the largest magnitude is identified as the 
second estimable parameter. The original matrix ݕଵis augmented by including the new 
column and the sequential process continues until all columns of ܯ are taken into 
account. 
3. The last part of the work opened a very interesting avenue about metabolic regulation. 
Preliminary results presented here suggest that introducing a sudden perturbation to a 
culture can improve our description of metabolic regulation. It would be interesting to 
further apply this approach to analyze model behavior under various other stresses such 
as those related to glucose and glutamine limitations and over-feeding. 
4. The model would get its best use if it would enable us to implement a control strategy 
based on the knowledge it provides. The scope of the strategy would be to include the 
explicit estimation of the current state of cell culture, which should then be driven toward 
and maintained at a desired state. The model should be first applied to the cell cultures in 
the bioreactor and at least one set of data should be obtained to calibrate the model. 
Afterwards, the model can be used as an on-line monitoring tool to predict culture 
behaviour with time. It can also be used to establish a control function relating growth 
and productivity to process variables. Such model-based control that utilizes controllable 
variables to maintain the desirable metabolic state can then be implemented in a 
bioreactor culture. 
5. Product quality is a major issue which is generally assessed  a posteriori via off-line 
quality control assays. Product quality is mostly affected by the availability of 
intracellular sugar nucleotides and culture conditions. Although the model can describe 
growth and productivity, product quality and in particular the production of sugar 
nucleotides and their contribution to mAb production is not addressed in the current 
model. It can be interesting to update the current model to also account for mass balances 
of sugar nucleotides. In parallel, analysis of glycans in mAb should also be performed 
with liquid chromatography techniques coupled to mass spectroscopy. 
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APPENDICES 
APPENDIX 1Protocol to thaw and pass CHO-cum2 cells 
 
 
 
I. Pre-Culture condition 
Static conditions: 25 cm2 or 75 cm2 T-flasks containing respectively 5.0-7.0 mL or 16-20 
ml of SFM4CHO medium culture supplemented with glutamine, dextran sulphate and 
hygromycine B. Starting density: between 0.4-0.5 *106 cells/ml; maintain cells at a 
density ranging from 1.5-2*106 cells/ml before passing them. Cultivate cells at 37°C, 5% 
CO2. 
Agitated conditions: 125 mL shaker-flasks containing 20 mL of medium culture 
supplemented with glutamine, dextran sulphate and hygromycine B. Starting density: 
between 0.15-0.2 *106 cells/ml; maintain cells at a density ranging from 1.5-2*106 
cells/ml before passing them. Cultivate cells at 37°C, 5% CO2, 100 rpm. 
II. Protocol to thaw and pass cells 
Purpose 
To ensure a proper thawing of cells 
Background information 
As the suspension of cells freezes in liquid nitrogen, ice crystals form. These ice crystals 
can puncture the plasma membrane, leading to cell death. Dimethyl sulfoxide 
(DMSO) protects the cells by partially solublizing the membrane to mekae it less prone to 
puncture in a way that the water can flow out of the cells preventing the formation of ice 
crystals inside the cells, and also interrupting the lattice of the ice, so that fewer crystals 
form. Freezing media contains DMSO. Since it is also toxic for the cells (it partially 
solublizes the membrane, after all), when thawing cells it's important to remove DMSO 
as soon as possible.  
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Materials: 
 
1. 15 ml Falcon tube 
2. 25 cm2 T-flasks 
3. 1.0 mL Glass Pipette, 10.0 mL Glass Pipette 
4. previously prepared fresh cold media 
 
Solution preparation 
 
1. Preparation of pre-culture Medium  
 
SFM4CHO medium culture requires supplementation of glutamine (4 mM), dextran 
sulphate (0.05 mg/ml) and hygromycine B (0.55-0.6 mg/ml). 
 
2. stock solutions of medium 
 
1. 100X solution of Dextran sulphate (5 mg/ml) 
(Dextran sulphate is a powder. So, Prepare a 100X solution and filter through a 
0.22 µm filter. Keep the filtered solution in a falcon at 4°C) 
2. 50X solution of glutamine (200 mmol/l) 
3. 100X solution of hygromycin B (50 mg/ml) 
 
Thawing of cells: 
 
1. Check the frozen cell log sheet to verify the place of  the cell aliquot cryovial in 
the tray rack of liquid N2 tank  (example:Rack 8 ,tray 4) 
 
2. Slowly remove appropriate rack from liquid N2 tank.  Remove long safety pin and 
take out one cryovial from clones and sub-clones tubes in appropriate tray (each 
vial contains 5 million cells) 
 
3. Put tray back in slot and put safety pin back in place.  Return tray rack to liquid 
N2 tank and cap tank again. 
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4. Thaw the cell suspension gently swirling the cryovial into a 37°C water bath until 
cells are defrosted(less than one minute). To avoid contamination Do not immerge 
the cap into water 
 
5. Gently wipe cryovial with EtOH and transfer it under the hood. 
 
6. Under the hood, transfer the contents of the cryovial into a 15 ml Falcon tube 
containing 10 mL of cold fresh culture medium . Pipet contents of vial (~ 1 mL) 
into the falcon. 
 
7. Centrifuge 5 min at 1000 rpm at 4°C. A compact cell pellet should be visible 
 
8. Carefully remove the supernatant by aspirating with a 10 mL pipette. 
 
9. Re-suspend the cells pellet into 7.5 ml of fresh medium culture by transferring  
cells to a 25 Cm2 T-flask containing 7.5 mL of media( previously  placed in the 
incubator  and equilibrated at 37°C ). Pipet  slowly several times to obtain a 
homogenous cell suspension. 
 
10. Close the flask by screwing the cap. 
 
11. Cultivate cells at 37°C,5% CO2. 
 
Note: if the cap does not have a filter, it should be loosely screwed to allow 
proper ventilation and CO2 equilibration.) 
 
12.  At day3, count manually the number of cells, using a hematocymeter) and check 
the viability of cells. If they are in a good shape, dilute them to 0.2-0.4 *106 cells 
with the final volumn of 7.5 mL. 
 
13.  At day five follow the same structure as 9 
 
14.  At day seven transfer cells to a shaker-flask to be expanded to the quantity 
needed to start the experiment. 
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APPENDIX 2    Protocol to expand CHO-cum2 cells suspension 
culture 
 
Purpose 
To ensure a reproducible expansion of CHO cells by in vitro culture at a desired level 
with no loss of cell properties. 
 
Notes 
 
The following SOPs have to be red and understood before performing the present 
Protocol: 
1. Protocol to thaw and pass cellS 
2. Hemacotymeter cell counting SOP 
 
This protocol has to be performed rapidly without any lag between manipulations: all 
material and calculations have to be done prior to each step, or be rapidly performed 
while proceeding with the protocol when needed. 
 
Materials 
Static condition 
1. 25 cm2 T-flask with Vent Cap (Corning, 32-90), QTY:1 
2. 75 cm2 T-flask with Vent Cap (Corning, 32-90), QTY:10 
3. 5.0 mL  sterile glass pipette (VWR 89130-896), QTY:1 
4. 10.0 mL sterile glass pipette (VWR 89130-898), QTY:4 
5. 25.0  mL sterile Glass Pipette (VWR 89130-900), QTY:5 
6. 50 mL sterile Falcon tube( VWR 525-0402),QTY:1 
7. prepared  sterile fresh media ( please check the protocol of how to pass and thaw 
CHO cells for details), QTY: 160 mL 
 
Agitation condition 
 
1. 25 cm2 T-flask with Vent Cap (Corning, 32-90), QTY:1 
2. 75 cm2 T-flask with Vent Cap (Corning, 32-90), QTY:1 
3. 5.0 mL  sterile glass pipette (VWR 89130-896), QTY:1 
4. 10.0 mL sterile glass pipette (VWR 89130-898), QTY:4 
5. 25.0  mL sterile Glass Pipette (VWR 89130-900), QTY:3 
6. 50 mL sterile Falcon tube( VWR 525-0402),QTY:1 
7. prepared  sterile fresh media ( please check the protocol of how to pass and thaw 
CHO cells for details), QTY: 80 mL 
8. 125 ml sterile Erlenmeyer Flask with 2 µm vent cap (Corning,431143),QTY:3 
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Cell expansion in T-flasks 
 
The following protocol is to fulfill the total amount of 100*10 6 cells.  Expand cells until 
the number of viable cells needed is reached. 
1. Calculate the required amount of cells to inoculate and perform the experiment 
and write it down in your lab book. Some examples of calculations are given 
below. 
Imagine that you want to follow the protocol for freezing CHO cell line. Each 
freezing tube has to be contained 5*106 cells. So, to end up with 10 freezing 
tubes, the total amount of cells needed is 50*106. In another example, you want to 
perform an experiment in which you will have 10 batches of 125 ml shaker-flasks 
each of them contain 25 ml of cell culture with an initial cells density of 0.2*106 
cells. So, the total cell amount needed to start that experiment is calculated by 
multiplying the total volume of cell culture (mL) to initial cell density (cells/ml) 
which here is: 
 
10(number of shaker-flasks)* 25(volume of cell culture in each shaker-
flask)*0.2*106 (cell density at each culture) =50*106 cells. 
 
 
2. Count manually the number of cells (using a hematocymeter), as described in 
hemacotymeter cell counting SOP , in the pre-culture 25 cm2 T-flask (Corning, 
32-90) placed in the incubator at 37°C,5% CO2 and used as inoculum of the cell 
expansion cultures; verify  cell viability (as explained in hemacotymeter cell 
counting SOP ). Only use the cells if their viability is greater than or equal to 
95%. Dilute the required volume of cell suspension to obtain 0.2 *106 cells/mL 
(example of calculations given below) for a final volume of 6 ml of culture 
medium at 37°C (prepared as explained in the protocol of pass and thaw CHO cell 
culture), transfer this 6 mL cell suspension in a 25 cm2 T-flask used for cell 
expansion. Cultivate cells at 37°C, 5% CO2.  For example suppose you counted 
the total cell number of 350 in four large corner squares using a hemocytometer 
for a pre-culture 25 cm2 T-flask (as explained in hemacotymeter cell counting 
SOP) . You have then 1093570 cells/ml in that T-flask. In this case 1 mL of cell 
suspension should be diluted intoa 5 mL fresh mediumto get a special cell density 
of0.2 *106 cells/ml. Using a 1 ml glass pipette, 1 mL of a cell suspention is 
transferred into a new 25 cm2 T-flask and using a 5 ml glass pipette 5 mL of fresh 
media is added. 
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3. At day 2, count manually the number of cells (using a hematocymeter) and check 
the viability of cells.The viability must be of 95% or more and cell density should 
be around 1*106 cells/ml.  Using a 10 ml glass pipette, transfer the whole cell 
culture (around 6 mL) to a 75-cm2 T-flask (T-flask 1). Using another 10 ml glass 
pipette, add 9 mL of fresh medium at 37°C.  
 
4. At day 4,count manually the number of cells (using a hematocymeter) and check 
the viability of cells. Cell density should be around 1*106 cell/ml. Transfer 7 mL 
of the cell suspension in theT-flask 1 to a new 75-cm2 T-flask (T-flask 2). Add 
9mL of fresh medium to T-flasks 1 and 2at 37°C. 
 
5. At day 6, count manually the number of cells (using a hematocymeter) and check 
the viability of cells in one of the T-flasks in the incubator. Cell density should be 
around 1*106 cells/ml. transfer 8 new 75 cm2 T-flasks under the hood (T-flasks 
identified as 3,4,5,6,7,8,9, and 10). Using a 25 ml glass pipette, pipette 12 mL of 
the cell suspension in T-flask 1 and transfer 3 mL into each of the T-flasks 3,4,5, 
and 6. Using  another 25 mL glass pipette , add 12ml of fresh medium to each of 
the T-flasks 1,3,4,5, and 6.  Proceed with T-flask 2 and pipette 12 ml  of the cell 
suspension in T-flask 2  and transfer 3ml into each of the T-flasks 7,8,9, and 10 
Using a another 20 ml glass pipette , add 12ml of fresh medium to T-flasks 
2,7,8,9, and 10. Incubate 10 T-flasks at 37°C, 5% CO2 . 
 
6. At day 8, count manually the number of cells (using a hematocymeter) and check 
the viability of cells in one of the T-flasks in the incubator. Cell density should be 
around 1*106 cell/ml .Check your calculations in your lab book again to verify the 
total number of cells needed. Calculate the total volume of cell suspension should 
be collected considering that cell density in all T-flasks is almost the same. Here 
is an example of how to proceed with calculation:From the example in step 1, you 
can calculate that the total amount of 25 *106 cells is needed if you want to 
process 5 freezing tubes at a time.Divide this total cell numberby 1*106 cells/ml to 
calculate how much cell suspension is needed to be collected. It is calculated that 
25 mL of cell suspension should be collected for centrifugation. Using a 25 ml 
glass pipette, transfer 15 mL of culture in T-Flask 1 into a 50 ml Falcon tube. 
Transfer the remaining 10 mL from T-Flask 2 to the same Falcon tube. 
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Figure A. 0.1   Schematic diagram of cell expansion in T-flasks 
 
7. Harvest the cells in the 50 ml falcon tube by centrifugation(1000 rpm,5 min) 
 
 
Cell expansion in shake flasks 
 
1. Repeat the expansion process described above (steps 1,2,3). 
 
2. At day 4, count manually the number of cells (using a hematocymeter) and 
check the viability of cells. The viability must be around 95% or more. 
Cell density should be around 1*106 cell/ml. Transfer 3 new 125-cm2 
sterile Erlenmeyer Flask with 2 µm vent cap under the hood (Erlenmeyer 
Flasks identified as 1,2, and3). Using a 25 mL glass pipette, pipette 15 mL 
of the cell suspension in T-flask 1 and transfer 5 mL into each of the 125 
ml Erlenmeyer Flasks (identified as 1,2, and 3). Using another 25 ml glass 
pipette, add 20mL of fresh medium to each Erlenmeyer Flask. Incubate 3 
Erlenmeyer Flasks with a cell density of0.2 *106 cell/mlat 37°C, 5% CO2, 
100 rpm. 
 
3. At day 6, count manually the number of cells (using a hematocymeter) and 
check the viability of cells in one of the T-flasks in the incubator. Cell 
density should be around 1.5-2 *106 cells/ml. Check your calculations in 
your lab book again to verify the total number of cells needed. Calculate 
the total volume of cell suspension should be collected considering that 
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cell density in all Erlenmeyer Flasksis almost the same. Referring then to 
the second example in step 1, the total number of 50*10 6 cells is needed. 
Like the calculations in the last step, divide this total cell number by 2*106 
cells/ml to calculate how much cell suspension is needed to be collected. It 
is calculated that 50 ml of cell suspension should be collected for 
centrifugation.  
Using a 25 ml glass pipette, transfer 25 mL of culture in Erlenmeyer 
Flasks1 into a 50 ml Falcon tube. 
 
 
 
 
 
Figure A. 0.2   Schematic diagram of cell expansion in shake-flasks 
 
 
4. Harvest the cells in the 50 ml falcon tube by centrifugation(1000 rpm,5 
min) 
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APPENDIX 3    Protocol for the quantification of CD-20 expressed in 
CHO-cum2 cells 
 
 
 
Materials: 
 
1. Tween 20 
2. Casein 
3. PBS 
4. 1 N hydrochloric acid 
5. Sodium carbonate (Fischer Scientific, Burlington, Canada, cat. # S263-1) 
6. 3,3,5,5′-Tetramethylbenzidine (TMB) (Sigma, Oakville, Canada, cat. # T0440) 
7. Goat anti-human IgG1 (H+L) solution (Jackson ImmunoResearch, PA, USA, cat. 
# 109-165-003)  
8. Peroxidise-conjugated affinipure fragment Goat anti-human IgG (Jackson 
Immuno Research, PA, USA, cat. # 109-035-003) 
9. 96-well plates (Costar) (Fisher Scientific, Burlington, Canada,cat. # 3795) 
 
Solution preparation 
 
Washing solution 
 
1. Add 1 mL of Tween 20 in 1 L o PBS 10 mM (1 pack in 1 L of MilliQ water) 
Blockage solution 
 
1. Add 2g of Casein in 200 mL of PBS 10 mM 
2. Heat in microwave for 1 min (for larger volumn heat 30 seconds per each 100 Ml) 
3. Stir for 3 hours 
4. Centrifuge for 5 min at 2000 RPM 
5. Gently recuperate the supernatant 
6. Incubate overnight at 4ºC 
 
Steps 
 
 
Adsorbtion of capture antibody on plate 
 
1. Dilute 18 µL of anti-human IgG  in 10 mL of sodium Carbonate 50 mM 
2. Distribute 50 µL  of capture antibody in each well (# 3369) 
3. Incubate overnight at 4ºC 
 
Preparation of standard curve 
 
1. Add 0.89 µL of IgG (11.2 mg/mL) to 99.11 µL of blockage solution to prepare 
100 µg/mL solution 
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2. Add 10 µL of standard (100  µL/mL) to 990 µL of blockage solution to prepare 1 
µg/mL solution 
3. Add 50 µL of standard (1µg/mL) to 1950 µL of blockage solution to prepare 2.5 
ng/mL solution 
 
 
 
 
 
Concentration  
(ng/mL) Vol (µL) from STD (25 ng/mL) Vol (µL) from blockage solution 
10 400 600 
7 280 720 
5 200 800 
4 160 840 
3 120 880 
2 80 920 
1 40 960 
0 0 1000 
 
 
Sample loading 
 
1. Wash plate 3 times using 150 µL/well of washing solution 
2. Distribute 50 µL/well of sample and standard 
3. Incubate 1h at 37 ºC 
 
Secondary antibody 
 
1. Wash plate 3 times using 150 µL/well of washing solution 
2. Add 10 µL of peroxidase conjugated goat anti-human  IgG in 40 µL of blockage 
solution 
3. Add 6 µL of this solution to 6 mL of blockage solution 
4. Distribute 50 µL/well of peroxidase conjugate antibody 
5. Incubate1h at 37 ºC 
 
 Revelation 
 
1. Wash plate 3 times using 150 µL/well of washing solution 
2. Distribute 50 µL/well of substrate TMB 
3. Incubate for 5 to 10 min at room temperature in dark 
4. Stop reaction by adding 50 µL/well of HCL 
5. Read absorbance at 450 nm 
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APPENDIX 4    Protocol of cold methanol extraction of CHO cells 
 
 
Objectives 
This « procédure d’opération normalisée » (PON) or standard operating procedure (SOP) 
is established to describe the process of mammalian cell extraction in order to perform 
organic acid analysis by LC-MS 
 
Fields of use and application 
This SOP is valuable only for mammalian cell extraction in order to perform organic acid 
analysis by LC-MS, but one can inspire from it to generate another extraction SOP. 
 
Responsibilities 
It is the responsibility of each to respect the SOP directives of all reagents, instruments, or 
machines used in this SOP. 
 
Security 
By following the directives in this SOP and common sense, adequate security will be 
maintained. 
 
Principle 
In order to have as complete understanding as possible of the metabolic activity of cells, 
it is necessary to study many components of the cellular metabolic network in parallel. So 
the main challenge in metabolite analysis is the extraction of compounds of interest from 
biological sample. Several extraction methods have been reported. For example, 
Maharjan and Fernci (Maharjan & Ferenci, 2003) examined the efficiency of extracting  
E.Coli with boiling ethanol: water, cold methanol: water, and perchloric acid extraction, 
and they found cold methanol: water (50:50 mixture) to be the best approach. Kimbell et 
al (Kimball & Rabinowitz, 2006) used cold 80:20 methanol water mixture and found the 
higher methanol content is preferred. 
Based on the reported results (Faijes, Mars, & Smid, 2007; Luo et al., 2007; Faijes et al., 
2007) and our own studies, a modified procedure based on cold methanol extraction 
combined good extraction under mild extraction condition and high enzymatic 
inactivation and made it very suitable for metabolism studies. 
 
 
Materials, reagents, and instruments 
 
Material 
1. Tips (200 l-1000 l and 20-200 l) 
2. Eppendorf (1.5 ml) 
3. Dried ice 
4. Syringe filter (sigma cat, pore size of 0.2 m, 13 mm in diameter PTFE) 
5. Syringe (BD 0.5 ml Syringe) 
 
Reagents 
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1. 80% v/v of methanol (HPLC Grade, Fischer Chemical, Cat# A452-4) 
2. 50% v/v of methanol (HPLC Grade, Fischer Chemical, Cat# A452-4) 
3. SiO2 sand (A&C ,Cat# S1091) 
4. Phosphate buffered saline (PBS), pH ≈ 7-7.4 
5. Milli-Q water 
 
Instruments 
1. Micro-centrifuge (micromax RF, Thermo IEC) 
2. Vortex (mini vortexer, Fischer Scientific) 
3. Sonicator (Crest) 
 
 
 
 
Operation method 
 
Sample preparation 
 
1. Count cells to know the cell density; 
2. Transfer the appropriate sample of culture to have 5 million cells into extraction 
vial; 
3. Micro-centrifuge at 1050 RPM (200 g) for 5 min at 4C (need to pre-cool); 
4. Discard supernatant; 
5. Add 1 ml of cold PBS (pre-cold in ice-water bath); 
6. Suspend the cell pellet by pipetting; 
7. Centrifuge the cell suspension at 1050 RPM for 5 min at 4C (repeat washing 
with PBS twice); 
8. Important Note: all the steps before cell extraction should be done in less than 15 
mins 
9. Discard the supernatant; 
 
Extraction steps 
 
1. Add 0.4 ml of cold 80% methanol (-80C) and 0.2 g of sand into centrifuge tube; 
2. Keep tube on dry ice for 30 min; 
3. Vortex suspend cell pellet for 1 min; 
4. Cool down in ice-water bath for 1 min (repeat step 8.11 and 8.12 3 times); 
5. Sonicate in ice-water bath for 5 min; 
While sonicating keep cell pellets in ice-water  
6. Micro-centrifuge at 21 000 g for 7 min, 4C; 
7. Transfer supernatant into new vial (extract vial)  First extract; 
8. Add 0.2 ml of cold 50% methanol to the pellet; 
9. Suspend the cell pellet with the vortex for 1 min; 
10. Cool down in ice-water bath for 1 min ; 
11. Sonicate in ice-water bath for 5 min; 
While sonicating keep cell pellets in ice-water  
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12. Micro-centrifuge at 21 000 g for 5 min, 4C; 
13. Transfer supernatant to the extract vial  Second extract; 
14. Add 0.2 ml cold water to the pellet; 
15. Micro-centrifuge for 3 min; 
16. Transfer supernatant to the extract vial  Third extract; 
17. Micro-centrifuge the extract tube at 21 000 g at 4°C for 5 min; 
18. Syringe aspirate supernatant; 
19. Mount filter and dispense the 0.2 μm extract in a 2 ml screw cap glass vial; 
20. Identify vial box and store at -80C for further LC/MS analysis; 
 
Important note: in all the steps for extraction cell pellets should be kept in ice-water 
bath.FORMS / REGISTRATIONS 
 
 
Preparation of standards 
 
All the standard stocks of organic acids have to be prepared in 50% methanol. To prepare 
standards follow the steps and table: 
 
First part of the table/ how to prepare stock solutions: 
 
1. First weight the mass needed amount and by adding 50% methanol bring it to appropriate 
total volume (now the concentration would be the same as the first con.(mM)) 
2. Dilute the standards in order to reach the stock con. (mM) 
3. Keep the stock solutions in -20C for further usage 
 
Second part of the table/ how to prepare standards 
 
4. STD1: Take 100l of each stock solution and mix them, then dilute it to 10ml 
5. STD 2: Take 50l of each stock solution and mix them, then dilute it to 10ml 
6. STD 3: Take 30l of each stock solution and mix them, then dilute it to 10ml 
7. STD 4: Take 15l of each stock solution and mix them, then dilute it to 10ml 
8. STD 5: Take 10l of each stock solution and mix them, then dilute it to 10ml 
9. STD 6: Take 5 l of each stock solution and mix them, then dilute it to 10ml 
 
From the last part of following table you can find the concentration of each component in the 
STDs. 
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APPENDIX 5MATLAB files 
 
 
% MatLab code of the model     © Prof. Mario Jolicoeur’s group 
 
 
**********  
 
OVERVIEW                                                                                                                                       
                                       
This model describes the dynamics of CHO cells metabolism. The model doesnot discriminate 
between cellular populations and is thus representative of overall CHO cells metabolism. 
Moreover, unique cellular compartment is considered in the model. This implementation 
reproduces the results, as presented in the figures of the associated manuscript.  
 
The model is presented in: 
Atefeh Ghorbaniaghdam, Jingkui Chen, Olivier Henry, Mario Jolicoeur 
 Metabolomics and in-silico analysis of monoclonal antibody-producing CHO cell clones. 
Computational biology (2013) 
 Please cite the original article if you use this model. 
 
global Allpara Allpara_value 
% Paraopt: contains the names of the parameters to be optimized 
% Parafixed: contains the names of the parameters to be kept constant 
% Get the list of all parameters from Excel 
[numexcel,nameexcel]=xlsread('para.xlsx');  %Import parameter names and values from a file 
called Paralist.xlsx 
% All the name of the parameters  
Allpara=nameexcel(2:end,1); 
% All their corresponding values (fixed or initial guess) 
Allpara_value=numexcel(1:end,1); 
% All the name of the parameters to be kept constant 
for kk=1:length(Allpara_value) 
eval([Allpara(Edwards et al.)'=Allpara_value(kk);']); 
end 
%Initial values 
t=0:1:144; 
yinitial=[1.3999999999999999.*10^-7    %ACCOA                                                                                                                
1.94000000000000001.*10^-7              %AKG                                                                                                                                                                                                               
0.75                  %ALA                                                                                                                                                                                                                    
0.5                  %ASP                                                                                                                                                                                                                    
1.0900000000000001.*10^-6 %ATP                                                                                                                                                                                                                                   
4.7700000000000001.*10^-7 %ADP                                                                                                                                                                                                                                     
1.9999999999999999e-007  %CIT                                                                                                                                                                                                                                 
1                  %COA                                                                                                                                                                                                                                           
3.8999999999999999e-006   %Cr                                                                                                                                                                                                                                     
3e-007     %F6P                                                                                                                                                                                                                                              
5e-008       %G6P                                                                                                                                                                                                                                             
4e-07        %GAP                                                                                                                                                                                                                                            
7e-4          %GLU                                                                                                                                                                                                                               
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3.5e-007    %MAL                                                                                                                                                                                                                                                
6.0000000000000002e-005 %OXA                                                                                                                                                                                                                                    
1.9999999999999995e-006  %PCR                                                                                                                                                                                                                                   
0.4e-007       %PEP                                                                                                                                                                                                                                            
 
1.9999999999999999e-007      %PYR                                                                                                                                                                                                                                
0.42499999999999995e-007      %R5P                                                                                                                                                                                                                                
3.9999999999999998e-007     %SCOA                                                                                                                                                                                                                                
6e-008    %SUC                                                                                                                                                                                                                                  
9.2499999999999999e-008   %X5P                                                                                                                                     
28.010000000000002    %EGLC                                                                                                                                                                                                                                       
3.6       %EGLN                                                                                                                                                                                                                                 
0.75      %LAC                                                                                                                                                                                                                                                
9.00000000000003e-007   %NAD                                                                                                                                                    
1.090002000000000001e-008  %NADH                                                                                                                                               
8.999999999999997e-013   %NADP                                                                                                                                                                    
5.3799999999999999e-012    %NADPH                                                                                                                                                                
0.1               %NH4                                                                                                                                                                           
0.053                 %O2                                                                                                                                                                                      
0.0000042999999999999999   %PI                                                                                                                                                                             
0.18              %X                                                                                                                                                                                   
1e-5            %GLN 
1.9e-8      %AMP 
0.65          %EGLU 
2.80885      %ARG 
2.8          %ASX 
1           %ASP 
0.7          %CYS 
1.055029      %GLY 
0.940153      %HIS 
1.62      %ILE 
0.7941       %LEU 
1.18003      %LYS 
0.45          %MET 
0.55029      %PHE 
2.918        %PRO 
2.11         %SER 
0.55029      %THR 
0.54491      %TYR 
0.8];      %VAL 
 
%% Simulation 
[t,y]=ode23s(@eqdiff,t,yinitial,[],Allpara_value); 
ACCOA_P=y(:,1);AKG_P=y(:,2) ; ALA_P=y(:,3) ; ASP_P=y(:,4) ;ATP_P=y(:,5) ;  
ADP_P=y(:,6) 
;COA_P=y(:,8);CIT_P=y(:,7);Cr_P=y(:,9);F6P_P=y(:,10);G6P_P=y(:,11);;GLU_P=y(:,13);MAL
_P=y(:,14);GAP_P=y(:,12);;OXA_P=y(:,15);PCr_P=y(:,16);PEP_P=y(:,17);PYR_P=y(:,18);R5P
_P=y(:,19);SCOA_P=y(:,2);SUC_P=y(:,21);X5P_P=y(:,22);EGLC_P=y(:,23);EGLN_P=y(:,24);
LAC_P=y(:,25);NAD_P=y(:,26);NADH_P=y(:,27);NADP_P=y(:,28);NADPH_P=y(:,29);NH4_P
=y(:,30);O2_P=y(:,31);Pi_P=y(:,32);X_P=y(:,33);GLN_P=y(:,34);AMP_P=y(:,35);EGLU_P=y(:,
36);ARG_P=y(:,37);ASX_P=y(:,38);ASP_P=y(:,39);CYS_P=y(:,40);GLY_P=y(:,41);HIS_P=y(:,
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42);ILE_P=y(:,43);LEU_P=y(:,44);LYS_P=y(:,45);MET_P=y(:,46);PHE_P=y(:,47);PRO_P=y(:,
48);SER_P=y(:,49);THR_P=y(:,50);TYR_P=y(:,51);VAL_P=y(:,52). 
%% 
%identification of ratios 
for i=1:145 
B_P(i)= 
ADP_P(i)./ATP_P(i);C_P(i)=ATP_P(i)./ADP_P(i);E_P(i)=NADH_P(i)/NAD_P(i);P_P(i)=NADP
_P(i)/NADPH_P(i);PP_P(i)=NADPH_P(i)/NADP_P(i);D_P(i)=NAD_P(i)/NADH_P(i); 
End 
function dy=eqdifflastversionparental(t,x,Allpara_value1) 
global Allpara  
for kk=1:length(Allpara_value1) 
    eval([Allpara{kk} '=Allpara_value1(kk);']); 
end 
ACCOA_P=x(:,1);AKG_P=x(:,2) ; ALA_P=x(:,3) ; ASP_P=x(:,4) ;ATP_P=x(:,5) ;  
ADP_P=x(:,6) 
;COA_P=x(:,8);CIT_P=x(:,7);Cr_P=x(:,9);F6P_P=x(:,10);G6P_P=x(:,11);;GLU_P=x(:,13);MAL
_P=x(:,14);GAP_P=x(:,12);;OXA_P=x(:,15);PCr_P=x(:,16);PEP_P=x(:,17);PYR_P=x(:,18);R5P
_P=x(:,19);SCOA_P=x(:,2);SUC_P=x(:,21);X5P_P=x(:,22);EGLC_P=x(:,23);EGLN_P=x(:,24);
LAC_P=x(:,25);NAD_P=x(:,26);NADH_P=x(:,27);NADP_P=x(:,28);NADPH_P=x(:,29);NH4_P
=x(:,30);O2_P=x(:,31);Pi_P=x(:,32);X_P=x(:,33);GLN_P=x(:,34);AMP_P=x(:,35);EGLU_P=x(:,
36);ARG_P=x(:,37);ASX_P=x(:,38);ASP_P=x(:,39);CYS_P=x(:,40);GLY_P=x(:,41);HIS_P=x(:,
42);ILE_P=x(:,43);LEU_P=x(:,44);LYS_P=x(:,45);MET_P=x(:,46);PHE_P=x(:,47);PRO_P=x(:,
48);SER_P=x(:,49);THR_P=x(:,50);TYR_P=x(:,51);VAL_P=x(:,52). 
B= ADP./ATP; 
C=ATP./ADP; 
E=NADH/NAD; 
D=NAD/NADH; 
P=NADP/NADPH; 
V_HK = Vmax_HK*mm(EGLC,Km_EGLC,1)*mm(C,Km_C,1)*mm(Kd_G6P,G6P,1);                                                                                                                                                 
V_PGI = Vmaxf_PGI*mm(G6P,Km_G6P,1)*mm(Kd_PEP,PEP,1);                                                                                                                                                                
V_PFK = Vmax_PFK*mm(F6P,Km_F6P,1)*mm(C,Km_C,1);  
V_PGK = Vmax_PGK*mm(GAP,Km_GAP,1)*mm(B,Km_B,1)*mm(D,Km_D,1);                                                                                                
V_PK = Vmax_PK*mm(PEP,Km_PEP,1)*mm(B,Km_B,1);                                                                                                       
V_LDH = Vmaxf_LDH*mm(PYR,Km_PYR,1)*mm(E,Km_E,1)-
Vmaxr_LDH*mm(LAC,Km_LAC,1)*mm(D,Km_D,1);                                                                                                                                                                                                        
V_G6DPH = Vmax_G6DPH*mm(G6P,Km_G6P,1)*mm(P,Km_P,1); 
V_EP = Vmax_EP*mm(R5P,Km_R5P,1);                                                                                                                                                            
V_TK =Vmax_TK*mm(R5P,Km_R5P,1)*mm(X5P,Km_X5P,1) ;                                                                                                                               
V_PDH = Vmax_PDH*mm(PYR,Km_PYR,1)*mm(D,Km_D,1);                                                                                                                         
V_CS = Vmax_CS*mm(ACCOA,Km_ACCOA,1)*mm(OXA,Km_OXA,1);                                                                        
V_CITS = Vmax_CITS*mm(CIT,Km_CIT,1)*mm(D,Km_D,1); 
V_AKGDH = Vmax_AKGDH*mm(AKG,Km_AKG,1)*mm(D,Km_D,1); 
V_SOCAS =0; 
V_SDH = Vmax_SDH*mm(SUC,Km_SUC,1)*mm(D,Km_D,1)*mm(B,Km_B,1); 
V_MLD = Vmax_MLD*mm(MAL,Km_MAL,1)*mm(D,Km_D,1); 
V_ME = Vmax_ME*mm(MAL,Km_MAL,1)*mm(D,Km_D,1); 
V_PC = Vmax_PC*mm(PYR,Km_PYR,1); 
V_GlnT =Vmaxf_GlnT*mm(EGLN,Km_EGLN,1)*mm(C,Km_C,1)-
Vmaxr_GlnT*mm(GLU,Km_GLU,1)*mm(B,Km_B,1)*mm(NH4,Km_NH4,1); 
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V_GLNS=0; 
V_GLDH = Vmaxf_GLDH*mm(GLU,Km_GLU,1)*mm(D,Km_D,1)-
Vmaxr_GLDH*mm(AKG,Km_AKG,1)*mm(E,Km_E,1)*mm(NH4,Km_NH4,1); 
V_AlaTA = Vmaxf_AlaTA*mm(GLU,Km_GLU,1)*mm(PYR,Km_PYR,1)-
Vmaxr_AlaTA*mm(ALA,Km_ALA,1)*mm(AKG,Km_AKG,1)*(1+KaEGLN/EGLN); 
V_GluT=Vmax_GluT*mm(GLU,Km_GLU,1); 
V_resp= Vmax_resp*mm(O2,Km_O2,1)*mm(B,Km_B,1)*mm(NADH,Km_NADH,1); 
V_ATPase = Vmax_ATPase*mm(ATP,Km_ATP,1); 
V_CK =Vmaxf_CK*mm(PCr,Km_PCr,1)*mm(B,Km_B,1)-
Vmaxr_CK*mm(Cr,Km_Cr,1)*mm(C,Km_C,1); 
V_AK=Vmaxf_AK*mm(AMP,Km_AMP,1)*mm(ATP,Km_ATP,1)-
Vmaxr_AK*mm(ADP,Km_ADP,1); 
V_leak = Vmax_leak*mm(NADH,Km_NADH,1)*mm(O2,Km_O2,1); 
V_NADPHox = Vmax_NADPHox*mm(NADPH,Km_NADPH,1); 
V_PPRibP=Vmax_PPRibP*mm(R5P,Km_R5P,1)*mm(EGLN,Km_EGLN,1)*mm(ASP,Km_AS
P,1)*mm(GLY,Km_GLY,1); 
V_growth = 
Vmax_growth*mm(G6P,Km_G6P,1)*mm(EGLN,Km_EGLN,1)*mm(R5P,Km_R5P,1)*mm(LY
S,Km_LYS,1)*mm(ILE,Km_ILE,1)*mm(LEU,Km_LEU,1)*mm(VAL,Km_VAL,1)*mm(TYR,
Km_TYR,1)*mm(ASX,Km_ASX,1)*mm(HIS,Km_HIS,1)*mm(ARG,Km_ARG,1); 
V_growth_R5P = 9.11e-
5*Vmax_growth*mm(G6P,Km_G6P,1)*mm(EGLN,Km_EGLN,1)*mm(R5P,Km_R5P,1)*mm(
LYS,Km_LYS,1)*mm(ILE,Km_ILE,1)*mm(LEU,Km_LEU,1)*mm(VAL,Km_VAL,1)*mm(TY
R,Km_TYR,1)*mm(ASX,Km_ASX,1)*mm(HIS,Km_HIS,1)*mm(ARG,Km_ARG,1); 
V_growth_G6P =13.65e-
5*Vmax_growth*mm(G6P,Km_G6P,1)*mm(EGLN,Km_EGLN,1)*mm(R5P,Km_R5P,1)*mm(
LYS,Km_LYS,1)*mm(ILE,Km_ILE,1)*mm(LEU,Km_LEU,1)*mm(VAL,Km_VAL,1)*mm(TY
R,Km_TYR,1)*mm(ASX,Km_ASX,1)*mm(HIS,Km_HIS,1)*mm(ARG,Km_ARG,1); 
V_growth_CIT =5.25e-
6*Vmax_growth*mm(G6P,Km_G6P,1)*mm(EGLN,Km_EGLN,1)*mm(R5P,Km_R5P,1)*mm(
LYS,Km_LYS,1)*mm(ILE,Km_ILE,1)*mm(LEU,Km_LEU,1)*mm(VAL,Km_VAL,1)*mm(TY
R,Km_TYR,1)*mm(ASX,Km_ASX,1)*mm(HIS,Km_HIS,1)*mm(ARG,Km_ARG,1); 
V_growth_GLU=1.86e-
5*Vmax_growth*mm(G6P,Km_G6P,1)*mm(EGLN,Km_EGLN,1)*mm(R5P,Km_R5P,1)*mm(
LYS,Km_LYS,1)*mm(ILE,Km_ILE,1)*mm(LEU,Km_LEU,1)*mm(VAL,Km_VAL,1)*mm(TY
R,Km_TYR,1)*mm(ASX,Km_ASX,1)*mm(HIS,Km_HIS,1)*mm(ARG,Km_ARG,1); 
V_growth_GLN= 1.86e-
5*Vmax_growth*mm(G6P,Km_G6P,1)*mm(EGLN,Km_EGLN,1)*mm(R5P,Km_R5P,1)*mm(
LYS,Km_LYS,1)*mm(ILE,Km_ILE,1)*mm(LEU,Km_LEU,1)*mm(VAL,Km_VAL,1)*mm(TY
R,Km_TYR,1)*mm(ASX,Km_ASX,1)*mm(HIS,Km_HIS,1)*mm(ARG,Km_ARG,1); 
V_growth_ALA=0.00194*0.013*Vmax_growth*mm(G6P,Km_G6P,1)*mm(EGLN,Km_EGLN,
1)*mm(R5P,Km_R5P,1)*mm(LYS,Km_LYS,1)*mm(ILE,Km_ILE,1)*mm(LEU,Km_LEU,1)*m
m(VAL,Km_VAL,1)*mm(TYR,Km_TYR,1)*mm(ASX,Km_ASX,1)*mm(HIS,Km_HIS,1)*mm
(ARG,Km_ARG,1); 
V_growth_ARG=0.00194*0.007*Vmax_growth*mm(G6P,Km_G6P,1)*mm(EGLN,Km_EGLN,
1)*mm(R5P,Km_R5P,1)*mm(LYS,Km_LYS,1)*mm(ILE,Km_ILE,1)*mm(LEU,Km_LEU,1)*m
m(VAL,Km_VAL,1)*mm(TYR,Km_TYR,1)*mm(ASX,Km_ASX,1)*mm(HIS,Km_HIS,1)*mm
(ARG,Km_ARG,1); 
V_growth_ASX=0.00194*0.0*Vmax_growth*mm(G6P,Km_G6P,1)*mm(EGLN,Km_EGLN,1)*
mm(R5P,Km_R5P,1)*mm(LYS,Km_LYS,1)*mm(ILE,Km_ILE,1)*mm(LEU,Km_LEU,1)*mm(
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VAL,Km_VAL,1)*mm(TYR,Km_TYR,1)*mm(ASX,Km_ASX,1)*mm(HIS,Km_HIS,1)*mm(A
RG,Km_ARG,1); 
V_growth_ASP=0.00194*0.0261*Vmax_growth*mm(G6P,Km_G6P,1)*mm(EGLN,Km_EGLN,
1)*mm(R5P,Km_R5P,1)*mm(LYS,Km_LYS,1)*mm(ILE,Km_ILE,1)*mm(LEU,Km_LEU,1)*m
m(VAL,Km_VAL,1)*mm(TYR,Km_TYR,1)*mm(ASX,Km_ASX,1)*mm(HIS,Km_HIS,1)*mm
(ARG,Km_ARG,1); 
V_growth_GLY=0.00194*0.0165*Vmax_growth*mm(G6P,Km_G6P,1)*mm(GLU,Km_GLU,1)
*mm(GLN,Km_GLN,1)*mm(R5P,Km_R5P,1)*mm(CIT,Km_CIT,1); 
V_growth_HIS=0.00194*0.01*Vmax_growth*mm(G6P,Km_G6P,1)*mm(EGLN,Km_EGLN,1)
*mm(R5P,Km_R5P,1)*mm(LYS,Km_LYS,1)*mm(ILE,Km_ILE,1)*mm(LEU,Km_LEU,1)*mm
(VAL,Km_VAL,1)*mm(TYR,Km_TYR,1)*mm(ASX,Km_ASX,1)*mm(HIS,Km_HIS,1)*mm(
ARG,Km_ARG,1); 
V_growth_ILE=0.00194*0.01*Vmax_growth*mm(G6P,Km_G6P,1)*mm(EGLN,Km_EGLN,1)
*mm(R5P,Km_R5P,1)*mm(LYS,Km_LYS,1)*mm(ILE,Km_ILE,1)*mm(LEU,Km_LEU,1)*mm
(VAL,Km_VAL,1)*mm(TYR,Km_TYR,1)*mm(ASX,Km_ASX,1)*mm(HIS,Km_HIS,1)*mm(
ARG,Km_ARG,1); 
V_growth_LEU=0.00194*0.013*Vmax_growth*mm(G6P,Km_G6P,1)*mm(EGLN,Km_EGLN,
1)*mm(R5P,Km_R5P,1)*mm(LYS,Km_LYS,1)*mm(ILE,Km_ILE,1)*mm(LEU,Km_LEU,1)*m
m(VAL,Km_VAL,1)*mm(TYR,Km_TYR,1)*mm(ASX,Km_ASX,1)*mm(HIS,Km_HIS,1)*mm
(ARG,Km_ARG,1); 
V_growth_LYS=0.00194*0.01*Vmax_growth*mm(G6P,Km_G6P,1)*mm(EGLN,Km_EGLN,1)
*mm(R5P,Km_R5P,1)*mm(LYS,Km_LYS,1)*mm(ILE,Km_ILE,1)*mm(LEU,Km_LEU,1)*mm
(VAL,Km_VAL,1)*mm(TYR,Km_TYR,1)*mm(ASX,Km_ASX,1)*mm(HIS,Km_HIS,1)*mm(
ARG,Km_ARG,1); 
V_growth_MET=0.00194*0.0033*Vmax_growth*mm(G6P,Km_G6P,1)*mm(EGLN,Km_EGLN
,1)*mm(R5P,Km_R5P,1)*mm(LYS,Km_LYS,1)*mm(ILE,Km_ILE,1)*mm(LEU,Km_LEU,1)*
mm(VAL,Km_VAL,1)*mm(TYR,Km_TYR,1)*mm(ASX,Km_ASX,1)*mm(HIS,Km_HIS,1)*m
m(ARG,Km_ARG,1); 
V_growth_PRO=0.00194*0.0081*Vmax_growth*mm(G6P,Km_G6P,1)*mm(EGLN,Km_EGLN
,1)*mm(R5P,Km_R5P,1)*mm(LYS,Km_LYS,1)*mm(ILE,Km_ILE,1)*mm(LEU,Km_LEU,1)*
mm(VAL,Km_VAL,1)*mm(TYR,Km_TYR,1)*mm(ASX,Km_ASX,1)*mm(HIS,Km_HIS,1)*m
m(ARG,Km_ARG,1); 
V_growth_SER=0.00194*0.0099*Vmax_growth*mm(G6P,Km_G6P,1)*mm(EGLN,Km_EGLN,
1)*mm(R5P,Km_R5P,1)*mm(LYS,Km_LYS,1)*mm(ILE,Km_ILE,1)*mm(LEU,Km_LEU,1)*m
m(VAL,Km_VAL,1)*mm(TYR,Km_TYR,1)*mm(ASX,Km_ASX,1)*mm(HIS,Km_HIS,1)*mm
(ARG,Km_ARG,1); 
V_growth_THR=0;0.00194*0.008*Vmax_growth*mm(G6P,Km_G6P,1)*mm(EGLN,Km_EGL
N,1)*mm(R5P,Km_R5P,1)*mm(LYS,Km_LYS,1)*mm(ILE,Km_ILE,1)*mm(LEU,Km_LEU,1)
*mm(VAL,Km_VAL,1)*mm(TYR,Km_TYR,1)*mm(ASX,Km_ASX,1)*mm(HIS,Km_HIS,1)*
mm(ARG,Km_ARG,1); 
V_growth_TYR=0.00194*0.004*Vmax_growth*mm(G6P,Km_G6P,1)*mm(EGLN,Km_EGLN,
1)*mm(R5P,Km_R5P,1)*mm(LYS,Km_LYS,1)*mm(ILE,Km_ILE,1)*mm(LEU,Km_LEU,1)*m
m(VAL,Km_VAL,1)*mm(TYR,Km_TYR,1)*mm(ASX,Km_ASX,1)*mm(HIS,Km_HIS,1)*mm
(ARG,Km_ARG,1); 
V_growth_VAL=0.00194*0.0096*Vmax_growth*mm(G6P,Km_G6P,1)*mm(EGLN,Km_EGLN
,1)*mm(R5P,Km_R5P,1)*mm(LYS,Km_LYS,1)*mm(ILE,Km_ILE,1)*mm(LEU,Km_LEU,1)*
mm(VAL,Km_VAL,1)*mm(TYR,Km_TYR,1)*mm(ASX,Km_ASX,1)*mm(HIS,Km_HIS,1)*m
m(ARG,Km_ARG,1); 
%%************************************************************************* 
V_ASX=Vmax_asx*mm(ASX,Km_ASX,1); 
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V_ASTA= Vmaxf_ASTA*mm(ASP,Km_ASP,1)*mm(AKG,Km_AKG,1)- 
Vmaxr_ASTA*mm(GLU,Km_GLU,1)*mm(OXA,Km_OXA,1)*mm(NH4,Km_NH4,1); 
V_SDHH=Vmax_SDHH*mm(SER,Km_SER,1); 
V_HISARGTA=Vmax_HISARGTA*mm(HIS,Km_HIS,1)*mm(ARG,Km_ARG,1)*mm(AKG,K
m_AKG,1); 
V_LYSILELEUVALTYRTA=Vmax_LYSILELEUVALTYRTA*mm(LYS,Km_LYS,1)*mm(IL
E,Km_ILE,1)*mm(LEU,Km_LEU,1)*mm(VAL,Km_VAL,1)*mm(TYR,Km_TYR,1)*mm(AKG
,Km_AKG,1)*mm(D,Km_D,1)*mm(C,Km_C,1)*mm(P,Km_P,1); 
V_METSER=Vmax_METSER*mm(MET,Km_MET,1)*mm(SER,Km_SER,1)*mm(D,Km_D,1)
*mm(C,Km_C,1); 
V_SHMT=Vmax_SHMT*mm(SER,Km_SER,1); 
V_TDH=Vmax_TDH*mm(THR,Km_THR,1)*mm(D,Km_D,1); 
V_PRO=Vmax_PRO*mm(PRO,Km_PRO,1)*mm(NADP/NADPH,Km_NADP/NADPH,1); 
V_PAH=Vmax_PAH*mm(PHE,Km_PHE,1)*mm(E,Km_E,1); 
%%************************************************************************* 
V_mAbPro=0; 
V_mAb_GLU=0.00794*0.017*V_mAbPro; 
V_mAb_GLN= 0.00794*0.0104* V_mAbPro;  
V_mAb_ALA=0.00794*0.011*V_mAbPro; 
V_mAb_ARG=0.00794*0.005*V_mAbPro; 
V_mAb_ASX=0.00794*0.0072*V_mAbPro; 
V_mAb_ASP=0.00794*0.0082*V_mAbPro; 
V_mAb_CYS=0.00794*0.005*V_mAbPro; 
V_mAb_GLY=0.00794*0.0145*V_mAbPro; 
V_mAb_HIS=0.00794*0.0035*V_mAbPro; 
V_mAb_ILE=0.00794*0.005*V_mAbPro; 
V_mAb_LEU=0.00794*0.0142*V_mAbPro; 
V_mAb_LYS=0.00794*0.0145*V_mAbPro; 
V_mAb_MET=0.00794*0.0028*V_mAbPro; 
V_mAb_PHE=0.00794*0.0072*V_mAbPro; 
V_mAb_PRO=0.00794*0.0148*V_mAbPro; 
V_mAb_SER=0.00794*0.0267*V_mAbPro; 
V_mAb_THR=0.00794*0.016*V_mAbPro; 
V_mAb_TYR=0.00794*0.0085*V_mAbPro; 
V_mAb_VAL=0.00794*0.0189*V_mAbPro; 
%%************************************************************************* 
V_mAbPro=0; 
V_mAb_GLU=0.00794*0.017*V_mAbPro; 
V_mAb_GLN= 0.00794*0.0104* V_mAbPro;                                                                                                                                                                                                                          
V_mAb_ALA=0.00794*0.011*V_mAbPro; 
V_mAb_ARG=0.00794*0.005*V_mAbPro; 
V_mAb_ASX=0.00794*0.0072*V_mAbPro; 
V_mAb_ASP=0.00794*0.0082*V_mAbPro; 
V_mAb_CYS=0.00794*0.005*V_mAbPro; 
V_mAb_GLY=0.00794*0.0145*V_mAbPro; 
V_mAb_HIS=0.00794*0.0035*V_mAbPro; 
V_mAb_ILE=0.00794*0.005*V_mAbPro; 
V_mAb_LEU=0.00794*0.0142*V_mAbPro; 
V_mAb_LYS=0.00794*0.0145*V_mAbPro; 
V_mAb_MET=0.00794*0.0028*V_mAbPro; 
V_mAb_PHE=0.00794*0.0072*V_mAbPro; 
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V_mAb_PRO=0.00794*0.0148*V_mAbPro; 
V_mAb_SER=0.00794*0.0267*V_mAbPro; 
V_mAb_THR=0.00794*0.016*V_mAbPro; 
V_mAb_TYR=0.00794*0.0085*V_mAbPro; 
V_mAb_VAL=0.00794*0.0189*V_mAbPro; 
%%************************************************************************* 
dy(1) = +V_PDH-V_CS+8*V_LYSILELEUVALTYRTA-V_growth*ACCOA; 
dy(2) = +V_CITS-V_AKGDH+V_AlaTA+V_GLDH-V_ASTA-
7*V_LYSILELEUVALTYRTA-V_HISARGTA-V_growth*AKG; 
dy(3) = +(V_AlaTA)*X*1000; 
dy(4) = -2*V_PPRibP+V_ASX-V_growth*ASP; 
dy(5) =(-V_HK-V_PFK+V_PGK+V_PK+V_SOCAS+2*Pratio*V_resp-V_ATPase+V_CK-
V_AK-V_METSER);%/(1-d); 
dy(6) =-(-V_HK-V_PFK+V_PGK+V_PK+V_SOCAS+2*Pratio*V_resp-V_ATPase+V_CK-
2*V_AK+V_METSER); 
dy(7) = +V_CS-V_CITS-V_growth_CIT-V_growth*CIT; 
dy(8) = -V_PDH+V_CS-V_AKGDH+V_SOCAS-V_growth*COA; 
dy(9) = +V_CK-V_growth*Cr; 
dy(10) = +V_PGI-V_PFK+2*V_TK-V_growth*F6P; 
dy(11) = +V_HK-V_PGI-V_G6DPH-V_growth_G6P-V_growth*G6P; 
dy(12) = 2*V_PFK-V_PGK+V_TK-V_growth*GAP; 
dy(13)=V_GLNS+V_GlnT-V_GLDH-V_AlaTA-V_GluT+2*V_PPRibP-
V_growth_GLU+V_ASTA+4*V_LYSILELEUVALTYRTA+4*V_HISARGTA-
V_growth*GLU; 
dy(14) = V_SDH-V_MLD-V_ME-2*V_PPRibP+V_LYSILELEUVALTYRTA-
V_growth*MAL; 
dy(15) = -V_CS+V_MLD+V_PC+V_ASTA-V_growth*OXA; 
dy(16) = -V_CK-V_growth*PCr; 
dy(17)= +V_PGK-V_PK-V_growth*PEP; 
dy(18) = +V_PK-V_LDH-V_PDH-V_AlaTA+V_ME-V_PC+V_SDHH-V_growth*PYR; 
dy(19) = +V_G6DPH-V_EP-V_TK-0.6*V_PPRibP-V_growth_R5P-V_growth*R5P; 
dy(20) =0; %+V_AKGDH+3*V_LYSILELEUVALTYRTA+V_METSER-V_growth*SCOA; 
dy(21) = +V_AKGDH+3*V_LYSILELEUVALTYRTA+V_METSER-V_SDH-V_growth*SUC; 
dy(22) = +V_EP-2*V_TK-V_growth*X5P; 
dy(23) = (-V_HK)*X*1000; 
dy(24) = (-V_GlnT-V_growth_GLN-2*V_PPRibP)*X*1000;                                                                                                          
dy(25) = (V_LDH)*X*1000; 
dy(26) = -V_PDH-V_CITS-V_AKGDH-2/3*V_SDH-V_MLD+2*V_resp-
V_PK+V_LDH+2*V_leak-V_GLDH-9*V_LYSILELEUVALTYRTA-
8/3*V_LYSILELEUVALTYRTA-V_METSER; 
dy(27) = +V_PDH+V_CITS+V_AKGDH+2/3*V_SDH+V_MLD-2*V_resp+V_PK-V_LDH-
2*V_leak+V_GLDH+9*V_LYSILELEUVALTYRTA+8/3*V_LYSILELEUVALTYRTA+V_M
ETSER;                                                                                                                                                                                                
dy(28) = -V_G6DPH+V_NADPHox-2*V_LYSILELEUVALTYRTA; 
dy(29) = V_G6DPH-V_NADPHox+2*V_LYSILELEUVALTYRTA; 
dy(30) = (V_GlnT+V_GLNS+V_GLDH+V_ASX)*X*1000; 
dy(31)= 0; 
dy(32) =0; 
dy(33) = V_growth*X; 
dy(34) =V_GlnT-V_GLNS-2*V_PPRibP-V_growth*GLN ; 
dy(35)=-V_AK+V_PPRibP; 
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dy(36)=V_GluT*X*1000; 
dy(37)=(-V_HISARGTA-V_growth_ARG-V_mAb_ARG)*X*1000; 
dy(38)=(-V_ASX-V_growth_ASX-V_mAb_ASX)*X*1000; 
dy(39)=(-V_PPRibP-V_ASTA-V_growth_ASP-V_mAb_ASP)*X*1000; 
dy(40)=(V_METSER-V_growth_CYS-V_mAb_CYS)*X*1000; 
dy(41)=(-V_PPRibP+V_SHMT+V_TDH-V_growth_GLY-V_mAb_GLY)*1000; 
dy(42)=(-V_HISARGTA-V_growth_HIS-V_mAb_HIS)*1000; 
dy(43)=(-V_LYSILELEUVALTYRTA-V_growth_ILE-V_mAb_ILE)*X*1000; 
dy(44)=(-V_LYSILELEUVALTYRTA-V_growth_LEU-V_mAb_LEU)*X*1000; 
dy(45)=(-V_LYSILELEUVALTYRTA-V_growth_LYS-V_mAb_LYS)*X*1000; 
dy(46)=(-V_METSER-V_growth_MET-V_mAb_MET)*X*1000; 
dy(47)=(-V_PAH-V_growth_PHE-V_mAb_PHE)*X*1000; 
dy(48)=(-V_PPRibP-V_PRO-V_growth_PRO-V_mAb_PRO)*X*1000; 
dy(49)=(-V_SDHH-V_SHMT-V_growth_SER-V_mAb_SER)*X*1000; 
dy(50)=(-V_TDH-V_growth_THR-V_mAb_THR)*X*1000; 
dy(51)=(-V_LYSILELEUVALTYRTA+V_PAH-V_growth_TYR-V_mAb_TYR)*X*1000; 
dy(52)=(-V_LYSILELEUVALTYRTA-V_growth_VAL-V_mAb_VAL)*X*1000; 
dy=dy'; 
function K=mm(c,k,n) 
K= (c.^n)./(k.^n+c.^n) ; 
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APPENDIX 6    Model analysis 
 
 
 
Akaike information criterion 
 
 To select a model from a set of models, the chosen model should minimize the distance 
between the model simulation and experimental data (WSSRES). A systematic way is a 
criterion that seeks a model with a good fit to experimental data considering the number 
of model parameters.   
The Akaike information criterion (AICc) is a measure for model comparison when model 
formulations with different numbers of parameters are available. It is defined as: 
 
ܣܫܥܿ = ݊	ln ቆܹܴܵܵܧܵ
݊
ቇ + 	 2݊݌
݊ − ݌ − 1 
 
where, WSSRES  is the minimized sum of squared errors, ݊ is the sample size, and ݌is the 
number of model parameters. Therefore, the value of AICc, in itself, for a given 
experimental data set has no meaning. It becomes interesting when it is compared to the 
AICc of a series of model specified a priori.The model with the lowest AICc being the 
best model among all other model formulations specified for the data available. 
Therefore, we further evaluate different model formulations accounting for different 
combinations of regulatory mechanisms an check whether the model formulation with the 
lowest WSSRES identified for the parental,induced low- and induced high-
producercultures, the model accounts for hexokinase feedback-inhibition by its product 
(term I), G6P, and phosphoglucose isomerase (term II) by PEP, is also the best among the 
whole set of candidate models with regards to the AICc values. The results in Table 1 
indicate that the model formulation with both hexokinase and phosphoglucose 
isomerasefeedback-inhibition is the best, i.e.  lowest AICc value, given the set of four 
candidate model formulations in the three cultures. 
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Table A.1     Akaike information criterion (AICc) of the model formulations with 
different combinations of regulatory mechanisms of glycolysis 
 
                           Model Formulation                       AICc 
no regulation-parental 670.08 
 
with the addition of term I-parental 615.79 
with the addition of terms I and II-parental 514.97 
the addition of all terms-parental 536.07 
no regulation-low-producer 629.47 
with the addition of term I- low-producer 585.15 
with the addition of terms I and II- low-producer 528.46 
the addition of all terms- low-producer 545.41 
no regulation- high-producer 599.89 
with the addition of term I- high-producer 578.98 
with the addition of terms I and II- high-producer 510.25 
the addition of all terms- high-producer 554.29 
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Fisher Information matrix 
There is always a desire to compute the probability of obtaining the particular 
experimental sample, denoted by x1,x2,…,xn, for a special model formulation. Considering 
that the observations in the experimental sample are independent, the generic expression 
for obtaining this particular sample is as follows: 
 
ܲ( ଵܺ = ݔଵ,ܺଶ = ݔଶ, … ,ܺ௡ = ݔ௡) = ܲ( ଵܺ = ݔଵ)ܲ(ܺଶ = ݔଶ) …ܲ(ܺ௡ = ݔ௡) 											= ෑܲ(௡
௜ୀଵ
௜ܺ = ݔ௜) 
 
Considering the model formulation, dependent on a set of parameters, 
i.e.	݂(ݔ;ߠଵ … ߠ௣),the generic probability terms can be replaced by the proposed model. 
 
ܮ൫ߠଵ … ߠ௣, ݔଵ …ݔ௡൯ = ෑ Ɵܲ(௡
௜ୀଵ
௜ܺ = ݔ௜) = ෑ݂(௡
௜ୀଵ
ݔ௜;ߠଵ … ߠ௣) 
 
Working typically with the log of this expression,the above expression is modified as 
follows: 
logܮ൫ߠଵ … ߠ௣, ݔଵ … ݔ௡൯ = ෍ log ݂(ݔ௜; ߠଵ … ߠ௣)௡
௜ୀଵ
 
 
The maximum likelihood estimate of parameters are those values with the log-likelihood 
as large as possible. The analytical protocol is setting the derivatives equal to zero with 
the derivative of the log-likelihood considered as the score or gradient vector. 
The information matrixis an important quantity in likelihood theory which is the matrix 
of second partial derivatives of the log-likelihood.The matrix of second partial derivatives 
of the log-likelihood is also called the Hessian matrix. Therefore, the information matrix 
is just the negative of the Hessian matrix evaluated at the maximum likelihood estimates. 
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ܪ݁ݏݏ݅ܽ݊(ߠଵ … ߠ௣)
= 	
⎣
⎢
⎢
⎢
⎢
⎢
⎢
⎡
߲ଶ
߲ߠଵ
ଶ logܮ(ߠ) ⋯ ߲ଶ߲ߠଵ߲ߠ௉ିଵ log ܮ(ߠ) ߲ଶ߲ߠଵ߲ߠ௉ log ܮ(ߠ)
߲ଶ
߲ߠଶ߲ߠଵ
logܮ(ߠ) ߲ଶ
߲ߠଶ
ଶ logܮ(ߠ) ⋯ ߲ଶ߲ߠଶ߲ߠ௉ logܮ(ߠ)
⋮ ⋯ ⋱ ⋮
߲ଶ
߲ߠ௉߲ߠଵ
logܮ(ߠ) ⋯ ߲ଶ
߲ߠ௉߲ߠ௉ିଵ
logܮ(ߠ) ߲ଶ
߲ߠ௉
ଶ logܮ(ߠ) ⎦⎥⎥
⎥
⎥
⎥
⎥
⎤
 
 
The variance of a parameter estimate and its corresponding element in the fisher 
information matrix are reciprocals of each other. Therefore, using the relation between 
the fisher information matrix and the parameter estimate, the variability of the calibrated 
parameter values can be assessed by estimating associated confidence intervals via the 
Fisher Information Matrix. The standard error for a parameter estimate can be obtained 
by taking the square root of the reciprocal of the negative of the its corresponding value 
in Hessian matrix to construct the confidence intervals for estimate 
parameters.Considering the value of θ corresponding to the peak of the log-likelihoods 
and L(θ) as the elements of fisher information matrix, the following information can be 
drawn looking at corresponding figure.Low values of the fisher information matrix 
translates into a high variance of the estimate. Hence confidence intervals for parameter 
estimate will be wide. High information translates into a low variance of our estimator. 
Hence confidence intervals for parameter estimate will be narrow.  
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Figure A.3Second partial derivatives of the log-likelihoodand information 
 
 
Finally, since fisher information matrix presents the inverse of the parameter estimation 
error covariance, the correlation matrix whose elements can be drawn a follows: 
ܴ௞௟ = ܥ௞௟
ඥܥ௞௞ܥ௟௟
 
 
Further information on parameter correlations can be extracted from the correlation 
matrix.  
Due to the information the fisher information matrix can provide, the fisher information 
matrix is calculated for the estimated parameters of the parental culture. Using Least-
squares fit as an optimization routin, the hessian matrix cannot be calculated as an output. 
Once the solution using Least-squares fit is found, we run one additional iteration of 
Fmincon by calling it directly and starting from the known solution as the initial point. 
Calling Fmincon, with additional arguments let the hessian matrix be achieved as 
follows. 
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121 123 84 126 11 12 21 127 0 19 0.001 12 121 123 0.008 123 0.011 1 2 127 0 197 12 26 121 123 0.8 
123 125 200 129 11 120 210 129 0.5 190 0.01 121 121 200 0.08 300 0.11 10 20 259 0 19 120 260 12 13 8 
8 34 17 0.1 0 1 3 0.2 0.5 20 0.001 6 10 20 0.005 5 0 0 0 10 0 0.23 13 60 0.1 0.05 2 
126 127 200 110 0.2 11 360 132 0.4 207 0.8 120 110 86 0.04 204 0.32 10 20 0.1 2 204 81 193 80 450 0.6 
0.1 0.11 0 0.002 0 0.03 0.005 0.01 0.006 0.1 0 0 1 0 0 34 0 1 3 0 0.01 0.4 2 10 3 45 0 
0.01 0.3 0.2 0.01 0.03 385 171 8 0.1 382 0.03 0.2 20 0.6 24 0 0.1 0 0 34 0.002 0.005 0 35 0.004 3 0 
0.002 0.02 0.03 0.03 0.005 700 133 1 0.1 137 0.006 0.1 16 0.03 102 2 0.001 0 0 24 0.004 0.003 0 102 0.001 21 0 
127 129 0.0002 132 0.01 8 1 133 0.0005 204 0.001 0.003 141 201 0.002 76 0.009 0.8 8 154 0 100 23 43 10 18 0.3 
0 0.06 0.0005 0.004 0.0006 0.19 0.1 0.0005 0.2 1.3 0 0.4 43 10 0 2 0.0002 0 0 201 0 5 0 5 0.001 2 0 
19 198 0.02 207 0.11 738 137 20 1.3 223 0.07 2.4 202 150 24 100 0.3 10 4 300 5 198 25 9 100 165 2 
0.001 0.01 0.001 0.008 0 0.03 0.006 0.001 0 0.07 0 0 2 0.4 0 4 0.004 1 0.003 5 0 0.2 0.05 1 0.2 3 0.002 
0.002 0.1 0.0006 0.02 0.0009 0.2 0.1 0.003 0.4 2 0 0.6 0.4 0.02 0 1 0.02 0 0 2 0 0.04 1 0.5 0.03 0.2 0.0001 
20 14 0.002 0.004 0.0003 0.01 0.5 0.002 0.001 1 0 0.08 0.1 0.008 0.0003 1 0.009 0.5 0 0 0 0.1 0.1 0.07 0.2 0.1 0.0003 
80 35 0.006 0.01 0.04 0.08 1 0.05 0.01 10 0 0.6 0.9 0.01 0.009 10 0.01 2 0 0.003 0 0.8 0.9 0.1 0.1 0.005 0.001 
0.2 0.1 0.01 0.005 0 0.007 0.002 0.05 0.002 0.06 0 0.002 0.5 0 0.0001 20 0.04 0.0001 0 0 0 0.005 1 4 2 70 0.001 
10 12 0.001 0.003 0.0002 0.09 0.2 0.001 0.006 10 0 0.03 0.08 0.01 0.0007 6 0.003 0.2 0.001 0.05 0 0.08 0.2 0.03 0.1 0.1 0.0003 
0.1 0.3 0.2 0.001 0.05 185 17 80 0.1 282 0.05 0.1 10 0.5 14 0 0.5 0.001 0 44 0.02 0.005 0.001 30 0.04 5 0.01 
221 123 94 226 30 12 21 187 0.6 49 0.005 52 120 13 0.008 153 0.01 100 20 227 10 197 92 66 221 123 80 
151 121 90 126 40 22 11 87 0.5 39 0.05 32 120 80 0.001 53 0.005 80 10 127 80 97 2 0.6 21 100 40 
0.05 8 10 0.05 0.001 0.001 0.006 0.04 0.001 2 0 0.008 10 1 0.001 20 0.04 0.001 0.005 0 0 0.002 1 3 2 60 0.002 
0.03 5 10 0.01 0.006 0.007 0.004 0.02 0.0005 20 0.01 0.001 8 5 0.0001 10 0.02 0.002 0.001 0.1 0.001 0.002 4 0.3 20 100 0.02 
0.01 0.006 0.0001 0.002 0.0001 05 0.1 0.0005 0.2 1.7 0 0.2 41 15 0 20 0.002 0 0 201 0 4 0 0.1 0.001 1 0.1 
0.1 0.002 0.001 0.02 0.001 3 0.5 0.005 0.8 5.7 0.001 0.1 31 12 0.01 10 0.001 0.01 0.1 101 0 3 0 0.2 0.002 10 0.5 
0.2 0.09 0.005 0.01 0.005 2 0.2 0.001 0.4 3.7 0.005 0.5 20 15 0.05 20 0.003 0.001 0.2 50 0.01 2 0 0.1 0.001 5 0.2 
0.3 0.001 0.002 0.02 0.004 5 0.6 0.004 0.6 3.7 0.003 0.6 51 11 0.04 60 0.001 0.01 0.5 50 0 6 0 0.02 0.02 10 0.5 
5 0.06 0.003 0.03 0.002 1 0.1 0.002 0.2 3.5 0.002 0.4 10 19 0.02 20 0.003 0.001 3 40 0.001 2 0 0.1 0.001 10 0.5 
181 203 100 186 11 30 50 227 19 100 0.005 15 221 133 0.005 123 0.051 10 20 227 40 297 42 36 221 323 10 
 
